Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15247556,area under the concentration-time curve (AUC0-12h),"Following PHT addition, LPV area under the concentration-time curve (AUC0-12h) decreased from 70.9 +/-37.0 to 49.6 +/- 25.1 microg.h/mL (GMR 0.67, P = 0.011) and C0h decreased from 6.0 +/- 3.2 to 3.6 +/- 2.3 microg/mL (GMR 0.54, P = 0.001).",Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15247556/),[h·μg] / [ml],70.9,1079,DB00252,Phenytoin
,15247556,area under the concentration-time curve (AUC0-12h),"Following PHT addition, LPV area under the concentration-time curve (AUC0-12h) decreased from 70.9 +/-37.0 to 49.6 +/- 25.1 microg.h/mL (GMR 0.67, P = 0.011) and C0h decreased from 6.0 +/- 3.2 to 3.6 +/- 2.3 microg/mL (GMR 0.54, P = 0.001).",Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15247556/),[h·μg] / [ml],49.6,1080,DB00252,Phenytoin
,15247556,C0h,"Following PHT addition, LPV area under the concentration-time curve (AUC0-12h) decreased from 70.9 +/-37.0 to 49.6 +/- 25.1 microg.h/mL (GMR 0.67, P = 0.011) and C0h decreased from 6.0 +/- 3.2 to 3.6 +/- 2.3 microg/mL (GMR 0.54, P = 0.001).",Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15247556/),[μg] / [ml],6.0,1081,DB00252,Phenytoin
,15247556,C0h,"Following PHT addition, LPV area under the concentration-time curve (AUC0-12h) decreased from 70.9 +/-37.0 to 49.6 +/- 25.1 microg.h/mL (GMR 0.67, P = 0.011) and C0h decreased from 6.0 +/- 3.2 to 3.6 +/- 2.3 microg/mL (GMR 0.54, P = 0.001).",Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15247556/),[μg] / [ml],3.6,1082,DB00252,Phenytoin
,15247556,AUC0-24h,"Following LPV/RTV addition, PHT AUC0-24h decreased from 191.0+/-89.2 to 147.8+/-104.5 microg.h/mL (GMR 0.69, P = 0.009) and C0h decreased from 7.0+/-4.0 to 5.3+/-4.1 microg/mL (GMR 0.66, P = 0.033).",Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15247556/),[h·μg] / [ml],191.0,1083,DB00252,Phenytoin
,15247556,AUC0-24h,"Following LPV/RTV addition, PHT AUC0-24h decreased from 191.0+/-89.2 to 147.8+/-104.5 microg.h/mL (GMR 0.69, P = 0.009) and C0h decreased from 7.0+/-4.0 to 5.3+/-4.1 microg/mL (GMR 0.66, P = 0.033).",Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15247556/),[h·μg] / [ml],147.8,1084,DB00252,Phenytoin
,15247556,C0h,"Following LPV/RTV addition, PHT AUC0-24h decreased from 191.0+/-89.2 to 147.8+/-104.5 microg.h/mL (GMR 0.69, P = 0.009) and C0h decreased from 7.0+/-4.0 to 5.3+/-4.1 microg/mL (GMR 0.66, P = 0.033).",Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15247556/),[μg] / [ml],7.0,1085,DB00252,Phenytoin
,15247556,C0h,"Following LPV/RTV addition, PHT AUC0-24h decreased from 191.0+/-89.2 to 147.8+/-104.5 microg.h/mL (GMR 0.69, P = 0.009) and C0h decreased from 7.0+/-4.0 to 5.3+/-4.1 microg/mL (GMR 0.66, P = 0.033).",Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15247556/),[μg] / [ml],5.3,1086,DB00252,Phenytoin
,4076064,peak W-554 serum levels,"After a single 200-mg dose, peak W-554 serum levels of 2.65-4.10 mg/L were achieved in 1-4 h.",Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076064/),[mg] / [l],2.65-4.10,1357,DB00252,Phenytoin
,4076064,Half-lives,Half-lives were 11.2-16.1 h and clearance varied from 34.2-64.6 ml/h X kg.,Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076064/),h,11.2-16.1,1358,DB00252,Phenytoin
,4076064,clearance,Half-lives were 11.2-16.1 h and clearance varied from 34.2-64.6 ml/h X kg.,Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076064/),[ml] / [h·kg],34.2-64.6,1359,DB00252,Phenytoin
,4076064,apparent volume of distribution,The apparent volume of distribution was 0.726-1.046 L/kg.,Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076064/),[l] / [kg],0.726-1.046,1360,DB00252,Phenytoin
,4076064,steady-state trough levels,"Chronic dosing at 400, 800, 1,200, and 1,600 mg/day resulted in median steady-state trough levels of 5.1, 10.2, 14.6, and 20.3 mg/L.",Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076064/),[mg] / [l],5.1,1361,DB00252,Phenytoin
,4076064,steady-state trough levels,"Chronic dosing at 400, 800, 1,200, and 1,600 mg/day resulted in median steady-state trough levels of 5.1, 10.2, 14.6, and 20.3 mg/L.",Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076064/),[mg] / [l],10.2,1362,DB00252,Phenytoin
,4076064,steady-state trough levels,"Chronic dosing at 400, 800, 1,200, and 1,600 mg/day resulted in median steady-state trough levels of 5.1, 10.2, 14.6, and 20.3 mg/L.",Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076064/),[mg] / [l],14.6,1363,DB00252,Phenytoin
,4076064,steady-state trough levels,"Chronic dosing at 400, 800, 1,200, and 1,600 mg/day resulted in median steady-state trough levels of 5.1, 10.2, 14.6, and 20.3 mg/L.",Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076064/),[mg] / [l],20.3,1364,DB00252,Phenytoin
,4076064,Urinary excretion of unchanged,Urinary excretion of unchanged drug was 13.8-28.6% of the dose.,Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076064/),%,13.8-28.6,1365,DB00252,Phenytoin
,8229680,Total absorption,"Total absorption was 0.90 +/- 0.05 and 0.89 +/- 0.05 (mean +/- SE, n = 6) using the methods of numerical integration and quadratic curve fitting, respectively.",Application of a simplified method to determine bioavailability of an oral dose of phenytoin. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229680/),,0.90,3143,DB00252,Phenytoin
,8229680,Total absorption,"Total absorption was 0.90 +/- 0.05 and 0.89 +/- 0.05 (mean +/- SE, n = 6) using the methods of numerical integration and quadratic curve fitting, respectively.",Application of a simplified method to determine bioavailability of an oral dose of phenytoin. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229680/),,0.89,3144,DB00252,Phenytoin
,30086086,CD ratio,"In 10 patients using enzyme-inducing antiepileptic drugs (AEDs), the mean CD ratio increased by 53.5% [from 1389 to 2132 (ng/mL)/(mg/kg)] when they were CRP-positive.",Influence of Inflammation on the Pharmacokinetics of Perampanel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30086086/),[ml·ng] / [kg·mg],1389,3357,DB00252,Phenytoin
,30086086,CD ratio,"In 10 patients using enzyme-inducing antiepileptic drugs (AEDs), the mean CD ratio increased by 53.5% [from 1389 to 2132 (ng/mL)/(mg/kg)] when they were CRP-positive.",Influence of Inflammation on the Pharmacokinetics of Perampanel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30086086/),[ml·ng] / [kg·mg],2132,3358,DB00252,Phenytoin
,30086086,CD ratio,"In 13 patients without enzyme-inducing AEDs, the mean CD ratio increased by 100.8% [from 3826 ng/mL to 7683 (ng/mL)/(mg/kg)] when they were CRP-positive.",Influence of Inflammation on the Pharmacokinetics of Perampanel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30086086/),[ng] / [ml],3826,3359,DB00252,Phenytoin
,30086086,CD ratio,"In 13 patients without enzyme-inducing AEDs, the mean CD ratio increased by 100.8% [from 3826 ng/mL to 7683 (ng/mL)/(mg/kg)] when they were CRP-positive.",Influence of Inflammation on the Pharmacokinetics of Perampanel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30086086/),[ml·ng] / [kg·mg],7683,3360,DB00252,Phenytoin
,3689634,area under the curve (0 to 72 h),2. Omeprazole significantly increased the area under the curve (0 to 72 h) of phenytoin (mean +/- s.e. mean) from 121.6 +/- 14.0 to 151.4 +/- 13.6 micrograms ml-1 h) (P less than 0.01).,Oral phenytoin pharmacokinetics during omeprazole therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689634/),[h·μg] / [ml],121.6,3467,DB00252,Phenytoin
,3689634,area under the curve (0 to 72 h),2. Omeprazole significantly increased the area under the curve (0 to 72 h) of phenytoin (mean +/- s.e. mean) from 121.6 +/- 14.0 to 151.4 +/- 13.6 micrograms ml-1 h) (P less than 0.01).,Oral phenytoin pharmacokinetics during omeprazole therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689634/),[h·μg] / [ml],151.4,3468,DB00252,Phenytoin
,10389915,clearance,"Glioma patients had a higher clearance (1.0-18.0; median, 2.0 liters/h/m2) than lung cancer patients (0.3-5.1; median, 0.9 liters/h/m2).",Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10389915/),[l] / [h·m2],1.0-18.0,4286,DB00252,Phenytoin
,10389915,clearance,"Glioma patients had a higher clearance (1.0-18.0; median, 2.0 liters/h/m2) than lung cancer patients (0.3-5.1; median, 0.9 liters/h/m2).",Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10389915/),[l] / [h·m2],2.0,4287,DB00252,Phenytoin
,10389915,clearance,"Glioma patients had a higher clearance (1.0-18.0; median, 2.0 liters/h/m2) than lung cancer patients (0.3-5.1; median, 0.9 liters/h/m2).",Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10389915/),[l] / [h·m2],0.9,4288,DB00252,Phenytoin
,23325763,limit of detection,The limit of detection was 15 ng/mL; the limit of quantification was 50 ng/mL.,"A quantitative phenytoin GC-MS method and its validation for samples from human ex situ brain microdialysis, blood and saliva using solid-phase extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23325763/),[ng] / [ml],15,4368,DB00252,Phenytoin
,10210914,Vmax,"The mean Vmax for subjects less than 16 years of age was 10.35 mg/kg/day (SD = 0.73, range = 3.77-17.01), while for those above 16 years, the mean value was 7.99 mg/kg/day (SD = 0.15, range = 3.68-15.95).",Phenytoin dosage adjustment in Saudi epileptics: utilization of steady-state pharmacokinetic parameters. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10210914/),[mg] / [d·kg],10.35,4601,DB00252,Phenytoin
,10210914,Vmax,"The mean Vmax for subjects less than 16 years of age was 10.35 mg/kg/day (SD = 0.73, range = 3.77-17.01), while for those above 16 years, the mean value was 7.99 mg/kg/day (SD = 0.15, range = 3.68-15.95).",Phenytoin dosage adjustment in Saudi epileptics: utilization of steady-state pharmacokinetic parameters. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10210914/),[mg] / [d·kg],7.99,4602,DB00252,Phenytoin
,10210914,Km,Km values ranged from 1.01-20.87 mg/litre.,Phenytoin dosage adjustment in Saudi epileptics: utilization of steady-state pharmacokinetic parameters. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10210914/),[mg] / [l],1.01-20.87,4603,DB00252,Phenytoin
,10210914,Km,"The adult Km mean of 6.52 mg/l (SD = 0.24) was significantly higher than the mean of 4.79 mg/l (SD = 0.40) for pediatric patients (P < 0.01), but Km was correlated neither with age nor with weight.",Phenytoin dosage adjustment in Saudi epileptics: utilization of steady-state pharmacokinetic parameters. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10210914/),[mg] / [l],6.52,4604,DB00252,Phenytoin
,10210914,Km,"The adult Km mean of 6.52 mg/l (SD = 0.24) was significantly higher than the mean of 4.79 mg/l (SD = 0.40) for pediatric patients (P < 0.01), but Km was correlated neither with age nor with weight.",Phenytoin dosage adjustment in Saudi epileptics: utilization of steady-state pharmacokinetic parameters. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10210914/),[mg] / [l],4.79,4605,DB00252,Phenytoin
,6777108,free (unbound) fraction,"After valproate, the free (unbound) fraction of phenytoin in serum rose from 9.6 +/- 0.9% (SD) to 15.6 +/- 1.4% on average (p < 0.001).",Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6777108/),%,9.6,4678,DB00252,Phenytoin
,6777108,free (unbound) fraction,"After valproate, the free (unbound) fraction of phenytoin in serum rose from 9.6 +/- 0.9% (SD) to 15.6 +/- 1.4% on average (p < 0.001).",Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6777108/),%,15.6,4679,DB00252,Phenytoin
,6883953,steady-state serum phenytoin concentrations,The daily doses of phenytoin necessary to produce steady-state serum phenytoin concentrations of 10 and 20 micrograms/ml were also determined in patients whose values were definable.,Phenytoin dosage requirements and pharmacokinetic variables. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883953/),[μg] / [ml],10,4740,DB00252,Phenytoin
,6883953,steady-state serum phenytoin concentrations,The daily doses of phenytoin necessary to produce steady-state serum phenytoin concentrations of 10 and 20 micrograms/ml were also determined in patients whose values were definable.,Phenytoin dosage requirements and pharmacokinetic variables. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883953/),[μg] / [ml],20,4741,DB00252,Phenytoin
,8376481,flow-rate,"The drugs and metabolites are eluted with a mobile phase containing potassium phosphate buffer-acetonitrile-methanol (110:50:30, v/v/v) at a flow-rate of 0.2 ml/min.","Simultaneous determination of carbamazepine, phenytoin, phenobarbital, primidone and their principal metabolites by high-performance liquid chromatography with photodiode-array detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376481/),[ml] / [min],0.2,6438,DB00252,Phenytoin
,8376481,recovery rates,The recovery rates range from 95.12 to 104.42%.,"Simultaneous determination of carbamazepine, phenytoin, phenobarbital, primidone and their principal metabolites by high-performance liquid chromatography with photodiode-array detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376481/),%,95.12 to 104.42,6439,DB00252,Phenytoin
,7108766,percentages of unbound,"After 3 weeks of phenobarbital therapy, the percentages of unbound propranolol fell from 15.2 +/- 1.2 (mean +/- S.E.) to 2.4 +/- 0.3 (P less than .001).",Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7108766/),,15.2,6835,DB00252,Phenytoin
,7108766,percentages of unbound,"After 3 weeks of phenobarbital therapy, the percentages of unbound propranolol fell from 15.2 +/- 1.2 (mean +/- S.E.) to 2.4 +/- 0.3 (P less than .001).",Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7108766/),,2.4,6836,DB00252,Phenytoin
,7108766,Km,"Using this model, the Km for phenobarbital-stimulated production of the binding protein was 1200 ng/ml, the turnover T1/2 of the protein was 3.4 days and the T1/2 for the lag phase was also 3.4 days.",Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7108766/),[ng] / [ml],1200,6837,DB00252,Phenytoin
,7108766,turnover T1/2,"Using this model, the Km for phenobarbital-stimulated production of the binding protein was 1200 ng/ml, the turnover T1/2 of the protein was 3.4 days and the T1/2 for the lag phase was also 3.4 days.",Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7108766/),d,3.4,6838,DB00252,Phenytoin
,7108766,T1/2,"Using this model, the Km for phenobarbital-stimulated production of the binding protein was 1200 ng/ml, the turnover T1/2 of the protein was 3.4 days and the T1/2 for the lag phase was also 3.4 days.",Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7108766/),d,3.4,6839,DB00252,Phenytoin
,9578186,total area under the plasma buspirone concentration-time curve,"The total area under the plasma buspirone concentration-time curve after rifampicin was 10.4% (95% CI, 6.3-14.5%) of that after placebo (1.64+/-0.35 ng ml(-1) h vs 22.0+/-15.1 ng ml(-1) h (mean+/-s.d.); P< 0.01).",Concentrations and effects of buspirone are considerably reduced by rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),[h·ng] / [ml],1.64,7058,DB00252,Phenytoin
,9578186,total area under the plasma buspirone concentration-time curve,"The total area under the plasma buspirone concentration-time curve after rifampicin was 10.4% (95% CI, 6.3-14.5%) of that after placebo (1.64+/-0.35 ng ml(-1) h vs 22.0+/-15.1 ng ml(-1) h (mean+/-s.d.); P< 0.01).",Concentrations and effects of buspirone are considerably reduced by rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),[h·ng] / [ml],22.0,7059,DB00252,Phenytoin
,9578186,peak plasma concentration,Rifampicin decreased the peak plasma concentration of buspirone from 6.6+/-3.7 ng ml(-1) to 0.84+/-0.23 ng ml(-1) (P< 0.01) and the half-life from 2.8+/-0.7 h to 1.3+/-0.5 h (P< 0.01).,Concentrations and effects of buspirone are considerably reduced by rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),[ng] / [ml],6.6,7060,DB00252,Phenytoin
,9578186,peak plasma concentration,Rifampicin decreased the peak plasma concentration of buspirone from 6.6+/-3.7 ng ml(-1) to 0.84+/-0.23 ng ml(-1) (P< 0.01) and the half-life from 2.8+/-0.7 h to 1.3+/-0.5 h (P< 0.01).,Concentrations and effects of buspirone are considerably reduced by rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),[ng] / [ml],0.84,7061,DB00252,Phenytoin
,9578186,half-life,Rifampicin decreased the peak plasma concentration of buspirone from 6.6+/-3.7 ng ml(-1) to 0.84+/-0.23 ng ml(-1) (P< 0.01) and the half-life from 2.8+/-0.7 h to 1.3+/-0.5 h (P< 0.01).,Concentrations and effects of buspirone are considerably reduced by rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),h,2.8,7062,DB00252,Phenytoin
,9578186,half-life,Rifampicin decreased the peak plasma concentration of buspirone from 6.6+/-3.7 ng ml(-1) to 0.84+/-0.23 ng ml(-1) (P< 0.01) and the half-life from 2.8+/-0.7 h to 1.3+/-0.5 h (P< 0.01).,Concentrations and effects of buspirone are considerably reduced by rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),h,1.3,7063,DB00252,Phenytoin
,9620116,bioavailability,"There were no significant differences in bioavailability for PHT acid suspension and PHT sodium solution (0.88 +/- 0.15 vs 0.91 +/- 0.7, p=0.57, 90% CI -0.14-0.071).",Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620116/),,0.88,7976,DB00252,Phenytoin
,9620116,bioavailability,"There were no significant differences in bioavailability for PHT acid suspension and PHT sodium solution (0.88 +/- 0.15 vs 0.91 +/- 0.7, p=0.57, 90% CI -0.14-0.071).",Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620116/),,0.91,7977,DB00252,Phenytoin
,9620116,Cmax,"The Cmax was greater (7.4 +/- 0.9 mg/L vs 5.5 +/- 1.7 mg/L, p=0.019) and Tmax was less (2.5 +/- 3.8 vs.14.8 +/- 11.2 hrs, p=0.004) for the sodium solution.",Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620116/),[mg] / [l],7.4,7978,DB00252,Phenytoin
,9620116,Cmax,"The Cmax was greater (7.4 +/- 0.9 mg/L vs 5.5 +/- 1.7 mg/L, p=0.019) and Tmax was less (2.5 +/- 3.8 vs.14.8 +/- 11.2 hrs, p=0.004) for the sodium solution.",Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620116/),[mg] / [l],5.5,7979,DB00252,Phenytoin
,9620116,Tmax,"The Cmax was greater (7.4 +/- 0.9 mg/L vs 5.5 +/- 1.7 mg/L, p=0.019) and Tmax was less (2.5 +/- 3.8 vs.14.8 +/- 11.2 hrs, p=0.004) for the sodium solution.",Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620116/),h,2.5,7980,DB00252,Phenytoin
,9620116,Tmax,"The Cmax was greater (7.4 +/- 0.9 mg/L vs 5.5 +/- 1.7 mg/L, p=0.019) and Tmax was less (2.5 +/- 3.8 vs.14.8 +/- 11.2 hrs, p=0.004) for the sodium solution.",Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620116/),h,14.8,7981,DB00252,Phenytoin
,9620116,time to 50% fractional absorption,"The time to 50% fractional absorption (0.33 +/- 0.08 vs 3.2 +/- 2.4 hrs, p=0.004) and 90% fractional absorption (7.9 +/- 6.2 vs 22.3 +/- 17.2 hrs, p=0.021) was also significantly shorter for the sodium solution.",Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620116/),h,0.33,7982,DB00252,Phenytoin
,9620116,time to 50% fractional absorption,"The time to 50% fractional absorption (0.33 +/- 0.08 vs 3.2 +/- 2.4 hrs, p=0.004) and 90% fractional absorption (7.9 +/- 6.2 vs 22.3 +/- 17.2 hrs, p=0.021) was also significantly shorter for the sodium solution.",Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620116/),h,3.2,7983,DB00252,Phenytoin
,9620116,90% fractional absorption,"The time to 50% fractional absorption (0.33 +/- 0.08 vs 3.2 +/- 2.4 hrs, p=0.004) and 90% fractional absorption (7.9 +/- 6.2 vs 22.3 +/- 17.2 hrs, p=0.021) was also significantly shorter for the sodium solution.",Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620116/),h,7.9,7984,DB00252,Phenytoin
,9620116,90% fractional absorption,"The time to 50% fractional absorption (0.33 +/- 0.08 vs 3.2 +/- 2.4 hrs, p=0.004) and 90% fractional absorption (7.9 +/- 6.2 vs 22.3 +/- 17.2 hrs, p=0.021) was also significantly shorter for the sodium solution.",Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620116/),h,22.3,7985,DB00252,Phenytoin
,7223748,half-life,"Phenytoin half-life was 31.2 +/- 8.4 hours, total plasma clearance was 47.2 +/- 10.7 ml/kg/hr, and volume of distribution was 1.96 +/- 0.46 liters/kg.",Rapid infusion of phenytoin sodium loading doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223748/),h,31.2,9293,DB00252,Phenytoin
,7223748,total plasma clearance,"Phenytoin half-life was 31.2 +/- 8.4 hours, total plasma clearance was 47.2 +/- 10.7 ml/kg/hr, and volume of distribution was 1.96 +/- 0.46 liters/kg.",Rapid infusion of phenytoin sodium loading doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223748/),[ml] / [h·kg],47.2,9294,DB00252,Phenytoin
,7223748,volume of distribution,"Phenytoin half-life was 31.2 +/- 8.4 hours, total plasma clearance was 47.2 +/- 10.7 ml/kg/hr, and volume of distribution was 1.96 +/- 0.46 liters/kg.",Rapid infusion of phenytoin sodium loading doses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223748/),[l] / [kg],1.96,9295,DB00252,Phenytoin
,3573125,maximal phenytoin plasma concentrations,"Their maximal phenytoin plasma concentrations were 246, 200, 168 and 164 mumol/l; the lowest values were in the twins.",Pharmacokinetics of phenytoin in acute adult and child intoxication. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3573125/),[μM] / [l],246,10924,DB00252,Phenytoin
,3573125,maximal phenytoin plasma concentrations,"Their maximal phenytoin plasma concentrations were 246, 200, 168 and 164 mumol/l; the lowest values were in the twins.",Pharmacokinetics of phenytoin in acute adult and child intoxication. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3573125/),[μM] / [l],200,10925,DB00252,Phenytoin
,3573125,maximal phenytoin plasma concentrations,"Their maximal phenytoin plasma concentrations were 246, 200, 168 and 164 mumol/l; the lowest values were in the twins.",Pharmacokinetics of phenytoin in acute adult and child intoxication. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3573125/),[μM] / [l],168,10926,DB00252,Phenytoin
,3573125,maximal phenytoin plasma concentrations,"Their maximal phenytoin plasma concentrations were 246, 200, 168 and 164 mumol/l; the lowest values were in the twins.",Pharmacokinetics of phenytoin in acute adult and child intoxication. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3573125/),[μM] / [l],164,10927,DB00252,Phenytoin
,3573125,Km,"For the twins, a Km in the range of 10.3-48.6 mumol/l was calculated, indicating saturation kinetics even within the therapeutic range of 40-80 mumol/l.",Pharmacokinetics of phenytoin in acute adult and child intoxication. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3573125/),[μM] / [l],10.3-48.6,10928,DB00252,Phenytoin
,3573125,Vmax,"In the twins, the Vmax was in the range of 47.3-79.4 mumol/l/day with a maximal elimination rate of 37.7-63.6 mumol/l/kg/day.",Pharmacokinetics of phenytoin in acute adult and child intoxication. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3573125/),[μM] / [d·l],47.3-79.4,10929,DB00252,Phenytoin
,3573125,maximal elimination rate,"In the twins, the Vmax was in the range of 47.3-79.4 mumol/l/day with a maximal elimination rate of 37.7-63.6 mumol/l/kg/day.",Pharmacokinetics of phenytoin in acute adult and child intoxication. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3573125/),[μM] / [d·kg·l],37.7-63.6,10930,DB00252,Phenytoin
,1133166,steady-state plasma concentration,"However, there was also a lower steady-state plasma concentration of diphenylhydantoin (2.9 plus or minus 0.6 vs.",Pharmacokinetics of drugs in patients with the nephrotic syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1133166/),,2.9,11292,DB00252,Phenytoin
,1133166,plasms clearance,"6.8 plus or minus 0.6 mug/ml, P smaller than 0.001) secondary to an increase in the plasms clearance (0.048 plus or minus 0.019 vs. 0.022 plus or minus 0.006 liter/kg.h, P smaller than 0.001) in the nephrotic patients.",Pharmacokinetics of drugs in patients with the nephrotic syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1133166/),[l] / [h·kg],0.048,11293,DB00252,Phenytoin
,1133166,plasms clearance,"6.8 plus or minus 0.6 mug/ml, P smaller than 0.001) secondary to an increase in the plasms clearance (0.048 plus or minus 0.019 vs. 0.022 plus or minus 0.006 liter/kg.h, P smaller than 0.001) in the nephrotic patients.",Pharmacokinetics of drugs in patients with the nephrotic syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1133166/),[l] / [h·kg],0.022,11294,DB00252,Phenytoin
,1133166,absolute concentration,The net effect is no difference in the absolute concentration of unbound diphenylhydantoin in healthy individuals (0.69 plus or minus 0.05 mug/ml) and patients with the nephrotic syndrome (0.59 plus or minus 0.06 mug/ml).,Pharmacokinetics of drugs in patients with the nephrotic syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1133166/),[μg] / [ml],0.69,11295,DB00252,Phenytoin
,1133166,absolute concentration,The net effect is no difference in the absolute concentration of unbound diphenylhydantoin in healthy individuals (0.69 plus or minus 0.05 mug/ml) and patients with the nephrotic syndrome (0.59 plus or minus 0.06 mug/ml).,Pharmacokinetics of drugs in patients with the nephrotic syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1133166/),[μg] / [ml],0.59,11296,DB00252,Phenytoin
,12242602,AUC(0-24),The addition of phenytoin to an existing daily administration of mirtazapine resulted in a mean (+/-SD) decrease of the AUC(0-24) from 576+/-104 ng h/ml to 305+/-81.6 ng h/ml and a mean decrease of C(max) from 69.7+/-17.5 ng/ml to 46.9+/-10.9 ng/ml.,Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242602/),[h·ng] / [ml],576,11429,DB00252,Phenytoin
,12242602,AUC(0-24),The addition of phenytoin to an existing daily administration of mirtazapine resulted in a mean (+/-SD) decrease of the AUC(0-24) from 576+/-104 ng h/ml to 305+/-81.6 ng h/ml and a mean decrease of C(max) from 69.7+/-17.5 ng/ml to 46.9+/-10.9 ng/ml.,Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242602/),[h·ng] / [ml],305,11430,DB00252,Phenytoin
,12242602,C(max),The addition of phenytoin to an existing daily administration of mirtazapine resulted in a mean (+/-SD) decrease of the AUC(0-24) from 576+/-104 ng h/ml to 305+/-81.6 ng h/ml and a mean decrease of C(max) from 69.7+/-17.5 ng/ml to 46.9+/-10.9 ng/ml.,Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242602/),[ng] / [ml],69.7,11431,DB00252,Phenytoin
,12242602,C(max),The addition of phenytoin to an existing daily administration of mirtazapine resulted in a mean (+/-SD) decrease of the AUC(0-24) from 576+/-104 ng h/ml to 305+/-81.6 ng h/ml and a mean decrease of C(max) from 69.7+/-17.5 ng/ml to 46.9+/-10.9 ng/ml.,Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242602/),[ng] / [ml],46.9,11432,DB00252,Phenytoin
,11164700,time (Tmax),"At steady state, rufinamide reached a peak plasma concentration with a mean time (Tmax) of 3.4 h and a mean half-life (t1/2) of 7.3 h.","Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11164700/),h,3.4,11962,DB00252,Phenytoin
,11164700,half-life (t1/2),"At steady state, rufinamide reached a peak plasma concentration with a mean time (Tmax) of 3.4 h and a mean half-life (t1/2) of 7.3 h.","Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11164700/),h,7.3,11963,DB00252,Phenytoin
,27595590,apparent clearance,"Population PK results from 152 adolescent patients revealed a perampanel apparent clearance of 0.729L/h, consistent with previous analyses in adolescents and adults.","Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizures. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27595590/),[l] / [h],0.729,12175,DB00252,Phenytoin
,8840370,Trough plasma phenytoin concentrations,Trough plasma phenytoin concentrations were approximately 10 micrograms/ml or greater in patients receiving at least 3 days of intramuscular and intravenous fosphenytoin.,"The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8840370/),[μg] / [ml],10,12745,DB00252,Phenytoin
,7229122,elimination half-lives,"The elimination half-lives of primidone and phenobarbital of 6.2 and 83.5 hours, respectively, were within the ""normal range"" for patients on chronic therapy.",Acute phenytoin and primidone intoxication: a pharmacokinetic analysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229122/),h,6.2,14472,DB00252,Phenytoin
,7229122,elimination half-lives,"The elimination half-lives of primidone and phenobarbital of 6.2 and 83.5 hours, respectively, were within the ""normal range"" for patients on chronic therapy.",Acute phenytoin and primidone intoxication: a pharmacokinetic analysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229122/),h,83.5,14473,DB00252,Phenytoin
,34060344,Michaelis-Menten constant,"Michaelis-Menten constant was significantly higher in the polymorphism of CYP2C9IM/CYP2C19EM and CYP2C9IM/CYP2C19IM groups as compared with the control groups (CYP2C9EM/CYP2C19EM) at 2.16 and 1.55 mg/l (p < 0.00001, p < 0.0001).",A meta-analysis of effects of CYP2C9 and CYP2C19 polymorphisms on phenytoin pharmacokinetic parameters. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34060344/),[mg] / [l],2.16,15065,DB00252,Phenytoin
,34060344,Michaelis-Menten constant,"Michaelis-Menten constant was significantly higher in the polymorphism of CYP2C9IM/CYP2C19EM and CYP2C9IM/CYP2C19IM groups as compared with the control groups (CYP2C9EM/CYP2C19EM) at 2.16 and 1.55 mg/l (p < 0.00001, p < 0.0001).",A meta-analysis of effects of CYP2C9 and CYP2C19 polymorphisms on phenytoin pharmacokinetic parameters. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34060344/),[mg] / [l],1.55,15066,DB00252,Phenytoin
,16404803,Milk/maternal plasma concentration ratios,"Milk/maternal plasma concentration ratios close to 1 demonstrate extensive transfer to breast milk of many AEDs including ethosuximide, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, topiramate, and zonisamide.",Gender aspects of pharmacokinetics of new and old AEDs: pregnancy and breast-feeding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404803/),,1,16688,DB00252,Phenytoin
,31067540,trough concentration,"The patients received a phenytoin TDD of 330.5 (±104.5) mg/day, resulting in a trough concentration of 11.2 (±10.3) mg/L.",Estimation of Phenytoin Pharmacokinetic Parameters in Saudi Epileptic Patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31067540/),[mg] / [l],11.2,18085,DB00252,Phenytoin
,31067540,volume of distribution (V),"Average parameter estimates for phenytoin volume of distribution (V), maximal elimination rate (Vmax), and Michaelis-Menten constant (Km) were 0.61 L/h/kg, 6.12 mg/kg/day, and 5.33 mg/L, respectively.",Estimation of Phenytoin Pharmacokinetic Parameters in Saudi Epileptic Patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31067540/),[l] / [h·kg],0.61,18086,DB00252,Phenytoin
,31067540,maximal elimination rate (Vmax),"Average parameter estimates for phenytoin volume of distribution (V), maximal elimination rate (Vmax), and Michaelis-Menten constant (Km) were 0.61 L/h/kg, 6.12 mg/kg/day, and 5.33 mg/L, respectively.",Estimation of Phenytoin Pharmacokinetic Parameters in Saudi Epileptic Patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31067540/),[mg] / [d·kg],6.12,18087,DB00252,Phenytoin
,31067540,Michaelis-Menten constant (Km),"Average parameter estimates for phenytoin volume of distribution (V), maximal elimination rate (Vmax), and Michaelis-Menten constant (Km) were 0.61 L/h/kg, 6.12 mg/kg/day, and 5.33 mg/L, respectively.",Estimation of Phenytoin Pharmacokinetic Parameters in Saudi Epileptic Patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31067540/),[mg] / [l],5.33,18088,DB00252,Phenytoin
,9578008,time,"The time from initiation of high-dose barbiturate therapy to attainment of control of RSE was longer (123 min) than the time to attainment of seizure control in the group receiving propofol (2.6 min, p = 0.002).",Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578008/),min,123,18122,DB00252,Phenytoin
,9578008,time to attainment of seizure control,"The time from initiation of high-dose barbiturate therapy to attainment of control of RSE was longer (123 min) than the time to attainment of seizure control in the group receiving propofol (2.6 min, p = 0.002).",Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578008/),min,2.6,18123,DB00252,Phenytoin
,9578008,Plasma concentrations,Plasma concentrations of propofol associated with control of SE were 14 microM +/- 4 (2.5 microg/ml).,Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578008/),μM,14,18124,DB00252,Phenytoin
,9578008,Plasma concentrations,Plasma concentrations of propofol associated with control of SE were 14 microM +/- 4 (2.5 microg/ml).,Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578008/),[μg] / [ml],2.5,18125,DB00252,Phenytoin
,17433926,serum concentration,"The average (+/-SD) carbamazepine (CBZ) dose is 8.8 +/- 4.7 mg/kg/day, yielding a mean serum concentration of 6.3 +/- 2.2 mg/liter.",Pharmacokinetics of antiepileptic drugs in elderly nursing home residents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17433926/),[mg] / [l],6.3,18536,DB00252,Phenytoin
,33128207,clearance (CL),Median typical clearance (CL) was 0.22 L/h/kg and median typical volume of distribution was 0.69 L/kg.,Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128207/),[l] / [h·kg],0.22,18787,DB00252,Phenytoin
,33128207,volume of distribution,Median typical clearance (CL) was 0.22 L/h/kg and median typical volume of distribution was 0.69 L/kg.,Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128207/),[l] / [kg],0.69,18788,DB00252,Phenytoin
,33128207,area under the concentration-time curve,"One study observed a cumulative area under the concentration-time curve over all days of treatment of between 78 and 101 mg/L·h, and two studies observed an average concentration at first dose of < 600 ng/mL improved overall survival, transplant-related mortality, or relapse.",Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128207/),[mg] / [h·l],78 and 101,18789,DB00252,Phenytoin
<,33128207,concentration at first dose,"One study observed a cumulative area under the concentration-time curve over all days of treatment of between 78 and 101 mg/L·h, and two studies observed an average concentration at first dose of < 600 ng/mL improved overall survival, transplant-related mortality, or relapse.",Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128207/),[ng] / [ml],600,18790,DB00252,Phenytoin
>,33128207,maximum busulfan concentration,One study observed increased sinusoidal obstructive syndrome with maximum busulfan concentration > 1.88 ng/mL.,Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128207/),[ng] / [ml],1.88,18791,DB00252,Phenytoin
,15246117,CL/F,"On average, elderly patients were found to exhibit slightly higher CL/F values compared with controls (14.6 +/- 4.7 ml h(-1) kg(-1) versus 13.1 +/- 4.2 ml h(-1) kg(-1), P < 0.05), the difference being probably related to the dose-dependent nature of phenytoin metabolism and the fact that elderly patients received lower dosages (4.4 +/- 1.1 mg kg(-1)day(-1) versus 5.3 +/- 1.1 mg kg(-1) day(-1), P < 0.001) and had lower serum phenytoin concentrations (14.1 +/- 5.7 microg ml(-1) versus 18.6 +/- 6.8 microg ml(-1), P < 0.0001).",Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15246117/),[ml] / [h·kg],14.6,19210,DB00252,Phenytoin
,15246117,CL/F,"On average, elderly patients were found to exhibit slightly higher CL/F values compared with controls (14.6 +/- 4.7 ml h(-1) kg(-1) versus 13.1 +/- 4.2 ml h(-1) kg(-1), P < 0.05), the difference being probably related to the dose-dependent nature of phenytoin metabolism and the fact that elderly patients received lower dosages (4.4 +/- 1.1 mg kg(-1)day(-1) versus 5.3 +/- 1.1 mg kg(-1) day(-1), P < 0.001) and had lower serum phenytoin concentrations (14.1 +/- 5.7 microg ml(-1) versus 18.6 +/- 6.8 microg ml(-1), P < 0.0001).",Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15246117/),[ml] / [h·kg],13.1,19211,DB00252,Phenytoin
,23864647,half-life,The GM (95% CI) half-life of nevirapine was 63.2 (52.8-75.7) versus 25.5 (21.6-30.1) h in the control group versus the intervention group (P < 0.001).,Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23864647/),h,63.2,19245,DB00252,Phenytoin
,23864647,half-life,The GM (95% CI) half-life of nevirapine was 63.2 (52.8-75.7) versus 25.5 (21.6-30.1) h in the control group versus the intervention group (P < 0.001).,Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23864647/),h,25.5,19246,DB00252,Phenytoin
,6695161,peritoneal clearance,The peritoneal clearance of phenytoin varies from 1.6 to 2.4 ml/min.,[Pharmacokinetics of phenytoin in continuous ambulatory peritoneal dialysis. 2 cases and brief review of the literature]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6695161/),[ml] / [min],1.6 to 2.4,20065,DB00252,Phenytoin
,6695161,peritoneal mass transfer,"The peritoneal mass transfer varies from 0.022 to 0.059 mumol/min, depending on the phenytoin dose given.",[Pharmacokinetics of phenytoin in continuous ambulatory peritoneal dialysis. 2 cases and brief review of the literature]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6695161/),[μM] / [min],0.022 to 0.059,20066,DB00252,Phenytoin
,9159561,total area under the plasma z,The total area under the plasma zopiclone concentration-time curve after rifampicin was 18.0% (95% CI 13.5-22.5%) of that after placebo (86.1 +/- 34.5 ng ml(-1) h vs 473 +/- 114 ng ml(-1) h (mean +/- s.d.); P<0.001).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),[h·ng] / [ml],86.1,20158,DB00252,Phenytoin
,9159561,total area under the plasma z,The total area under the plasma zopiclone concentration-time curve after rifampicin was 18.0% (95% CI 13.5-22.5%) of that after placebo (86.1 +/- 34.5 ng ml(-1) h vs 473 +/- 114 ng ml(-1) h (mean +/- s.d.); P<0.001).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),[h·ng] / [ml],473,20159,DB00252,Phenytoin
,9159561,peak plasma concentration,Rifampicin decreased the peak plasma concentration of zopiclone from 76.9 +/- 27.2 ng ml(-1) to 22.5 +/- 6.0 ng ml(-1) (P<0.001) and the half-life from 3.8 +/- 0.6 h to 2.3 +/- 0.9 h (P<0.005).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),[ng] / [ml],76.9,20160,DB00252,Phenytoin
,9159561,peak plasma concentration,Rifampicin decreased the peak plasma concentration of zopiclone from 76.9 +/- 27.2 ng ml(-1) to 22.5 +/- 6.0 ng ml(-1) (P<0.001) and the half-life from 3.8 +/- 0.6 h to 2.3 +/- 0.9 h (P<0.005).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),[ng] / [ml],22.5,20161,DB00252,Phenytoin
,9159561,half-life,Rifampicin decreased the peak plasma concentration of zopiclone from 76.9 +/- 27.2 ng ml(-1) to 22.5 +/- 6.0 ng ml(-1) (P<0.001) and the half-life from 3.8 +/- 0.6 h to 2.3 +/- 0.9 h (P<0.005).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),h,3.8,20162,DB00252,Phenytoin
,9159561,half-life,Rifampicin decreased the peak plasma concentration of zopiclone from 76.9 +/- 27.2 ng ml(-1) to 22.5 +/- 6.0 ng ml(-1) (P<0.001) and the half-life from 3.8 +/- 0.6 h to 2.3 +/- 0.9 h (P<0.005).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),h,2.3,20163,DB00252,Phenytoin
,8641326,clearance,"Mean (95% confidence interval) phenobarbitone clearance values were 7.6 ml x h(-1) x kg(-1) (6.2, 9.0 ml x h(-1) x kg(-1) for the monotherapy group, 5.0 ml x h(-1) x hg(-1) (4.0, 6.0 ml x h(-1) x kg(-1)) in the presence of concomitant valproate and 6.8 ml x h(-1) x kg(-1) (5.6, 8.0 ml x h(-1) x kg(-1)) in the presence of concomitant carbamazepine or phenytoin.",Determination of phenobarbitone population clearance values for South African children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641326/),[ml] / [h·kg],7.6,21193,DB00252,Phenytoin
,8641326,clearance,"Mean (95% confidence interval) phenobarbitone clearance values were 7.6 ml x h(-1) x kg(-1) (6.2, 9.0 ml x h(-1) x kg(-1) for the monotherapy group, 5.0 ml x h(-1) x hg(-1) (4.0, 6.0 ml x h(-1) x kg(-1)) in the presence of concomitant valproate and 6.8 ml x h(-1) x kg(-1) (5.6, 8.0 ml x h(-1) x kg(-1)) in the presence of concomitant carbamazepine or phenytoin.",Determination of phenobarbitone population clearance values for South African children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641326/),[ml] / [h·hg],5.0,21194,DB00252,Phenytoin
,8641326,clearance,"Mean (95% confidence interval) phenobarbitone clearance values were 7.6 ml x h(-1) x kg(-1) (6.2, 9.0 ml x h(-1) x kg(-1) for the monotherapy group, 5.0 ml x h(-1) x hg(-1) (4.0, 6.0 ml x h(-1) x kg(-1)) in the presence of concomitant valproate and 6.8 ml x h(-1) x kg(-1) (5.6, 8.0 ml x h(-1) x kg(-1)) in the presence of concomitant carbamazepine or phenytoin.",Determination of phenobarbitone population clearance values for South African children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641326/),[ml] / [h·kg],6.8,21195,DB00252,Phenytoin
,11573664,elimination half-life,"The elimination half-life of vecuronium was significantly reduced in both anticonvulsant groups compared with control [control 48.2 (SD 40.3), phenytoin 23.5 (13.1), carbamazepine 18.4 (16.6) min, P<0.05].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),min,48.2,21612,DB00252,Phenytoin
,11573664,elimination half-life,"The elimination half-life of vecuronium was significantly reduced in both anticonvulsant groups compared with control [control 48.2 (SD 40.3), phenytoin 23.5 (13.1), carbamazepine 18.4 (16.6) min, P<0.05].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),min,23.5,21613,DB00252,Phenytoin
,11573664,elimination half-life,"The elimination half-life of vecuronium was significantly reduced in both anticonvulsant groups compared with control [control 48.2 (SD 40.3), phenytoin 23.5 (13.1), carbamazepine 18.4 (16.6) min, P<0.05].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),min,18.4,21614,DB00252,Phenytoin
,11573664,clearance,"Vecuronium clearance was increased in both anticonvulsant groups [control 9.0 (3.6), phenytoin 15.1 (8.9), carbamazepine 18.8 (13.1) ml kg(-1) min(-1), 0.05<P<0.1].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),[ml] / [kg·min],9.0,21615,DB00252,Phenytoin
,11573664,clearance,"Vecuronium clearance was increased in both anticonvulsant groups [control 9.0 (3.6), phenytoin 15.1 (8.9), carbamazepine 18.8 (13.1) ml kg(-1) min(-1), 0.05<P<0.1].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),[ml] / [kg·min],15.1,21616,DB00252,Phenytoin
,11573664,clearance,"Vecuronium clearance was increased in both anticonvulsant groups [control 9.0 (3.6), phenytoin 15.1 (8.9), carbamazepine 18.8 (13.1) ml kg(-1) min(-1), 0.05<P<0.1].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),[ml] / [kg·min],18.8,21617,DB00252,Phenytoin
,11573664,RI,"Children on chronic anticonvulsant therapy had a significantly shorter RI than control [control 21.8 (11), phenytoin 12.5 (8.3), carbamazepine 10.6 (5.9) min, P<0.05].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),min,21.8,21618,DB00252,Phenytoin
,11573664,RI,"Children on chronic anticonvulsant therapy had a significantly shorter RI than control [control 21.8 (11), phenytoin 12.5 (8.3), carbamazepine 10.6 (5.9) min, P<0.05].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),min,12.5,21619,DB00252,Phenytoin
,11573664,RI,"Children on chronic anticonvulsant therapy had a significantly shorter RI than control [control 21.8 (11), phenytoin 12.5 (8.3), carbamazepine 10.6 (5.9) min, P<0.05].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),min,10.6,21620,DB00252,Phenytoin
,8269597,clearance,"Patients who received phenytoin demonstrated significantly higher clearance (mean +/- SD, 3.32 +/- 0.99 ml min-1 kg-1), a lower area under the concentration-time curve (AUC, 5,412 +/- 1,534 ng h ml-1; corrected for dose/kilogram) and a shorter elimination half-life (3.03 +/- 0.57 h) for the last dose of d8-BU (dose 16) as compared with the first dose (2.80 +/- 0.78 ml min-1 kg-1, 6,475 +/- 2,223 ng h ml-1 and 3.94 +/- 1.10 h, respectively).",Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269597/),[ml] / [kg·min],3.32,21672,DB00252,Phenytoin
,8269597,area under the concentration-time curve (AUC,"Patients who received phenytoin demonstrated significantly higher clearance (mean +/- SD, 3.32 +/- 0.99 ml min-1 kg-1), a lower area under the concentration-time curve (AUC, 5,412 +/- 1,534 ng h ml-1; corrected for dose/kilogram) and a shorter elimination half-life (3.03 +/- 0.57 h) for the last dose of d8-BU (dose 16) as compared with the first dose (2.80 +/- 0.78 ml min-1 kg-1, 6,475 +/- 2,223 ng h ml-1 and 3.94 +/- 1.10 h, respectively).",Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269597/),[h·ng] / [ml],"5,412",21673,DB00252,Phenytoin
,8269597,elimination half-life,"Patients who received phenytoin demonstrated significantly higher clearance (mean +/- SD, 3.32 +/- 0.99 ml min-1 kg-1), a lower area under the concentration-time curve (AUC, 5,412 +/- 1,534 ng h ml-1; corrected for dose/kilogram) and a shorter elimination half-life (3.03 +/- 0.57 h) for the last dose of d8-BU (dose 16) as compared with the first dose (2.80 +/- 0.78 ml min-1 kg-1, 6,475 +/- 2,223 ng h ml-1 and 3.94 +/- 1.10 h, respectively).",Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269597/),h,3.03,21674,DB00252,Phenytoin
,8269597,elimination half-life,"Patients who received phenytoin demonstrated significantly higher clearance (mean +/- SD, 3.32 +/- 0.99 ml min-1 kg-1), a lower area under the concentration-time curve (AUC, 5,412 +/- 1,534 ng h ml-1; corrected for dose/kilogram) and a shorter elimination half-life (3.03 +/- 0.57 h) for the last dose of d8-BU (dose 16) as compared with the first dose (2.80 +/- 0.78 ml min-1 kg-1, 6,475 +/- 2,223 ng h ml-1 and 3.94 +/- 1.10 h, respectively).",Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269597/),[ml] / [kg·min],2.80,21675,DB00252,Phenytoin
,8269597,elimination half-life,"Patients who received phenytoin demonstrated significantly higher clearance (mean +/- SD, 3.32 +/- 0.99 ml min-1 kg-1), a lower area under the concentration-time curve (AUC, 5,412 +/- 1,534 ng h ml-1; corrected for dose/kilogram) and a shorter elimination half-life (3.03 +/- 0.57 h) for the last dose of d8-BU (dose 16) as compared with the first dose (2.80 +/- 0.78 ml min-1 kg-1, 6,475 +/- 2,223 ng h ml-1 and 3.94 +/- 1.10 h, respectively).",Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269597/),[h·ng] / [ml],"6,475",21676,DB00252,Phenytoin
,8269597,elimination half-life,"Patients who received phenytoin demonstrated significantly higher clearance (mean +/- SD, 3.32 +/- 0.99 ml min-1 kg-1), a lower area under the concentration-time curve (AUC, 5,412 +/- 1,534 ng h ml-1; corrected for dose/kilogram) and a shorter elimination half-life (3.03 +/- 0.57 h) for the last dose of d8-BU (dose 16) as compared with the first dose (2.80 +/- 0.78 ml min-1 kg-1, 6,475 +/- 2,223 ng h ml-1 and 3.94 +/- 1.10 h, respectively).",Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269597/),h,3.94,21677,DB00252,Phenytoin
,7850794,Vmax,"The mean (SD) Vmax and Km values were 1.47 (0.89) microM/min and 575 (347) microM, respectively.",Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850794/),[μM] / [min],1.47,22186,DB00252,Phenytoin
,7850794,Km,"The mean (SD) Vmax and Km values were 1.47 (0.89) microM/min and 575 (347) microM, respectively.",Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850794/),μM,575,22187,DB00252,Phenytoin
,7850794,initial,"The mean (SD) initial and final clearance rates were 51 (16) ml/min and 106 (48) ml/min, respectively.",Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850794/),[ml] / [min],51,22188,DB00252,Phenytoin
,7850794,final clearance rates,"The mean (SD) initial and final clearance rates were 51 (16) ml/min and 106 (48) ml/min, respectively.",Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850794/),[ml] / [min],106,22189,DB00252,Phenytoin
,7850794,renal clearance rate,The mean renal clearance rate was 17 ml/min in the first course and 16 ml/min in the second course.,Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850794/),[ml] / [min],17,22190,DB00252,Phenytoin
,7850794,renal clearance rate,The mean renal clearance rate was 17 ml/min in the first course and 16 ml/min in the second course.,Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850794/),[ml] / [min],16,22191,DB00252,Phenytoin
,7297025,systemic clearance,Meperidine systemic clearance rose from 1017 +/- 225 ml/min (mean +/- SD) to 1280 +/- 130 ml/min during phenytoin dosing (P less than 0.01).,Effect of phenytoin on meperidine clearance and normeperidine formation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297025/),[ml] / [min],1017,22547,DB00252,Phenytoin
,7297025,systemic clearance,Meperidine systemic clearance rose from 1017 +/- 225 ml/min (mean +/- SD) to 1280 +/- 130 ml/min during phenytoin dosing (P less than 0.01).,Effect of phenytoin on meperidine clearance and normeperidine formation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297025/),[ml] / [min],1280,22548,DB00252,Phenytoin
,7297025,elimination half-life,Meperidine elimination half-life fell from 6.4 +/- 1.0 hr to 4.3 +/- 0.4 hr during phenytoin dosing (P less than 0.05).,Effect of phenytoin on meperidine clearance and normeperidine formation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297025/),h,6.4,22549,DB00252,Phenytoin
,7297025,elimination half-life,Meperidine elimination half-life fell from 6.4 +/- 1.0 hr to 4.3 +/- 0.4 hr during phenytoin dosing (P less than 0.05).,Effect of phenytoin on meperidine clearance and normeperidine formation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297025/),h,4.3,22550,DB00252,Phenytoin
,7297025,Bioavailability,Bioavailability fell from 0.61 +/- 0.08 to 0.43 +/- 0.14 (P less than 0.07).,Effect of phenytoin on meperidine clearance and normeperidine formation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297025/),,0.61,22551,DB00252,Phenytoin
,7297025,Bioavailability,Bioavailability fell from 0.61 +/- 0.08 to 0.43 +/- 0.14 (P less than 0.07).,Effect of phenytoin on meperidine clearance and normeperidine formation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297025/),,0.43,22552,DB00252,Phenytoin
,7297025,area under the blood concentration-time curve from 0 to 24 hr,The normeperdine area under the blood concentration-time curve from 0 to 24 hr after intravenous meperidine rose from 385 +/- 105 ng/hr/ml-1 to 589 +/- 108 ng/hr/ml-1 during phenytoin dosing (P less than 0.01); after oral meperidine it rose from 592 +/- 50 ng/hr/ml-1 to 738 +/- 178 ng/hr/ml-1.,Effect of phenytoin on meperidine clearance and normeperidine formation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297025/),[ng] / [h·ml],385,22553,DB00252,Phenytoin
,7297025,area under the blood concentration-time curve from 0 to 24 hr,The normeperdine area under the blood concentration-time curve from 0 to 24 hr after intravenous meperidine rose from 385 +/- 105 ng/hr/ml-1 to 589 +/- 108 ng/hr/ml-1 during phenytoin dosing (P less than 0.01); after oral meperidine it rose from 592 +/- 50 ng/hr/ml-1 to 738 +/- 178 ng/hr/ml-1.,Effect of phenytoin on meperidine clearance and normeperidine formation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297025/),[ng] / [h·ml],589,22554,DB00252,Phenytoin
,7297025,area under the blood concentration-time curve from 0 to 24 hr,The normeperdine area under the blood concentration-time curve from 0 to 24 hr after intravenous meperidine rose from 385 +/- 105 ng/hr/ml-1 to 589 +/- 108 ng/hr/ml-1 during phenytoin dosing (P less than 0.01); after oral meperidine it rose from 592 +/- 50 ng/hr/ml-1 to 738 +/- 178 ng/hr/ml-1.,Effect of phenytoin on meperidine clearance and normeperidine formation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297025/),[ng] / [h·ml],592,22555,DB00252,Phenytoin
,7297025,area under the blood concentration-time curve from 0 to 24 hr,The normeperdine area under the blood concentration-time curve from 0 to 24 hr after intravenous meperidine rose from 385 +/- 105 ng/hr/ml-1 to 589 +/- 108 ng/hr/ml-1 during phenytoin dosing (P less than 0.01); after oral meperidine it rose from 592 +/- 50 ng/hr/ml-1 to 738 +/- 178 ng/hr/ml-1.,Effect of phenytoin on meperidine clearance and normeperidine formation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297025/),[ng] / [h·ml],738,22556,DB00252,Phenytoin
,11442282,Cmax,The mean Cmax for the four administrations ranged from 1.71-1.79 microg/ml and mean AUC(0-infinity) values from ranged 53.0-54.1 microg*hr/ml.,Variability in the bioavailability of phenytoin capsules in males and females. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11442282/),[μg] / [ml],1.71-1.79,23911,DB00252,Phenytoin
,11442282,AUC(0-infinity),The mean Cmax for the four administrations ranged from 1.71-1.79 microg/ml and mean AUC(0-infinity) values from ranged 53.0-54.1 microg*hr/ml.,Variability in the bioavailability of phenytoin capsules in males and females. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11442282/),[h·μg] / [ml],53.0-54.1,23912,DB00252,Phenytoin
,11442282,elimination half-life,"The elimination half-life was 3 hr shorter, and the AUC(0-infinity) adjusted for the mg/kg dose was 30% lower for females.",Variability in the bioavailability of phenytoin capsules in males and females. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11442282/),h,3,23913,DB00252,Phenytoin
,871217,half-life,"The plasma DPH half-life during the first week of life in term infants was prolonged and very variable (20-7 +/- 11-6 h, mean +/-SD).",Pharmacokinetic observations of phenytoin disposition in the newborn and young infant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/871217/),h,20-7,24656,DB00252,Phenytoin
,871217,plasma half-life,Thereafter the plasma half-life was much shorter (7-6 +/- 3-5 h).,Pharmacokinetic observations of phenytoin disposition in the newborn and young infant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/871217/),h,7-6,24657,DB00252,Phenytoin
,871217,half-life,In preterm infants the half-life was much longer (75-4 +/- 64-5 h) and more variable.,Pharmacokinetic observations of phenytoin disposition in the newborn and young infant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/871217/),h,75,24658,DB00252,Phenytoin
,871217,apparent volume of distribution,"The mean apparent volume of distribution was similar in these groups of infants: preterm newborn 0-80 +/- 0-22 l/kg, term infants during the first week of life 0-80 +/- 0-26 l/kg, and term infants greater than 2 weeks of age 0-73 +/- 0-18 l/kg.",Pharmacokinetic observations of phenytoin disposition in the newborn and young infant. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/871217/),[l] / [kg],0-,24659,DB00252,Phenytoin
,871217,apparent volume of distribution,"The mean apparent volume of distribution was similar in these groups of infants: preterm newborn 0-80 +/- 0-22 l/kg, term infants during the first week of life 0-80 +/- 0-26 l/kg, and term infants greater than 2 weeks of age 0-73 +/- 0-18 l/kg.",Pharmacokinetic observations of phenytoin disposition in the newborn and young infant. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/871217/),l,0-,24660,DB00252,Phenytoin
,3095675,partial pressure (Pa) of oxygen,"Five groups of 6 rabbits were used, a control [with a mean partial pressure (Pa) of oxygen of 84 +/- 2 (SEM) mmHg, partial pressure of carbon dioxide (PaCO2) of 23 +/- 1 mmHg and pH = 7.512 +/- 0.018], a second group with hypercapnia (PaCO2 = 65 +/- 3 mmHg, pH = 7.244 +/- 0.008), a third group with hypoxemia (PaO2 = 48 +/- 2 mmHg), a fourth group with hypercapnia combined with hypoxemia (PaCO2 = 72 +/- 3 mmHg, PaO2 = 51 +/- 1 mmHg and pH = 7.252 +/- 0.008) and a fifth group with metabolic acidosis (pH = 7.232 +/- 0.011).",Effect of hypercapnia and/or hypoxemia and metabolic acidosis on kinetics and concentrations of phenytoin in the cerebrospinal fluid of conscious rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3095675/),mmhg,84,24751,DB00252,Phenytoin
,3095675,partial pressure of carbon dioxide (PaCO2),"Five groups of 6 rabbits were used, a control [with a mean partial pressure (Pa) of oxygen of 84 +/- 2 (SEM) mmHg, partial pressure of carbon dioxide (PaCO2) of 23 +/- 1 mmHg and pH = 7.512 +/- 0.018], a second group with hypercapnia (PaCO2 = 65 +/- 3 mmHg, pH = 7.244 +/- 0.008), a third group with hypoxemia (PaO2 = 48 +/- 2 mmHg), a fourth group with hypercapnia combined with hypoxemia (PaCO2 = 72 +/- 3 mmHg, PaO2 = 51 +/- 1 mmHg and pH = 7.252 +/- 0.008) and a fifth group with metabolic acidosis (pH = 7.232 +/- 0.011).",Effect of hypercapnia and/or hypoxemia and metabolic acidosis on kinetics and concentrations of phenytoin in the cerebrospinal fluid of conscious rabbits. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3095675/),,23,24752,DB00252,Phenytoin
,3095675,PaO2,"Five groups of 6 rabbits were used, a control [with a mean partial pressure (Pa) of oxygen of 84 +/- 2 (SEM) mmHg, partial pressure of carbon dioxide (PaCO2) of 23 +/- 1 mmHg and pH = 7.512 +/- 0.018], a second group with hypercapnia (PaCO2 = 65 +/- 3 mmHg, pH = 7.244 +/- 0.008), a third group with hypoxemia (PaO2 = 48 +/- 2 mmHg), a fourth group with hypercapnia combined with hypoxemia (PaCO2 = 72 +/- 3 mmHg, PaO2 = 51 +/- 1 mmHg and pH = 7.252 +/- 0.008) and a fifth group with metabolic acidosis (pH = 7.232 +/- 0.011).",Effect of hypercapnia and/or hypoxemia and metabolic acidosis on kinetics and concentrations of phenytoin in the cerebrospinal fluid of conscious rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3095675/),,51,24753,DB00252,Phenytoin
,3095675,clearance,"All animals were conscious during the experiments following the administration of 10 mg/kg (i.v.) of phenytoin, hypoxemia decreased the clearance of phenytoin from 4.20 +/- 0.55 to 2.65 +/- 0.44 ml/min per kg (P less than 0.05) and consequently the area under the plasma concentration/time curve (AUC) for phenytoin increased (2575 +/- 319 to 4316 +/- 740 micrograms min/ml; P less than 0.05).",Effect of hypercapnia and/or hypoxemia and metabolic acidosis on kinetics and concentrations of phenytoin in the cerebrospinal fluid of conscious rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3095675/),[ml] / [kg·min],4.20,24754,DB00252,Phenytoin
,3095675,clearance,"All animals were conscious during the experiments following the administration of 10 mg/kg (i.v.) of phenytoin, hypoxemia decreased the clearance of phenytoin from 4.20 +/- 0.55 to 2.65 +/- 0.44 ml/min per kg (P less than 0.05) and consequently the area under the plasma concentration/time curve (AUC) for phenytoin increased (2575 +/- 319 to 4316 +/- 740 micrograms min/ml; P less than 0.05).",Effect of hypercapnia and/or hypoxemia and metabolic acidosis on kinetics and concentrations of phenytoin in the cerebrospinal fluid of conscious rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3095675/),[ml] / [kg·min],2.65,24755,DB00252,Phenytoin
,3095675,area under the plasma concentration/time curve (AUC),"All animals were conscious during the experiments following the administration of 10 mg/kg (i.v.) of phenytoin, hypoxemia decreased the clearance of phenytoin from 4.20 +/- 0.55 to 2.65 +/- 0.44 ml/min per kg (P less than 0.05) and consequently the area under the plasma concentration/time curve (AUC) for phenytoin increased (2575 +/- 319 to 4316 +/- 740 micrograms min/ml; P less than 0.05).",Effect of hypercapnia and/or hypoxemia and metabolic acidosis on kinetics and concentrations of phenytoin in the cerebrospinal fluid of conscious rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3095675/),[min·μg] / [ml],2575,24756,DB00252,Phenytoin
,3095675,area under the plasma concentration/time curve (AUC),"All animals were conscious during the experiments following the administration of 10 mg/kg (i.v.) of phenytoin, hypoxemia decreased the clearance of phenytoin from 4.20 +/- 0.55 to 2.65 +/- 0.44 ml/min per kg (P less than 0.05) and consequently the area under the plasma concentration/time curve (AUC) for phenytoin increased (2575 +/- 319 to 4316 +/- 740 micrograms min/ml; P less than 0.05).",Effect of hypercapnia and/or hypoxemia and metabolic acidosis on kinetics and concentrations of phenytoin in the cerebrospinal fluid of conscious rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3095675/),[min·μg] / [ml],4316,24757,DB00252,Phenytoin
,3095675,volume of distribution,Metabolic acidosis increased the volume of distribution of phenytoin from 780 +/- 70 to 1103 +/- 65 ml/kg (P less than 0.01).,Effect of hypercapnia and/or hypoxemia and metabolic acidosis on kinetics and concentrations of phenytoin in the cerebrospinal fluid of conscious rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3095675/),[ml] / [kg],780,24758,DB00252,Phenytoin
,3095675,volume of distribution,Metabolic acidosis increased the volume of distribution of phenytoin from 780 +/- 70 to 1103 +/- 65 ml/kg (P less than 0.01).,Effect of hypercapnia and/or hypoxemia and metabolic acidosis on kinetics and concentrations of phenytoin in the cerebrospinal fluid of conscious rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3095675/),[ml] / [kg],1103,24759,DB00252,Phenytoin
,22747744,distribution volume,"At baseline, substrate tracers such as R-[11C]verapamil display low brain concentrations with a distribution volume of around 1.",[11C]phenytoin revisited: synthesis by [11C]CO carbonylation and first evaluation as a P-gp tracer in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22747744/),,1,25546,DB00252,Phenytoin
,3997495,maximum elimination rate,"The maximum elimination rate of phenytoin, estimated from steady state dose-concentration pairs, was significantly higher on the old formulation (9.5 +/- 2.8 vs. 7.2 +/- 1.1 mg/kg per day, P less than 0.025) even though there was no difference in the estimates of the Michaelis-Menten constant.",Phenytoin bioavailability assessed by steady state serum concentrations. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997495/),[mg] / [d·kg],9.5,26581,DB00252,Phenytoin
,3997495,maximum elimination rate,"The maximum elimination rate of phenytoin, estimated from steady state dose-concentration pairs, was significantly higher on the old formulation (9.5 +/- 2.8 vs. 7.2 +/- 1.1 mg/kg per day, P less than 0.025) even though there was no difference in the estimates of the Michaelis-Menten constant.",Phenytoin bioavailability assessed by steady state serum concentrations. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997495/),[mg] / [d·kg],7.2,26582,DB00252,Phenytoin
,1442090,flow rate,"Separation of PPF, 5-OHP and NDP was achieved by reversed phase chromatography using a mobile phase consisting of 57% methanol and 43% 10 mmol/L potassium dibasic phosphate (pH 2.7) at a flow rate of 1.0 ml/min on a 5 microns ODS-C18 column.",[Simultaneous determination of propafenone and its active metabolite in serum by high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442090/),[ml] / [min],1.0,26628,DB00252,Phenytoin
,1442090,recoveries,"The recoveries of PPF, 5-OHP and NDP were found to be 99.54 +/- 2.13%, 100.02 +/- 3.66% and 100.48 +/- 3.10%, respectively.",[Simultaneous determination of propafenone and its active metabolite in serum by high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442090/),%,99.54,26629,DB00252,Phenytoin
,1442090,recoveries,"The recoveries of PPF, 5-OHP and NDP were found to be 99.54 +/- 2.13%, 100.02 +/- 3.66% and 100.48 +/- 3.10%, respectively.",[Simultaneous determination of propafenone and its active metabolite in serum by high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442090/),%,100.02,26630,DB00252,Phenytoin
,1442090,recoveries,"The recoveries of PPF, 5-OHP and NDP were found to be 99.54 +/- 2.13%, 100.02 +/- 3.66% and 100.48 +/- 3.10%, respectively.",[Simultaneous determination of propafenone and its active metabolite in serum by high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442090/),%,100.48,26631,DB00252,Phenytoin
,17295362,AUC,"After oral administration of warfarin at a dose of 2 mg/kg to male rats with oxolamine at doses of 10 and 50 mg/kg, the AUC values of warfarin were significantly greater than the controls (254 and 330 versus 180 microg h/ml).",Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17295362/),[h·μg] / [ml],254,28416,DB00252,Phenytoin
,17295362,AUC,"After oral administration of warfarin at a dose of 2 mg/kg to male rats with oxolamine at doses of 10 and 50 mg/kg, the AUC values of warfarin were significantly greater than the controls (254 and 330 versus 180 microg h/ml).",Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17295362/),[h·μg] / [ml],330,28417,DB00252,Phenytoin
,17295362,AUC,"After oral administration of warfarin at a dose of 2 mg/kg to male rats with oxolamine at doses of 10 and 50 mg/kg, the AUC values of warfarin were significantly greater than the controls (254 and 330 versus 180 microg h/ml).",Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17295362/),[h·μg] / [ml],180,28418,DB00252,Phenytoin
,17295362,AUC,"After oral oxolamine at doses of 10 and 50 mg/kg, the AUC of phenytoin was significantly greater (1280 and 1640 versus 938 microg min/ml), however, the AUC values of torasemide and clarithromycin were independent of oxolamine.",Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17295362/),[min·μg] / [ml],1280,28419,DB00252,Phenytoin
,17295362,AUC,"After oral oxolamine at doses of 10 and 50 mg/kg, the AUC of phenytoin was significantly greater (1280 and 1640 versus 938 microg min/ml), however, the AUC values of torasemide and clarithromycin were independent of oxolamine.",Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17295362/),[min·μg] / [ml],1640,28420,DB00252,Phenytoin
,17295362,AUC,"After oral oxolamine at doses of 10 and 50 mg/kg, the AUC of phenytoin was significantly greater (1280 and 1640 versus 938 microg min/ml), however, the AUC values of torasemide and clarithromycin were independent of oxolamine.",Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17295362/),[min·μg] / [ml],938,28421,DB00252,Phenytoin
,4054206,elimination half-life,Coadministration of phenytoin caused a significant reduction in the elimination half-life of digoxin from 33.9 to 23.7 h and a diminution in AUC0-48 from 31.6 to 24.4 ng X ml-1 X h.,On the interaction between phenytoin and digoxin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4054206/),h,33.9 to 23.7,29163,DB00252,Phenytoin
,4054206,AUC0-48,Coadministration of phenytoin caused a significant reduction in the elimination half-life of digoxin from 33.9 to 23.7 h and a diminution in AUC0-48 from 31.6 to 24.4 ng X ml-1 X h.,On the interaction between phenytoin and digoxin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4054206/),[h·ng] / [ml],31,29164,DB00252,Phenytoin
,4054206,AUC0-48,Coadministration of phenytoin caused a significant reduction in the elimination half-life of digoxin from 33.9 to 23.7 h and a diminution in AUC0-48 from 31.6 to 24.4 ng X ml-1 X h.,On the interaction between phenytoin and digoxin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4054206/),[h·ng] / [ml],24,29165,DB00252,Phenytoin
,4054206,Renal digoxin clearance,Renal digoxin clearance was not significantly altered from 135.7 to 120.3 ml X min-1.,On the interaction between phenytoin and digoxin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4054206/),[ml] / [min],135.7 to 120.3,29166,DB00252,Phenytoin
,4054206,clearance,"Assuming no change in beta-acetyldigoxin absorption, the in decrease time-course the serum digoxin concentration was due to a significantly increased total digoxin clearance from 258.6 to 328.3 ml X min-1.",On the interaction between phenytoin and digoxin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4054206/),[ml] / [min],258.6,29167,DB00252,Phenytoin
,4054206,clearance,"Assuming no change in beta-acetyldigoxin absorption, the in decrease time-course the serum digoxin concentration was due to a significantly increased total digoxin clearance from 258.6 to 328.3 ml X min-1.",On the interaction between phenytoin and digoxin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4054206/),[ml] / [min],328.3,29168,DB00252,Phenytoin
,4054206,distribution volume,An insignificant reduction in the digoxin distribution volume from 749.4 to 668.0 l was also observed.,On the interaction between phenytoin and digoxin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4054206/),l,749.4,29169,DB00252,Phenytoin
,4054206,distribution volume,An insignificant reduction in the digoxin distribution volume from 749.4 to 668.0 l was also observed.,On the interaction between phenytoin and digoxin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4054206/),l,668.0,29170,DB00252,Phenytoin
,2384074,"apparent terminal half-life (t1/2, beta)","Analysis of plasma and whole brain homogenates of mice indicated that AHR-11748 has an apparent terminal half-life (t1/2, beta) of 1.0 h.","Pharmacodynamics and pharmacokinetics of AHR-11748, a new antiepileptic agent, in rodents. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384074/),h,1.0,29349,DB00252,Phenytoin
,2384074,brain:plasma ratio,The brain:plasma ratio of AHR-11748 was 3.4:1 from 0.5 h to 6 h.,"Pharmacodynamics and pharmacokinetics of AHR-11748, a new antiepileptic agent, in rodents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384074/),,3.4,29350,DB00252,Phenytoin
,2384074,brain:plasma ratio,The brain:plasma ratio of AHR-11748 was 3.4:1 from 0.5 h to 6 h.,"Pharmacodynamics and pharmacokinetics of AHR-11748, a new antiepileptic agent, in rodents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384074/),h,0.,29351,DB00252,Phenytoin
,2384074,brain:plasma ratio,The brain:plasma ratio of AHR-11748 was 3.4:1 from 0.5 h to 6 h.,"Pharmacodynamics and pharmacokinetics of AHR-11748, a new antiepileptic agent, in rodents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384074/),h,6,29352,DB00252,Phenytoin
,3367304,plasma,"Base-line plasma theophylline clearance was 30% lower in old compared with young nonsmokers (34.0 +/- 2.5 vs. 48.8 +/- 2.6 ml/hr/kg, P less than .001), whereas the small age difference between old and young smokers (86.0 +/- 8.4 vs. 72.4 +/- 8.0 ml/hr/kg) was not significant.",Aging and drug interactions. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3367304/),[ml] / [h·kg],34.0,30124,DB00252,Phenytoin
,3367304,plasma,"Base-line plasma theophylline clearance was 30% lower in old compared with young nonsmokers (34.0 +/- 2.5 vs. 48.8 +/- 2.6 ml/hr/kg, P less than .001), whereas the small age difference between old and young smokers (86.0 +/- 8.4 vs. 72.4 +/- 8.0 ml/hr/kg) was not significant.",Aging and drug interactions. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3367304/),[ml] / [h·kg],48.8,30125,DB00252,Phenytoin
,3367304,clearance,"Base-line plasma theophylline clearance was 30% lower in old compared with young nonsmokers (34.0 +/- 2.5 vs. 48.8 +/- 2.6 ml/hr/kg, P less than .001), whereas the small age difference between old and young smokers (86.0 +/- 8.4 vs. 72.4 +/- 8.0 ml/hr/kg) was not significant.",Aging and drug interactions. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3367304/),[ml] / [h·kg],34.0,30126,DB00252,Phenytoin
,3367304,clearance,"Base-line plasma theophylline clearance was 30% lower in old compared with young nonsmokers (34.0 +/- 2.5 vs. 48.8 +/- 2.6 ml/hr/kg, P less than .001), whereas the small age difference between old and young smokers (86.0 +/- 8.4 vs. 72.4 +/- 8.0 ml/hr/kg) was not significant.",Aging and drug interactions. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3367304/),[ml] / [h·kg],48.8,30127,DB00252,Phenytoin
,3367304,clearance,"Base-line plasma theophylline clearance was 30% lower in old compared with young nonsmokers (34.0 +/- 2.5 vs. 48.8 +/- 2.6 ml/hr/kg, P less than .001), whereas the small age difference between old and young smokers (86.0 +/- 8.4 vs. 72.4 +/- 8.0 ml/hr/kg) was not significant.",Aging and drug interactions. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3367304/),,86.0,30128,DB00252,Phenytoin
,3367304,clearance,"Base-line plasma theophylline clearance was 30% lower in old compared with young nonsmokers (34.0 +/- 2.5 vs. 48.8 +/- 2.6 ml/hr/kg, P less than .001), whereas the small age difference between old and young smokers (86.0 +/- 8.4 vs. 72.4 +/- 8.0 ml/hr/kg) was not significant.",Aging and drug interactions. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3367304/),,72.,30129,DB00252,Phenytoin
,12374451,Relapse rates,"Relapse rates were 21% for 34 patients with acute myeloid leukemia (AML) in complete remission or chronic myeloid leukemia in chronic phase (low-risk), 66% for 19 patients with high-risk AML, and 18% for 17 patients with other active malignancy.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,21,30243,DB00252,Phenytoin
,12374451,Relapse rates,"Relapse rates were 21% for 34 patients with acute myeloid leukemia (AML) in complete remission or chronic myeloid leukemia in chronic phase (low-risk), 66% for 19 patients with high-risk AML, and 18% for 17 patients with other active malignancy.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,66,30244,DB00252,Phenytoin
,12374451,Relapse rates,"Relapse rates were 21% for 34 patients with acute myeloid leukemia (AML) in complete remission or chronic myeloid leukemia in chronic phase (low-risk), 66% for 19 patients with high-risk AML, and 18% for 17 patients with other active malignancy.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,18,30245,DB00252,Phenytoin
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,74,30246,DB00252,Phenytoin
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,26,30247,DB00252,Phenytoin
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,37,30248,DB00252,Phenytoin
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,65,30249,DB00252,Phenytoin
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,88,30250,DB00252,Phenytoin
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,26,30251,DB00252,Phenytoin
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,37,30252,DB00252,Phenytoin
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,65,30253,DB00252,Phenytoin
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,71,30254,DB00252,Phenytoin
,12374451,half-lives,"Kinetics were linear, and for the first and fourth doses, the half-lives were 2.60 +/- 0.44 and 2.57 +/- 0.36 hours, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),h,2.60,30255,DB00252,Phenytoin
,12374451,half-lives,"Kinetics were linear, and for the first and fourth doses, the half-lives were 2.60 +/- 0.44 and 2.57 +/- 0.36 hours, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),h,2.57,30256,DB00252,Phenytoin
,12374451,Clearances,"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[ml] / [m2·min],106.77,30257,DB00252,Phenytoin
,12374451,Clearances,"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[ml] / [m2·min],106.86,30258,DB00252,Phenytoin
,12374451,peak concentrations (Cmax),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[mcg] / [ml],3.92,30259,DB00252,Phenytoin
,12374451,peak concentrations (Cmax),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[mcg] / [ml],3.96,30260,DB00252,Phenytoin
,12374451,areas under the plasma concentration versus time curve (AUC),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),min·μM,4866.51,30261,DB00252,Phenytoin
,12374451,areas under the plasma concentration versus time curve (AUC),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),min·μM,4980,30262,DB00252,Phenytoin
,18223475,Total body clearance,"Total body clearance of MDZ (33 L/kg) and intrinsic hepatic clearance (19 mL/min/kg) at steady state were both five to 10 times higher than after normal therapeutic doses, demonstrating hepatic cytochrome (CYP) 3A induction.",Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223475/),[l] / [kg],33,30671,DB00252,Phenytoin
,18223475,intrinsic hepatic clearance,"Total body clearance of MDZ (33 L/kg) and intrinsic hepatic clearance (19 mL/min/kg) at steady state were both five to 10 times higher than after normal therapeutic doses, demonstrating hepatic cytochrome (CYP) 3A induction.",Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223475/),[ml] / [kg·min],19,30672,DB00252,Phenytoin
,18223475,half-life,"Despite the high body clearance, the half-life of MDZ was in the range of 24 hours, approximately 10 times higher than after normal therapeutic doses.",Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223475/),h,24,30673,DB00252,Phenytoin
,18223475,volume of distribution at steady state,"The volume of distribution at steady state was 33 L/kg, approximately 50 times higher than after normal therapeutic doses.",Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223475/),[l] / [kg],33,30674,DB00252,Phenytoin
,18223475,free fraction,"The free fraction of MDZ was 58% at steady state, much higher than the 3% to 6% at normal therapeutic doses.",Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223475/),%,58,30675,DB00252,Phenytoin
,18223475,free fraction,"The free fraction of MDZ was 58% at steady state, much higher than the 3% to 6% at normal therapeutic doses.",Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223475/),%,3,30676,DB00252,Phenytoin
,18223475,free fraction,"The free fraction of MDZ was 58% at steady state, much higher than the 3% to 6% at normal therapeutic doses.",Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223475/),%,6,30677,DB00252,Phenytoin
,683430,relative degree of bioavailability,"It was found that the relative degree of bioavailability of Phenytoin in relation to Epanutin as a standard is 70,7 +/- 6,3% (SD).",[Evaluation of the bioavailability of Polfa phenytoin tablets]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/683430/),%,"70,7",30768,DB00252,Phenytoin
,25383231,AUC,"In terms of AUC, there was an increase from 2471 ± 586 to 4560 ± 1396 ng·h/mL.",Time Course of the Changes in Novel Trioxane Antimalarial 99/411 Pharmacokinetics upon Antiepileptic Drugs Co-Administration in SD Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25383231/),[h·ng] / [ml],2471,31227,DB00252,Phenytoin
,25383231,AUC,"In terms of AUC, there was an increase from 2471 ± 586 to 4560 ± 1396 ng·h/mL.",Time Course of the Changes in Novel Trioxane Antimalarial 99/411 Pharmacokinetics upon Antiepileptic Drugs Co-Administration in SD Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25383231/),[h·ng] / [ml],4560,31228,DB00252,Phenytoin
,25331445,partitioning coefficient,The partitioning coefficient describing protein binding and distribution to bound phenytoin was estimated to be 8.22.,Population pharmacokinetics of phenytoin in critically ill children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25331445/),,8.22,31387,DB00252,Phenytoin
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],302.7,31407,DB00252,Phenytoin
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],383.2,31408,DB00252,Phenytoin
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],378.9,31409,DB00252,Phenytoin
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],214.0,31410,DB00252,Phenytoin
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],1179.1,31411,DB00252,Phenytoin
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],1687.0,31412,DB00252,Phenytoin
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],2209.5,31413,DB00252,Phenytoin
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],381.7,31414,DB00252,Phenytoin
,3665340,Bioavailability,Bioavailability of prednisolone after the oral administration of prednisone and methylprednisolone ranged from 86% to 104% during anticonvulsant therapy.,Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),%,86,31415,DB00252,Phenytoin
,3665340,Bioavailability,Bioavailability of prednisolone after the oral administration of prednisone and methylprednisolone ranged from 86% to 104% during anticonvulsant therapy.,Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),%,104,31416,DB00252,Phenytoin
,9545146,Residual variability,Residual variability was 1.8 mg/L.,Population pharmacokinetics of carbamazepine in adults with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545146/),[mg] / [l],1.8,31609,DB00252,Phenytoin
,3052985,bioavailability,"The bioavailability varies between 40 and 100%: the presence of food may reduce the peak serum concentration, but does not reduce the amount of digoxin absorbed.","Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3052985/),%,40 and 100,31991,DB00252,Phenytoin
,3052985,Plasma protein binding,Plasma protein binding varies between 20 and 30%: displacement of digoxin from protein binding sites does not cause significant clinical effects.,"Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3052985/),%,20 and 30,31992,DB00252,Phenytoin
,3052985,apparent volume of distribution,"The apparent volume of distribution of digoxin varies between 5 and 7.3 L/kg; this may be reduced by, for example, electrolyte abnormalities which reduce digoxin binding to the myocardium.","Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3052985/),[l] / [kg],5 and 7.3,31993,DB00252,Phenytoin
,3052985,elimination half-life,"The elimination half-life of digoxin is 36 hours, with 60 to 80% being excreted unchanged, by passive glomerular filtration and active tubular secretion.","Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3052985/),h,36,31994,DB00252,Phenytoin
,11240597,serum concentrations,Total PHT serum concentrations 10 microg/mL were obtained in 5 min in 14.3% of patients and in 26.3% after 10 min.,Fosphenytoin: pharmacokinetics and tolerance of intramuscular loading doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240597/),[μg] / [ml],10,33517,DB00252,Phenytoin
,30940470,V,"One-compartment model with first-order elimination where allometry scaling was considered best described the data, yielding the estimates of V and CL of 68.19 (L) and 0.63 (L/h), respectively, for patients with a body weight of 60 kg.",Optimal Dosing Regimen of Phenytoin for Korean Epilepsy Patients: From Premature Babies to the Elderly. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30940470/),l,68.19,33797,DB00252,Phenytoin
,30940470,CL,"One-compartment model with first-order elimination where allometry scaling was considered best described the data, yielding the estimates of V and CL of 68.19 (L) and 0.63 (L/h), respectively, for patients with a body weight of 60 kg.",Optimal Dosing Regimen of Phenytoin for Korean Epilepsy Patients: From Premature Babies to the Elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30940470/),[l] / [h],0.63,33798,DB00252,Phenytoin
>,24947446,CL,"2. The clearance (CL) values of high CL compounds (CL > 50 mL/min/kg, namely propranolol, diazepam, phenytoin, ethinylestradiol, lorcaserin and fenfluramine) decreased significantly (1.5- to 6-fold) in DIO and AM rats as compared to lean rats, while there was no clear trend for change in CL for the low-to-moderate CL compounds (CL < 50 mL/min/kg, namely atenolol, chlorzoxazone, vancomycin and sibutramine).","Role of hepatic blood flow and metabolism in the pharmacokinetics of ten drugs in lean, aged and obese rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24947446/),[ml] / [kg·min],50,34154,DB00252,Phenytoin
<,24947446,CL,"2. The clearance (CL) values of high CL compounds (CL > 50 mL/min/kg, namely propranolol, diazepam, phenytoin, ethinylestradiol, lorcaserin and fenfluramine) decreased significantly (1.5- to 6-fold) in DIO and AM rats as compared to lean rats, while there was no clear trend for change in CL for the low-to-moderate CL compounds (CL < 50 mL/min/kg, namely atenolol, chlorzoxazone, vancomycin and sibutramine).","Role of hepatic blood flow and metabolism in the pharmacokinetics of ten drugs in lean, aged and obese rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24947446/),[ml] / [kg·min],50,34155,DB00252,Phenytoin
,7586933,peak concentration (Cmax),"Diclofenac peak concentration (Cmax) increased over time (0.28 [SD, 0.12], 0.38 [0.20], and 0.45 [0.4] mg/L on days 0, 1, and 8, respectively).",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),[mg] / [l],0.28,35122,DB00252,Phenytoin
,7586933,peak concentration (Cmax),"Diclofenac peak concentration (Cmax) increased over time (0.28 [SD, 0.12], 0.38 [0.20], and 0.45 [0.4] mg/L on days 0, 1, and 8, respectively).",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),[mg] / [l],0.38,35123,DB00252,Phenytoin
,7586933,peak concentration (Cmax),"Diclofenac peak concentration (Cmax) increased over time (0.28 [SD, 0.12], 0.38 [0.20], and 0.45 [0.4] mg/L on days 0, 1, and 8, respectively).",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),[mg] / [l],0.45,35124,DB00252,Phenytoin
,7586933,urinary metabolic ratio (MR,"A time-dependent decrease in urinary metabolic ratio (MR, 4'-hydroxydiclofenac/diclofenac) was noted (1.07 [0.34], 0.90 [0.23] and 0.70 [0.18] on days 0, 1, and 8, respectively [p < 0.0001]) for the first 4 hours.",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),,1.07,35125,DB00252,Phenytoin
,7586933,urinary metabolic ratio (MR,"A time-dependent decrease in urinary metabolic ratio (MR, 4'-hydroxydiclofenac/diclofenac) was noted (1.07 [0.34], 0.90 [0.23] and 0.70 [0.18] on days 0, 1, and 8, respectively [p < 0.0001]) for the first 4 hours.",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),,0.90,35126,DB00252,Phenytoin
,7586933,urinary metabolic ratio (MR,"A time-dependent decrease in urinary metabolic ratio (MR, 4'-hydroxydiclofenac/diclofenac) was noted (1.07 [0.34], 0.90 [0.23] and 0.70 [0.18] on days 0, 1, and 8, respectively [p < 0.0001]) for the first 4 hours.",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),,0.70,35127,DB00252,Phenytoin
,7586933,Cmax,"Fluvastatin Cmax (0.18 [0.11] and 0.32 [0.1] mg/L on days 1 and 8, respectively) and area under the curve (0.28 [0.12] and 0.43 [0.15] hr.mg/L on days 1 and 8, respectively; p < 0.001) increased over time.",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),[mg] / [l],0.18,35128,DB00252,Phenytoin
,7586933,Cmax,"Fluvastatin Cmax (0.18 [0.11] and 0.32 [0.1] mg/L on days 1 and 8, respectively) and area under the curve (0.28 [0.12] and 0.43 [0.15] hr.mg/L on days 1 and 8, respectively; p < 0.001) increased over time.",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),[mg] / [l],0.32,35129,DB00252,Phenytoin
,7586933,area under the curve,"Fluvastatin Cmax (0.18 [0.11] and 0.32 [0.1] mg/L on days 1 and 8, respectively) and area under the curve (0.28 [0.12] and 0.43 [0.15] hr.mg/L on days 1 and 8, respectively; p < 0.001) increased over time.",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),[h·mg] / [l],0.28,35130,DB00252,Phenytoin
,7586933,area under the curve,"Fluvastatin Cmax (0.18 [0.11] and 0.32 [0.1] mg/L on days 1 and 8, respectively) and area under the curve (0.28 [0.12] and 0.43 [0.15] hr.mg/L on days 1 and 8, respectively; p < 0.001) increased over time.",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),[h·mg] / [l],0.43,35131,DB00252,Phenytoin
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,105.15,35400,DB00252,Phenytoin
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,84.76,35401,DB00252,Phenytoin
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,94.45,35402,DB00252,Phenytoin
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,96.52,35403,DB00252,Phenytoin
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,98.62,35404,DB00252,Phenytoin
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,95.08,35405,DB00252,Phenytoin
,9260732,Vmax,"Comparison of slow and normal metabolizers revealed that the maximum rate of metabolism, Vmax, differed significantly between the two groups, the borderline Vmax value between the two groups being approximately 4.5-4.8 mg/kg/day.",Phenytoin kinetics in Japanese adult epileptics: phenotype of phenytoin slow metabolizers. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260732/),[mg] / [d·kg],4.5-4.8,36216,DB00252,Phenytoin
>,12959634,bioavailability,The bioavailability of the oral formulation of oxcarbazepine is high (>95%).,Clinical pharmacokinetics of oxcarbazepine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),%,95,36869,DB00252,Phenytoin
,12959634,plasma protein binding,The plasma protein binding of MHD is about 40%.,Clinical pharmacokinetics of oxcarbazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),%,40,36870,DB00252,Phenytoin
,12959634,Elimination half-lives,Elimination half-lives in healthy volunteers are 1-5 hours for oxcarbazepine and 7-20 hours for MHD.,Clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),h,1-5,36871,DB00252,Phenytoin
,12959634,Elimination half-lives,Elimination half-lives in healthy volunteers are 1-5 hours for oxcarbazepine and 7-20 hours for MHD.,Clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),h,7-20,36872,DB00252,Phenytoin
,3097715,Terminal half-lives,Terminal half-lives were 4.3 +/- 1.5 h in the patients and 4.3 +/- 1.8 h in the controls.,Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3097715/),h,4.3,37445,DB00252,Phenytoin
,3097715,Terminal half-lives,Terminal half-lives were 4.3 +/- 1.5 h in the patients and 4.3 +/- 1.8 h in the controls.,Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3097715/),h,4.3,37446,DB00252,Phenytoin
,3097715,Clearance,"Clearance and volume of distribution calculated after IV dosing in the patients were 124 +/- 11 ml h-1 kg-1 and 0.73 +/- 0.28 l/kg, respectively.",Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3097715/),[ml] / [h·kg],124,37447,DB00252,Phenytoin
,3097715,volume of distribution,"Clearance and volume of distribution calculated after IV dosing in the patients were 124 +/- 11 ml h-1 kg-1 and 0.73 +/- 0.28 l/kg, respectively.",Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3097715/),[l] / [kg],0.73,37448,DB00252,Phenytoin
,3097715,absolute oral availability,The absolute oral availability was 85 +/- 14%.,Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3097715/),%,85,37449,DB00252,Phenytoin
<,24554646,trough concentrations,"Among patients receiving 200 mg of voriconazole twice daily, predicted trough concentrations on day 7 were <2 mg/L for oral and intravenous regimens for 72% and 63% of patients without CYP2C19 LoF alleles, respectively, with 49% and 35% below this threshold with 300 mg twice daily dosing.",Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24554646/),[mg] / [l],2,37709,DB00252,Phenytoin
≥,24554646,trough concentrations,"Conversely, these regimens resulted in 29%, 39%, 57% and 77% of patients with CYP2C19 LoF alleles with voriconazole trough concentrations ≥5 mg/L.",Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24554646/),[mg] / [l],5,37710,DB00252,Phenytoin
,22406657,apparent clearance (CL/F),The apparent clearance (CL/F) of carbamazepine in this community-dwelling elderly population was estimated to be 3.59 L/h with an interindividual variability of 18.1%.,Population pharmacokinetics of carbamazepine in elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22406657/),[l] / [h],3.59,39143,DB00252,Phenytoin
,22406657,volume of distribution (V/F),The volume of distribution (V/F) was estimated to be 102 L with an interindividual variability of 74.7%.,Population pharmacokinetics of carbamazepine in elderly patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22406657/),l,102,39144,DB00252,Phenytoin
,3608344,half-life,The half-life of nafimidone was 1.34 +/- 0.48 hours after a 100mg single dose and 1.69 +/- 0.91 hours after a 300mg single dose.,Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608344/),h,1.34,40410,DB00252,Phenytoin
,3608344,half-life,The half-life of nafimidone was 1.34 +/- 0.48 hours after a 100mg single dose and 1.69 +/- 0.91 hours after a 300mg single dose.,Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608344/),h,1.69,40411,DB00252,Phenytoin
,3608344,half-life,"However, the half-life of nafimidone alcohol increased from 2.84 +/- 0.72 hours after a 100mg single dose to 4.22 +/- 1.09 hours after a 300mg single dose (p less than 0.02).",Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608344/),h,2.84,40412,DB00252,Phenytoin
,3608344,half-life,"However, the half-life of nafimidone alcohol increased from 2.84 +/- 0.72 hours after a 100mg single dose to 4.22 +/- 1.09 hours after a 300mg single dose (p less than 0.02).",Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608344/),h,4.22,40413,DB00252,Phenytoin
,3608344,clearance,The clearance of nafimidone was 43.56 +/- 22.11 L/h/kg after a 100mg single dose and 35.51 +/- 28.93 L/h/kg after the 300mg single dose.,Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608344/),[l] / [h·kg],43.56,40414,DB00252,Phenytoin
,3608344,clearance,The clearance of nafimidone was 43.56 +/- 22.11 L/h/kg after a 100mg single dose and 35.51 +/- 28.93 L/h/kg after the 300mg single dose.,Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608344/),[l] / [h·kg],35.51,40415,DB00252,Phenytoin
,3608344,apparent volumes of distribution,The respective apparent volumes of distribution of nafimidone after single 100 and 300mg doses were 80.78 +/- 46.11 L/kg and 71.01 +/- 36.86 L/kg.,Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608344/),[l] / [kg],80.78,40416,DB00252,Phenytoin
,3608344,apparent volumes of distribution,The respective apparent volumes of distribution of nafimidone after single 100 and 300mg doses were 80.78 +/- 46.11 L/kg and 71.01 +/- 36.86 L/kg.,Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608344/),[l] / [kg],71.01,40417,DB00252,Phenytoin
,3608344,half-life,"After short term (9 to 10 weeks) and long term (127 to 152 weeks) maintenance therapy on nafimidone 600mg per day the half-life of nafimidone alcohol was 2.23 +/- 0.36 hours and 2.16 +/- 0.60 hours, respectively.",Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608344/),h,2.23,40418,DB00252,Phenytoin
,3608344,half-life,"After short term (9 to 10 weeks) and long term (127 to 152 weeks) maintenance therapy on nafimidone 600mg per day the half-life of nafimidone alcohol was 2.23 +/- 0.36 hours and 2.16 +/- 0.60 hours, respectively.",Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608344/),h,2.16,40419,DB00252,Phenytoin
,6723598,peak concentration,"It was found that the peak concentration in serum was 8 micrograms/ml 1 h postadministration , with little variation being noted for up to 8 h.",Serum concentrations of phenytoin after oral administration in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723598/),[μg] / [ml],8,40983,DB00252,Phenytoin
,8403961,plasma concentration,Each patient received phenytoin sufficient to maintain a plasma concentration at 15 micrograms/mL (60 mumol/L) both before and after barbiturate therapy.,Effect of barbiturate therapy on phenytoin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),[μg] / [ml],15,40986,DB00252,Phenytoin
,8403961,maximum metabolic velocity,"For total phenytoin, maximum metabolic velocity was increased by 62% (1.09 +/- 0.62 to 1.77 +/- 0.52 mg/L/hr, 1.20 +/- 0.68 to 1.95 +/- 0.57 nmol/L/sec, p < .05), and area under the plasma concentration-time curve (0 to infinity) and mean residence time were each decreased by 73% (32.5 +/- 20.0 to 8.7 +/- 3.1 min.mg/mL, 2.14 +/- 1.25 to 0.57 +/- 0.19 sec.mmol/L, p < .01, and 135,000 +/- 69,000 to 37,000 +/- 11,000 secs, p < .005, respectively) after barbiturate therapy.",Effect of barbiturate therapy on phenytoin pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),[mg] / [h·l],1.09,40987,DB00252,Phenytoin
,8403961,maximum metabolic velocity,"For total phenytoin, maximum metabolic velocity was increased by 62% (1.09 +/- 0.62 to 1.77 +/- 0.52 mg/L/hr, 1.20 +/- 0.68 to 1.95 +/- 0.57 nmol/L/sec, p < .05), and area under the plasma concentration-time curve (0 to infinity) and mean residence time were each decreased by 73% (32.5 +/- 20.0 to 8.7 +/- 3.1 min.mg/mL, 2.14 +/- 1.25 to 0.57 +/- 0.19 sec.mmol/L, p < .01, and 135,000 +/- 69,000 to 37,000 +/- 11,000 secs, p < .005, respectively) after barbiturate therapy.",Effect of barbiturate therapy on phenytoin pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),[mg] / [h·l],1.77,40988,DB00252,Phenytoin
,8403961,maximum metabolic velocity,"For total phenytoin, maximum metabolic velocity was increased by 62% (1.09 +/- 0.62 to 1.77 +/- 0.52 mg/L/hr, 1.20 +/- 0.68 to 1.95 +/- 0.57 nmol/L/sec, p < .05), and area under the plasma concentration-time curve (0 to infinity) and mean residence time were each decreased by 73% (32.5 +/- 20.0 to 8.7 +/- 3.1 min.mg/mL, 2.14 +/- 1.25 to 0.57 +/- 0.19 sec.mmol/L, p < .01, and 135,000 +/- 69,000 to 37,000 +/- 11,000 secs, p < .005, respectively) after barbiturate therapy.",Effect of barbiturate therapy on phenytoin pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),[nM] / [l·s],1.20,40989,DB00252,Phenytoin
,8403961,maximum metabolic velocity,"For total phenytoin, maximum metabolic velocity was increased by 62% (1.09 +/- 0.62 to 1.77 +/- 0.52 mg/L/hr, 1.20 +/- 0.68 to 1.95 +/- 0.57 nmol/L/sec, p < .05), and area under the plasma concentration-time curve (0 to infinity) and mean residence time were each decreased by 73% (32.5 +/- 20.0 to 8.7 +/- 3.1 min.mg/mL, 2.14 +/- 1.25 to 0.57 +/- 0.19 sec.mmol/L, p < .01, and 135,000 +/- 69,000 to 37,000 +/- 11,000 secs, p < .005, respectively) after barbiturate therapy.",Effect of barbiturate therapy on phenytoin pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),[nM] / [l·s],1.95,40990,DB00252,Phenytoin
,8403961,area under the plasma concentration-time curve (0 to infinity),"For total phenytoin, maximum metabolic velocity was increased by 62% (1.09 +/- 0.62 to 1.77 +/- 0.52 mg/L/hr, 1.20 +/- 0.68 to 1.95 +/- 0.57 nmol/L/sec, p < .05), and area under the plasma concentration-time curve (0 to infinity) and mean residence time were each decreased by 73% (32.5 +/- 20.0 to 8.7 +/- 3.1 min.mg/mL, 2.14 +/- 1.25 to 0.57 +/- 0.19 sec.mmol/L, p < .01, and 135,000 +/- 69,000 to 37,000 +/- 11,000 secs, p < .005, respectively) after barbiturate therapy.",Effect of barbiturate therapy on phenytoin pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),[mg·min] / [ml],32.5,40991,DB00252,Phenytoin
,8403961,area under the plasma concentration-time curve (0 to infinity),"For total phenytoin, maximum metabolic velocity was increased by 62% (1.09 +/- 0.62 to 1.77 +/- 0.52 mg/L/hr, 1.20 +/- 0.68 to 1.95 +/- 0.57 nmol/L/sec, p < .05), and area under the plasma concentration-time curve (0 to infinity) and mean residence time were each decreased by 73% (32.5 +/- 20.0 to 8.7 +/- 3.1 min.mg/mL, 2.14 +/- 1.25 to 0.57 +/- 0.19 sec.mmol/L, p < .01, and 135,000 +/- 69,000 to 37,000 +/- 11,000 secs, p < .005, respectively) after barbiturate therapy.",Effect of barbiturate therapy on phenytoin pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),[mg·min] / [ml],8.7,40992,DB00252,Phenytoin
,8403961,mean residence time,"For total phenytoin, maximum metabolic velocity was increased by 62% (1.09 +/- 0.62 to 1.77 +/- 0.52 mg/L/hr, 1.20 +/- 0.68 to 1.95 +/- 0.57 nmol/L/sec, p < .05), and area under the plasma concentration-time curve (0 to infinity) and mean residence time were each decreased by 73% (32.5 +/- 20.0 to 8.7 +/- 3.1 min.mg/mL, 2.14 +/- 1.25 to 0.57 +/- 0.19 sec.mmol/L, p < .01, and 135,000 +/- 69,000 to 37,000 +/- 11,000 secs, p < .005, respectively) after barbiturate therapy.",Effect of barbiturate therapy on phenytoin pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),[mg·min] / [ml],8.7,40993,DB00252,Phenytoin
,8403961,mean residence time,"For total phenytoin, maximum metabolic velocity was increased by 62% (1.09 +/- 0.62 to 1.77 +/- 0.52 mg/L/hr, 1.20 +/- 0.68 to 1.95 +/- 0.57 nmol/L/sec, p < .05), and area under the plasma concentration-time curve (0 to infinity) and mean residence time were each decreased by 73% (32.5 +/- 20.0 to 8.7 +/- 3.1 min.mg/mL, 2.14 +/- 1.25 to 0.57 +/- 0.19 sec.mmol/L, p < .01, and 135,000 +/- 69,000 to 37,000 +/- 11,000 secs, p < .005, respectively) after barbiturate therapy.",Effect of barbiturate therapy on phenytoin pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),[mM·s] / [l],2.14,40994,DB00252,Phenytoin
,8403961,mean residence time,"For total phenytoin, maximum metabolic velocity was increased by 62% (1.09 +/- 0.62 to 1.77 +/- 0.52 mg/L/hr, 1.20 +/- 0.68 to 1.95 +/- 0.57 nmol/L/sec, p < .05), and area under the plasma concentration-time curve (0 to infinity) and mean residence time were each decreased by 73% (32.5 +/- 20.0 to 8.7 +/- 3.1 min.mg/mL, 2.14 +/- 1.25 to 0.57 +/- 0.19 sec.mmol/L, p < .01, and 135,000 +/- 69,000 to 37,000 +/- 11,000 secs, p < .005, respectively) after barbiturate therapy.",Effect of barbiturate therapy on phenytoin pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),[mM·s] / [l],0.57,40995,DB00252,Phenytoin
,8403961,mean residence time,"For total phenytoin, maximum metabolic velocity was increased by 62% (1.09 +/- 0.62 to 1.77 +/- 0.52 mg/L/hr, 1.20 +/- 0.68 to 1.95 +/- 0.57 nmol/L/sec, p < .05), and area under the plasma concentration-time curve (0 to infinity) and mean residence time were each decreased by 73% (32.5 +/- 20.0 to 8.7 +/- 3.1 min.mg/mL, 2.14 +/- 1.25 to 0.57 +/- 0.19 sec.mmol/L, p < .01, and 135,000 +/- 69,000 to 37,000 +/- 11,000 secs, p < .005, respectively) after barbiturate therapy.",Effect of barbiturate therapy on phenytoin pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),secs,"135,000",40996,DB00252,Phenytoin
,8403961,mean residence time,"For total phenytoin, maximum metabolic velocity was increased by 62% (1.09 +/- 0.62 to 1.77 +/- 0.52 mg/L/hr, 1.20 +/- 0.68 to 1.95 +/- 0.57 nmol/L/sec, p < .05), and area under the plasma concentration-time curve (0 to infinity) and mean residence time were each decreased by 73% (32.5 +/- 20.0 to 8.7 +/- 3.1 min.mg/mL, 2.14 +/- 1.25 to 0.57 +/- 0.19 sec.mmol/L, p < .01, and 135,000 +/- 69,000 to 37,000 +/- 11,000 secs, p < .005, respectively) after barbiturate therapy.",Effect of barbiturate therapy on phenytoin pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),secs,"37,000",40997,DB00252,Phenytoin
,7128675,half-lives,"After IV PB distributive half-lives were 75 to 126 h, steady state volume of distribution (Vss) was 0.54 +/- 0.03 l/kg, and clearance (CL) was 3.8 +/- 0.77 ml/h/kg.",Kinetics of phenobarbital in normal subjects and epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128675/),h,75 to 126,41767,DB00252,Phenytoin
,7128675,steady state volume of distribution (Vss),"After IV PB distributive half-lives were 75 to 126 h, steady state volume of distribution (Vss) was 0.54 +/- 0.03 l/kg, and clearance (CL) was 3.8 +/- 0.77 ml/h/kg.",Kinetics of phenobarbital in normal subjects and epileptic patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128675/),[l] / [kg],0.54,41768,DB00252,Phenytoin
,7128675,clearance (CL),"After IV PB distributive half-lives were 75 to 126 h, steady state volume of distribution (Vss) was 0.54 +/- 0.03 l/kg, and clearance (CL) was 3.8 +/- 0.77 ml/h/kg.",Kinetics of phenobarbital in normal subjects and epileptic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128675/),[ml] / [h·kg],3.8,41769,DB00252,Phenytoin
,7128675,Absolute bioavailability,Absolute bioavailability of IM PB was 101 +/- 11%.,Kinetics of phenobarbital in normal subjects and epileptic patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128675/),%,101,41770,DB00252,Phenytoin
,7128675,disposition half-lives,"Epileptic patients exhibited similar PB kinetics: disposition half-lives were 77 to 128 h, Vss 0.61 +/- 0.05 l/kg, and Cl 3.9 +/- 0.76 ml/h/kg.",Kinetics of phenobarbital in normal subjects and epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128675/),h,77 to 128,41771,DB00252,Phenytoin
,7128675,Vss,"Epileptic patients exhibited similar PB kinetics: disposition half-lives were 77 to 128 h, Vss 0.61 +/- 0.05 l/kg, and Cl 3.9 +/- 0.76 ml/h/kg.",Kinetics of phenobarbital in normal subjects and epileptic patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128675/),[l] / [kg],0.61,41772,DB00252,Phenytoin
,7128675,Cl,"Epileptic patients exhibited similar PB kinetics: disposition half-lives were 77 to 128 h, Vss 0.61 +/- 0.05 l/kg, and Cl 3.9 +/- 0.76 ml/h/kg.",Kinetics of phenobarbital in normal subjects and epileptic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128675/),[ml] / [h·kg],3.9,41773,DB00252,Phenytoin
,11740344,elimination half-life,She exhibited extremely poor clearance of phenytoin with an elimination half-life of approximately 13 days.,Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11740344/),d,13,42025,DB00252,Phenytoin
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1404,43042,DB00252,Phenytoin
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1374,43043,DB00252,Phenytoin
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1400,43044,DB00252,Phenytoin
,18781906,trough levels,"Mean trough levels of imatinib were reduced up to 2.9-fold (477 ng/ml, CV 70%) in patients treated with EIAEDs.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],477,43045,DB00252,Phenytoin
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],240,43046,DB00252,Phenytoin
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],351,43047,DB00252,Phenytoin
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],356,43048,DB00252,Phenytoin
,19943867,maximum total dosage,Nine patients received 20 mg/kg; the maximum total dosage administered was 80 mg/kg with a concentration of 283 micromol/L.,Rescue therapy with high-dose oral phenobarbitone loading for refractory status epilepticus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19943867/),[mg] / [kg],80,43527,DB00252,Phenytoin
,19943867,volume of distribution,"The typical population value of the volume of distribution was 1.2 (95% confidence interval (CI): 0.8-1.6) L/kg with interindividual variability (as coefficient of variation) of 53% (95% CI, 9-74%).",Rescue therapy with high-dose oral phenobarbitone loading for refractory status epilepticus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19943867/),[l] / [kg],1.2,43528,DB00252,Phenytoin
,29095797,CD ratio,The mean CD ratio of perampanel was 1740 ± 966 ng·mL·mg·kg in the 17 patients with normal renal function using phenytoin.,Influence of Renal Function on Pharmacokinetics of Antiepileptic Drugs Metabolized by CYP3A4 in a Patient With Renal Impairment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29095797/),kg·mg·ml·ng,1740,43752,DB00252,Phenytoin
,29095797,CD ratio,"By contrast, the CD ratio of perampanel was markedly higher (range: 5327-9113 ng·mL·mg·kg) in the patient with renal impairment (CCr: <20 mL/min).",Influence of Renal Function on Pharmacokinetics of Antiepileptic Drugs Metabolized by CYP3A4 in a Patient With Renal Impairment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29095797/),kg·mg·ml·ng,5327-9113,43753,DB00252,Phenytoin
,2253670,Kmax,"Kmax and KM were estimated to be 30.72 mg.kg-0.656 day-1 and 2.307 mg.l-1, respectively.",Population pharmacokinetics of phenytoin in Singapore Chinese. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253670/),[mg] / [(kg)^0],30.72,44845,DB00252,Phenytoin
,2253670,KM,"Kmax and KM were estimated to be 30.72 mg.kg-0.656 day-1 and 2.307 mg.l-1, respectively.",Population pharmacokinetics of phenytoin in Singapore Chinese. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253670/),[mg] / [l],2.307,44846,DB00252,Phenytoin
,18503564,elimination half-life,"During repeated dosing, steady state is reached within 2 days, consistent with its elimination half-life of 6-10 h.",Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18503564/),h,6-10,45117,DB00252,Phenytoin
,1425879,unbound fraction,"The unbound fraction of phenytoin was 0.082, 0.085, and 0.077 in the control, single-dose CBZ, multi-dose CBZ phases, respectively.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),,0.082,46344,DB00252,Phenytoin
,1425879,unbound fraction,"The unbound fraction of phenytoin was 0.082, 0.085, and 0.077 in the control, single-dose CBZ, multi-dose CBZ phases, respectively.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),,0.085,46345,DB00252,Phenytoin
,1425879,unbound fraction,"The unbound fraction of phenytoin was 0.082, 0.085, and 0.077 in the control, single-dose CBZ, multi-dose CBZ phases, respectively.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),,0.077,46346,DB00252,Phenytoin
,1425879,AUC,"The 72-h AUC of phenytoin was 276, 237, and 176 mg h.l-1 in the 3 phases, respectively, and the 72-h AUC of unbound phenytoin was 22.8, 20.5, 13.0 mg h.l-1.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),[h·mg] / [l],276,46347,DB00252,Phenytoin
,1425879,AUC,"The 72-h AUC of phenytoin was 276, 237, and 176 mg h.l-1 in the 3 phases, respectively, and the 72-h AUC of unbound phenytoin was 22.8, 20.5, 13.0 mg h.l-1.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),[h·mg] / [l],237,46348,DB00252,Phenytoin
,1425879,AUC,"The 72-h AUC of phenytoin was 276, 237, and 176 mg h.l-1 in the 3 phases, respectively, and the 72-h AUC of unbound phenytoin was 22.8, 20.5, 13.0 mg h.l-1.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),[h·mg] / [l],176,46349,DB00252,Phenytoin
,1425879,AUC,"The 72-h AUC of phenytoin was 276, 237, and 176 mg h.l-1 in the 3 phases, respectively, and the 72-h AUC of unbound phenytoin was 22.8, 20.5, 13.0 mg h.l-1.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),[h·mg] / [l],22.8,46350,DB00252,Phenytoin
,1425879,AUC,"The 72-h AUC of phenytoin was 276, 237, and 176 mg h.l-1 in the 3 phases, respectively, and the 72-h AUC of unbound phenytoin was 22.8, 20.5, 13.0 mg h.l-1.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),[h·mg] / [l],20.5,46351,DB00252,Phenytoin
,1425879,AUC,"The 72-h AUC of phenytoin was 276, 237, and 176 mg h.l-1 in the 3 phases, respectively, and the 72-h AUC of unbound phenytoin was 22.8, 20.5, 13.0 mg h.l-1.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),[h·mg] / [l],13.0,46352,DB00252,Phenytoin
,1425879,apparent volume of distribution (Vz/f),"The apparent volume of distribution (Vz/f) was 89.9, 110.3, and 121.3 l in the 3 phases, respectively.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),l,89.9,46353,DB00252,Phenytoin
,1425879,apparent volume of distribution (Vz/f),"The apparent volume of distribution (Vz/f) was 89.9, 110.3, and 121.3 l in the 3 phases, respectively.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),l,110.3,46354,DB00252,Phenytoin
,1425879,apparent volume of distribution (Vz/f),"The apparent volume of distribution (Vz/f) was 89.9, 110.3, and 121.3 l in the 3 phases, respectively.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),l,121.3,46355,DB00252,Phenytoin
,3161430,total duration of,"Similarly, the total duration of neuromuscular blockade, measured to recovery to 90% of control ECEMG, was significantly shorter in the phenytoin group (122 +/- 25 min compared with 269 +/- 64 min in the control group, P less than 0.01).",Resistance to metocurine-induced neuromuscular blockade in patients receiving phenytoin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3161430/),min,122,46564,DB00252,Phenytoin
,3161430,total duration of,"Similarly, the total duration of neuromuscular blockade, measured to recovery to 90% of control ECEMG, was significantly shorter in the phenytoin group (122 +/- 25 min compared with 269 +/- 64 min in the control group, P less than 0.01).",Resistance to metocurine-induced neuromuscular blockade in patients receiving phenytoin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3161430/),min,269,46565,DB00252,Phenytoin
,7656504,plasma elimination half-life (t1/2),Mean plasma elimination half-life (t1/2) is between 1.3 and 2.1 hours in healthy volunteers.,Clinical pharmacokinetics of lansoprazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7656504/),h,1.3 and 2.1,47682,DB00252,Phenytoin
,3656062,exsorption rate,"The exsorption rate of the drug at the dose of 10 mg/kg was 1.1% in 120 min, while that at 50 mg/kg was 2.5% in 120 min.",The intestinal dialysis of intravenously administered phenytoin by oral activated charcoal in rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3656062/),%,1.1,48730,DB00252,Phenytoin
,3656062,exsorption rate,"The exsorption rate of the drug at the dose of 10 mg/kg was 1.1% in 120 min, while that at 50 mg/kg was 2.5% in 120 min.",The intestinal dialysis of intravenously administered phenytoin by oral activated charcoal in rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3656062/),%,2.5,48731,DB00252,Phenytoin
,25447695,LOQ,"LOQ and LOD were 1.0mg/l and 0.3mg/l, respectively.",Dried blood spot assay for the quantification of phenytoin using Liquid Chromatography-Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25447695/),[mg] / [l],1.0,49690,DB00252,Phenytoin
,25447695,LOD,"LOQ and LOD were 1.0mg/l and 0.3mg/l, respectively.",Dried blood spot assay for the quantification of phenytoin using Liquid Chromatography-Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25447695/),[mg] / [l],0.3,49691,DB00252,Phenytoin
,25447695,recovery,The recovery ranged from 85 to 90%; PHT in DBS showed to be stable at different storage temperatures for one month.,Dried blood spot assay for the quantification of phenytoin using Liquid Chromatography-Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25447695/),%,85 to 90,49692,DB00252,Phenytoin
,11802095,CL/F,Population estimates of CL/F and V/F for lamotrigine generated in the final model were 2.14 +/- 0.81 L/h and 78.1 +/- 5.1 L/kg.,Population pharmacokinetics of lamotrigine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11802095/),[l] / [h],2.14,51797,DB00252,Phenytoin
,11802095,V/F,Population estimates of CL/F and V/F for lamotrigine generated in the final model were 2.14 +/- 0.81 L/h and 78.1 +/- 5.1 L/kg.,Population pharmacokinetics of lamotrigine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11802095/),[l] / [kg],78.1,51798,DB00252,Phenytoin
,6403891,accumulation half-life,"N-desmethylmethsuximide was the principal substance detected in plasma and had the following pharmacokinetic values: accumulation half-life, 49.7 hours; time to steady state, 10.4 days; elimination half-life, 72.2 hours; therapeutic range of plasma concentration, 10 to 30 mg per liter.","Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6403891/),h,49.7,52153,DB00252,Phenytoin
,6403891,time to steady state,"N-desmethylmethsuximide was the principal substance detected in plasma and had the following pharmacokinetic values: accumulation half-life, 49.7 hours; time to steady state, 10.4 days; elimination half-life, 72.2 hours; therapeutic range of plasma concentration, 10 to 30 mg per liter.","Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6403891/),d,10.4,52154,DB00252,Phenytoin
,6403891,elimination half-life,"N-desmethylmethsuximide was the principal substance detected in plasma and had the following pharmacokinetic values: accumulation half-life, 49.7 hours; time to steady state, 10.4 days; elimination half-life, 72.2 hours; therapeutic range of plasma concentration, 10 to 30 mg per liter.","Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6403891/),h,72.2,52155,DB00252,Phenytoin
,6832191,oral bioavailability,"Unlike the previously published mean figure of 0.78 for the oral bioavailability of the drug given in single doses to healthy volunteers, the mean bioavailability of dexamethasone in the patients studied was 0.53 +/- SD 0.40.",Bioavailability of oral dexamethasone during high dose steroid therapy in neurological patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832191/),,0.78,52501,DB00252,Phenytoin
,6832191,bioavailability,"Unlike the previously published mean figure of 0.78 for the oral bioavailability of the drug given in single doses to healthy volunteers, the mean bioavailability of dexamethasone in the patients studied was 0.53 +/- SD 0.40.",Bioavailability of oral dexamethasone during high dose steroid therapy in neurological patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832191/),,0.53,52502,DB00252,Phenytoin
,6832191,clearance,"The intravenous clearance of the drug was relatively high (0.4902 +/- SD 2291 1 kg-1, approximately 65% of expected hepatic plasma flow), the oral clearance higher (2.5804 +/- SD 3.2181 1 kg-1 h-1) while the absorption rate constant (4.8729 +/- 8.4998 h-1), suggested rapid absorption after oral administration.",Bioavailability of oral dexamethasone during high dose steroid therapy in neurological patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832191/),[1] / [kg],0.4902,52503,DB00252,Phenytoin
,6832191,oral clearance,"The intravenous clearance of the drug was relatively high (0.4902 +/- SD 2291 1 kg-1, approximately 65% of expected hepatic plasma flow), the oral clearance higher (2.5804 +/- SD 3.2181 1 kg-1 h-1) while the absorption rate constant (4.8729 +/- 8.4998 h-1), suggested rapid absorption after oral administration.",Bioavailability of oral dexamethasone during high dose steroid therapy in neurological patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832191/),[1] / [h·kg],2.5804,52504,DB00252,Phenytoin
,6832191,absorption rate constant,"The intravenous clearance of the drug was relatively high (0.4902 +/- SD 2291 1 kg-1, approximately 65% of expected hepatic plasma flow), the oral clearance higher (2.5804 +/- SD 3.2181 1 kg-1 h-1) while the absorption rate constant (4.8729 +/- 8.4998 h-1), suggested rapid absorption after oral administration.",Bioavailability of oral dexamethasone during high dose steroid therapy in neurological patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832191/),1/[h],4.8729,52505,DB00252,Phenytoin
,29927880,serum concentrations,"Mean serum concentrations of 17.5 ± 7.8 mg/L were at a median 4.2 hours (interquartile range, 2.5-7.8 hr) after a dose.",Fosphenytoin Population Pharmacokinetics in the Acutely Ill Pediatric Population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29927880/),[mg] / [l],17.5,52777,DB00252,Phenytoin
,33336359,total plasma concentrations,"The total plasma concentrations ranged from 69 to 151.3 μg/mL for LEV, 11.3 to 26.7 μg/mL for PHT and 126 to 223 μg/mL for VPA.","Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336359/),[μg] / [ml],69 to 151.3,52778,DB00252,Phenytoin
,33336359,total plasma concentrations,"The total plasma concentrations ranged from 69 to 151.3 μg/mL for LEV, 11.3 to 26.7 μg/mL for PHT and 126 to 223 μg/mL for VPA.","Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336359/),[μg] / [ml],11.3 to 26.7,52779,DB00252,Phenytoin
,33336359,total plasma concentrations,"The total plasma concentrations ranged from 69 to 151.3 μg/mL for LEV, 11.3 to 26.7 μg/mL for PHT and 126 to 223 μg/mL for VPA.","Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336359/),[μg] / [ml],126 to 223,52780,DB00252,Phenytoin
,33336359,Free fraction,Free fraction ranged from 4% to 19% for PHT and 17% to 51% for VPA.,"Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336359/),%,4,52781,DB00252,Phenytoin
,33336359,Free fraction,Free fraction ranged from 4% to 19% for PHT and 17% to 51% for VPA.,"Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336359/),%,19,52782,DB00252,Phenytoin
,33336359,Free fraction,Free fraction ranged from 4% to 19% for PHT and 17% to 51% for VPA.,"Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336359/),%,17,52783,DB00252,Phenytoin
,33336359,Free fraction,Free fraction ranged from 4% to 19% for PHT and 17% to 51% for VPA.,"Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336359/),%,51,52784,DB00252,Phenytoin
,2612061,Ratios of clearance,"2. Ratios of clearance of PHT, p-OH-PHT and p-OH-PHT-glucuronide to clearance of antipyrine were 1.08 +/- 0.03, 0.52 +/- 0.02 and 0.12 +/- 0.01 (mean and s.e.m.), respectively.","Maternofetal transfer of phenytoin, p-hydroxy-phenytoin and p-hydroxy-phenytoin-glucuronide in the perfused human placenta. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612061/),,1.08,53357,DB00252,Phenytoin
,2612061,Ratios of clearance,"2. Ratios of clearance of PHT, p-OH-PHT and p-OH-PHT-glucuronide to clearance of antipyrine were 1.08 +/- 0.03, 0.52 +/- 0.02 and 0.12 +/- 0.01 (mean and s.e.m.), respectively.","Maternofetal transfer of phenytoin, p-hydroxy-phenytoin and p-hydroxy-phenytoin-glucuronide in the perfused human placenta. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612061/),,0.52,53358,DB00252,Phenytoin
,2612061,Ratios of clearance,"2. Ratios of clearance of PHT, p-OH-PHT and p-OH-PHT-glucuronide to clearance of antipyrine were 1.08 +/- 0.03, 0.52 +/- 0.02 and 0.12 +/- 0.01 (mean and s.e.m.), respectively.","Maternofetal transfer of phenytoin, p-hydroxy-phenytoin and p-hydroxy-phenytoin-glucuronide in the perfused human placenta. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612061/),,0.12,53359,DB00252,Phenytoin
,2741186,partition ratio,"In vitro, the partition ratio of DPH in a system of erythrocytes in plasma water was 4.5 at concentrations between 0.8 and 100.8 micrograms DPH/ml.",Distribution of drugs over whole blood: II. The transport function of whole blood for phenytoin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741186/),,4.5,53426,DB00252,Phenytoin
,2741186,elimination half-life,"In vivo, the elimination half-life of DPH in erythrocytes was 21.4 h and in plasma proteins 67.9 h.",Distribution of drugs over whole blood: II. The transport function of whole blood for phenytoin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741186/),h,21.4,53427,DB00252,Phenytoin
,2741186,elimination half-life,"In vivo, the elimination half-life of DPH in erythrocytes was 21.4 h and in plasma proteins 67.9 h.",Distribution of drugs over whole blood: II. The transport function of whole blood for phenytoin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741186/),h,67.9,53428,DB00252,Phenytoin
,22171585,CL/F,"Eslicarbazepine CL/F was affected by bodyweight, dose of carbamazepine (D(CAR)) and co-administration of barbiturates or phenytoin (AED(PB)), as predicted by the equation CL/F = (2.36 + 0.00149 • D(CAR) + 1.41 • AED(PB)) • (weight/70)0.75, which means that CL/F is 2.36 L/h for a subject with a bodyweight of 70 kg and without concomitant carbamazepine and barbiturates/phenytoin.","Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22171585/),[l] / [h],2.36,53544,DB00252,Phenytoin
,627139,saliva/plasma ratio,The saliva/plasma ratio for CBZ concentration was 0.26 +/- 0.01 (SD).,"Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/627139/),,0.26,53852,DB00252,Phenytoin
,627139,binding,"Since CBZ binding to plasma proteins is in the order of 76%, saliva CBZ concentration seems to reflect the unbound fraction of the drug in plasma.","Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/627139/),%,76,53853,DB00252,Phenytoin
,6653035,Vmax,"Mean Vmax and Km values were 13.95 mg/kg/day and 6.59 micrograms/ml for 0.5 to 3-year-old patients, 10.93 mg/kg/day and 6.82 micrograms/ml for the 4 to 6 year age group, 10.05 mg/kg/day and 6.51 micrograms/ml for the 7 to 9-year-olds, and 8.25 mg/kg/day and 5.69 micrograms/ml for the 10 to 16 year group.",Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653035/),[mg] / [d·kg],13.95,54172,DB00252,Phenytoin
,6653035,Vmax,"Mean Vmax and Km values were 13.95 mg/kg/day and 6.59 micrograms/ml for 0.5 to 3-year-old patients, 10.93 mg/kg/day and 6.82 micrograms/ml for the 4 to 6 year age group, 10.05 mg/kg/day and 6.51 micrograms/ml for the 7 to 9-year-olds, and 8.25 mg/kg/day and 5.69 micrograms/ml for the 10 to 16 year group.",Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653035/),[μg] / [ml],6.59,54173,DB00252,Phenytoin
,6653035,Vmax,"Mean Vmax and Km values were 13.95 mg/kg/day and 6.59 micrograms/ml for 0.5 to 3-year-old patients, 10.93 mg/kg/day and 6.82 micrograms/ml for the 4 to 6 year age group, 10.05 mg/kg/day and 6.51 micrograms/ml for the 7 to 9-year-olds, and 8.25 mg/kg/day and 5.69 micrograms/ml for the 10 to 16 year group.",Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653035/),[mg] / [d·kg],10.93,54174,DB00252,Phenytoin
,6653035,Vmax,"Mean Vmax and Km values were 13.95 mg/kg/day and 6.59 micrograms/ml for 0.5 to 3-year-old patients, 10.93 mg/kg/day and 6.82 micrograms/ml for the 4 to 6 year age group, 10.05 mg/kg/day and 6.51 micrograms/ml for the 7 to 9-year-olds, and 8.25 mg/kg/day and 5.69 micrograms/ml for the 10 to 16 year group.",Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653035/),[mg] / [d·kg],10.05,54175,DB00252,Phenytoin
,6653035,Vmax,"Mean Vmax and Km values were 13.95 mg/kg/day and 6.59 micrograms/ml for 0.5 to 3-year-old patients, 10.93 mg/kg/day and 6.82 micrograms/ml for the 4 to 6 year age group, 10.05 mg/kg/day and 6.51 micrograms/ml for the 7 to 9-year-olds, and 8.25 mg/kg/day and 5.69 micrograms/ml for the 10 to 16 year group.",Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653035/),[mg] / [d·kg],8.25,54176,DB00252,Phenytoin
,6653035,Vmax,"Mean Vmax and Km values were 13.95 mg/kg/day and 6.59 micrograms/ml for 0.5 to 3-year-old patients, 10.93 mg/kg/day and 6.82 micrograms/ml for the 4 to 6 year age group, 10.05 mg/kg/day and 6.51 micrograms/ml for the 7 to 9-year-olds, and 8.25 mg/kg/day and 5.69 micrograms/ml for the 10 to 16 year group.",Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653035/),[μg] / [ml],5.69,54177,DB00252,Phenytoin
,6653035,Km,"Mean Vmax and Km values were 13.95 mg/kg/day and 6.59 micrograms/ml for 0.5 to 3-year-old patients, 10.93 mg/kg/day and 6.82 micrograms/ml for the 4 to 6 year age group, 10.05 mg/kg/day and 6.51 micrograms/ml for the 7 to 9-year-olds, and 8.25 mg/kg/day and 5.69 micrograms/ml for the 10 to 16 year group.",Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653035/),[μg] / [ml],6.59,54178,DB00252,Phenytoin
,6653035,Km,"Mean Vmax and Km values were 13.95 mg/kg/day and 6.59 micrograms/ml for 0.5 to 3-year-old patients, 10.93 mg/kg/day and 6.82 micrograms/ml for the 4 to 6 year age group, 10.05 mg/kg/day and 6.51 micrograms/ml for the 7 to 9-year-olds, and 8.25 mg/kg/day and 5.69 micrograms/ml for the 10 to 16 year group.",Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653035/),[mg] / [d·kg],10.05,54179,DB00252,Phenytoin
,6653035,Km,"Mean Vmax and Km values were 13.95 mg/kg/day and 6.59 micrograms/ml for 0.5 to 3-year-old patients, 10.93 mg/kg/day and 6.82 micrograms/ml for the 4 to 6 year age group, 10.05 mg/kg/day and 6.51 micrograms/ml for the 7 to 9-year-olds, and 8.25 mg/kg/day and 5.69 micrograms/ml for the 10 to 16 year group.",Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653035/),[μg] / [ml],6.51,54180,DB00252,Phenytoin
,6653035,Km,"Mean Vmax and Km values were 13.95 mg/kg/day and 6.59 micrograms/ml for 0.5 to 3-year-old patients, 10.93 mg/kg/day and 6.82 micrograms/ml for the 4 to 6 year age group, 10.05 mg/kg/day and 6.51 micrograms/ml for the 7 to 9-year-olds, and 8.25 mg/kg/day and 5.69 micrograms/ml for the 10 to 16 year group.",Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653035/),[mg] / [d·kg],8.25,54181,DB00252,Phenytoin
,6653035,Km,"Mean Vmax and Km values were 13.95 mg/kg/day and 6.59 micrograms/ml for 0.5 to 3-year-old patients, 10.93 mg/kg/day and 6.82 micrograms/ml for the 4 to 6 year age group, 10.05 mg/kg/day and 6.51 micrograms/ml for the 7 to 9-year-olds, and 8.25 mg/kg/day and 5.69 micrograms/ml for the 10 to 16 year group.",Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653035/),[μg] / [ml],5.69,54182,DB00252,Phenytoin
,6653035,steady-state phenytoin concentration,"Based on this data, the youngest age group would require on average 62% more phenytoin/kg/day than the oldest age group in order to maintain a steady-state phenytoin concentration of 15 micrograms/ml.",Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653035/),[μg] / [ml],15,54183,DB00252,Phenytoin
,15355124,oral clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],22-36,55128,DB00252,Phenytoin
,15355124,renal clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],10-20,55129,DB00252,Phenytoin
,15355124,half-life,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),h,19-25,55130,DB00252,Phenytoin
,15355124,absolute bioavailability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55131,DB00252,Phenytoin
,15355124,oral availability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55132,DB00252,Phenytoin
,7394315,apparent half-life ((t 1/2),"In a randomized study on nine animals (not crossed over) it was observed that the apparent half-life ((t 1/2) of this drug increased four-fold as dose was increased from 10 to 50 mg/kg (6 1/2 - 64 +/- 42 min vs. 267 +/- 118 min, respectively; mean +/- S.D.).",Dose-dependence of the apparent half-life of phenytoin in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7394315/),min,64,55991,DB00252,Phenytoin
,7394315,6 1/2,"In a randomized study on nine animals (not crossed over) it was observed that the apparent half-life ((t 1/2) of this drug increased four-fold as dose was increased from 10 to 50 mg/kg (6 1/2 - 64 +/- 42 min vs. 267 +/- 118 min, respectively; mean +/- S.D.).",Dose-dependence of the apparent half-life of phenytoin in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7394315/),min,64,55992,DB00252,Phenytoin
,7394315,6 1/2,"In a randomized study on nine animals (not crossed over) it was observed that the apparent half-life ((t 1/2) of this drug increased four-fold as dose was increased from 10 to 50 mg/kg (6 1/2 - 64 +/- 42 min vs. 267 +/- 118 min, respectively; mean +/- S.D.).",Dose-dependence of the apparent half-life of phenytoin in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7394315/),min,267,55993,DB00252,Phenytoin
,7394315,t 1/2,"In a crossover study on three animals, an even larger dose-dependent increase in t 1/2 was observed (37.8 vs. 271 min).",Dose-dependence of the apparent half-life of phenytoin in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7394315/),min,37.8,55994,DB00252,Phenytoin
,7394315,t 1/2,"In a crossover study on three animals, an even larger dose-dependent increase in t 1/2 was observed (37.8 vs. 271 min).",Dose-dependence of the apparent half-life of phenytoin in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7394315/),min,271,55995,DB00252,Phenytoin
,8924916,volume of distribution (V),"The volume of distribution (V) was estimated to be 1.231/kg in a typical 42-kg patient, assuming that the bioavailability of orally administered phenytoin is 100%.",Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8924916/),1/[kg],1.231,57232,DB00252,Phenytoin
,8924916,bioavailability,"The volume of distribution (V) was estimated to be 1.231/kg in a typical 42-kg patient, assuming that the bioavailability of orally administered phenytoin is 100%.",Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8924916/),%,100,57233,DB00252,Phenytoin
,8924916,maximal elimination rate (V(max)),"The maximal elimination rate (V(max)) and the Michaelis-Menten constant (K(m)) were 9.80 mg/d/kg and 9.19 micrograms/ml, respectively.",Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8924916/),[mg] / [d·kg],9.80,57234,DB00252,Phenytoin
,8924916,Michaelis-Menten constant (K(m)),"The maximal elimination rate (V(max)) and the Michaelis-Menten constant (K(m)) were 9.80 mg/d/kg and 9.19 micrograms/ml, respectively.",Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8924916/),[μg] / [ml],9.19,57235,DB00252,Phenytoin
,12405865,bioavailability,Methadone has a mean bioavailability of around 75% (range 36-100%).,Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),%,75,57243,DB00252,Phenytoin
,12405865,free fraction,"Its mean free fraction is around 13%, with a 4-fold interindividual variation.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),%,13,57244,DB00252,Phenytoin
,12405865,volume of distribution,Its volume of distribution is about 4 L/kg (range 2-13 L/kg).,Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[l] / [kg],4,57245,DB00252,Phenytoin
,12405865,Total body clearance,"Total body clearance is about 0.095 L/min, with wide interindividual variation (range 0.02-2 L/min).",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[l] / [min],0.095,57246,DB00252,Phenytoin
,12405865,elimination half-life,"Plasma concentrations of methadone decrease in a biexponential manner, with a mean value of around 22 hours (range 5-130 hours) for elimination half-life.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),h,22,57247,DB00252,Phenytoin
,12405865,elimination half-life,"Plasma concentrations of methadone decrease in a biexponential manner, with a mean value of around 22 hours (range 5-130 hours) for elimination half-life.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),h,5,57248,DB00252,Phenytoin
,12405865,trough plasma concentrations,"In the case of non-response trough plasma concentrations of 400 microg/L for (R,S)-methadone or 250 microg/L for (R)-methadone might be used as target values.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[μg] / [l],400,57249,DB00252,Phenytoin
,12405865,trough plasma concentrations,"In the case of non-response trough plasma concentrations of 400 microg/L for (R,S)-methadone or 250 microg/L for (R)-methadone might be used as target values.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[μg] / [l],250,57250,DB00252,Phenytoin
,33217013,total clearance,"A 1-compartment PK model with first-order absorption and elimination best described the parent carbamazepine data, with a total clearance of 1.96 L/h, central distribution volume of 164 L and absorption rate constant of 0.45 h-1 .",Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33217013/),[l] / [h],1.96,58761,DB00252,Phenytoin
,33217013,central distribution volume,"A 1-compartment PK model with first-order absorption and elimination best described the parent carbamazepine data, with a total clearance of 1.96 L/h, central distribution volume of 164 L and absorption rate constant of 0.45 h-1 .",Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33217013/),l,164,58762,DB00252,Phenytoin
,33217013,absorption rate constant,"A 1-compartment PK model with first-order absorption and elimination best described the parent carbamazepine data, with a total clearance of 1.96 L/h, central distribution volume of 164 L and absorption rate constant of 0.45 h-1 .",Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33217013/),1/[h],0.45,58763,DB00252,Phenytoin
,7341282,elimination half lives,"The median elimination half lives of cinromide and the amide and acid metabolites were 0.73, 1.65, and 4.85 h respectively.",Differential kinetics of cinromide and two of its metabolites in epileptic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341282/),h,0.73,59470,DB00252,Phenytoin
,7341282,elimination half lives,"The median elimination half lives of cinromide and the amide and acid metabolites were 0.73, 1.65, and 4.85 h respectively.",Differential kinetics of cinromide and two of its metabolites in epileptic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341282/),h,1.65,59471,DB00252,Phenytoin
,7341282,elimination half lives,"The median elimination half lives of cinromide and the amide and acid metabolites were 0.73, 1.65, and 4.85 h respectively.",Differential kinetics of cinromide and two of its metabolites in epileptic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341282/),h,4.85,59472,DB00252,Phenytoin
,7341282,oral clearance,The oral clearance of cinromide (median = 135 l/h) suggests that it is subject to first pass metabolism.,Differential kinetics of cinromide and two of its metabolites in epileptic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341282/),[l] / [h],135,59473,DB00252,Phenytoin
,7341282,area under the curve (AUC),In all subjects the area under the curve (AUC) of acid metabolite (632 to 1777 microM/l) was greater than the AUC of amide metabolite (77 to 185 microM/l) which was greater than the AUC of cinromide (5 to 89 microM/l).,Differential kinetics of cinromide and two of its metabolites in epileptic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341282/),[μM] / [l],632 to 1777,59474,DB00252,Phenytoin
,7341282,AUC,In all subjects the area under the curve (AUC) of acid metabolite (632 to 1777 microM/l) was greater than the AUC of amide metabolite (77 to 185 microM/l) which was greater than the AUC of cinromide (5 to 89 microM/l).,Differential kinetics of cinromide and two of its metabolites in epileptic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341282/),[μM] / [l],77 to 185,59475,DB00252,Phenytoin
,7341282,AUC,In all subjects the area under the curve (AUC) of acid metabolite (632 to 1777 microM/l) was greater than the AUC of amide metabolite (77 to 185 microM/l) which was greater than the AUC of cinromide (5 to 89 microM/l).,Differential kinetics of cinromide and two of its metabolites in epileptic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341282/),[μM] / [l],5 to 89,59476,DB00252,Phenytoin
,3757729,serum concentration,"The mean phenytoin dose (+/- SD) in infants was 8.1 +/- 4.4 mg/kg/day, and the mean serum concentration (+/- SD) was 4.8 +/- 4.6 micrograms/ml.",Phenytoin metabolism in infants following intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757729/),[μg] / [ml],4.8,62177,DB00252,Phenytoin
,31222537,apparent clearance (CL/F),"Average parameter estimates for valproic acid apparent clearance (CL/F) and apparent volume of distribution (V/F) were 0.14 L/h and 37.7 L (fixed), respectively.",Estimation of apparent clearance of valproic acid in adult Saudi patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31222537/),[l] / [h],0.14,63153,DB00252,Phenytoin
,31222537,apparent volume of distribution (V/F),"Average parameter estimates for valproic acid apparent clearance (CL/F) and apparent volume of distribution (V/F) were 0.14 L/h and 37.7 L (fixed), respectively.",Estimation of apparent clearance of valproic acid in adult Saudi patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31222537/),l,37.7,63154,DB00252,Phenytoin
,12576167,concentration at 1h (C(1h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],2.1,63306,DB00252,Phenytoin
,12576167,concentration at 12h (C(12h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],0.8,63307,DB00252,Phenytoin
,12576167,area under the curve from 0 to 12h (AUC(0-12h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],17.1,63308,DB00252,Phenytoin
,12576167,half-life (t(1/2)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),h,8.1,63309,DB00252,Phenytoin
,12576167,apparent oral clearance (CL/F),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),1/[mlmin],0.97,63310,DB00252,Phenytoin
,6681550,half-life,Declining serum levels from postnatal days 8 to 13 on a constant dose of 9 mg per kilogram per day suggested that the rate of phenytoin metabolism was gradually increasing; rapid elimination was documented on day 18 by a half-life measurement of 8.8 hours from three samples.,High intravenous phenytoin dosage requirement in a newborn infant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6681550/),h,8.8,64285,DB00252,Phenytoin
,15730534,CL/F,PB CL/F values were significantly lower in elderly patients than in controls (3.2 +/- 0.8 vs. 4.1 +/- 1.2 ml/h/kg; p < 0.0001).,Phenobarbital pharmacokinetics in old age: a case-matched evaluation based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730534/),[ml] / [h·kg],3.2,65549,DB00252,Phenytoin
,15730534,CL/F,PB CL/F values were significantly lower in elderly patients than in controls (3.2 +/- 0.8 vs. 4.1 +/- 1.2 ml/h/kg; p < 0.0001).,Phenobarbital pharmacokinetics in old age: a case-matched evaluation based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730534/),[ml] / [h·kg],4.1,65550,DB00252,Phenytoin
,10466903,Maximum mean concentrations,Maximum mean concentrations of 2.4+/-1.1 mg/L (mean +/- SD) following rectal administration and 11.2+/-1.6 mg/L following intravenous administration were achieved during the first one to two hours (tmax in both treatment arms).,Absorption of rectally administered phenytoin: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10466903/),[mg] / [l],2.4,66739,DB00252,Phenytoin
,10466903,Maximum mean concentrations,Maximum mean concentrations of 2.4+/-1.1 mg/L (mean +/- SD) following rectal administration and 11.2+/-1.6 mg/L following intravenous administration were achieved during the first one to two hours (tmax in both treatment arms).,Absorption of rectally administered phenytoin: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10466903/),[mg] / [l],11.2,66740,DB00252,Phenytoin
,10466903,apparent bioavailability,Mean apparent bioavailability of the rectally administered phenytoin was 24.4+/-13.4% (15.8-44.1%).,Absorption of rectally administered phenytoin: a pilot study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10466903/),%,24.4,66741,DB00252,Phenytoin
,16671554,flow rate,"The analytes and the internal standard, diphenhydramine, were isolated from plasma by protein precipitation with methanol, then chromatographied on a Zorbax SB-C18 column (150 mm x 4.6 mm ID) using a mobile phase consisted of methanol-water-formic acid (80: 20: 0.5, v/v), at a flow rate of 0.5 mL x min(-1).",[Simultaneous determination of ephedrine and chlorpheniramine in human plasma by a highly sensitive liquid chromatography-tandem mass spectrometric method]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671554/),[ml] / [min],0.5,67438,DB00252,Phenytoin
,3595702,half-life,"The half-life of chlorpropamide was significantly shorter in the patients (34.4 h) than in the healthy volunteers (50.2 h), but the difference between the groups in the half-life of antipyrine was even more pronounced (5.1 vs 11.4 h).",Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),h,34.4,67748,DB00252,Phenytoin
,3595702,half-life,"The half-life of chlorpropamide was significantly shorter in the patients (34.4 h) than in the healthy volunteers (50.2 h), but the difference between the groups in the half-life of antipyrine was even more pronounced (5.1 vs 11.4 h).",Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),h,50.2,67749,DB00252,Phenytoin
,3595702,half-life,"The half-life of chlorpropamide was significantly shorter in the patients (34.4 h) than in the healthy volunteers (50.2 h), but the difference between the groups in the half-life of antipyrine was even more pronounced (5.1 vs 11.4 h).",Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),h,5.1,67750,DB00252,Phenytoin
,3595702,half-life,"The half-life of chlorpropamide was significantly shorter in the patients (34.4 h) than in the healthy volunteers (50.2 h), but the difference between the groups in the half-life of antipyrine was even more pronounced (5.1 vs 11.4 h).",Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),h,11.4,67751,DB00252,Phenytoin
,3595702,clearance,The clearance and volume of distribution of total chlorpropamide were significantly higher in the patients (2.99 ml X h-1 X kg-1 and 126 ml X kg-1) than in the healthy volunteers (1.60 ml X h-1 X kg-1 and 106 ml X kg-1).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),[ml] / [h·kg],2.99,67752,DB00252,Phenytoin
,3595702,clearance,The clearance and volume of distribution of total chlorpropamide were significantly higher in the patients (2.99 ml X h-1 X kg-1 and 126 ml X kg-1) than in the healthy volunteers (1.60 ml X h-1 X kg-1 and 106 ml X kg-1).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),[ml] / [h·kg],1.60,67753,DB00252,Phenytoin
,3595702,volume of distribution,The clearance and volume of distribution of total chlorpropamide were significantly higher in the patients (2.99 ml X h-1 X kg-1 and 126 ml X kg-1) than in the healthy volunteers (1.60 ml X h-1 X kg-1 and 106 ml X kg-1).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),[ml] / [kg],126,67754,DB00252,Phenytoin
,3595702,volume of distribution,The clearance and volume of distribution of total chlorpropamide were significantly higher in the patients (2.99 ml X h-1 X kg-1 and 126 ml X kg-1) than in the healthy volunteers (1.60 ml X h-1 X kg-1 and 106 ml X kg-1).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),[ml] / [kg],106,67755,DB00252,Phenytoin
,3595702,unbound fraction,The unbound fraction of chlorpropamide in serum was also higher in the patients (5.7%) than in the healthy subjects (4.4%).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),%,5.7,67756,DB00252,Phenytoin
,3595702,unbound fraction,The unbound fraction of chlorpropamide in serum was also higher in the patients (5.7%) than in the healthy subjects (4.4%).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),%,4.4,67757,DB00252,Phenytoin
,3243914,Cmax,"The prodrug, after achieving a maximum concentration at the end of the 30-minute infusion (Cmax 20, 36, 75, 129 micrograms/mL) declined rapidly with a half-life (t1/2) of about 8 minutes.","Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243914/),[μg] / [ml],20,67975,DB00252,Phenytoin
,3243914,Cmax,"The prodrug, after achieving a maximum concentration at the end of the 30-minute infusion (Cmax 20, 36, 75, 129 micrograms/mL) declined rapidly with a half-life (t1/2) of about 8 minutes.","Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243914/),[μg] / [ml],36,67976,DB00252,Phenytoin
,3243914,Cmax,"The prodrug, after achieving a maximum concentration at the end of the 30-minute infusion (Cmax 20, 36, 75, 129 micrograms/mL) declined rapidly with a half-life (t1/2) of about 8 minutes.","Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243914/),[μg] / [ml],75,67977,DB00252,Phenytoin
,3243914,Cmax,"The prodrug, after achieving a maximum concentration at the end of the 30-minute infusion (Cmax 20, 36, 75, 129 micrograms/mL) declined rapidly with a half-life (t1/2) of about 8 minutes.","Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243914/),[μg] / [ml],",",67978,DB00252,Phenytoin
,3243914,Cmax,"The prodrug, after achieving a maximum concentration at the end of the 30-minute infusion (Cmax 20, 36, 75, 129 micrograms/mL) declined rapidly with a half-life (t1/2) of about 8 minutes.","Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243914/),[μg] / [ml],129,67979,DB00252,Phenytoin
,3243914,half-life (t1/2),"The prodrug, after achieving a maximum concentration at the end of the 30-minute infusion (Cmax 20, 36, 75, 129 micrograms/mL) declined rapidly with a half-life (t1/2) of about 8 minutes.","Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243914/),min,8,67980,DB00252,Phenytoin
,3243914,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve (10, 19, 43, 77 mg.hr/L) was proportional to dose whereas the total clearance, 14 L/hr, was independent of dose.","Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243914/),[h·mg] / [l],10,67981,DB00252,Phenytoin
,3243914,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve (10, 19, 43, 77 mg.hr/L) was proportional to dose whereas the total clearance, 14 L/hr, was independent of dose.","Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243914/),[h·mg] / [l],"43,",67982,DB00252,Phenytoin
,3243914,total clearance,"The area under the plasma concentration-time curve (10, 19, 43, 77 mg.hr/L) was proportional to dose whereas the total clearance, 14 L/hr, was independent of dose.","Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243914/),[l] / [h],14,67983,DB00252,Phenytoin
,3243914,volume of distribution,"The volume of distribution of the prodrug, a polar, water-soluble molecule was about 2.6 L, indicating that most of the dose remained in the plasma.","Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243914/),l,2.6,67984,DB00252,Phenytoin
,3243914,peak concentration,"At the dose of 1200 mg of prodrug, the average peak concentration of phenytoin was about 17 micrograms/mL, near the upper limit of the therapeutic range.","Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243914/),[μg] / [ml],17,67985,DB00252,Phenytoin
,2670535,Tmax,"The Tmax of the prodrug averaged 5.7 and 36 min (0.095 and 0.606 h) after i.v. and i.m. administrations, respectively.",Phenytoin prodrug: preclinical and clinical studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670535/),min,5.7,70381,DB00252,Phenytoin
,2670535,Tmax,"The Tmax of the prodrug averaged 5.7 and 36 min (0.095 and 0.606 h) after i.v. and i.m. administrations, respectively.",Phenytoin prodrug: preclinical and clinical studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670535/),min,36,70382,DB00252,Phenytoin
,2670535,Tmax,"The Tmax of the prodrug averaged 5.7 and 36 min (0.095 and 0.606 h) after i.v. and i.m. administrations, respectively.",Phenytoin prodrug: preclinical and clinical studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670535/),h,0.095,70383,DB00252,Phenytoin
,2670535,Tmax,"The Tmax of the prodrug averaged 5.7 and 36 min (0.095 and 0.606 h) after i.v. and i.m. administrations, respectively.",Phenytoin prodrug: preclinical and clinical studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670535/),h,0.606,70384,DB00252,Phenytoin
,2670535,elimination half-life,"The elimination half-life of ACC-9653 (conversion from prodrug to PHT) after i.v. and i.m. administration was 8.4 and 32.7 min (0.140 and 0.545 h), respectively, and both were independent of the dose.",Phenytoin prodrug: preclinical and clinical studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670535/),min,8.4,70385,DB00252,Phenytoin
,2670535,elimination half-life,"The elimination half-life of ACC-9653 (conversion from prodrug to PHT) after i.v. and i.m. administration was 8.4 and 32.7 min (0.140 and 0.545 h), respectively, and both were independent of the dose.",Phenytoin prodrug: preclinical and clinical studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670535/),min,32.7,70386,DB00252,Phenytoin
,2670535,elimination half-life,"The elimination half-life of ACC-9653 (conversion from prodrug to PHT) after i.v. and i.m. administration was 8.4 and 32.7 min (0.140 and 0.545 h), respectively, and both were independent of the dose.",Phenytoin prodrug: preclinical and clinical studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670535/),h,0.140,70387,DB00252,Phenytoin
,2670535,elimination half-life,"The elimination half-life of ACC-9653 (conversion from prodrug to PHT) after i.v. and i.m. administration was 8.4 and 32.7 min (0.140 and 0.545 h), respectively, and both were independent of the dose.",Phenytoin prodrug: preclinical and clinical studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670535/),h,0.545,70388,DB00252,Phenytoin
,2670535,plasma clearance,"The plasma clearance of ACC-9653 was not dependent on dose or route of administration and averaged 19.8 +/- 1.16 and 17.8 +/- 0.83 L/h after i.v. and i.m. administrations, respectively.",Phenytoin prodrug: preclinical and clinical studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670535/),[l] / [h],19.8,70389,DB00252,Phenytoin
,2670535,plasma clearance,"The plasma clearance of ACC-9653 was not dependent on dose or route of administration and averaged 19.8 +/- 1.16 and 17.8 +/- 0.83 L/h after i.v. and i.m. administrations, respectively.",Phenytoin prodrug: preclinical and clinical studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670535/),[l] / [h],17.8,70390,DB00252,Phenytoin
,2670535,area under curve ratio,The area under curve ratio of PHT after i.m. and i.v. ACC-9653 was 1.17 +/- 0.13 which was not significantly different from 1.,Phenytoin prodrug: preclinical and clinical studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670535/),,1.17,70391,DB00252,Phenytoin
,26751267,total C/D ratio,"The interindividual pharmacokinetic variability was extensive, as illustrated by a 100-fold variability in serum concentration compared with dose (total C/D ratio 0.03-3.29 µmol·L·mg).",Therapeutic Drug Monitoring of Clobazam and Its Metabolite-Impact of Age and Comedication on Pharmacokinetic Variability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26751267/),l·mg·μM,0.03-3.29,70769,DB00252,Phenytoin
,1298635,Peak phenytoin serum levels,Peak phenytoin serum levels were detected six hours post-dosing at 2.98 +/- 0.53 micrograms/ml.,"Some characteristics of serum phenytoin concentration, in black Zimbabwean volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1298635/),[μg] / [ml],2.98,72432,DB00252,Phenytoin
,1298635,elimination half life (t1/2),The mean elimination half life (t1/2) was calculated at 40.2 hours with a range of 36.7 to 40.5 hours.,"Some characteristics of serum phenytoin concentration, in black Zimbabwean volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1298635/),h,40.2,72433,DB00252,Phenytoin
,1298635,area under the curve,The area under the curve was calculated to be 142.5 with a range of 118 to 192.,"Some characteristics of serum phenytoin concentration, in black Zimbabwean volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1298635/),,142.5,72434,DB00252,Phenytoin
,10698674,C(max),"At 150 mg/kg ip high concentrations of long duration (C(max) 240 microM and AUC 5300 microMhl(-1) - total) and marked developmental toxicity (embryonic death, decreased fetal weights, and orofacial clefts) were observed.",Pharmacokinetic data support pharmacologically induced embryonic dysrhythmia as explanation to Fetal Hydantoin Syndrome in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10698674/),μM,240,72906,DB00252,Phenytoin
,10698674,AUC,"At 150 mg/kg ip high concentrations of long duration (C(max) 240 microM and AUC 5300 microMhl(-1) - total) and marked developmental toxicity (embryonic death, decreased fetal weights, and orofacial clefts) were observed.",Pharmacokinetic data support pharmacologically induced embryonic dysrhythmia as explanation to Fetal Hydantoin Syndrome in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10698674/),[-·total] / [μMhl],5300,72907,DB00252,Phenytoin
,10698674,C(max),"After 100 mg/kg ip (C(max) 150 microM, AUC 2600 microMhl(-1) - total) only slight developmental toxicity (decreased fetal weights) was recorded and after 150 mg/kg po the plasma concentrations were even lower (C(max) 63 microM and AUC 1100 microMhl(-1) - total) and no adverse effects at all were observed.",Pharmacokinetic data support pharmacologically induced embryonic dysrhythmia as explanation to Fetal Hydantoin Syndrome in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10698674/),μM,150,72908,DB00252,Phenytoin
,10698674,AUC,"After 100 mg/kg ip (C(max) 150 microM, AUC 2600 microMhl(-1) - total) only slight developmental toxicity (decreased fetal weights) was recorded and after 150 mg/kg po the plasma concentrations were even lower (C(max) 63 microM and AUC 1100 microMhl(-1) - total) and no adverse effects at all were observed.",Pharmacokinetic data support pharmacologically induced embryonic dysrhythmia as explanation to Fetal Hydantoin Syndrome in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10698674/),[-·total] / [μMhl],2600,72909,DB00252,Phenytoin
,10698674,C(max),"After 100 mg/kg ip (C(max) 150 microM, AUC 2600 microMhl(-1) - total) only slight developmental toxicity (decreased fetal weights) was recorded and after 150 mg/kg po the plasma concentrations were even lower (C(max) 63 microM and AUC 1100 microMhl(-1) - total) and no adverse effects at all were observed.",Pharmacokinetic data support pharmacologically induced embryonic dysrhythmia as explanation to Fetal Hydantoin Syndrome in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10698674/),μM,63,72910,DB00252,Phenytoin
,10698674,AUC,"After 100 mg/kg ip (C(max) 150 microM, AUC 2600 microMhl(-1) - total) only slight developmental toxicity (decreased fetal weights) was recorded and after 150 mg/kg po the plasma concentrations were even lower (C(max) 63 microM and AUC 1100 microMhl(-1) - total) and no adverse effects at all were observed.",Pharmacokinetic data support pharmacologically induced embryonic dysrhythmia as explanation to Fetal Hydantoin Syndrome in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10698674/),[-·total] / [μMhl],1100,72911,DB00252,Phenytoin
,7751591,plasma half-life,There were significant changes in caffeine plasma half-life (6.2 vs. 3.5 h; p < 0.004) and caffeine plasma clearance (1.3 vs. 2.2 ml/kg per min; p < 0.004) with rifampin.,The influence of rifampin treatment on caffeine clearance in healthy man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751591/),h,6.2,73374,DB00252,Phenytoin
,7751591,plasma half-life,There were significant changes in caffeine plasma half-life (6.2 vs. 3.5 h; p < 0.004) and caffeine plasma clearance (1.3 vs. 2.2 ml/kg per min; p < 0.004) with rifampin.,The influence of rifampin treatment on caffeine clearance in healthy man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751591/),h,3.5,73375,DB00252,Phenytoin
,7751591,plasma clearance,There were significant changes in caffeine plasma half-life (6.2 vs. 3.5 h; p < 0.004) and caffeine plasma clearance (1.3 vs. 2.2 ml/kg per min; p < 0.004) with rifampin.,The influence of rifampin treatment on caffeine clearance in healthy man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751591/),[ml] / [kg·min],1.3,73376,DB00252,Phenytoin
,7751591,plasma clearance,There were significant changes in caffeine plasma half-life (6.2 vs. 3.5 h; p < 0.004) and caffeine plasma clearance (1.3 vs. 2.2 ml/kg per min; p < 0.004) with rifampin.,The influence of rifampin treatment on caffeine clearance in healthy man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751591/),[ml] / [kg·min],2.2,73377,DB00252,Phenytoin
,9579299,Vmax,"But divided into genotype groups, Vmax values were 3.9 +/- 0.4, 5.3 +/- 0.7, and 5.7 +/- 1.4 mg/kg/day for the patients with the m2 allele, with the m1 allele, and with neither the m1 or m2 allele, respectively.",The relationship between phenytoin pharmacokinetics and the CYP2C19 genotype in Japanese epileptic patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579299/),[mg] / [d·kg],3.9,73533,DB00252,Phenytoin
,9579299,Vmax,"But divided into genotype groups, Vmax values were 3.9 +/- 0.4, 5.3 +/- 0.7, and 5.7 +/- 1.4 mg/kg/day for the patients with the m2 allele, with the m1 allele, and with neither the m1 or m2 allele, respectively.",The relationship between phenytoin pharmacokinetics and the CYP2C19 genotype in Japanese epileptic patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579299/),[mg] / [d·kg],5.3,73534,DB00252,Phenytoin
,9579299,Vmax,"But divided into genotype groups, Vmax values were 3.9 +/- 0.4, 5.3 +/- 0.7, and 5.7 +/- 1.4 mg/kg/day for the patients with the m2 allele, with the m1 allele, and with neither the m1 or m2 allele, respectively.",The relationship between phenytoin pharmacokinetics and the CYP2C19 genotype in Japanese epileptic patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579299/),[mg] / [d·kg],5.7,73535,DB00252,Phenytoin
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.32,73970,DB00252,Phenytoin
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.34,73971,DB00252,Phenytoin
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.45,73972,DB00252,Phenytoin
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.46,73973,DB00252,Phenytoin
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.52,73974,DB00252,Phenytoin
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.53,73975,DB00252,Phenytoin
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.54,73976,DB00252,Phenytoin
,3168142,total plasma concentrations,Phenytoin infusion was guided by plasma phenytoin estimation to maintain total plasma concentrations between 20 and 30 micrograms/ml.,Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3168142/),[μg] / [ml],20 and 30,74278,DB00252,Phenytoin
,3168142,Clearance,"Clearance of doxorubicin during phenytoin administration (60.9 +/- 5.8 ml/min per kg, mean +/- SE) was similar to that during vehicle infusion (67.5 +/- 5.4 ml/min per kg).",Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3168142/),[ml] / [kg·min],60.9,74279,DB00252,Phenytoin
,3168142,Clearance,"Clearance of doxorubicin during phenytoin administration (60.9 +/- 5.8 ml/min per kg, mean +/- SE) was similar to that during vehicle infusion (67.5 +/- 5.4 ml/min per kg).",Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3168142/),[ml] / [kg·min],67.5,74280,DB00252,Phenytoin
,3168142,elimination half-life,Phenytoin administration was associated with a significant decrease in doxorubicinol elimination half-life from 41.0 +/- 4.8 to 25.6 +/- 2.8 h.,Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3168142/),h,41.0,74281,DB00252,Phenytoin
,3168142,elimination half-life,Phenytoin administration was associated with a significant decrease in doxorubicinol elimination half-life from 41.0 +/- 4.8 to 25.6 +/- 2.8 h.,Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3168142/),h,25.6,74282,DB00252,Phenytoin
,3168142,area under the plasma concentration/time curve (AUC),The area under the plasma concentration/time curve (AUC) for doxorubicinol decreased significantly from 666.8 +/- 100.4 to 491.5 +/- 65.7 n.h.ml-1.,Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3168142/),[h·n] / [ml],666.8,74283,DB00252,Phenytoin
,3168142,area under the plasma concentration/time curve (AUC),The area under the plasma concentration/time curve (AUC) for doxorubicinol decreased significantly from 666.8 +/- 100.4 to 491.5 +/- 65.7 n.h.ml-1.,Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3168142/),[h·n] / [ml],491.5,74284,DB00252,Phenytoin
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],2.52,74496,DB00252,Phenytoin
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],2.17,74497,DB00252,Phenytoin
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],1.803,74498,DB00252,Phenytoin
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],1.636,74499,DB00252,Phenytoin
,25137530,gradient flow rate,"Chromatographic separation was conducted on a Shimadzu CLC-C8 column using a mobile phase consisting of water-acetonitrile (70:30; v/v) adjusted to pH 4.0 ± 0.1 with formic acid at a gradient flow rate of 1.0-0.6 mL/min, an injection volume of 30 μL and UV detection at 210 nm.",HPLC-UV method for quantifying etoposide in plasma and tumor interstitial fluid by microdialysis: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25137530/),[ml] / [min],1.0-0.6,74867,DB00252,Phenytoin
,25137530,injection volume,"Chromatographic separation was conducted on a Shimadzu CLC-C8 column using a mobile phase consisting of water-acetonitrile (70:30; v/v) adjusted to pH 4.0 ± 0.1 with formic acid at a gradient flow rate of 1.0-0.6 mL/min, an injection volume of 30 μL and UV detection at 210 nm.",HPLC-UV method for quantifying etoposide in plasma and tumor interstitial fluid by microdialysis: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25137530/),μl,30,74868,DB00252,Phenytoin
,19930798,detection limits,"The calibration graphs were linear at the concentration range of 5-30 mg/mL, and the detection limits for phenytoin and 5-(4-hydroxyphenyl)-5-phenylhydantoin added to blank serum were 1.8 and 1.5 mg/mL, respectively.",Determination of phenytoin and its major metabolite in human serum by MEKC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19930798/),[mg] / [ml],1.8,76517,DB00252,Phenytoin
,19930798,detection limits,"The calibration graphs were linear at the concentration range of 5-30 mg/mL, and the detection limits for phenytoin and 5-(4-hydroxyphenyl)-5-phenylhydantoin added to blank serum were 1.8 and 1.5 mg/mL, respectively.",Determination of phenytoin and its major metabolite in human serum by MEKC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19930798/),[mg] / [ml],1.5,76518,DB00252,Phenytoin
,25163570,BuCL/CBW,"Twenty-nine patients ≥ 60 years old (median 66; range 60-74) had a significantly higher BuCL versus those <60 years old (median 50; range 18-60): BuCL 236 versus 168 mL/min, p = 0.0002; BuCL/ABW 3.0 versus 2.1 mL/min/kg, p = 0.0001; BuCL/IBW 3.8 versus 2.6 mL/min/kg, p = 0.0035; BuCL/CBW 3.4 versus 2.6 mL/min/kg, p = 0.0005.","Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25163570/),[ml] / [kg·min],3.4,76523,DB00252,Phenytoin
,25163570,BuCL/CBW,"Twenty-nine patients ≥ 60 years old (median 66; range 60-74) had a significantly higher BuCL versus those <60 years old (median 50; range 18-60): BuCL 236 versus 168 mL/min, p = 0.0002; BuCL/ABW 3.0 versus 2.1 mL/min/kg, p = 0.0001; BuCL/IBW 3.8 versus 2.6 mL/min/kg, p = 0.0035; BuCL/CBW 3.4 versus 2.6 mL/min/kg, p = 0.0005.","Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25163570/),[ml] / [kg·min],2.6,76524,DB00252,Phenytoin
,11704788,CL/F,"CL/F and the volume of distribution (V/F) were estimated to 9.23 l/h and 39.3 l, respectively, in a typical individual.",Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11704788/),[l] / [h],9.23,77230,DB00252,Phenytoin
,11704788,volume of distribution (V/F),"CL/F and the volume of distribution (V/F) were estimated to 9.23 l/h and 39.3 l, respectively, in a typical individual.",Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11704788/),l,39.3,77231,DB00252,Phenytoin
,6631719,systemic availability,"Also, the systemic availability of orally administered propranolol (6 mg/kg) increased from 4.1 to 7.8% from the 1st to the 2nd study day, indicating a decrease in the presystemic clearance of the drug.",Alterations in serum protein binding and pharmacokinetics of l-propranolol in the rat elicited by the presence of an indwelling venous catheter. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631719/),,4,77644,DB00252,Phenytoin
,6631719,systemic availability,"Also, the systemic availability of orally administered propranolol (6 mg/kg) increased from 4.1 to 7.8% from the 1st to the 2nd study day, indicating a decrease in the presystemic clearance of the drug.",Alterations in serum protein binding and pharmacokinetics of l-propranolol in the rat elicited by the presence of an indwelling venous catheter. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631719/),,7.8,77645,DB00252,Phenytoin
,8864327,peak plasma concentrations (Cmax),"The mean (+/- s.d.) peak plasma concentrations (Cmax), apparent total clearance (CL/F) and terminal half-life (t1/2) for phenytoin when administered alone were 10.6(1.8) mg 1(-1), 24.3 (7.7) ml min-1 and 25(8) h, respectively.",Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864327/),mg,10.6,78003,DB00252,Phenytoin
,8864327,apparent total clearance (CL/F),"The mean (+/- s.d.) peak plasma concentrations (Cmax), apparent total clearance (CL/F) and terminal half-life (t1/2) for phenytoin when administered alone were 10.6(1.8) mg 1(-1), 24.3 (7.7) ml min-1 and 25(8) h, respectively.",Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864327/),[ml] / [min],24.3,78004,DB00252,Phenytoin
,8864327,terminal half-life (t1/2),"The mean (+/- s.d.) peak plasma concentrations (Cmax), apparent total clearance (CL/F) and terminal half-life (t1/2) for phenytoin when administered alone were 10.6(1.8) mg 1(-1), 24.3 (7.7) ml min-1 and 25(8) h, respectively.",Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864327/),h,25,78005,DB00252,Phenytoin
,8864327,Cmax,"When administered together with atovaquone, phenytoin Cmax, CL/F and t1/2,z were 10.9 (2.0) mg 1(-1), 23.8 ml min-1 and 24(6) h, respectively.",Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864327/),mg,10.9,78006,DB00252,Phenytoin
,8864327,CL/F,"When administered together with atovaquone, phenytoin Cmax, CL/F and t1/2,z were 10.9 (2.0) mg 1(-1), 23.8 ml min-1 and 24(6) h, respectively.",Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864327/),[ml] / [min],23.8,78007,DB00252,Phenytoin
,8864327,"t1/2,z","When administered together with atovaquone, phenytoin Cmax, CL/F and t1/2,z were 10.9 (2.0) mg 1(-1), 23.8 ml min-1 and 24(6) h, respectively.",Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864327/),h,24,78008,DB00252,Phenytoin
< or =,11145056,absolute recovery,The absolute recovery of the analyte in brain and plasma samples was < or = 90%.,"Determination of the enaminone DM5, an anti-epileptic agent, in mouse plasma and brain tissue by high-performance liquid chromatography with ultraviolet detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145056/),%,90,79604,DB00252,Phenytoin
,8119045,bioavailability,The bioavailability of the oral formulation is about 98%.,Lamotrigine clinical pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),%,98,80086,DB00252,Phenytoin
,8119045,plasma protein binding,The degree of plasma protein binding is 56%.,Lamotrigine clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),%,56,80087,DB00252,Phenytoin
,8119045,half-lives,Mean half-lives of lamotrigine in healthy volunteers (single and multiple doses) as well as in epileptic patients receiving lamotrigine monotherapy range from 22.8 to 37.4 hours.,Lamotrigine clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),h,22.8 to 37.4,80088,DB00252,Phenytoin
,8119045,half-life,"Enzyme-inducing antiepileptic drugs such as phenytoin, phenobarbital (phenobarbitone) or carbamazepine reduce the half-life of lamotrigine (to mean values of 13.5 to 15 hours), whereas valproic acid increases the half-life of the drug (to mean values of 48.3 to 59 hours).",Lamotrigine clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),h,13.5 to 15,80089,DB00252,Phenytoin
,8119045,half-life,"Enzyme-inducing antiepileptic drugs such as phenytoin, phenobarbital (phenobarbitone) or carbamazepine reduce the half-life of lamotrigine (to mean values of 13.5 to 15 hours), whereas valproic acid increases the half-life of the drug (to mean values of 48.3 to 59 hours).",Lamotrigine clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),h,48.3 to 59,80090,DB00252,Phenytoin
,8120112,peak height,Linear relationships between the amount of drug and peak height were confirmed at 1-20 micrograms/ml in serum for carbamazepine and 5-40 micrograms/ml in serum for phenytoin and phenobarbital.,Simple and accurate high-performance liquid chromatographic method for the measurement of three antiepileptics in therapeutic drug monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8120112/),,1,80668,DB00252,Phenytoin
,8120112,peak height,Linear relationships between the amount of drug and peak height were confirmed at 1-20 micrograms/ml in serum for carbamazepine and 5-40 micrograms/ml in serum for phenytoin and phenobarbital.,Simple and accurate high-performance liquid chromatographic method for the measurement of three antiepileptics in therapeutic drug monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8120112/),,5-40,80669,DB00252,Phenytoin
,1287181,elimination half-life,The elimination half-life of PRM was decreased from 19.4 +/- 2.2 (mean +/- S.E.) to 10.2 +/- 5.1 h (p < 0.05) and the total body clearance was increased from 24.6 +/- 3.1 to 45.1 +/- 5.1 ml/h/kg (p < 0.01) in the presence of PHT.,"Single-dose kinetics of primidone in human subjects: effect of phenytoin on formation and elimination of active metabolites of primidone, phenobarbital and phenylethylmalonamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287181/),h,19.4,80682,DB00252,Phenytoin
,1287181,elimination half-life,The elimination half-life of PRM was decreased from 19.4 +/- 2.2 (mean +/- S.E.) to 10.2 +/- 5.1 h (p < 0.05) and the total body clearance was increased from 24.6 +/- 3.1 to 45.1 +/- 5.1 ml/h/kg (p < 0.01) in the presence of PHT.,"Single-dose kinetics of primidone in human subjects: effect of phenytoin on formation and elimination of active metabolites of primidone, phenobarbital and phenylethylmalonamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287181/),h,10.2,80683,DB00252,Phenytoin
,1287181,total body clearance,The elimination half-life of PRM was decreased from 19.4 +/- 2.2 (mean +/- S.E.) to 10.2 +/- 5.1 h (p < 0.05) and the total body clearance was increased from 24.6 +/- 3.1 to 45.1 +/- 5.1 ml/h/kg (p < 0.01) in the presence of PHT.,"Single-dose kinetics of primidone in human subjects: effect of phenytoin on formation and elimination of active metabolites of primidone, phenobarbital and phenylethylmalonamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287181/),[ml] / [h·kg],24.6,80684,DB00252,Phenytoin
,1287181,total body clearance,The elimination half-life of PRM was decreased from 19.4 +/- 2.2 (mean +/- S.E.) to 10.2 +/- 5.1 h (p < 0.05) and the total body clearance was increased from 24.6 +/- 3.1 to 45.1 +/- 5.1 ml/h/kg (p < 0.01) in the presence of PHT.,"Single-dose kinetics of primidone in human subjects: effect of phenytoin on formation and elimination of active metabolites of primidone, phenobarbital and phenylethylmalonamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287181/),[ml] / [h·kg],45.1,80685,DB00252,Phenytoin
,1287181,peak concentrations,About a 6-fold increase in the peak concentrations of both the metabolites were observed (PB 8.2 mumol/l; PEMA 11.0 mumol/l).,"Single-dose kinetics of primidone in human subjects: effect of phenytoin on formation and elimination of active metabolites of primidone, phenobarbital and phenylethylmalonamide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287181/),[μM] / [l],8.2,80686,DB00252,Phenytoin
,1287181,peak concentrations,About a 6-fold increase in the peak concentrations of both the metabolites were observed (PB 8.2 mumol/l; PEMA 11.0 mumol/l).,"Single-dose kinetics of primidone in human subjects: effect of phenytoin on formation and elimination of active metabolites of primidone, phenobarbital and phenylethylmalonamide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287181/),[μM] / [l],11.0,80687,DB00252,Phenytoin
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],378,80807,DB00252,Phenytoin
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],309,80808,DB00252,Phenytoin
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],66.7,80809,DB00252,Phenytoin
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],48,80810,DB00252,Phenytoin
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],42.9,80811,DB00252,Phenytoin
,11103752,elimination half-life,The elimination half-life of repaglinide was shortened from 1.5 to 1.1 hours (P < .01).,Rifampin decreases the plasma concentrations and effects of repaglinide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103752/),h,1.5,82164,DB00252,Phenytoin
,11103752,elimination half-life,The elimination half-life of repaglinide was shortened from 1.5 to 1.1 hours (P < .01).,Rifampin decreases the plasma concentrations and effects of repaglinide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103752/),h,1.1,82165,DB00252,Phenytoin
,11103752,area under the concentration-time curve from 0 to 3 hours,"The blood glucose decremental area under the concentration-time curve from 0 to 3 hours was reduced from 0.94 to -0.23 mmol/L x h (P < .05), and the maximum decrease in blood glucose concentration from 1.6 to 1.0 mmol/L (P < .05) by rifampin.",Rifampin decreases the plasma concentrations and effects of repaglinide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103752/),[mM] / [h·l],0.94,82166,DB00252,Phenytoin
,11103752,area under the concentration-time curve from 0 to 3 hours,"The blood glucose decremental area under the concentration-time curve from 0 to 3 hours was reduced from 0.94 to -0.23 mmol/L x h (P < .05), and the maximum decrease in blood glucose concentration from 1.6 to 1.0 mmol/L (P < .05) by rifampin.",Rifampin decreases the plasma concentrations and effects of repaglinide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103752/),[mM] / [h·l],-,82167,DB00252,Phenytoin
,11103752,area under the concentration-time curve from 0 to 3 hours,"The blood glucose decremental area under the concentration-time curve from 0 to 3 hours was reduced from 0.94 to -0.23 mmol/L x h (P < .05), and the maximum decrease in blood glucose concentration from 1.6 to 1.0 mmol/L (P < .05) by rifampin.",Rifampin decreases the plasma concentrations and effects of repaglinide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103752/),[mM] / [h·l],0.23,82168,DB00252,Phenytoin
,25220641,Ka,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),1/[h],0.83,82170,DB00252,Phenytoin
,25220641,Vd,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[l] / [kg],0.67,82171,DB00252,Phenytoin
,25220641,CL,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[l] / [h·kg],0.035,82172,DB00252,Phenytoin
,25220641,MP,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[mg] / [l],0.01,82173,DB00252,Phenytoin
,25220641,MAE,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[mg] / [l],0.46,82174,DB00252,Phenytoin
,25220641,MSE,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),,0.39,82175,DB00252,Phenytoin
,2260347,peak serum concentrations,Mean peak serum concentrations achieved in human volunteers after 50 and 100 mg (oral) are 3.1 and 7.0 mumols/L respectively.,Fluconazole: a new triazole antifungal agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),[mumols] / [l],3.1,82553,DB00252,Phenytoin
,2260347,peak serum concentrations,Mean peak serum concentrations achieved in human volunteers after 50 and 100 mg (oral) are 3.1 and 7.0 mumols/L respectively.,Fluconazole: a new triazole antifungal agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),[mumols] / [l],7.0,82554,DB00252,Phenytoin
,2260347,Protein binding,Protein binding is low (11 percent) and cerebrospinal fluid to serum ratio is 0.58 to 0.89.,Fluconazole: a new triazole antifungal agent. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),%,11,82555,DB00252,Phenytoin
,2260347,cerebrospinal fluid to serum ratio,Protein binding is low (11 percent) and cerebrospinal fluid to serum ratio is 0.58 to 0.89.,Fluconazole: a new triazole antifungal agent. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),,0.58 to 0.89,82556,DB00252,Phenytoin
,2260347,Serum half-life,Serum half-life is long (22-32 hours) and elimination is via renal clearance of unchanged drug.,Fluconazole: a new triazole antifungal agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),h,22-32,82557,DB00252,Phenytoin
,2089056,resolution,Calculated resolution of 2H10 CBZ from CBZ and of 2H10 PHT from PHT were 1.3.,Simultaneous separation and determination (in serum) of phenytoin and carbamazepine and their deuterated analogues by high-performance liquid chromatography--ultraviolet detection for tracer studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2089056/),,1.3,83183,DB00252,Phenytoin
,12492612,"area under the plasma unbound phenytoin concentration-time curve (AUC(0, infinity )","The area under the plasma unbound phenytoin concentration-time curve (AUC(0, infinity ); means (CAP, CEF): 58.5, 47.6 micro g ml-1 h; 95% CI for difference between means: -35.0, 11.4), the peak unbound phenytoin concentrations (Cmax; medians: 1.12, 1.29 micro g ml-1; 95% CI: -0.5, 0.04), the times to Cmax (tmax; medians: 4.0, 4.0 h; 95% CI: -2.0, 3.7), the CSF:plasma phenytoin ratios (means: 0.21, 0.22; 95% CI: -0.8, 0.10), the fraction of phenytoin unbound (means: 0.06, 0.09; 95% CI: -0.01, 0.07) and the cardiovascular parameters were not significantly different between CAP and CEF groups.",Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492612/),[h·μg] / [ml],58.5,84435,DB00252,Phenytoin
,12492612,"area under the plasma unbound phenytoin concentration-time curve (AUC(0, infinity )","The area under the plasma unbound phenytoin concentration-time curve (AUC(0, infinity ); means (CAP, CEF): 58.5, 47.6 micro g ml-1 h; 95% CI for difference between means: -35.0, 11.4), the peak unbound phenytoin concentrations (Cmax; medians: 1.12, 1.29 micro g ml-1; 95% CI: -0.5, 0.04), the times to Cmax (tmax; medians: 4.0, 4.0 h; 95% CI: -2.0, 3.7), the CSF:plasma phenytoin ratios (means: 0.21, 0.22; 95% CI: -0.8, 0.10), the fraction of phenytoin unbound (means: 0.06, 0.09; 95% CI: -0.01, 0.07) and the cardiovascular parameters were not significantly different between CAP and CEF groups.",Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492612/),[h·μg] / [ml],47.6,84436,DB00252,Phenytoin
,12492612,peak unbound phenytoin concentrations (Cmax,"The area under the plasma unbound phenytoin concentration-time curve (AUC(0, infinity ); means (CAP, CEF): 58.5, 47.6 micro g ml-1 h; 95% CI for difference between means: -35.0, 11.4), the peak unbound phenytoin concentrations (Cmax; medians: 1.12, 1.29 micro g ml-1; 95% CI: -0.5, 0.04), the times to Cmax (tmax; medians: 4.0, 4.0 h; 95% CI: -2.0, 3.7), the CSF:plasma phenytoin ratios (means: 0.21, 0.22; 95% CI: -0.8, 0.10), the fraction of phenytoin unbound (means: 0.06, 0.09; 95% CI: -0.01, 0.07) and the cardiovascular parameters were not significantly different between CAP and CEF groups.",Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492612/),[μg] / [ml],1,84437,DB00252,Phenytoin
,12492612,times to Cmax (tmax,"The area under the plasma unbound phenytoin concentration-time curve (AUC(0, infinity ); means (CAP, CEF): 58.5, 47.6 micro g ml-1 h; 95% CI for difference between means: -35.0, 11.4), the peak unbound phenytoin concentrations (Cmax; medians: 1.12, 1.29 micro g ml-1; 95% CI: -0.5, 0.04), the times to Cmax (tmax; medians: 4.0, 4.0 h; 95% CI: -2.0, 3.7), the CSF:plasma phenytoin ratios (means: 0.21, 0.22; 95% CI: -0.8, 0.10), the fraction of phenytoin unbound (means: 0.06, 0.09; 95% CI: -0.01, 0.07) and the cardiovascular parameters were not significantly different between CAP and CEF groups.",Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492612/),h,4.0,84438,DB00252,Phenytoin
,12492612,"terminal elimination half-life (t1/2,z)","However, mean terminal elimination half-life (t1/2,z) was significantly longer (23.7, 15.5 h; 95% CI: 1.71, 14.98) in the CAP group compared with the CEF group.",Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492612/),h,23,84439,DB00252,Phenytoin
,6157786,Relative bioavailability,Relative bioavailability for the conventional tablet in comparison with the microcrystallin was in the range of 48-80% during single dose administration and in the range 54-95% at steady-rate.,A comparison between microcrystalline and conventional phenytoin preparations: relative bioavailability and steady-state plasma concentrations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6157786/),%,48-80,84481,DB00252,Phenytoin
,6157786,Relative bioavailability,Relative bioavailability for the conventional tablet in comparison with the microcrystallin was in the range of 48-80% during single dose administration and in the range 54-95% at steady-rate.,A comparison between microcrystalline and conventional phenytoin preparations: relative bioavailability and steady-state plasma concentrations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6157786/),%,54-95,84482,DB00252,Phenytoin
,6617043,Vm,"The Vm and Km of a 70 kg adult male European were estimated to be 415 mg/day and 5.7 mg/L, respectively.",Steady-state pharmacokinetics of phenytoin from routinely collected patient data. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617043/),[mg] / [d],415,84561,DB00252,Phenytoin
,6617043,Km,"The Vm and Km of a 70 kg adult male European were estimated to be 415 mg/day and 5.7 mg/L, respectively.",Steady-state pharmacokinetics of phenytoin from routinely collected patient data. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617043/),[mg] / [l],5.7,84562,DB00252,Phenytoin
,2273084,ASC,"Observed ASC during weeks 5 and 6 were (mean +/- SD) 0.25 +/- 0.09 micrograms/mL and 0.19 +/- 0.07 micrograms/mL, respectively.",Effect of phenytoin on the clinical pharmacokinetics of amiodarone. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273084/),[μg] / [ml],0.25,84977,DB00252,Phenytoin
,2273084,ASC,"Observed ASC during weeks 5 and 6 were (mean +/- SD) 0.25 +/- 0.09 micrograms/mL and 0.19 +/- 0.07 micrograms/mL, respectively.",Effect of phenytoin on the clinical pharmacokinetics of amiodarone. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273084/),[μg] / [ml],0.19,84978,DB00252,Phenytoin
,2273084,ASC,Corresponding predicted ASC were 0.36 +/- 0.12 micrograms/mL (P = .011) and 0.38 +/- 0.13 micrograms/mL (P = .004).,Effect of phenytoin on the clinical pharmacokinetics of amiodarone. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273084/),[μg] / [ml],0.36,84979,DB00252,Phenytoin
,2273084,ASC,Corresponding predicted ASC were 0.36 +/- 0.12 micrograms/mL (P = .011) and 0.38 +/- 0.13 micrograms/mL (P = .004).,Effect of phenytoin on the clinical pharmacokinetics of amiodarone. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273084/),[μg] / [ml],0.38,84980,DB00252,Phenytoin
,8799524,half-lives,"2. Compared with controls, epileptic patients showed markedly shorter ethosuximide half-lives (29.0 +/- 7.8 vs 53.7 +/- 14.3 h, means +/- s.d., P < 0.001) and higher apparent oral clearance (CL/F) values (15.3 +/- 3.8 vs 9.2 +/- 1.9 ml kg-1 h-1, P < 0.001).",Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799524/),h,29.0,85129,DB00252,Phenytoin
,8799524,half-lives,"2. Compared with controls, epileptic patients showed markedly shorter ethosuximide half-lives (29.0 +/- 7.8 vs 53.7 +/- 14.3 h, means +/- s.d., P < 0.001) and higher apparent oral clearance (CL/F) values (15.3 +/- 3.8 vs 9.2 +/- 1.9 ml kg-1 h-1, P < 0.001).",Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799524/),h,53.7,85130,DB00252,Phenytoin
,8799524,apparent oral clearance (CL/F),"2. Compared with controls, epileptic patients showed markedly shorter ethosuximide half-lives (29.0 +/- 7.8 vs 53.7 +/- 14.3 h, means +/- s.d., P < 0.001) and higher apparent oral clearance (CL/F) values (15.3 +/- 3.8 vs 9.2 +/- 1.9 ml kg-1 h-1, P < 0.001).",Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799524/),[ml] / [h·kg],15.3,85131,DB00252,Phenytoin
,8799524,apparent oral clearance (CL/F),"2. Compared with controls, epileptic patients showed markedly shorter ethosuximide half-lives (29.0 +/- 7.8 vs 53.7 +/- 14.3 h, means +/- s.d., P < 0.001) and higher apparent oral clearance (CL/F) values (15.3 +/- 3.8 vs 9.2 +/- 1.9 ml kg-1 h-1, P < 0.001).",Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799524/),[ml] / [h·kg],9.2,85132,DB00252,Phenytoin
,8799524,apparent volume of distribution (V/F),"The apparent volume of distribution (V/F) of ethosuximide was slightly lower in the patients than in controls (0.6 +/- 0.1 vs 0.7 +/- 0.1 l kg-1, P < 0.05).",Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799524/),[l] / [kg],0.6,85133,DB00252,Phenytoin
,8799524,apparent volume of distribution (V/F),"The apparent volume of distribution (V/F) of ethosuximide was slightly lower in the patients than in controls (0.6 +/- 0.1 vs 0.7 +/- 0.1 l kg-1, P < 0.05).",Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799524/),[l] / [kg],0.7,85134,DB00252,Phenytoin
,1139863,half-life (T/2),"In 8 patients DPH means half-life (T/2) increased from 11.8 plus or minus 3.6 hr to 19.6 plus or minus 5.2 hr and mean metabolic clearance rate (MCR) decreased from 43.7 plus or minus 16,8 to 28.1 plus or minus 9.1 ml/min durus or minus 1.2 to 9.2 plus or minus 1.2 hr MCR decrease from 17.0 plus or minus 5.4 to 10.5 plus or minus 1.2 ml/min.","Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),h,11.8,85544,DB00252,Phenytoin
,1139863,half-life (T/2),"In 8 patients DPH means half-life (T/2) increased from 11.8 plus or minus 3.6 hr to 19.6 plus or minus 5.2 hr and mean metabolic clearance rate (MCR) decreased from 43.7 plus or minus 16,8 to 28.1 plus or minus 9.1 ml/min durus or minus 1.2 to 9.2 plus or minus 1.2 hr MCR decrease from 17.0 plus or minus 5.4 to 10.5 plus or minus 1.2 ml/min.","Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),h,19.6,85545,DB00252,Phenytoin
,1139863,metabolic clearance rate (MCR),"In 8 patients DPH means half-life (T/2) increased from 11.8 plus or minus 3.6 hr to 19.6 plus or minus 5.2 hr and mean metabolic clearance rate (MCR) decreased from 43.7 plus or minus 16,8 to 28.1 plus or minus 9.1 ml/min durus or minus 1.2 to 9.2 plus or minus 1.2 hr MCR decrease from 17.0 plus or minus 5.4 to 10.5 plus or minus 1.2 ml/min.","Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),[ml] / [min],43.7,85546,DB00252,Phenytoin
,1139863,metabolic clearance rate (MCR),"In 8 patients DPH means half-life (T/2) increased from 11.8 plus or minus 3.6 hr to 19.6 plus or minus 5.2 hr and mean metabolic clearance rate (MCR) decreased from 43.7 plus or minus 16,8 to 28.1 plus or minus 9.1 ml/min durus or minus 1.2 to 9.2 plus or minus 1.2 hr MCR decrease from 17.0 plus or minus 5.4 to 10.5 plus or minus 1.2 ml/min.","Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),[ml] / [min],28.1,85547,DB00252,Phenytoin
,1139863,metabolic clearance rate (MCR),"In 8 patients DPH means half-life (T/2) increased from 11.8 plus or minus 3.6 hr to 19.6 plus or minus 5.2 hr and mean metabolic clearance rate (MCR) decreased from 43.7 plus or minus 16,8 to 28.1 plus or minus 9.1 ml/min durus or minus 1.2 to 9.2 plus or minus 1.2 hr MCR decrease from 17.0 plus or minus 5.4 to 10.5 plus or minus 1.2 ml/min.","Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),h,9.2,85548,DB00252,Phenytoin
,1139863,MCR,"In 8 patients DPH means half-life (T/2) increased from 11.8 plus or minus 3.6 hr to 19.6 plus or minus 5.2 hr and mean metabolic clearance rate (MCR) decreased from 43.7 plus or minus 16,8 to 28.1 plus or minus 9.1 ml/min durus or minus 1.2 to 9.2 plus or minus 1.2 hr MCR decrease from 17.0 plus or minus 5.4 to 10.5 plus or minus 1.2 ml/min.","Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),[ml] / [min],17.0,85549,DB00252,Phenytoin
,1139863,MCR,"In 8 patients DPH means half-life (T/2) increased from 11.8 plus or minus 3.6 hr to 19.6 plus or minus 5.2 hr and mean metabolic clearance rate (MCR) decreased from 43.7 plus or minus 16,8 to 28.1 plus or minus 9.1 ml/min durus or minus 1.2 to 9.2 plus or minus 1.2 hr MCR decrease from 17.0 plus or minus 5.4 to 10.5 plus or minus 1.2 ml/min.","Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),[ml] / [min],10.5,85550,DB00252,Phenytoin
,1139863,T/2,In 2 patients warfarin T/2 increased fron an average of 64.7 to 92.7 hr and MCR decreased from 1.65 ml/min to 1.05 ml/min.,"Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),h,64.7 to 92.7,85551,DB00252,Phenytoin
,1139863,MCR,In 2 patients warfarin T/2 increased fron an average of 64.7 to 92.7 hr and MCR decreased from 1.65 ml/min to 1.05 ml/min.,"Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),[ml] / [min],1.65,85552,DB00252,Phenytoin
,1139863,MCR,In 2 patients warfarin T/2 increased fron an average of 64.7 to 92.7 hr and MCR decreased from 1.65 ml/min to 1.05 ml/min.,"Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),[ml] / [min],1.05,85553,DB00252,Phenytoin
,7311392,Bioavailability,"Bioavailability of Hct showed considerable intra- and interindividual variation (32--87% and 42--77% respectively), but phenytoin did not influence the disposition parameters of the diuretic.",Disposition of hydrochlorothiazide (Hct) during phenytoin (Ph) treatment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7311392/),,32,85619,DB00252,Phenytoin
,7311392,Bioavailability,"Bioavailability of Hct showed considerable intra- and interindividual variation (32--87% and 42--77% respectively), but phenytoin did not influence the disposition parameters of the diuretic.",Disposition of hydrochlorothiazide (Hct) during phenytoin (Ph) treatment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7311392/),,42,85620,DB00252,Phenytoin
,20205992,elimination half-life,"Its elimination half-life is very long, around 60 h.",[Therapeutic drug monitoring of zonisamide]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20205992/),h,60,86087,DB00252,Phenytoin
,26658225,t1/2,The t1/2 for CYP3A4 mRNA was 26 hours and that for the functional protein was 49 hours.,Application of Micropatterned Cocultured Hepatocytes to Evaluate the Inductive Potential and Degradation Rate of Major Xenobiotic Metabolizing Enzymes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26658225/),h,26,88520,DB00252,Phenytoin
,26658225,t1/2,The t1/2 for CYP3A4 mRNA was 26 hours and that for the functional protein was 49 hours.,Application of Micropatterned Cocultured Hepatocytes to Evaluate the Inductive Potential and Degradation Rate of Major Xenobiotic Metabolizing Enzymes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26658225/),h,49,88521,DB00252,Phenytoin
,26658225,t1/2,"The t1/2 of CYP2B6 was 38 hours (mRNA) and 68 hours (activity), which is longer than CYP3A4 and shows the differential turnover of these two proteins.",Application of Micropatterned Cocultured Hepatocytes to Evaluate the Inductive Potential and Degradation Rate of Major Xenobiotic Metabolizing Enzymes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26658225/),h,38,88522,DB00252,Phenytoin
,26658225,t1/2,"The t1/2 of CYP2B6 was 38 hours (mRNA) and 68 hours (activity), which is longer than CYP3A4 and shows the differential turnover of these two proteins.",Application of Micropatterned Cocultured Hepatocytes to Evaluate the Inductive Potential and Degradation Rate of Major Xenobiotic Metabolizing Enzymes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26658225/),h,68,88523,DB00252,Phenytoin
,9712466,Vd,"The Vd was estimated to be 0.95 l/kg, assuming an albumin level of 3 g/dl.",Non-steady state population kinetics of intravenous phenytoin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712466/),[l] / [kg],0.95,90165,DB00252,Phenytoin
,9712466,Michaelis-Menten constant (km),The Michaelis-Menten constant (km) was estimated to be 7.9 mg/l.,Non-steady state population kinetics of intravenous phenytoin. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712466/),[mg] / [l],7.9,90166,DB00252,Phenytoin
,9712466,maximum metabolic rate,The baseline maximum metabolic rate was 580 mg/day for a 70-kg patient.,Non-steady state population kinetics of intravenous phenytoin. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712466/),[mg] / [d],580,90167,DB00252,Phenytoin
,9712466,time to onset of induction,The average time to onset of induction was 59.5 hours.,Non-steady state population kinetics of intravenous phenytoin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712466/),h,59.5,90168,DB00252,Phenytoin
,7273603,total phenytoin clearance,The mean (+/- SD) total phenytoin clearance in 9 of 11 subjects was 0.023 +/- 0.006 l/kg/hr during the alcohol ingestion period.,Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7273603/),[l] / [h·kg],0.023,90737,DB00252,Phenytoin
,7273603,Clearance,Clearance rose to 0.033 +/- 0.013 l/kg/hr (P less than 0.05) during alcohol withdrawal.,Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7273603/),[l] / [h·kg],0.033,90738,DB00252,Phenytoin
,7273603,Total steady-state concentration,"Total steady-state concentration after 3 wk ranged from 3.4 to 29.9 mg/l, while the weight-corrected dose range was only 3.7 to 5.5 mg/kg/day.",Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7273603/),[mg] / [l],3.4 to 29.9,90739,DB00252,Phenytoin
,11510628,time to reach maximum observed plasma concentration,"In pharmacokinetic studies in humans, quetiapine was rapidly absorbed after oral administration, with median time to reach maximum observed plasma concentration ranging from 1 to 2 hours.",Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510628/),h,1 to 2,91263,DB00252,Phenytoin
,11510628,terminal half-life,The drug is eliminated with a mean terminal half-life of approximately 7 hours.,Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510628/),h,7,91264,DB00252,Phenytoin
,9821815,rate constant,"EDPH was rapidly hydrolyzed to DPH in the intestinal fluid and the mucosa (rate constant, 0.055 and 0.169 min(-1), respectively).",Enhancement of the oral bioavailability of phenytoin by N-acetylation and absorptive characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821815/),1/[min],0.055,91395,DB00252,Phenytoin
,9821815,rate constant,"EDPH was rapidly hydrolyzed to DPH in the intestinal fluid and the mucosa (rate constant, 0.055 and 0.169 min(-1), respectively).",Enhancement of the oral bioavailability of phenytoin by N-acetylation and absorptive characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821815/),1/[min],0.169,91396,DB00252,Phenytoin
,9821815,bioavailability,"When dosed orally (25 mg/kg, DPH equivalent), the plasma levels of DPH converted from the prodrug were significantly higher and more sustained than those after DPH alone, giving bioavailability 11.4 (rapid decay) and 9.1 times (slow decay) as high, respectively, as that after DPH alone.",Enhancement of the oral bioavailability of phenytoin by N-acetylation and absorptive characteristics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821815/),,11,91397,DB00252,Phenytoin
,9821815,bioavailability,"When dosed orally (25 mg/kg, DPH equivalent), the plasma levels of DPH converted from the prodrug were significantly higher and more sustained than those after DPH alone, giving bioavailability 11.4 (rapid decay) and 9.1 times (slow decay) as high, respectively, as that after DPH alone.",Enhancement of the oral bioavailability of phenytoin by N-acetylation and absorptive characteristics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821815/),,9,91398,DB00252,Phenytoin
,27174459,Vmax,"The final PPK model equations of oral phenytoin were found to be as follows: for patients with CYP2C9 *1/*1, Vmax=22.66.(BWT/60.96)0.454(mg/h) and Km; =4.03 (mg/L); for patients with CYP2C9*1/*3, Vmax = 16.65.",Population Pharmacokinetics of Phenytoin Based on NONMEM in Patients with Intracranial Tumor During the First Week of Post-Craniotomy. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174459/),[mg] / [h],22,91966,DB00252,Phenytoin
,27174459,Km;,"The final PPK model equations of oral phenytoin were found to be as follows: for patients with CYP2C9 *1/*1, Vmax=22.66.(BWT/60.96)0.454(mg/h) and Km; =4.03 (mg/L); for patients with CYP2C9*1/*3, Vmax = 16.65.",Population Pharmacokinetics of Phenytoin Based on NONMEM in Patients with Intracranial Tumor During the First Week of Post-Craniotomy. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174459/),[mg] / [l],4.03,91967,DB00252,Phenytoin
,27174459,Vmax,"The final PPK model equations of oral phenytoin were found to be as follows: for patients with CYP2C9 *1/*1, Vmax=22.66.(BWT/60.96)0.454(mg/h) and Km; =4.03 (mg/L); for patients with CYP2C9*1/*3, Vmax = 16.65.",Population Pharmacokinetics of Phenytoin Based on NONMEM in Patients with Intracranial Tumor During the First Week of Post-Craniotomy. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174459/),,16.65,91968,DB00252,Phenytoin
,27174459,BWT / 60.96,(BWT / 60.96 )0.454(mg/h) and Km =5.96 (mg/L).,Population Pharmacokinetics of Phenytoin Based on NONMEM in Patients with Intracranial Tumor During the First Week of Post-Craniotomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174459/),[mg] / [h],0.454,91969,DB00252,Phenytoin
,27174459,Km,(BWT / 60.96 )0.454(mg/h) and Km =5.96 (mg/L).,Population Pharmacokinetics of Phenytoin Based on NONMEM in Patients with Intracranial Tumor During the First Week of Post-Craniotomy. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174459/),[mg] / [l],5.96,91970,DB00252,Phenytoin
,1877275,first-order elimination rate constant,The effect of MDAC on the clearance of phenytoin can be described by a first-order elimination rate constant of approximately 0.02-0.04/h.,Pharmacokinetic simulation of the effect of multiple-dose activated charcoal in phenytoin poisoning--report of two pediatric cases. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1877275/),1/[h],0.02-0.04,92079,DB00252,Phenytoin
,7843173,Tmax,"After administration, phenytoin rapidly appeared in both serum (Tmax mean range 0.15-0.38 h) and CSF (Tmax mean range 0.9-1.4 h), suggesting ready penetration of the blood-brain barrier.",Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: phenytoin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7843173/),h,0.15-0.38,92440,DB00252,Phenytoin
,7843173,Tmax,"After administration, phenytoin rapidly appeared in both serum (Tmax mean range 0.15-0.38 h) and CSF (Tmax mean range 0.9-1.4 h), suggesting ready penetration of the blood-brain barrier.",Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: phenytoin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7843173/),h,0.9-1.4,92441,DB00252,Phenytoin
,15777995,Vm,"The population estimates of F-PHT for Vm and Km were 9.1 mg/kg/day and 7.3 mg/L, respectively.",Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15777995/),[mg] / [d·kg],9.1,95064,DB00252,Phenytoin
,15777995,Km,"The population estimates of F-PHT for Vm and Km were 9.1 mg/kg/day and 7.3 mg/L, respectively.",Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15777995/),[mg] / [l],7.3,95065,DB00252,Phenytoin
,7104173,area under the plasma mexiletine concentration-time curve,3 The mean +/- s.d. area under the plasma mexiletine concentration-time curve decreased from 17.67 +/- 6.21 to 8.01 +/- 3.64 micrograms ml-1 h (P less than 0.003).,Enhanced metabolism of mexiletine after phenytoin administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104173/),[h·μg] / [ml],17.67,96627,DB00252,Phenytoin
,7104173,area under the plasma mexiletine concentration-time curve,3 The mean +/- s.d. area under the plasma mexiletine concentration-time curve decreased from 17.67 +/- 6.21 to 8.01 +/- 3.64 micrograms ml-1 h (P less than 0.003).,Enhanced metabolism of mexiletine after phenytoin administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104173/),[h·μg] / [ml],8.01,96628,DB00252,Phenytoin
,7104173,half-life of elimination,4 The mean +/- s.d. half-life of elimination of mexiletine decreased from 17.2 +/- 5.26 to 8.4 +/- 4.17 h (P less than 0.02) 5,Enhanced metabolism of mexiletine after phenytoin administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104173/),h,17.2,96629,DB00252,Phenytoin
,7104173,half-life of elimination,4 The mean +/- s.d. half-life of elimination of mexiletine decreased from 17.2 +/- 5.26 to 8.4 +/- 4.17 h (P less than 0.02) 5,Enhanced metabolism of mexiletine after phenytoin administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104173/),h,8.4,96630,DB00252,Phenytoin
,3975264,unbound drug,"Mean (+/- SD) values were 0.026 +/- 0.009 1 . h-1 . kg-1, 0.385 +/- 0.148 1 . h-1 . kg-1, 12.6 +/- 3.5 l/kg (referenced to unbound drug), 28.0 +/- 12.1 h, and 25.9 +/- 13.5 h, respectively.",Phenytoin as a probe of drug metabolism. Predicting clearance with a salivary sample. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3975264/),[l] / [kg],12.6,97413,DB00252,Phenytoin
,3975264,unbound drug,"Mean (+/- SD) values were 0.026 +/- 0.009 1 . h-1 . kg-1, 0.385 +/- 0.148 1 . h-1 . kg-1, 12.6 +/- 3.5 l/kg (referenced to unbound drug), 28.0 +/- 12.1 h, and 25.9 +/- 13.5 h, respectively.",Phenytoin as a probe of drug metabolism. Predicting clearance with a salivary sample. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3975264/),h,25.9,97414,DB00252,Phenytoin
,3975264,V/F,"When V/F referenced to unbound PHT was set at 14 l/kg, CL'int/F estimates were good predictors of the actual CL'int/F values demonstrating a mean prediction error of -9.012 1.h-1.kg-1.",Phenytoin as a probe of drug metabolism. Predicting clearance with a salivary sample. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3975264/),[l] / [kg],14,97415,DB00252,Phenytoin
less,4006737,clearance rate,This dialysis resulted in a clearance rate less than 1 ml/min.,Phenytoin clearance by continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006737/),[ml] / [min],1,98055,DB00252,Phenytoin
,2038745,systemic clearance (Cls),"The mean systemic clearance (Cls) for AC in the adults and pups was 16.1 and 13.7 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],16.1,99215,DB00252,Phenytoin
,2038745,systemic clearance (Cls),"The mean systemic clearance (Cls) for AC in the adults and pups was 16.1 and 13.7 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],13.7,99216,DB00252,Phenytoin
,2038745,half-lives,"The mean half-lives of AC (t1/2) were 25.5 and 33.3 min in the adult and pup groups, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,25.5,99217,DB00252,Phenytoin
,2038745,half-lives,"The mean half-lives of AC (t1/2) were 25.5 and 33.3 min in the adult and pup groups, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,33.3,99218,DB00252,Phenytoin
,2038745,t1/2,"In a younger group of pups (18-21 days old) it declined with a longer t1/2 (97.5, 95.1, and 347.6 min in the adults, older pups, and younger pups, respectively).","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,97.5,99219,DB00252,Phenytoin
,2038745,t1/2,"In a younger group of pups (18-21 days old) it declined with a longer t1/2 (97.5, 95.1, and 347.6 min in the adults, older pups, and younger pups, respectively).","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,95.1,99220,DB00252,Phenytoin
,2038745,t1/2,"In a younger group of pups (18-21 days old) it declined with a longer t1/2 (97.5, 95.1, and 347.6 min in the adults, older pups, and younger pups, respectively).","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,347.6,99221,DB00252,Phenytoin
,2038745,Cls,"The mean AN Cls in the adults, the older pups, and the younger pups was 5.34, 6.30, and 1.91 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],5.34,99222,DB00252,Phenytoin
,2038745,Cls,"The mean AN Cls in the adults, the older pups, and the younger pups was 5.34, 6.30, and 1.91 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],6.30,99223,DB00252,Phenytoin
,2038745,Cls,"The mean AN Cls in the adults, the older pups, and the younger pups was 5.34, 6.30, and 1.91 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],1.91,99224,DB00252,Phenytoin
,2038745,t1/2,The time course of SA was prolonged in the suckling pups (t1/2 of 633 min in the pups vs 78.7 min in the adult).,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,633,99225,DB00252,Phenytoin
,2038745,t1/2,The time course of SA was prolonged in the suckling pups (t1/2 of 633 min in the pups vs 78.7 min in the adult).,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,78.7,99226,DB00252,Phenytoin
,2038745,Cls,"The mean Cls values in the adults and the pups were 1.05 and 0.27 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],1.05,99227,DB00252,Phenytoin
,2038745,Cls,"The mean Cls values in the adults and the pups were 1.05 and 0.27 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],0.27,99228,DB00252,Phenytoin
,2038745,systemic clearance of unbound drug (Clu),The mean systemic clearance of unbound drug (Clu) for SA was 11.2 ml/min/kg in the adults and 0.92 ml/min/kg in the pups.,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],11.2,99229,DB00252,Phenytoin
,2038745,systemic clearance of unbound drug (Clu),The mean systemic clearance of unbound drug (Clu) for SA was 11.2 ml/min/kg in the adults and 0.92 ml/min/kg in the pups.,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],0.92,99230,DB00252,Phenytoin
,2038745,free fraction,"The serum protein binding of AC and AN was limited, whereas the mean free fraction for SA was 9.7% in adult serum and 32.5% in pup serum.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),%,9.7,99231,DB00252,Phenytoin
,2038745,free fraction,"The serum protein binding of AC and AN was limited, whereas the mean free fraction for SA was 9.7% in adult serum and 32.5% in pup serum.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),%,32.5,99232,DB00252,Phenytoin
,475946,half life of elimination,"The half life of elimination of the drug was shorter in the bypass group (15.1 h) than in the controls (17.8 h, P less than 0.05).",Phenytoin absorption in patients with ileojejunal bypass. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/475946/),h,15.1,99719,DB00252,Phenytoin
,475946,half life of elimination,"The half life of elimination of the drug was shorter in the bypass group (15.1 h) than in the controls (17.8 h, P less than 0.05).",Phenytoin absorption in patients with ileojejunal bypass. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/475946/),h,17.8,99720,DB00252,Phenytoin
,10604819,metabolite-to-parent drug ratio,"The metabolite-to-parent drug ratio shifted from a median value of 2.8 in group A to 13 in group B, and up to 29 in patients receiving polytherapy with FBM (p < 0.001).",Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604819/),,2.8,99721,DB00252,Phenytoin
,10604819,metabolite-to-parent drug ratio,"The metabolite-to-parent drug ratio shifted from a median value of 2.8 in group A to 13 in group B, and up to 29 in patients receiving polytherapy with FBM (p < 0.001).",Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604819/),,13,99722,DB00252,Phenytoin
,10604819,metabolite-to-parent drug ratio,"The metabolite-to-parent drug ratio shifted from a median value of 2.8 in group A to 13 in group B, and up to 29 in patients receiving polytherapy with FBM (p < 0.001).",Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604819/),,29,99723,DB00252,Phenytoin
,24259740,clearance,Phenytoin clearance by CVVH ranged from 11 to 13 mL/min in these patients.,Phenytoin removal by continuous venovenous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24259740/),[ml] / [min],11 to 13,101362,DB00252,Phenytoin
,17240061,"maximal concentration, C(max)","In pre-treated rats with V, hippocampal PHT concentrations were lower in MP (maximal concentration, C(max): 2.7+/-0.3 microg ml(-1), p<0.05 versus C rats) than in C animals (C(max): 5.3+/-0.9 microg ml(-1)).",Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240061/),[μg] / [ml],2.7,101476,DB00252,Phenytoin
,17240061,C(max),"In pre-treated rats with V, hippocampal PHT concentrations were lower in MP (maximal concentration, C(max): 2.7+/-0.3 microg ml(-1), p<0.05 versus C rats) than in C animals (C(max): 5.3+/-0.9 microg ml(-1)).",Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240061/),[μg] / [ml],5.3,101477,DB00252,Phenytoin
,17240061,C(max),"Control rats pre-treated with NIMO showed similar results (C(max): 4.5+/-0.8 microg ml(-1)) than those pre-treated with V. NIMO pre-treatment of MP rats showed higher PHT concentrations (C(max): 6.8+/-1.0 microg ml(-1), p<0.05) when compared with V pre-treated MP group.",Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240061/),[μg] / [ml],4.5,101478,DB00252,Phenytoin
,17240061,C(max),"Control rats pre-treated with NIMO showed similar results (C(max): 4.5+/-0.8 microg ml(-1)) than those pre-treated with V. NIMO pre-treatment of MP rats showed higher PHT concentrations (C(max): 6.8+/-1.0 microg ml(-1), p<0.05) when compared with V pre-treated MP group.",Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240061/),[μg] / [ml],6.8,101479,DB00252,Phenytoin
,9200141,Mortality rates,"Mortality rates were 12.5% and 35.2% in males and 15.3% and 33.3% in females for the 25 and 35 mg/kg PHT-treated groups during the PHT treatment, respectively.",Effects of low-dose phenytoin administered to newborn mice on developing cerebellum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9200141/),%,12.5,102040,DB00252,Phenytoin
,9200141,Mortality rates,"Mortality rates were 12.5% and 35.2% in males and 15.3% and 33.3% in females for the 25 and 35 mg/kg PHT-treated groups during the PHT treatment, respectively.",Effects of low-dose phenytoin administered to newborn mice on developing cerebellum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9200141/),%,35.2,102041,DB00252,Phenytoin
,9200141,Mortality rates,"Mortality rates were 12.5% and 35.2% in males and 15.3% and 33.3% in females for the 25 and 35 mg/kg PHT-treated groups during the PHT treatment, respectively.",Effects of low-dose phenytoin administered to newborn mice on developing cerebellum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9200141/),%,15.3,102042,DB00252,Phenytoin
,9200141,Mortality rates,"Mortality rates were 12.5% and 35.2% in males and 15.3% and 33.3% in females for the 25 and 35 mg/kg PHT-treated groups during the PHT treatment, respectively.",Effects of low-dose phenytoin administered to newborn mice on developing cerebellum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9200141/),%,33.3,102043,DB00252,Phenytoin
,12076842,Cl(o),"In a subset analysis of completers, LTG Cl(o) determined prior to withdrawal of the inducers was significantly greater in patients (n=28) on LTG+PHT (160% increase) than in those (n=48) receiving LTG+CBZ (62% increase): 1.77+/-0.77 vs. 1.06+/-0.41 ml/min/kg, respectively, p=0.017.",Time course of lamotrigine de-induction: impact of step-wise withdrawal of carbamazepine or phenytoin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12076842/),[ml] / [kg·min],1.77,103868,DB00252,Phenytoin
,12076842,Cl(o),"In a subset analysis of completers, LTG Cl(o) determined prior to withdrawal of the inducers was significantly greater in patients (n=28) on LTG+PHT (160% increase) than in those (n=48) receiving LTG+CBZ (62% increase): 1.77+/-0.77 vs. 1.06+/-0.41 ml/min/kg, respectively, p=0.017.",Time course of lamotrigine de-induction: impact of step-wise withdrawal of carbamazepine or phenytoin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12076842/),[ml] / [kg·min],1.06,103869,DB00252,Phenytoin
,26536021,serum concentration,"All patients achieved the therapeutic level of free phenytoin (1-2 mg/L) at the end of infusion, but most patients (28/30) entered the markedly supratherapeutic range and the mean serum concentration was 17.7 ± 8.13 mg/L; higher serum concentration was maintained up to 20 minutes after infusion (mean concentration; 3.46 ± 3.75 mg/L).","Safety, Tolerability, and Pharmacokinetics of Fosphenytoin Loading in Patients With Subarachnoid Hemorrhage. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26536021/),[mg] / [l],17.7,104219,DB00252,Phenytoin
,28179720,tRAT scores,"Mean tRAT scores were 78.5% for the Tampa cohort and 82.2% for the Las Vegas cohort, compared to 89.5% for the online cohort.",Using Team-based Learning to Teach a Hybrid Pharmacokinetics Course Online and in Class. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28179720/),%,78.5,104315,DB00252,Phenytoin
,28179720,tRAT scores,"Mean tRAT scores were 78.5% for the Tampa cohort and 82.2% for the Las Vegas cohort, compared to 89.5% for the online cohort.",Using Team-based Learning to Teach a Hybrid Pharmacokinetics Course Online and in Class. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28179720/),%,82.2,104316,DB00252,Phenytoin
,28179720,tRAT scores,"Mean tRAT scores were 78.5% for the Tampa cohort and 82.2% for the Las Vegas cohort, compared to 89.5% for the online cohort.",Using Team-based Learning to Teach a Hybrid Pharmacokinetics Course Online and in Class. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28179720/),%,89.5,104317,DB00252,Phenytoin
,797496,half-life,It has a relatively long half-life (in adults 2 to 3 days; in children shorter).,Clinical pharmacokinetics of anticonvulsants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/797496/),d,2 to 3,104851,DB00252,Phenytoin
,18982494,AUC,"The absorption (k(a)) and elimination rate constant (k(e)) were not altered significantly, however the AUC increased from 65.6 to 106.7 mug.hr/ml after phenytoin suspension or emulsion oral administration, respectively.",Gastrointestinal absorption of phenytoin from an oil-in-water microemulsion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18982494/),[h·μg] / [ml],65.6,106128,DB00252,Phenytoin
,18982494,AUC,"The absorption (k(a)) and elimination rate constant (k(e)) were not altered significantly, however the AUC increased from 65.6 to 106.7 mug.hr/ml after phenytoin suspension or emulsion oral administration, respectively.",Gastrointestinal absorption of phenytoin from an oil-in-water microemulsion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18982494/),[h·μg] / [ml],106.7,106129,DB00252,Phenytoin
,18982494,diffusion rate constant (k(IE)),"From an equilibrium dialysis study, the diffusion rate constant (k(IE)) was considerably higher from the phenytoin Na emulsion (0.0439 hr(-1)) than phenytoin suspension (0.0014 hr(-1)).",Gastrointestinal absorption of phenytoin from an oil-in-water microemulsion. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18982494/),1/[hr],0.0439,106130,DB00252,Phenytoin
,18982494,diffusion rate constant (k(IE)),"From an equilibrium dialysis study, the diffusion rate constant (k(IE)) was considerably higher from the phenytoin Na emulsion (0.0439 hr(-1)) than phenytoin suspension (0.0014 hr(-1)).",Gastrointestinal absorption of phenytoin from an oil-in-water microemulsion. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18982494/),1/[hr],0.0014,106131,DB00252,Phenytoin
,1769232,"""","The ""half-life"" increases with concentration, varying from 8-24 hr up to weeks, making it difficult to obtain the steady state levels needed by most prediction algorithms and nomograms.",A method for prediction of phenytoin levels in the acute clinical setting. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1769232/),h,8-24,106422,DB00252,Phenytoin
,1769232,"half-life""","The ""half-life"" increases with concentration, varying from 8-24 hr up to weeks, making it difficult to obtain the steady state levels needed by most prediction algorithms and nomograms.",A method for prediction of phenytoin levels in the acute clinical setting. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1769232/),h,8-24,106423,DB00252,Phenytoin
over,10612356,elimination half-lives,"The route of elimination differs to an important extent from one compound to another, and elimination half-lives range from over 30 h for zonisamide to 5-7 h for gabapentin.",The clinical pharmacokinetics of the new antiepileptic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10612356/),h,30,106800,DB00252,Phenytoin
,10612356,elimination half-lives,"The route of elimination differs to an important extent from one compound to another, and elimination half-lives range from over 30 h for zonisamide to 5-7 h for gabapentin.",The clinical pharmacokinetics of the new antiepileptic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10612356/),h,5-7,106801,DB00252,Phenytoin
,17164696,volume of,[1 + 0.0692.(postnatal age (d) - 11)]; volume of distribution (L) = 74.2.[WT (kg) / 70]; absolute enteral bioavailability = 0.76; absorption rate constant (h) = 0.167.,Application of routine monitoring data for determination of the population pharmacokinetics and enteral bioavailability of phenytoin in neonates and infants with seizures. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17164696/),,74.2,107026,DB00252,Phenytoin
,17164696,absolute enteral bioavailability,[1 + 0.0692.(postnatal age (d) - 11)]; volume of distribution (L) = 74.2.[WT (kg) / 70]; absolute enteral bioavailability = 0.76; absorption rate constant (h) = 0.167.,Application of routine monitoring data for determination of the population pharmacokinetics and enteral bioavailability of phenytoin in neonates and infants with seizures. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17164696/),,0.76,107027,DB00252,Phenytoin
,17164696,absorption rate constant (h),[1 + 0.0692.(postnatal age (d) - 11)]; volume of distribution (L) = 74.2.[WT (kg) / 70]; absolute enteral bioavailability = 0.76; absorption rate constant (h) = 0.167.,Application of routine monitoring data for determination of the population pharmacokinetics and enteral bioavailability of phenytoin in neonates and infants with seizures. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17164696/),,0.167,107028,DB00252,Phenytoin
,577918,bioavailability,The highest bioavailability was obtained with suspension prepared from the micronized raw material of DPH and the lowest bioavailability (26% of that of the former suspension) with the tablets having the largest particle size of DPH.,Factors affecting the bioavailability of phenytoin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/577918/),%,26,107548,DB00252,Phenytoin
,2242706,terminal half-life,"The terminal half-life of thiopental averaged 9 h, the total plasma clearance 0.20 l/h/kg, and the steady-state volume of distribution 3.6 l/h/kg.",Thiopental efficacy in phenobarbital-resistant neonatal seizures. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2242706/),h,9,107849,DB00252,Phenytoin
,2242706,total plasma clearance,"The terminal half-life of thiopental averaged 9 h, the total plasma clearance 0.20 l/h/kg, and the steady-state volume of distribution 3.6 l/h/kg.",Thiopental efficacy in phenobarbital-resistant neonatal seizures. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2242706/),[l] / [h·kg],0.20,107850,DB00252,Phenytoin
,2242706,steady-state volume of distribution,"The terminal half-life of thiopental averaged 9 h, the total plasma clearance 0.20 l/h/kg, and the steady-state volume of distribution 3.6 l/h/kg.",Thiopental efficacy in phenobarbital-resistant neonatal seizures. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2242706/),[l] / [h·kg],3.6,107851,DB00252,Phenytoin
,6509876,time to reach the,"The maximum plasma concentration (Cmax), time to reach maximum plasma concentration, time to reach the lower end (10 mg/liter) of the therapeutic range, time to reach a plasma concentration greater than 15 mg/liter, and time within the therapeutic range were determined for each loading-dose regimen.",Absorption characteristics of three phenytoin sodium products after administration of oral loading doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6509876/),,10,108188,DB00252,Phenytoin
greater,6509876,time to reach a plasma concentration,"The maximum plasma concentration (Cmax), time to reach maximum plasma concentration, time to reach the lower end (10 mg/liter) of the therapeutic range, time to reach a plasma concentration greater than 15 mg/liter, and time within the therapeutic range were determined for each loading-dose regimen.",Absorption characteristics of three phenytoin sodium products after administration of oral loading doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6509876/),[mg] / [l],15,108189,DB00252,Phenytoin
,6509876,Cmax,"Prompt phenytoin sodium capsules (prompt PHT) given in divided doses produced a mean Cmax of 22.0 mg/liter, which was significantly higher than that observed with any of the other loading-dose regimens.",Absorption characteristics of three phenytoin sodium products after administration of oral loading doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6509876/),[mg] / [l],22.0,108190,DB00252,Phenytoin
,3504397,plasma elimination half-life (T1/2),Patients taking liver enzyme inducing antiepileptic drugs showed a mean lamotrigine plasma elimination half-life (T1/2) of 14 h (+/- 7) (T1/2 of normal volunteers = 24 h) and those taking sodium valproate and an inducing AED showed a mean lamotrigine T1/2 of 30 h (+/- 10).,Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3504397/),h,14,108309,DB00252,Phenytoin
,3504397,T1/2,Patients taking liver enzyme inducing antiepileptic drugs showed a mean lamotrigine plasma elimination half-life (T1/2) of 14 h (+/- 7) (T1/2 of normal volunteers = 24 h) and those taking sodium valproate and an inducing AED showed a mean lamotrigine T1/2 of 30 h (+/- 10).,Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3504397/),h,24,108310,DB00252,Phenytoin
,3504397,T1/2,Patients taking liver enzyme inducing antiepileptic drugs showed a mean lamotrigine plasma elimination half-life (T1/2) of 14 h (+/- 7) (T1/2 of normal volunteers = 24 h) and those taking sodium valproate and an inducing AED showed a mean lamotrigine T1/2 of 30 h (+/- 10).,Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3504397/),h,30,108311,DB00252,Phenytoin
,12973408,volume of distribution,"The volume of distribution is 0.6-0.8 l/kg, suggesting distribution into total body water.",Pharmacokinetics and metabolism of topiramate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12973408/),[l] / [kg],0.6-0.8,108482,DB00252,Phenytoin
,3662159,half-life,The administration of multiple-dose activated charcoal reduced the phenytoin half-life from 44.5 to 22.3 hours.,Enhancement of phenytoin elimination by multiple-dose activated charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662159/),h,44.5,109113,DB00252,Phenytoin
,3662159,half-life,The administration of multiple-dose activated charcoal reduced the phenytoin half-life from 44.5 to 22.3 hours.,Enhancement of phenytoin elimination by multiple-dose activated charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662159/),h,22,109114,DB00252,Phenytoin
,30826570,TID20,The experimentally determined TID20 value for TP427 was 11.71 mg/kg.,"New derivative of 1,2,4-triazole-3-thione (TP427) potentiates the anticonvulsant action of valproate, but not that of carbamazepine, phenytoin or phenobarbital in the mouse tonic-clonic seizure model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30826570/),[mg] / [kg],11.71,109717,DB00252,Phenytoin
,7408408,time to reach maximum phenytoin serum concentrations,"Although no statistically significant difference in extent of phenytoin absorption was detected, the time to reach maximum phenytoin serum concentrations increased from 8.4 hr for the 400-mg dose and 13.2 hr for the 800-mg dose to 31.5 hr for the 1,600-mg dose.",Effect of dose on phenytoin absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408408/),h,8.4,110130,DB00252,Phenytoin
,7408408,time to reach maximum phenytoin serum concentrations,"Although no statistically significant difference in extent of phenytoin absorption was detected, the time to reach maximum phenytoin serum concentrations increased from 8.4 hr for the 400-mg dose and 13.2 hr for the 800-mg dose to 31.5 hr for the 1,600-mg dose.",Effect of dose on phenytoin absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408408/),h,13.2,110131,DB00252,Phenytoin
,7408408,time to reach maximum phenytoin serum concentrations,"Although no statistically significant difference in extent of phenytoin absorption was detected, the time to reach maximum phenytoin serum concentrations increased from 8.4 hr for the 400-mg dose and 13.2 hr for the 800-mg dose to 31.5 hr for the 1,600-mg dose.",Effect of dose on phenytoin absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408408/),h,31.5,110132,DB00252,Phenytoin
,7408408,serum concentration peaks,"After the 400, 800, and 1,600-mg doses and 1,600-mg divided doses, the serum concentration peaks were 3,9, 5.7, 10.7, and 15.3 mg/l.",Effect of dose on phenytoin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408408/),[mg] / [l],3,110133,DB00252,Phenytoin
,7408408,serum concentration peaks,"After the 400, 800, and 1,600-mg doses and 1,600-mg divided doses, the serum concentration peaks were 3,9, 5.7, 10.7, and 15.3 mg/l.",Effect of dose on phenytoin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408408/),[mg] / [l],9,110134,DB00252,Phenytoin
,7408408,serum concentration peaks,"After the 400, 800, and 1,600-mg doses and 1,600-mg divided doses, the serum concentration peaks were 3,9, 5.7, 10.7, and 15.3 mg/l.",Effect of dose on phenytoin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408408/),[mg] / [l],5.7,110135,DB00252,Phenytoin
,7408408,serum concentration peaks,"After the 400, 800, and 1,600-mg doses and 1,600-mg divided doses, the serum concentration peaks were 3,9, 5.7, 10.7, and 15.3 mg/l.",Effect of dose on phenytoin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408408/),[mg] / [l],10.7,110136,DB00252,Phenytoin
,7408408,serum concentration peaks,"After the 400, 800, and 1,600-mg doses and 1,600-mg divided doses, the serum concentration peaks were 3,9, 5.7, 10.7, and 15.3 mg/l.",Effect of dose on phenytoin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408408/),[mg] / [l],15.3,110137,DB00252,Phenytoin
,10999732,CER20 min,"The values of the conventional EBT parameter CER20 min obtained on day 1 were comparable for most subjects (0.03-0.06% dose/min), with the exception of an individual receiving the known CYP3A4 inducers dexamethasone and phenytoin who returned a value of 0.14% dose/min.",Optimizing the erythromycin breath test for use in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999732/),%,0.03-0.06,110157,DB00252,Phenytoin
,10999732,CER20 min,"The values of the conventional EBT parameter CER20 min obtained on day 1 were comparable for most subjects (0.03-0.06% dose/min), with the exception of an individual receiving the known CYP3A4 inducers dexamethasone and phenytoin who returned a value of 0.14% dose/min.",Optimizing the erythromycin breath test for use in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999732/),%,0.14,110158,DB00252,Phenytoin
,19160725,clearance,The population mean values of phenobarbitone clearance obtained were 0.250 litres/day/kg for children on phenobarbitone only and 0.208 litres/day/ kg for those on concomitant CBZ or PTO.,Determination of phenobarbitone population clearance values for physically and mentally handicapped Chinese children with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19160725/),[l] / [d·kg],0.250,111732,DB00252,Phenytoin
,19160725,clearance,The population mean values of phenobarbitone clearance obtained were 0.250 litres/day/kg for children on phenobarbitone only and 0.208 litres/day/ kg for those on concomitant CBZ or PTO.,Determination of phenobarbitone population clearance values for physically and mentally handicapped Chinese children with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19160725/),[l] / [·d·kg],0.208,111733,DB00252,Phenytoin
,18184536,recovery,"The mean recovery of phenoxymethylpenicillin was 94.8%, while the retention time observed for phenoxymethylpenicillin and phenytoin (internal standard) was 4 and 10 min, respectively.",Comparative bioavailability study of two phenoxymethylpenicillin potassium tablet formulations in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18184536/),%,94.8,113189,DB00252,Phenytoin
,18184536,retention time,"The mean recovery of phenoxymethylpenicillin was 94.8%, while the retention time observed for phenoxymethylpenicillin and phenytoin (internal standard) was 4 and 10 min, respectively.",Comparative bioavailability study of two phenoxymethylpenicillin potassium tablet formulations in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18184536/),min,4,113190,DB00252,Phenytoin
,18184536,retention time,"The mean recovery of phenoxymethylpenicillin was 94.8%, while the retention time observed for phenoxymethylpenicillin and phenytoin (internal standard) was 4 and 10 min, respectively.",Comparative bioavailability study of two phenoxymethylpenicillin potassium tablet formulations in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18184536/),min,10,113191,DB00252,Phenytoin
,10589372,bioavailability,"Mexiletine, a class Ib antiarrhythmic agent, is rapidly and completely absorbed following oral administration with a bioavailability of about 90%.",Clinical pharmacokinetics of mexiletine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),%,90,113401,DB00252,Phenytoin
,10589372,volume of distribution,Its volume of distribution is large and varies from 5 to 9 L/kg in healthy individuals.,Clinical pharmacokinetics of mexiletine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),[l] / [kg],5 to 9,113402,DB00252,Phenytoin
,10589372,elimination half-life,Mexiletine is eliminated slowly in humans (with an elimination half-life of 10 hours).,Clinical pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),h,10,113403,DB00252,Phenytoin
,15673889,clearance,"The clearance of cisatracurium was significantly faster in Group A when compared with Group C (7.12 +/- 1.87 versus 5.72 +/- 0.70 L . kg(-1) . min(-1), P = 0.01).",Cisatracurium-induced neuromuscular blockade is affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15673889/),[l] / [kg·min],7.12,113790,DB00252,Phenytoin
,15673889,clearance,"The clearance of cisatracurium was significantly faster in Group A when compared with Group C (7.12 +/- 1.87 versus 5.72 +/- 0.70 L . kg(-1) . min(-1), P = 0.01).",Cisatracurium-induced neuromuscular blockade is affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15673889/),[l] / [kg·min],5.72,113791,DB00252,Phenytoin
,15673889,Cp(ss)95,"The Cp(ss)95 was also significantly larger in Group A (191 +/- 45 versus 159 +/- 36 ng/mL, P = 0.04).",Cisatracurium-induced neuromuscular blockade is affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15673889/),[ng] / [ml],191,113792,DB00252,Phenytoin
,15673889,Cp(ss)95,"The Cp(ss)95 was also significantly larger in Group A (191 +/- 45 versus 159 +/- 36 ng/mL, P = 0.04).",Cisatracurium-induced neuromuscular blockade is affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15673889/),[ng] / [ml],159,113793,DB00252,Phenytoin
up to,6143468,time to the steady-state,"Due to the long half-life of phenobarbital its plasma concentrations change slowly, and time to the steady-state may be up to 30 days, if no loading dose is given.",Pharmacokinetics of antiepileptic drugs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143468/),d,30,115019,DB00252,Phenytoin
,6143468,half-lives,"Diazepam, clonazepam and nitrazepam are largely bound to plasma proteins and extensively metabolized with the half-lives of 20 to 60 hours.",Pharmacokinetics of antiepileptic drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143468/),h,20 to 60,115020,DB00252,Phenytoin
,12507057,elimination half-life,The elimination half-life was calculated to be 5.14 hours.,A case of levetiracetam (Keppra) poisoning with clinical and toxicokinetic data. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507057/),h,5.14,117772,DB00252,Phenytoin
,9109044,AUC0-6,The AUC0-6 (are under the concentration-time curve at 0-6 h) for tirilazad mesylate on day 5 in patients receiving anticonvulsants (median = 4972 ng h/mL) differed significantly from that in patients not receiving anticonvulsants (median = 9704 ng h/mL) (p = 0.0051).,"Pharmacokinetics of tirilazad and U-89678, an active, reduced metabolite, following acute head trauma in adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109044/),[h·ng] / [ml],4972,118877,DB00252,Phenytoin
,9109044,AUC0-6,The AUC0-6 (are under the concentration-time curve at 0-6 h) for tirilazad mesylate on day 5 in patients receiving anticonvulsants (median = 4972 ng h/mL) differed significantly from that in patients not receiving anticonvulsants (median = 9704 ng h/mL) (p = 0.0051).,"Pharmacokinetics of tirilazad and U-89678, an active, reduced metabolite, following acute head trauma in adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109044/),[h·ng] / [ml],9704,118878,DB00252,Phenytoin
,9109044,are under the concentration-time curve at 0-6 h,The AUC0-6 (are under the concentration-time curve at 0-6 h) for tirilazad mesylate on day 5 in patients receiving anticonvulsants (median = 4972 ng h/mL) differed significantly from that in patients not receiving anticonvulsants (median = 9704 ng h/mL) (p = 0.0051).,"Pharmacokinetics of tirilazad and U-89678, an active, reduced metabolite, following acute head trauma in adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109044/),[h·ng] / [ml],4972,118879,DB00252,Phenytoin
,9109044,are under the concentration-time curve at 0-6 h,The AUC0-6 (are under the concentration-time curve at 0-6 h) for tirilazad mesylate on day 5 in patients receiving anticonvulsants (median = 4972 ng h/mL) differed significantly from that in patients not receiving anticonvulsants (median = 9704 ng h/mL) (p = 0.0051).,"Pharmacokinetics of tirilazad and U-89678, an active, reduced metabolite, following acute head trauma in adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109044/),[h·ng] / [ml],9704,118880,DB00252,Phenytoin
,9109044,AUC0-6,"Similarly, the AUC0-6 of U-89678 in patients receiving anticonvulsants (median = 561 ng h/mL) was significantly different from that in patients who were not (median = 2494 ng h/mL) (p = 0.0016).","Pharmacokinetics of tirilazad and U-89678, an active, reduced metabolite, following acute head trauma in adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109044/),[h·ng] / [ml],561,118881,DB00252,Phenytoin
,9109044,AUC0-6,"Similarly, the AUC0-6 of U-89678 in patients receiving anticonvulsants (median = 561 ng h/mL) was significantly different from that in patients who were not (median = 2494 ng h/mL) (p = 0.0016).","Pharmacokinetics of tirilazad and U-89678, an active, reduced metabolite, following acute head trauma in adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109044/),[h·ng] / [ml],2494,118882,DB00252,Phenytoin
,24487703,plasma clearance,Dexmedetomidine plasma clearance was 43% higher in the seizure group compared with the control group (42.7 vs. 29.9 l/h; P = 0.007).,Enzyme-inducing anticonvulsants increase plasma clearance of dexmedetomidine: a pharmacokinetic and pharmacodynamic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487703/),[l] / [h],42.7,119473,DB00252,Phenytoin
,24487703,plasma clearance,Dexmedetomidine plasma clearance was 43% higher in the seizure group compared with the control group (42.7 vs. 29.9 l/h; P = 0.007).,Enzyme-inducing anticonvulsants increase plasma clearance of dexmedetomidine: a pharmacokinetic and pharmacodynamic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487703/),[l] / [h],29.9,119474,DB00252,Phenytoin
,10052855,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve was reduced by 56.49% (from 43.23+/-7.0 to 18.81+/-2.03 microg h mL(-1)), the elimination half-life was also significantly (P<0.01) reduced (from 2.68+/-0.35 to 1.04+/-0.07 h) and the clearance was increased (from 0.35 to 0.81 L h(-1) kg(-1)).","Pharmacokinetic interaction in rabbits between a new anticonvulsant, DL-3-hydroxy-3-ethyl-3-phenylpropionamide, and phenytoin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052855/),[h·μg] / [ml],43.23,121694,DB00252,Phenytoin
,10052855,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve was reduced by 56.49% (from 43.23+/-7.0 to 18.81+/-2.03 microg h mL(-1)), the elimination half-life was also significantly (P<0.01) reduced (from 2.68+/-0.35 to 1.04+/-0.07 h) and the clearance was increased (from 0.35 to 0.81 L h(-1) kg(-1)).","Pharmacokinetic interaction in rabbits between a new anticonvulsant, DL-3-hydroxy-3-ethyl-3-phenylpropionamide, and phenytoin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052855/),[h·μg] / [ml],18.81,121695,DB00252,Phenytoin
,10052855,elimination half-life,"The area under the plasma concentration-time curve was reduced by 56.49% (from 43.23+/-7.0 to 18.81+/-2.03 microg h mL(-1)), the elimination half-life was also significantly (P<0.01) reduced (from 2.68+/-0.35 to 1.04+/-0.07 h) and the clearance was increased (from 0.35 to 0.81 L h(-1) kg(-1)).","Pharmacokinetic interaction in rabbits between a new anticonvulsant, DL-3-hydroxy-3-ethyl-3-phenylpropionamide, and phenytoin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052855/),h,2.68,121696,DB00252,Phenytoin
,10052855,elimination half-life,"The area under the plasma concentration-time curve was reduced by 56.49% (from 43.23+/-7.0 to 18.81+/-2.03 microg h mL(-1)), the elimination half-life was also significantly (P<0.01) reduced (from 2.68+/-0.35 to 1.04+/-0.07 h) and the clearance was increased (from 0.35 to 0.81 L h(-1) kg(-1)).","Pharmacokinetic interaction in rabbits between a new anticonvulsant, DL-3-hydroxy-3-ethyl-3-phenylpropionamide, and phenytoin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052855/),h,1.04,121697,DB00252,Phenytoin
,10052855,clearance,"The area under the plasma concentration-time curve was reduced by 56.49% (from 43.23+/-7.0 to 18.81+/-2.03 microg h mL(-1)), the elimination half-life was also significantly (P<0.01) reduced (from 2.68+/-0.35 to 1.04+/-0.07 h) and the clearance was increased (from 0.35 to 0.81 L h(-1) kg(-1)).","Pharmacokinetic interaction in rabbits between a new anticonvulsant, DL-3-hydroxy-3-ethyl-3-phenylpropionamide, and phenytoin. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052855/),[l] / [h·kg],0.35,121698,DB00252,Phenytoin
,10052855,clearance,"The area under the plasma concentration-time curve was reduced by 56.49% (from 43.23+/-7.0 to 18.81+/-2.03 microg h mL(-1)), the elimination half-life was also significantly (P<0.01) reduced (from 2.68+/-0.35 to 1.04+/-0.07 h) and the clearance was increased (from 0.35 to 0.81 L h(-1) kg(-1)).","Pharmacokinetic interaction in rabbits between a new anticonvulsant, DL-3-hydroxy-3-ethyl-3-phenylpropionamide, and phenytoin. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052855/),[l] / [h·kg],0.81,121699,DB00252,Phenytoin
,10052855,Plasma protein binding,Plasma protein binding was low (between 33.69 and 37.43% at concentrations ranging from 6.25 to 100 microg mL(-1)).,"Pharmacokinetic interaction in rabbits between a new anticonvulsant, DL-3-hydroxy-3-ethyl-3-phenylpropionamide, and phenytoin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052855/),%,33.69 and 37.43,121700,DB00252,Phenytoin
,10052855,association constant (Ka),The compound binds preferentially to albumin with an association constant (Ka) of 3.81 x 10(3) M(-1) at 37 degrees C.,"Pharmacokinetic interaction in rabbits between a new anticonvulsant, DL-3-hydroxy-3-ethyl-3-phenylpropionamide, and phenytoin. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052855/),1/[M],3.81 x 10(3),121701,DB00252,Phenytoin
,33171342,concentration,"In 206 patients, the seizure reduction from baseline was > 50 % and the median perampanel concentration was 351 ng/mL (interquartile range, 191-603 ng/mL).","Pharmacokinetics, tolerability, and clinical effectiveness of perampanel in Japanese patients with epilepsy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33171342/),,35,122290,DB00252,Phenytoin
,8649612,conversion half-life,Fosphenytoin is metabolized (conversion half-life of 8 to 15 min) to phenytoin by endogenous phosphatases.,Pharmacology and pharmacokinetics of fosphenytoin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8649612/),min,8 to 15,122368,DB00252,Phenytoin
,3582477,trough plasma concentration at steady-state,"In 30 subjects, trough plasma concentration at steady-state were 12.0 +/- 4.9 micrograms X ml-1 (mean +/- SD) and differed by -2.7 +/- 39.3% from a mean target plasma concentration of 12.5 +/- 1.5 micrograms X ml-1.",Evaluation of a proposed method for phenytoin maintenance dose prediction following an intravenous loading dose. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582477/),[μg] / [ml],12.0,123513,DB00252,Phenytoin
,3582477,target plasma concentration,"In 30 subjects, trough plasma concentration at steady-state were 12.0 +/- 4.9 micrograms X ml-1 (mean +/- SD) and differed by -2.7 +/- 39.3% from a mean target plasma concentration of 12.5 +/- 1.5 micrograms X ml-1.",Evaluation of a proposed method for phenytoin maintenance dose prediction following an intravenous loading dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582477/),[μg] / [ml],12.5,123514,DB00252,Phenytoin
,832662,half time of disappearance,The half time of disappearance of phenytoin after 100 or 300 mg doses is 12.2 +/- 3.0 (SD) h in serum and 12.3 +/- 3.2 (SD) h in saliva.,Salivary phenytoin radioimmunoassay. A simple method of the assessment of non-protein bound drug concentrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/832662/),h,12.2,123860,DB00252,Phenytoin
,832662,half time of disappearance,The half time of disappearance of phenytoin after 100 or 300 mg doses is 12.2 +/- 3.0 (SD) h in serum and 12.3 +/- 3.2 (SD) h in saliva.,Salivary phenytoin radioimmunoassay. A simple method of the assessment of non-protein bound drug concentrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/832662/),h,12.3,123861,DB00252,Phenytoin
,12235444,area under the concentration-time curve from time zero to 24 hours [AUC(0-24)],"Coadministration of phenytoin increased the mean area under the concentration-time curve from time zero to 24 hours [AUC(0-24)] of losartan by 17% (355 +/- 220 ng x h/mL versus 427 +/- 177 ng x h/mL; P =.1), but this difference was not statistically significant.",Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235444/),[h·ng] / [ml],355,124126,DB00252,Phenytoin
,12235444,area under the concentration-time curve from time zero to 24 hours [AUC(0-24)],"Coadministration of phenytoin increased the mean area under the concentration-time curve from time zero to 24 hours [AUC(0-24)] of losartan by 17% (355 +/- 220 ng x h/mL versus 427 +/- 177 ng x h/mL; P =.1), but this difference was not statistically significant.",Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235444/),[h·ng] / [ml],427,124127,DB00252,Phenytoin
,12235444,AUC(0-24),"In the 14 CYP2C9*1/*1 subjects, the mean AUC(0-24) of losartan was increased by 29% (284 +/- 84 ng x h/mL versus 402 +/- 128 ng x h/mL; P =.008).",Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235444/),[h·ng] / [ml],284,124128,DB00252,Phenytoin
,12235444,AUC(0-24),"In the 14 CYP2C9*1/*1 subjects, the mean AUC(0-24) of losartan was increased by 29% (284 +/- 84 ng x h/mL versus 402 +/- 128 ng x h/mL; P =.008).",Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235444/),[h·ng] / [ml],402,124129,DB00252,Phenytoin
,12235444,AUC(0-24),Coadministration of phenytoin significantly reduced the AUC(0-24) of E3174 by 63% (1254 +/- 256 ng x h/mL versus 466 +/- 174 ng x h/mL; P =.0001) and the formation clearance of losartan to E3174 (1.91 +/- 0.8 mL/h per kilogram versus 0.62 +/- 0.4 mL/h per kilogram; P =.0001).,Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235444/),[h·ng] / [ml],1254,124130,DB00252,Phenytoin
,12235444,AUC(0-24),Coadministration of phenytoin significantly reduced the AUC(0-24) of E3174 by 63% (1254 +/- 256 ng x h/mL versus 466 +/- 174 ng x h/mL; P =.0001) and the formation clearance of losartan to E3174 (1.91 +/- 0.8 mL/h per kilogram versus 0.62 +/- 0.4 mL/h per kilogram; P =.0001).,Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235444/),[h·ng] / [ml],466,124131,DB00252,Phenytoin
,12235444,formation clearance,Coadministration of phenytoin significantly reduced the AUC(0-24) of E3174 by 63% (1254 +/- 256 ng x h/mL versus 466 +/- 174 ng x h/mL; P =.0001) and the formation clearance of losartan to E3174 (1.91 +/- 0.8 mL/h per kilogram versus 0.62 +/- 0.4 mL/h per kilogram; P =.0001).,Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235444/),[ml] / [h·kg],1.91,124132,DB00252,Phenytoin
,12235444,formation clearance,Coadministration of phenytoin significantly reduced the AUC(0-24) of E3174 by 63% (1254 +/- 256 ng x h/mL versus 466 +/- 174 ng x h/mL; P =.0001) and the formation clearance of losartan to E3174 (1.91 +/- 0.8 mL/h per kilogram versus 0.62 +/- 0.4 mL/h per kilogram; P =.0001).,Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235444/),[ml] / [h·kg],0.62,124133,DB00252,Phenytoin
,971708,half life,"The mean DPH half life increased significantly from 11.0 +/- a.2 h to 19.0 +/- 3.3 h, and the mean DPH metabolic clearance rate decreased significantly from 51.2 +/- 17.2 ml/min to 33.9 +/- 12.0 ml/min during medication.",The influence of disulfiram on the half life and metabolic clearance rate of diphenylhydantoin and tolbtamide in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/971708/),h,11.0,125321,DB00252,Phenytoin
,971708,half life,"The mean DPH half life increased significantly from 11.0 +/- a.2 h to 19.0 +/- 3.3 h, and the mean DPH metabolic clearance rate decreased significantly from 51.2 +/- 17.2 ml/min to 33.9 +/- 12.0 ml/min during medication.",The influence of disulfiram on the half life and metabolic clearance rate of diphenylhydantoin and tolbtamide in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/971708/),h,19.0,125322,DB00252,Phenytoin
,971708,metabolic clearance rate,"The mean DPH half life increased significantly from 11.0 +/- a.2 h to 19.0 +/- 3.3 h, and the mean DPH metabolic clearance rate decreased significantly from 51.2 +/- 17.2 ml/min to 33.9 +/- 12.0 ml/min during medication.",The influence of disulfiram on the half life and metabolic clearance rate of diphenylhydantoin and tolbtamide in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/971708/),[ml] / [min],51.2,125323,DB00252,Phenytoin
,971708,metabolic clearance rate,"The mean DPH half life increased significantly from 11.0 +/- a.2 h to 19.0 +/- 3.3 h, and the mean DPH metabolic clearance rate decreased significantly from 51.2 +/- 17.2 ml/min to 33.9 +/- 12.0 ml/min during medication.",The influence of disulfiram on the half life and metabolic clearance rate of diphenylhydantoin and tolbtamide in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/971708/),[ml] / [min],33.9,125324,DB00252,Phenytoin
,10448826,Cmax,"PHT Cmax increased from 15.9 microg/ml at baseline to 20.9 microg/ml after 1,200 mg/day FBM and to 26.8 microg/ml after 1,800 mg/day FBM.",Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10448826/),[μg] / [ml],15.9,125567,DB00252,Phenytoin
,10448826,Cmax,"PHT Cmax increased from 15.9 microg/ml at baseline to 20.9 microg/ml after 1,200 mg/day FBM and to 26.8 microg/ml after 1,800 mg/day FBM.",Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10448826/),[μg] / [ml],20.9,125568,DB00252,Phenytoin
,10448826,Cmax,"PHT Cmax increased from 15.9 microg/ml at baseline to 20.9 microg/ml after 1,200 mg/day FBM and to 26.8 microg/ml after 1,800 mg/day FBM.",Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10448826/),[μg] / [ml],26.8,125569,DB00252,Phenytoin
,2337037,area under the serum concentration time curve,"During amiodarone therapy, area under the serum concentration time curve for phenytoin was increased from 208 +/- 82.8 (mean +/- standard deviation) to 292 +/- 108 mg.hr/liter (p = 0.015).",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[h·mg] / [l],208,125630,DB00252,Phenytoin
,2337037,area under the serum concentration time curve,"During amiodarone therapy, area under the serum concentration time curve for phenytoin was increased from 208 +/- 82.8 (mean +/- standard deviation) to 292 +/- 108 mg.hr/liter (p = 0.015).",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[h·mg] / [l],292,125631,DB00252,Phenytoin
,2337037,maximum,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],10.75,125632,DB00252,Phenytoin
,2337037,24-hour,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],10.75,125633,DB00252,Phenytoin
,2337037,24-hour,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],6.67,125634,DB00252,Phenytoin
,2337037,24-hour,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],14.26,125635,DB00252,Phenytoin
,2337037,24-hour,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],10.27,125636,DB00252,Phenytoin
,2337037,p,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],10.75,125637,DB00252,Phenytoin
,2337037,p,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],6.67,125638,DB00252,Phenytoin
,2337037,p,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],14.26,125639,DB00252,Phenytoin
,2337037,p,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],10.27,125640,DB00252,Phenytoin
,2337037,concentrations,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],6.67,125641,DB00252,Phenytoin
,2337037,concentrations,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],14.26,125642,DB00252,Phenytoin
,2337037,concentrations,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],10.27,125643,DB00252,Phenytoin
,2337037,oral clearance,Amiodarone caused a decrease in the oral clearance of phenytoin from 1.29 +/- 0.30 to 0.93 +/- 0.25 liters/hr (p = 0.002).,Steady-state interaction between amiodarone and phenytoin in normal subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[l] / [h],1.29,125644,DB00252,Phenytoin
,2337037,oral clearance,Amiodarone caused a decrease in the oral clearance of phenytoin from 1.29 +/- 0.30 to 0.93 +/- 0.25 liters/hr (p = 0.002).,Steady-state interaction between amiodarone and phenytoin in normal subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[l] / [h],0.93,125645,DB00252,Phenytoin
,6726620,bioavailability,The extent of bioavailability of I-Na was almost 100% of the dose in the range of 100-400 mg/dog when it was administered 0.5 h after meal.,"Biopharmaceutical studies on hydantoin derivatives. Factors affecting bioavailability of 5,5-diphenylhydantoin in dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726620/),%,100,125792,DB00252,Phenytoin
,6726620,bioavailability,"While, when I-Na was administered in the fasting state, the extent of bioavailability was about 60% of the dose.","Biopharmaceutical studies on hydantoin derivatives. Factors affecting bioavailability of 5,5-diphenylhydantoin in dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726620/),%,60,125793,DB00252,Phenytoin
,1341770,oral residence half time,"After oral administration, significant differences were observed between young and old adults for absorption, measured through oral residence half time (36.89 +/- 5.07 h in young and 29.25 +/- 8.64 h in old adults p < 0.05), absorption half time (6.91 +/- 3.6 vs 3.29 +/- 2.35 h) and maximal concentration (1.45 +/- 0.37 vs 2.0 +/- 0.79 micrograms/ml).",[Phenytoin pharmacokinetics in young and older adults]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1341770/),h,36.89,126002,DB00252,Phenytoin
,1341770,oral residence half time,"After oral administration, significant differences were observed between young and old adults for absorption, measured through oral residence half time (36.89 +/- 5.07 h in young and 29.25 +/- 8.64 h in old adults p < 0.05), absorption half time (6.91 +/- 3.6 vs 3.29 +/- 2.35 h) and maximal concentration (1.45 +/- 0.37 vs 2.0 +/- 0.79 micrograms/ml).",[Phenytoin pharmacokinetics in young and older adults]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1341770/),h,29.25,126003,DB00252,Phenytoin
,1341770,absorption half time,"After oral administration, significant differences were observed between young and old adults for absorption, measured through oral residence half time (36.89 +/- 5.07 h in young and 29.25 +/- 8.64 h in old adults p < 0.05), absorption half time (6.91 +/- 3.6 vs 3.29 +/- 2.35 h) and maximal concentration (1.45 +/- 0.37 vs 2.0 +/- 0.79 micrograms/ml).",[Phenytoin pharmacokinetics in young and older adults]. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1341770/),h,6.91,126004,DB00252,Phenytoin
,1341770,absorption half time,"After oral administration, significant differences were observed between young and old adults for absorption, measured through oral residence half time (36.89 +/- 5.07 h in young and 29.25 +/- 8.64 h in old adults p < 0.05), absorption half time (6.91 +/- 3.6 vs 3.29 +/- 2.35 h) and maximal concentration (1.45 +/- 0.37 vs 2.0 +/- 0.79 micrograms/ml).",[Phenytoin pharmacokinetics in young and older adults]. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1341770/),h,3.29,126005,DB00252,Phenytoin
,1341770,maximal concentration,"After oral administration, significant differences were observed between young and old adults for absorption, measured through oral residence half time (36.89 +/- 5.07 h in young and 29.25 +/- 8.64 h in old adults p < 0.05), absorption half time (6.91 +/- 3.6 vs 3.29 +/- 2.35 h) and maximal concentration (1.45 +/- 0.37 vs 2.0 +/- 0.79 micrograms/ml).",[Phenytoin pharmacokinetics in young and older adults]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1341770/),[μg] / [ml],1.45,126006,DB00252,Phenytoin
,1341770,maximal concentration,"After oral administration, significant differences were observed between young and old adults for absorption, measured through oral residence half time (36.89 +/- 5.07 h in young and 29.25 +/- 8.64 h in old adults p < 0.05), absorption half time (6.91 +/- 3.6 vs 3.29 +/- 2.35 h) and maximal concentration (1.45 +/- 0.37 vs 2.0 +/- 0.79 micrograms/ml).",[Phenytoin pharmacokinetics in young and older adults]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1341770/),[μg] / [ml],2.0,126007,DB00252,Phenytoin
,1341770,absolute bioavailability,"However, absolute bioavailability of the drug was not different in both age groups (72.9 and 67.6% in young and old adults respectively).",[Phenytoin pharmacokinetics in young and older adults]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1341770/),%,72.9,126008,DB00252,Phenytoin
,1341770,absolute bioavailability,"However, absolute bioavailability of the drug was not different in both age groups (72.9 and 67.6% in young and old adults respectively).",[Phenytoin pharmacokinetics in young and older adults]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1341770/),%,67.6,126009,DB00252,Phenytoin
,19054418,time,The median time from hospital admission to ivLEV was 36 min.,Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),min,36,126739,DB00252,Phenytoin
,19054418,volume of distribution of central compartment,"Mean (standard deviation, SD) population parameters included volume of distribution of central compartment: 0.45 (0.084) L/kg; total body clearance: 0.0476 (0.0147) L/h/kg; distribution rate constants, central to peripheral compartment (k(12)): 0.24 (0.12)/h, and peripheral to central (k(21)): 0.70 (0.22)/h.",Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),[l] / [kg],0.45,126740,DB00252,Phenytoin
,19054418,total body clearance,"Mean (standard deviation, SD) population parameters included volume of distribution of central compartment: 0.45 (0.084) L/kg; total body clearance: 0.0476 (0.0147) L/h/kg; distribution rate constants, central to peripheral compartment (k(12)): 0.24 (0.12)/h, and peripheral to central (k(21)): 0.70 (0.22)/h.",Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),[l] / [h·kg],0.0476,126741,DB00252,Phenytoin
,19054418,"distribution rate constants, central to peripheral compartment (k(12))","Mean (standard deviation, SD) population parameters included volume of distribution of central compartment: 0.45 (0.084) L/kg; total body clearance: 0.0476 (0.0147) L/h/kg; distribution rate constants, central to peripheral compartment (k(12)): 0.24 (0.12)/h, and peripheral to central (k(21)): 0.70 (0.22)/h.",Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),1/[h],0.24,126742,DB00252,Phenytoin
,19054418,peripheral to central (k(21)),"Mean (standard deviation, SD) population parameters included volume of distribution of central compartment: 0.45 (0.084) L/kg; total body clearance: 0.0476 (0.0147) L/h/kg; distribution rate constants, central to peripheral compartment (k(12)): 0.24 (0.12)/h, and peripheral to central (k(21)): 0.70 (0.22)/h.",Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),1/[h],0.70,126743,DB00252,Phenytoin
,19054418,maximal plasma concentration,Mean maximal plasma concentration was 85 (19) mg/L.,Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),[mg] / [l],85,126744,DB00252,Phenytoin
,3622413,ED50,"Aminophylline decreased anticonvulsant activity of PB, PHT, CBZ, and VPA, increasing the respective ED50 values from 16 to 28 mg/kg, 7.4 to 14 mg/kg, 18 to 26 mg/kg, and 260 to 335 mg/kg.",Effect of aminophylline and enprofylline on the protective efficacy of common antiepileptic drugs against electroconvulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3622413/),[mg] / [kg],16 to 28,126871,DB00252,Phenytoin
,3622413,ED50,"Aminophylline decreased anticonvulsant activity of PB, PHT, CBZ, and VPA, increasing the respective ED50 values from 16 to 28 mg/kg, 7.4 to 14 mg/kg, 18 to 26 mg/kg, and 260 to 335 mg/kg.",Effect of aminophylline and enprofylline on the protective efficacy of common antiepileptic drugs against electroconvulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3622413/),[mg] / [kg],7.4 to 14,126872,DB00252,Phenytoin
,3622413,ED50,"Aminophylline decreased anticonvulsant activity of PB, PHT, CBZ, and VPA, increasing the respective ED50 values from 16 to 28 mg/kg, 7.4 to 14 mg/kg, 18 to 26 mg/kg, and 260 to 335 mg/kg.",Effect of aminophylline and enprofylline on the protective efficacy of common antiepileptic drugs against electroconvulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3622413/),[mg] / [kg],18 to 26,126873,DB00252,Phenytoin
,3622413,ED50,"Aminophylline decreased anticonvulsant activity of PB, PHT, CBZ, and VPA, increasing the respective ED50 values from 16 to 28 mg/kg, 7.4 to 14 mg/kg, 18 to 26 mg/kg, and 260 to 335 mg/kg.",Effect of aminophylline and enprofylline on the protective efficacy of common antiepileptic drugs against electroconvulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3622413/),[mg] / [kg],260 to 335,126874,DB00252,Phenytoin
,3197366,Km,"The median values (ranges) for the parameters were Km = 4.8 (2.6 to 20) mg/L, Vmax infinity = 1348 (372 to 4741) mg/day, and kind = 0.0115 (0.0045 to 0.132) hr-1.",Phenytoin pharmacokinetics in critically ill trauma patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197366/),[mg] / [l],4.8,127673,DB00252,Phenytoin
,3197366,Vmax infinity,"The median values (ranges) for the parameters were Km = 4.8 (2.6 to 20) mg/L, Vmax infinity = 1348 (372 to 4741) mg/day, and kind = 0.0115 (0.0045 to 0.132) hr-1.",Phenytoin pharmacokinetics in critically ill trauma patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197366/),[mg] / [d],1348,127674,DB00252,Phenytoin
,3197366,kind,"The median values (ranges) for the parameters were Km = 4.8 (2.6 to 20) mg/L, Vmax infinity = 1348 (372 to 4741) mg/day, and kind = 0.0115 (0.0045 to 0.132) hr-1.",Phenytoin pharmacokinetics in critically ill trauma patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197366/),1/[h],0.0115,127675,DB00252,Phenytoin
,350128,half-life,"The drug had a relatively short half-life of 8.7 hours, necessitating administration in divided daily doses.",Valproic acid in epilepsy: clinical and pharmacological effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/350128/),h,8.7,127800,DB00252,Phenytoin
,12021623,area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],6.1,128709,DB00252,Phenytoin
,12021623,area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],2.1,128710,DB00252,Phenytoin
,12021623,area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],3.1,128711,DB00252,Phenytoin
,12021623,area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],2.4,128712,DB00252,Phenytoin
,12021623,maximum plasma concentration (C(max)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.8,128713,DB00252,Phenytoin
,12021623,maximum plasma concentration (C(max)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.3,128714,DB00252,Phenytoin
,12021623,maximum plasma concentration (C(max)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.4,128715,DB00252,Phenytoin
,12021623,half-life (t1/2),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),h,8.0,128716,DB00252,Phenytoin
,12021623,half-life (t1/2),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),h,3.8,128717,DB00252,Phenytoin
,12021623,half-life (t1/2),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),h,4.1,128718,DB00252,Phenytoin
,12021623,half-life (t1/2),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),h,4.9,128719,DB00252,Phenytoin
,12021623,AUC(0-12),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],1.8,128720,DB00252,Phenytoin
,12021623,AUC(0-12),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],0.4,128721,DB00252,Phenytoin
,12021623,AUC(0-12),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],0.6,128722,DB00252,Phenytoin
,12021623,AUC(0-12),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],0.5,128723,DB00252,Phenytoin
,12021623,C(max),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.2,128724,DB00252,Phenytoin
,12021623,C(max),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.06,128725,DB00252,Phenytoin
,12021623,C(max),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.1,128726,DB00252,Phenytoin
,12021623,t(1/2)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),,4.3,128727,DB00252,Phenytoin
,12021623,t(1/2)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),,1.9,128728,DB00252,Phenytoin
,12021623,t(1/2)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),,2.2,128729,DB00252,Phenytoin
,16940857,half-life,"The median decreases in the NVP half-life were 18.8, 19.0, and 16.9 hours, respectively.",Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940857/),h,19.0,129028,DB00252,Phenytoin
,16940857,half-life,"The median decreases in the NVP half-life were 18.8, 19.0, and 16.9 hours, respectively.",Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940857/),h,16.9,129029,DB00252,Phenytoin
,8917062,areas under the concentration-time curve (AUC0-tn),"Geometric means for areas under the concentration-time curve (AUC0-tn) normalized to a 20-mg dose were 1.6 micrograms/L/h (95% confidence intervals, 0.6-3.8 micrograms/L/h) in the patients compared with 15.2 (10.7-21.6) micrograms/L/h in control subjects (p < 0.002).",Reduced plasma nisoldipine concentrations in phenytoin-treated patients with epilepsy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917062/),[μg] / [h·l],1.6,129374,DB00252,Phenytoin
,8917062,areas under the concentration-time curve (AUC0-tn),"Geometric means for areas under the concentration-time curve (AUC0-tn) normalized to a 20-mg dose were 1.6 micrograms/L/h (95% confidence intervals, 0.6-3.8 micrograms/L/h) in the patients compared with 15.2 (10.7-21.6) micrograms/L/h in control subjects (p < 0.002).",Reduced plasma nisoldipine concentrations in phenytoin-treated patients with epilepsy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917062/),[μg] / [h·l],15.2,129375,DB00252,Phenytoin
,1773780,peak plasma concentrations,"In an open dose-escalating study, LTG 240 mg produced peak plasma concentrations of around 3 micrograms/mg with no significant adverse events.",Clinical pharmacology of lamotrigine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773780/),[μg] / [mg],3,130119,DB00252,Phenytoin
,1773780,half-life,"Subsequent pharmacokinetic studies revealed complete oral absorption, first-order kinetics with a mean half-life of approximately 1 day, and elimination mainly as a glucuronide in the urine.",Clinical pharmacology of lamotrigine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773780/),d,1,130120,DB00252,Phenytoin
,6489420,oral bioavailability,"However assessed, the mean oral bioavailability of the drug proved to be about 90% of the intravenous bioavailability.",Bioavailability and pharmacokinetics of phenytoin during pregnancy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489420/),%,90,131200,DB00252,Phenytoin
,7153871,bioavailability,"In addition, expected changes in steady-state plasma phenytoin concentrations were calculated assuming initial levels of 15 mg/liter, with increases and decreases in bioavailability of 10%.",Rapid and slow release phenytoin in epileptic patients at steady state: assessment of relative bioavailability utilizing Michaelis-Menten parameters. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7153871/),%,10,131357,DB00252,Phenytoin
,23222687,Michaelis-Menten constant (km),"The Michaelis-Menten constant (km) and volume of distribution (V) were fixed at 9.08 mg/L and 1.23 L/kg, respectively.",Developing a nomogram for dose individualization of phenytoin in Asian pediatric patients derived from population pharmacokinetic modeling of saturable pharmacokinetic profiles of the drug. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222687/),[mg] / [l],9.08,131943,DB00252,Phenytoin
,23222687,volume of distribution (V),"The Michaelis-Menten constant (km) and volume of distribution (V) were fixed at 9.08 mg/L and 1.23 L/kg, respectively.",Developing a nomogram for dose individualization of phenytoin in Asian pediatric patients derived from population pharmacokinetic modeling of saturable pharmacokinetic profiles of the drug. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222687/),[l] / [kg],1.23,131944,DB00252,Phenytoin
,23222687,saturated elimination rate (V × Vmax),The saturated elimination rate (V × Vmax) of phenytoin was then found to be 0.525 mg/kg per hour (352.9 4 mg/d for a 28.0 kg individual).,Developing a nomogram for dose individualization of phenytoin in Asian pediatric patients derived from population pharmacokinetic modeling of saturable pharmacokinetic profiles of the drug. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222687/),[mg] / [h·kg],0.525,131945,DB00252,Phenytoin
,23222687,saturated elimination rate (V × Vmax),The saturated elimination rate (V × Vmax) of phenytoin was then found to be 0.525 mg/kg per hour (352.9 4 mg/d for a 28.0 kg individual).,Developing a nomogram for dose individualization of phenytoin in Asian pediatric patients derived from population pharmacokinetic modeling of saturable pharmacokinetic profiles of the drug. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222687/),,352.9,131946,DB00252,Phenytoin
more,2191442,oral bioavailability,"The pharmacokinetic profile of fluconazole clearly distinguishes it from other antifungal agents; oral bioavailability is more than 90%, and plasma protein binding is 12%.",The clinical pharmacology of fluconazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2191442/),%,90,132916,DB00252,Phenytoin
,2191442,plasma protein binding,"The pharmacokinetic profile of fluconazole clearly distinguishes it from other antifungal agents; oral bioavailability is more than 90%, and plasma protein binding is 12%.",The clinical pharmacology of fluconazole. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2191442/),%,12,132917,DB00252,Phenytoin
,2191442,elimination half-life,The mean elimination half-life is approximately 30 hours.,The clinical pharmacology of fluconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2191442/),h,30,132918,DB00252,Phenytoin
,2314588,conversion half-lives,"The conversion half-lives of ACC-9653 after intravenous and intramuscular administration averaged 8.4 and 32.7 minutes, respectively.",Pharmacokinetics and safety of a phenytoin prodrug given i.v. or i.m. in patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2314588/),min,8.4,133226,DB00252,Phenytoin
,2314588,conversion half-lives,"The conversion half-lives of ACC-9653 after intravenous and intramuscular administration averaged 8.4 and 32.7 minutes, respectively.",Pharmacokinetics and safety of a phenytoin prodrug given i.v. or i.m. in patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2314588/),min,32.7,133227,DB00252,Phenytoin
,2714918,Vmax,"The mean (+/- s.e.m) for Vmax and Km were, respectively, 10.93 +/- 0.78 mg.kg-1.day-1 and 7.75 +/- 0.66 mg.l-1 for children and 6.91 +/- 0.4 mg.kg-1.day-1 and 6.44 +/- 1.01 mg.l-1 for adults.",Phenytoin Michaelis-Menten pharmacokinetics in Saudi patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2714918/),[mg] / [d·kg],10.93,133232,DB00252,Phenytoin
,2714918,Vmax,"The mean (+/- s.e.m) for Vmax and Km were, respectively, 10.93 +/- 0.78 mg.kg-1.day-1 and 7.75 +/- 0.66 mg.l-1 for children and 6.91 +/- 0.4 mg.kg-1.day-1 and 6.44 +/- 1.01 mg.l-1 for adults.",Phenytoin Michaelis-Menten pharmacokinetics in Saudi patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2714918/),[mg] / [d·kg],6.91,133233,DB00252,Phenytoin
,2714918,Km,"The mean (+/- s.e.m) for Vmax and Km were, respectively, 10.93 +/- 0.78 mg.kg-1.day-1 and 7.75 +/- 0.66 mg.l-1 for children and 6.91 +/- 0.4 mg.kg-1.day-1 and 6.44 +/- 1.01 mg.l-1 for adults.",Phenytoin Michaelis-Menten pharmacokinetics in Saudi patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2714918/),[mg] / [l],7.75,133234,DB00252,Phenytoin
,2714918,Km,"The mean (+/- s.e.m) for Vmax and Km were, respectively, 10.93 +/- 0.78 mg.kg-1.day-1 and 7.75 +/- 0.66 mg.l-1 for children and 6.91 +/- 0.4 mg.kg-1.day-1 and 6.44 +/- 1.01 mg.l-1 for adults.",Phenytoin Michaelis-Menten pharmacokinetics in Saudi patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2714918/),[mg] / [l],6.44,133235,DB00252,Phenytoin
,2714918,steady-state phenytoin concentration,"kg-1, respectively, in order to achieve and maintain a steady-state phenytoin concentration of 15 mg.l-1.",Phenytoin Michaelis-Menten pharmacokinetics in Saudi patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2714918/),[mg] / [l],15,133236,DB00252,Phenytoin
,31518217,Vm,"The population typical values for Vm, Km and the apparent volume of distribution (V) in the final model were 17.5 mg/h, 6.41 mg/L and 54.8 L, respectively.",The Evolution of Population Pharmacokinetic Model of Oral Phenytoin for Early Seizure Prophylaxis Post-Craniotomy. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31518217/),[mg] / [h],17.5,134418,DB00252,Phenytoin
,31518217,Km,"The population typical values for Vm, Km and the apparent volume of distribution (V) in the final model were 17.5 mg/h, 6.41 mg/L and 54.8 L, respectively.",The Evolution of Population Pharmacokinetic Model of Oral Phenytoin for Early Seizure Prophylaxis Post-Craniotomy. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31518217/),[mg] / [l],6.41,134419,DB00252,Phenytoin
,31518217,apparent volume of distribution (V),"The population typical values for Vm, Km and the apparent volume of distribution (V) in the final model were 17.5 mg/h, 6.41 mg/L and 54.8 L, respectively.",The Evolution of Population Pharmacokinetic Model of Oral Phenytoin for Early Seizure Prophylaxis Post-Craniotomy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31518217/),l,54.8,134420,DB00252,Phenytoin
,12640710,Vm,The children's phenytoin population pharmacokinetic parameters Vm and Km were 9.8 mg.,[Population pharmacokinetics of phenytoin in pediatric patients]. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12640710/),mg,9.8,134513,DB00252,Phenytoin
,9527647,ED50,"4-amino-(2-methyl-4-aminophenyl)benzamide (4A-2M4A-PB) gave anti maximal electroshock seizures ED50 of 63 micromol/kg (15.4 mg/kg) and a TD50 of 676 micromol/kg (163 mg/kg), yielding a PI of 10.7; the potency is similar to that of the 4-amino-(2-methyl-3-aminophenyl)phthalimide (4A-2M3A-PP), superior to that of 4-amino-(2,6-dimethylphenyl)phthalimide (4A-2,6-DMPP), close to that of phenytoin and carbamazepine and inferior to that of ameltolide.",Anticonvulsant profile of 4-amino-(2-methyl-4-aminophenyl)benzamide in mice and rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527647/),[μM] / [kg],63,134606,DB00252,Phenytoin
,9527647,TD50,"4-amino-(2-methyl-4-aminophenyl)benzamide (4A-2M4A-PB) gave anti maximal electroshock seizures ED50 of 63 micromol/kg (15.4 mg/kg) and a TD50 of 676 micromol/kg (163 mg/kg), yielding a PI of 10.7; the potency is similar to that of the 4-amino-(2-methyl-3-aminophenyl)phthalimide (4A-2M3A-PP), superior to that of 4-amino-(2,6-dimethylphenyl)phthalimide (4A-2,6-DMPP), close to that of phenytoin and carbamazepine and inferior to that of ameltolide.",Anticonvulsant profile of 4-amino-(2-methyl-4-aminophenyl)benzamide in mice and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527647/),[μM] / [kg],676,134607,DB00252,Phenytoin
,9527647,ED50,"4A-2M4A-PB with an ED50 of 41[28-60] micromol/kg (9.9 mg/kg) is as active after oral administration to rats as carbamazepine, more active than ameltolide, 4-A-2M3A-PP and phenytoin and slightly less active than the 4A-2,6-DMPP.",Anticonvulsant profile of 4-amino-(2-methyl-4-aminophenyl)benzamide in mice and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527647/),[μM] / [kg],41,134608,DB00252,Phenytoin
,26865186,half-life,"The half-life of retigabine in plasma was 2.5 h, with appreciable concentrations reached in the brain within 1 h of administration.",Profile of retigabine-induced neuronal apoptosis in the developing rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865186/),h,2.5,135025,DB00252,Phenytoin
,2804994,clearances (dose/AUC),"On these days, the mean (+/- SD) LTG clearances (dose/AUC) were 0.0436 +/- 0.0171, 0.0468 +/- 0.0093, and 0.0575 +/- 0.0160 L/h/kg, respectively.","Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804994/),[l] / [h·kg],0.0436,135251,DB00252,Phenytoin
,2804994,clearances (dose/AUC),"On these days, the mean (+/- SD) LTG clearances (dose/AUC) were 0.0436 +/- 0.0171, 0.0468 +/- 0.0093, and 0.0575 +/- 0.0160 L/h/kg, respectively.","Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804994/),[l] / [h·kg],0.0468,135252,DB00252,Phenytoin
,2804994,clearances (dose/AUC),"On these days, the mean (+/- SD) LTG clearances (dose/AUC) were 0.0436 +/- 0.0171, 0.0468 +/- 0.0093, and 0.0575 +/- 0.0160 L/h/kg, respectively.","Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804994/),[l] / [h·kg],0.0575,135253,DB00252,Phenytoin
,2804994,trough levels,"In conclusion, when given for long periods of time (9.5 months to 2 years), LTG was well tolerated in doses up to 400 mg/day and mean trough levels of 3.0 +/- 0.6 microgram/ml; LTG has a favorable pharmacokinetic profile and appears to exhibit first-order linear kinetics during long-term chronic dosing; LTG shows preliminary evidence of efficacy during long-term administration; and to date, our patients represent the longest reported experience of continuous and closely monitored LTG therapy in the literature.","Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804994/),[μg] / [ml],3.0,135254,DB00252,Phenytoin
,1940127,plasma half-life,"It is cleared rapidly by renal elimination (giving a plasma half-life of approximately 7 to 9 hours), and therefore the effect of the drug long outlasts its presence in the body.",Pharmacology and clinical pharmacology of vigabatrin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1940127/),h,7 to 9,136060,DB00252,Phenytoin
,18641550,CL,"The administration of inducers led to a significant increase in mean LTG CL (values of 0.045-0.070 L/h/kg vs. 0.028 L/h/kg being reached in monotherapy), whereas VPA led to a significant decrease in CL (0.014 L/h/kg).",Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641550/),[l] / [h·kg],0.045-0.070,137436,DB00252,Phenytoin
,18641550,CL,"The administration of inducers led to a significant increase in mean LTG CL (values of 0.045-0.070 L/h/kg vs. 0.028 L/h/kg being reached in monotherapy), whereas VPA led to a significant decrease in CL (0.014 L/h/kg).",Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641550/),[l] / [h·kg],0.028,137437,DB00252,Phenytoin
,18641550,CL,"The administration of inducers led to a significant increase in mean LTG CL (values of 0.045-0.070 L/h/kg vs. 0.028 L/h/kg being reached in monotherapy), whereas VPA led to a significant decrease in CL (0.014 L/h/kg).",Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641550/),[l] / [h·kg],0.014,137438,DB00252,Phenytoin
,6834851,total body clearance,"For propranolol the total body clearance (0,178 +/- 0,064 and 0,115 +/- 0,048 l.kg-1.mn-1; p less than 0,05) and the volume of distribution (9,32 +/- 3,10 and 6,02 +/- 0,96 l.kg-1; p less than 0,01) were significantly diminished; half-life (40,25 +/- 19,45 and 45,62 +/- 32,20 mn) remained inchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg·mn],"0,178",137594,DB00252,Phenytoin
,6834851,total body clearance,"For propranolol the total body clearance (0,178 +/- 0,064 and 0,115 +/- 0,048 l.kg-1.mn-1; p less than 0,05) and the volume of distribution (9,32 +/- 3,10 and 6,02 +/- 0,96 l.kg-1; p less than 0,01) were significantly diminished; half-life (40,25 +/- 19,45 and 45,62 +/- 32,20 mn) remained inchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg·mn],"0,115",137595,DB00252,Phenytoin
,6834851,volume of distribution,"For propranolol the total body clearance (0,178 +/- 0,064 and 0,115 +/- 0,048 l.kg-1.mn-1; p less than 0,05) and the volume of distribution (9,32 +/- 3,10 and 6,02 +/- 0,96 l.kg-1; p less than 0,01) were significantly diminished; half-life (40,25 +/- 19,45 and 45,62 +/- 32,20 mn) remained inchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg],"9,32",137596,DB00252,Phenytoin
,6834851,volume of distribution,"For propranolol the total body clearance (0,178 +/- 0,064 and 0,115 +/- 0,048 l.kg-1.mn-1; p less than 0,05) and the volume of distribution (9,32 +/- 3,10 and 6,02 +/- 0,96 l.kg-1; p less than 0,01) were significantly diminished; half-life (40,25 +/- 19,45 and 45,62 +/- 32,20 mn) remained inchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg],"6,02",137597,DB00252,Phenytoin
,6834851,half-life,"For propranolol the total body clearance (0,178 +/- 0,064 and 0,115 +/- 0,048 l.kg-1.mn-1; p less than 0,05) and the volume of distribution (9,32 +/- 3,10 and 6,02 +/- 0,96 l.kg-1; p less than 0,01) were significantly diminished; half-life (40,25 +/- 19,45 and 45,62 +/- 32,20 mn) remained inchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),mn,"40,25",137598,DB00252,Phenytoin
,6834851,half-life,"For propranolol the total body clearance (0,178 +/- 0,064 and 0,115 +/- 0,048 l.kg-1.mn-1; p less than 0,05) and the volume of distribution (9,32 +/- 3,10 and 6,02 +/- 0,96 l.kg-1; p less than 0,01) were significantly diminished; half-life (40,25 +/- 19,45 and 45,62 +/- 32,20 mn) remained inchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),mn,"45,62",137599,DB00252,Phenytoin
,6834851,total body clearance,"For phenytoin, total body clearance (3,28 +/- 0,94 and 1,43 +/- 0,50 l.kg-1.mn-1; p less than 0,001) was significantly diminished; half-life (136,4 +/- 29,4 and 324,9 +/- 131,6 mn; p less than 0,001) significantly increased; volume of distribution (0,62 +/- 0,13 and 0,62 +/- 0,10 l.kg-1) remained unchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg·mn],"3,28",137600,DB00252,Phenytoin
,6834851,total body clearance,"For phenytoin, total body clearance (3,28 +/- 0,94 and 1,43 +/- 0,50 l.kg-1.mn-1; p less than 0,001) was significantly diminished; half-life (136,4 +/- 29,4 and 324,9 +/- 131,6 mn; p less than 0,001) significantly increased; volume of distribution (0,62 +/- 0,13 and 0,62 +/- 0,10 l.kg-1) remained unchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg·mn],"1,43",137601,DB00252,Phenytoin
,6834851,half-life,"For phenytoin, total body clearance (3,28 +/- 0,94 and 1,43 +/- 0,50 l.kg-1.mn-1; p less than 0,001) was significantly diminished; half-life (136,4 +/- 29,4 and 324,9 +/- 131,6 mn; p less than 0,001) significantly increased; volume of distribution (0,62 +/- 0,13 and 0,62 +/- 0,10 l.kg-1) remained unchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),mn,"136,4",137602,DB00252,Phenytoin
,6834851,half-life,"For phenytoin, total body clearance (3,28 +/- 0,94 and 1,43 +/- 0,50 l.kg-1.mn-1; p less than 0,001) was significantly diminished; half-life (136,4 +/- 29,4 and 324,9 +/- 131,6 mn; p less than 0,001) significantly increased; volume of distribution (0,62 +/- 0,13 and 0,62 +/- 0,10 l.kg-1) remained unchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),mn,"324,9",137603,DB00252,Phenytoin
,6834851,volume of distribution,"For phenytoin, total body clearance (3,28 +/- 0,94 and 1,43 +/- 0,50 l.kg-1.mn-1; p less than 0,001) was significantly diminished; half-life (136,4 +/- 29,4 and 324,9 +/- 131,6 mn; p less than 0,001) significantly increased; volume of distribution (0,62 +/- 0,13 and 0,62 +/- 0,10 l.kg-1) remained unchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg],"0,62",137604,DB00252,Phenytoin
,6834851,volume of distribution,"For phenytoin, total body clearance (3,28 +/- 0,94 and 1,43 +/- 0,50 l.kg-1.mn-1; p less than 0,001) was significantly diminished; half-life (136,4 +/- 29,4 and 324,9 +/- 131,6 mn; p less than 0,001) significantly increased; volume of distribution (0,62 +/- 0,13 and 0,62 +/- 0,10 l.kg-1) remained unchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg],"0,62",137605,DB00252,Phenytoin
,12489978,bioavailability,The bioavailability of the derived phenytoin relative to intravenous phenytoin is approximately 100% following intravenous or intramuscular administration.,Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12489978/),%,100,137729,DB00252,Phenytoin
,12489978,half-life,The half-life for conversion of fosphenytoin to phenytoin ranges from 7-15 minutes.,Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12489978/),min,7-15,137730,DB00252,Phenytoin
,18287342,survival time,"With 31 of 35 patients deceased, estimated median survival time for all patients was 12 months (+EIASD, 11.5 months; - EIASD, 16 months; p = 0.11).",Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18287342/),month,12,137791,DB00252,Phenytoin
,18287342,survival time,"With 31 of 35 patients deceased, estimated median survival time for all patients was 12 months (+EIASD, 11.5 months; - EIASD, 16 months; p = 0.11).",Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18287342/),month,11.5,137792,DB00252,Phenytoin
,18287342,survival time,"With 31 of 35 patients deceased, estimated median survival time for all patients was 12 months (+EIASD, 11.5 months; - EIASD, 16 months; p = 0.11).",Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18287342/),month,16,137793,DB00252,Phenytoin
,21351809,absolute bioavailability,"Rufinamide is well absorbed when taken with food, with an absolute bioavailability between 70% and 85%.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),%,70,138159,DB00252,Phenytoin
,21351809,absolute bioavailability,"Rufinamide is well absorbed when taken with food, with an absolute bioavailability between 70% and 85%.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),%,85,138160,DB00252,Phenytoin
,21351809,elimination half-life,"The elimination half-life of the drug is around 6-10 hours, with a time to maximum plasma concentration (C(max)) of approximately 4-6 hours.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),h,6-10,138161,DB00252,Phenytoin
,21351809,time to maximum plasma concentration (C(max)),"The elimination half-life of the drug is around 6-10 hours, with a time to maximum plasma concentration (C(max)) of approximately 4-6 hours.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),h,4-6,138162,DB00252,Phenytoin
,21351809,C(max),"The C(max) at a dosage of 10 mg/kg/day and 30 mg/kg/day is 4.01 μg/mL and 8.68 μg/mL, respectively, and the area under the plasma concentration-time curve from time 0 to 12 hours was 37.8 ± 47 μg · h/mL and 89.3 ± 58 μg · h/mL, respectively.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),[μg] / [ml],4.01,138163,DB00252,Phenytoin
,21351809,C(max),"The C(max) at a dosage of 10 mg/kg/day and 30 mg/kg/day is 4.01 μg/mL and 8.68 μg/mL, respectively, and the area under the plasma concentration-time curve from time 0 to 12 hours was 37.8 ± 47 μg · h/mL and 89.3 ± 58 μg · h/mL, respectively.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),[μg] / [ml],8.68,138164,DB00252,Phenytoin
,21351809,area under the plasma concentration-time curve from time 0 to 12 hours,"The C(max) at a dosage of 10 mg/kg/day and 30 mg/kg/day is 4.01 μg/mL and 8.68 μg/mL, respectively, and the area under the plasma concentration-time curve from time 0 to 12 hours was 37.8 ± 47 μg · h/mL and 89.3 ± 58 μg · h/mL, respectively.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),[h·μg] / [ml],37.8,138165,DB00252,Phenytoin
,21351809,area under the plasma concentration-time curve from time 0 to 12 hours,"The C(max) at a dosage of 10 mg/kg/day and 30 mg/kg/day is 4.01 μg/mL and 8.68 μg/mL, respectively, and the area under the plasma concentration-time curve from time 0 to 12 hours was 37.8 ± 47 μg · h/mL and 89.3 ± 58 μg · h/mL, respectively.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),[h·μg] / [ml],89.3,138166,DB00252,Phenytoin
,21351809,volume of distribution,The volume of distribution in children is similar to that in adults (0.8-1.2 L/kg) and the drug binds rather poorly to plasma protein (26.2-34.8%).,Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),[l] / [kg],0.8-1.2,138167,DB00252,Phenytoin
,8991789,half-lives,The harmonic mean half-lives of 3.8 to 4.9 h were remarkably constant across dosages and shorter than those of historical control subjects not taking enzyme-inducing AEDs suggesting that epilepsy patients not taking enzyme-inducing AEDs may require lower tiagabine.,Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991789/),h,3.8 to 4.9,138431,DB00252,Phenytoin
,9698715,seizure frequency,Mean seizure frequency was reduced from 3.39 to 1.18 per month.,Benefits of a clinical pharmacokinetic service in optimising phenytoin use in the western Cape. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698715/),1/[month],3.39,138755,DB00252,Phenytoin
,9698715,seizure frequency,Mean seizure frequency was reduced from 3.39 to 1.18 per month.,Benefits of a clinical pharmacokinetic service in optimising phenytoin use in the western Cape. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698715/),1/[month],1.18,138756,DB00252,Phenytoin
,10774639,Km,"Pharmacokinetic parameters were estimated by a kinetic analysis, MULTI, using 17 observed dose-concentration data sets: a lower Vmax (5.6 mg/kg/day) and a higher Km (11.5 microg/mL) were observed.",Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10774639/),[μg] / [ml],11.5,140320,DB00252,Phenytoin
,3191893,apparent clearance,"Following a single dose, mean values (and ranges) for apparent clearance, volume distribution, and elimination half-life (t1/2) were 0.504 L/h/kg (0.086-1.119), 12,431 L (1,959-20,920), and 308 h (61-506), respectively.",Pharmacokinetic profile of flunarizine after single and multiple dosing in epileptic patients receiving comedication. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3191893/),[l] / [h·kg],0.504,140423,DB00252,Phenytoin
,3191893,elimination half-life (t1/2),"Following a single dose, mean values (and ranges) for apparent clearance, volume distribution, and elimination half-life (t1/2) were 0.504 L/h/kg (0.086-1.119), 12,431 L (1,959-20,920), and 308 h (61-506), respectively.",Pharmacokinetic profile of flunarizine after single and multiple dosing in epileptic patients receiving comedication. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3191893/),h,308,140424,DB00252,Phenytoin
,7359372,Clearance,Clearance increased from 1.08 +/- 0.28 liters/hr/kg in control rats to 1.50 +/- 0.38 liters/hr/kg in burned rats (P less than .05).,Phenytoin pharmacokinetics in burned rats and plasma protein binding of phenytoin in burned patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7359372/),[l] / [h·kg],1.08,140781,DB00252,Phenytoin
,7359372,Clearance,Clearance increased from 1.08 +/- 0.28 liters/hr/kg in control rats to 1.50 +/- 0.38 liters/hr/kg in burned rats (P less than .05).,Phenytoin pharmacokinetics in burned rats and plasma protein binding of phenytoin in burned patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7359372/),[l] / [h·kg],1.50,140782,DB00252,Phenytoin
,7359372,volume of distribution,The volume of distribution increased from 0.82 +/- 0.058 liters/kg in control rats to 1.01 +/- 0.11 liters/kg in burned rats (P less than .0005).,Phenytoin pharmacokinetics in burned rats and plasma protein binding of phenytoin in burned patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7359372/),[l] / [kg],0.82,140783,DB00252,Phenytoin
,7359372,volume of distribution,The volume of distribution increased from 0.82 +/- 0.058 liters/kg in control rats to 1.01 +/- 0.11 liters/kg in burned rats (P less than .0005).,Phenytoin pharmacokinetics in burned rats and plasma protein binding of phenytoin in burned patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7359372/),[l] / [kg],1.01,140784,DB00252,Phenytoin
,7359372,first order elimination rate constant (KE),The first order elimination rate constant (KE) did not change significantly (1.31 +/- 0.37) hr-1 in control rats vs. 1.52 +/- 0.48 hr-1 in burned rats; P greater than .05).,Phenytoin pharmacokinetics in burned rats and plasma protein binding of phenytoin in burned patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7359372/),1/[h],1.31,140785,DB00252,Phenytoin
,7359372,first order elimination rate constant (KE),The first order elimination rate constant (KE) did not change significantly (1.31 +/- 0.37) hr-1 in control rats vs. 1.52 +/- 0.48 hr-1 in burned rats; P greater than .05).,Phenytoin pharmacokinetics in burned rats and plasma protein binding of phenytoin in burned patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7359372/),1/[h],1.52,140786,DB00252,Phenytoin
,7359372,free fraction,The free fraction in plasma increased from 27.1% +/- 1.2 in controls to 33.4% +/- 1.6 in burned rats (P less than .0005).,Phenytoin pharmacokinetics in burned rats and plasma protein binding of phenytoin in burned patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7359372/),%,27.1,140787,DB00252,Phenytoin
,7359372,free fraction,The free fraction in plasma increased from 27.1% +/- 1.2 in controls to 33.4% +/- 1.6 in burned rats (P less than .0005).,Phenytoin pharmacokinetics in burned rats and plasma protein binding of phenytoin in burned patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7359372/),%,33.4,140788,DB00252,Phenytoin
,1777370,half-lives,"3. Nimodipine half-lives were shorter in enzyme-induced patients than in controls (3.9 +/- 2.0 h vs 9.1 +/- 3.4 h, means +/- s.d., P less than 0.01), but this difference could be artifactual since in the patients drug concentrations declined rapidly below the limit of assay, thus preventing identification of a possible slower terminal phase.",Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777370/),h,3.9,140864,DB00252,Phenytoin
,1777370,half-lives,"3. Nimodipine half-lives were shorter in enzyme-induced patients than in controls (3.9 +/- 2.0 h vs 9.1 +/- 3.4 h, means +/- s.d., P less than 0.01), but this difference could be artifactual since in the patients drug concentrations declined rapidly below the limit of assay, thus preventing identification of a possible slower terminal phase.",Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777370/),h,9.1,140865,DB00252,Phenytoin
,1777370,half-lives,"In valproate-treated patients, half-lives (8.2 +/- 1.8 h) were similar to those found in controls.",Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777370/),h,8.2,140866,DB00252,Phenytoin
,29130833,area under the plasma concentration-time curve extrapolated to infinity (AUCinf,"Animals given DSS also exhibited a higher area under the plasma concentration-time curve extrapolated to infinity (AUCinf, 315 μg·h/mL), a delayed elimination half-life ( T1/2, 8.1 hours), and a decreased body clearance (CL/F, 3.52 mL/h) compared with that of control animals (AUCinf, 215 μg·h/mL; T1/2, 3.6 h; CL/F, 5.58 mL/h).",Changes in the Pharmacokinetics of Phenytoin in Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29130833/),[h·μg] / [ml],315,144046,DB00252,Phenytoin
,29130833,elimination half-life ( T1/2,"Animals given DSS also exhibited a higher area under the plasma concentration-time curve extrapolated to infinity (AUCinf, 315 μg·h/mL), a delayed elimination half-life ( T1/2, 8.1 hours), and a decreased body clearance (CL/F, 3.52 mL/h) compared with that of control animals (AUCinf, 215 μg·h/mL; T1/2, 3.6 h; CL/F, 5.58 mL/h).",Changes in the Pharmacokinetics of Phenytoin in Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29130833/),h,8.1,144047,DB00252,Phenytoin
,29130833,body clearance (CL/F,"Animals given DSS also exhibited a higher area under the plasma concentration-time curve extrapolated to infinity (AUCinf, 315 μg·h/mL), a delayed elimination half-life ( T1/2, 8.1 hours), and a decreased body clearance (CL/F, 3.52 mL/h) compared with that of control animals (AUCinf, 215 μg·h/mL; T1/2, 3.6 h; CL/F, 5.58 mL/h).",Changes in the Pharmacokinetics of Phenytoin in Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29130833/),[ml] / [h],3.52,144048,DB00252,Phenytoin
,29130833,AUCinf,"Animals given DSS also exhibited a higher area under the plasma concentration-time curve extrapolated to infinity (AUCinf, 315 μg·h/mL), a delayed elimination half-life ( T1/2, 8.1 hours), and a decreased body clearance (CL/F, 3.52 mL/h) compared with that of control animals (AUCinf, 215 μg·h/mL; T1/2, 3.6 h; CL/F, 5.58 mL/h).",Changes in the Pharmacokinetics of Phenytoin in Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29130833/),[h·μg] / [ml],215,144049,DB00252,Phenytoin
,29130833,T1/2,"Animals given DSS also exhibited a higher area under the plasma concentration-time curve extrapolated to infinity (AUCinf, 315 μg·h/mL), a delayed elimination half-life ( T1/2, 8.1 hours), and a decreased body clearance (CL/F, 3.52 mL/h) compared with that of control animals (AUCinf, 215 μg·h/mL; T1/2, 3.6 h; CL/F, 5.58 mL/h).",Changes in the Pharmacokinetics of Phenytoin in Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29130833/),h,3.6,144050,DB00252,Phenytoin
,29130833,CL/F,"Animals given DSS also exhibited a higher area under the plasma concentration-time curve extrapolated to infinity (AUCinf, 315 μg·h/mL), a delayed elimination half-life ( T1/2, 8.1 hours), and a decreased body clearance (CL/F, 3.52 mL/h) compared with that of control animals (AUCinf, 215 μg·h/mL; T1/2, 3.6 h; CL/F, 5.58 mL/h).",Changes in the Pharmacokinetics of Phenytoin in Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29130833/),[ml] / [h],5.58,144051,DB00252,Phenytoin
,7639079,Vm,"The Vm and Km of phenytoin in a 60 kg adult out-patient, without combination with other drugs (phenobarbital, clonazepam or diazepam) were estimated to be 439 mg.d-1 and 6.21 micrograms.",[NONMEM approach for estimating population pharmacokinetic parameters of phenytoin in Chinese epileptics]. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639079/),[mg] / [d],439,144566,DB00252,Phenytoin
,7639079,Km,"The Vm and Km of phenytoin in a 60 kg adult out-patient, without combination with other drugs (phenobarbital, clonazepam or diazepam) were estimated to be 439 mg.d-1 and 6.21 micrograms.",[NONMEM approach for estimating population pharmacokinetic parameters of phenytoin in Chinese epileptics]. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639079/),μg,6.21,144567,DB00252,Phenytoin
,7639079,Vm,"The Vm of patients treated with phenytoin combined with phenobarbital, clonazepam or diazepam will increase 8.4 mg.",[NONMEM approach for estimating population pharmacokinetic parameters of phenytoin in Chinese epileptics]. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639079/),mg,8.4,144568,DB00252,Phenytoin
,1243985,areas under the serum DPH concentration-time curves (AUC),"The areas under the serum DPH concentration-time curves (AUC) were 26, 59, 68 and 90 per cent of the AUC of the DPH suspension.",Bioavailability of four brands of phenytoin tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1243985/),%,26,145310,DB00252,Phenytoin
,1243985,areas under the serum DPH concentration-time curves (AUC),"The areas under the serum DPH concentration-time curves (AUC) were 26, 59, 68 and 90 per cent of the AUC of the DPH suspension.",Bioavailability of four brands of phenytoin tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1243985/),%,59,145311,DB00252,Phenytoin
,1243985,areas under the serum DPH concentration-time curves (AUC),"The areas under the serum DPH concentration-time curves (AUC) were 26, 59, 68 and 90 per cent of the AUC of the DPH suspension.",Bioavailability of four brands of phenytoin tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1243985/),%,68,145312,DB00252,Phenytoin
,1243985,areas under the serum DPH concentration-time curves (AUC),"The areas under the serum DPH concentration-time curves (AUC) were 26, 59, 68 and 90 per cent of the AUC of the DPH suspension.",Bioavailability of four brands of phenytoin tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1243985/),%,90,145313,DB00252,Phenytoin
,1243985,peak serum DPH concentrations,"The peak serum DPH concentrations using the different tablets were 24, 54, 55 and 80 per cent of the peak value of the DPH suspension.",Bioavailability of four brands of phenytoin tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1243985/),%,24,145314,DB00252,Phenytoin
,1243985,peak serum DPH concentrations,"The peak serum DPH concentrations using the different tablets were 24, 54, 55 and 80 per cent of the peak value of the DPH suspension.",Bioavailability of four brands of phenytoin tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1243985/),%,54,145315,DB00252,Phenytoin
,1243985,peak serum DPH concentrations,"The peak serum DPH concentrations using the different tablets were 24, 54, 55 and 80 per cent of the peak value of the DPH suspension.",Bioavailability of four brands of phenytoin tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1243985/),%,55,145316,DB00252,Phenytoin
,1243985,peak serum DPH concentrations,"The peak serum DPH concentrations using the different tablets were 24, 54, 55 and 80 per cent of the peak value of the DPH suspension.",Bioavailability of four brands of phenytoin tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1243985/),%,80,145317,DB00252,Phenytoin
,17898646,volume,"Both volume and absorption rate constant were fixed (14 L and 1 hr, respectively).",Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898646/),l,14,146382,DB00252,Phenytoin
,17898646,absorption rate constant,"Both volume and absorption rate constant were fixed (14 L and 1 hr, respectively).",Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898646/),h,1,146383,DB00252,Phenytoin
,17898646,CL/F,The population CL/F was 0.843 L/hr.,Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898646/),[l] / [h],0.843,146384,DB00252,Phenytoin
,1682464,n,The value of n for phenytoin was estimated to be 0.312 in this study.,One-point feedback control method for phenytoin dosage adjustment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682464/),,0.312,147131,DB00252,Phenytoin
,8453849,log metabolic ratio,"In 110 healthy white adults, the log metabolic ratio ranged from 1.28 to 2.05 (mean +/- SD, 1.68 +/- 0.155).",Measurement of in vivo microsomal epoxide hydrolase activity in white subjects. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453849/),,1.28 to 2.05,147593,DB00252,Phenytoin
,8453849,log metabolic ratio,"In 110 healthy white adults, the log metabolic ratio ranged from 1.28 to 2.05 (mean +/- SD, 1.68 +/- 0.155).",Measurement of in vivo microsomal epoxide hydrolase activity in white subjects. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453849/),,1.68,147594,DB00252,Phenytoin
,2089048,Vm,"The average Vm and Km for this age group was found to be 8.45 mg/kg/day and 6.72 mg/litre, respectively.",Michaelis-Menten pharmacokinetics of phenytoin in adult Malaysian patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2089048/),[mg] / [d·kg],8.45,148567,DB00252,Phenytoin
,2089048,Km,"The average Vm and Km for this age group was found to be 8.45 mg/kg/day and 6.72 mg/litre, respectively.",Michaelis-Menten pharmacokinetics of phenytoin in adult Malaysian patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2089048/),[mg] / [l],6.72,148568,DB00252,Phenytoin
,6795343,half-life,VPA was excreted in the neonates with a mean half-life of 47 +/- 15 hr (n = 8) which is approximately 4 times the mean value found in adult epileptics.,"Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother's milk and clinical status in neonates of epileptic mothers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6795343/),h,47,148806,DB00252,Phenytoin
,2670536,absolute bioavailability,The mean absolute bioavailability of ACC-9653 was 0.992 after intravenous administration and 1.012 after intramuscular administration.,Bioavailability of ACC-9653 (phenytoin prodrug). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670536/),,0.992,148914,DB00252,Phenytoin
,2670536,absolute bioavailability,The mean absolute bioavailability of ACC-9653 was 0.992 after intravenous administration and 1.012 after intramuscular administration.,Bioavailability of ACC-9653 (phenytoin prodrug). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670536/),,1.012,148915,DB00252,Phenytoin
,1184723,MCR,"The MCR, half-life, and volume of distribution were, respectively, 383 +/- 72 (SD) liters/day, 165 +/- 49 minutes, and 61 +/- 12 liters for MP, and 234 +/- 37, 160 +/- 19, and 41 +/- 6 for MPHS.","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),[l] / [d],383,149337,DB00252,Phenytoin
,1184723,volume of distribution,"The MCR, half-life, and volume of distribution were, respectively, 383 +/- 72 (SD) liters/day, 165 +/- 49 minutes, and 61 +/- 12 liters for MP, and 234 +/- 37, 160 +/- 19, and 41 +/- 6 for MPHS.","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),l,61,149338,DB00252,Phenytoin
,1184723,MCR,"Diphenylhydantoin (DPH) administered to 4 subjects increased the MCR of MP from 424 +/- 71 to 977 +/- 132 (P less than 0.01), and decreased the half-life from 149 +/- 44 to 69 +/- 7 (P less than 0.001).","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),,424,149339,DB00252,Phenytoin
,1184723,MCR,"Diphenylhydantoin (DPH) administered to 4 subjects increased the MCR of MP from 424 +/- 71 to 977 +/- 132 (P less than 0.01), and decreased the half-life from 149 +/- 44 to 69 +/- 7 (P less than 0.001).","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),,977,149340,DB00252,Phenytoin
,1184723,half-life,"Diphenylhydantoin (DPH) administered to 4 subjects increased the MCR of MP from 424 +/- 71 to 977 +/- 132 (P less than 0.01), and decreased the half-life from 149 +/- 44 to 69 +/- 7 (P less than 0.001).","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),,149,149341,DB00252,Phenytoin
,1184723,half-life,"Diphenylhydantoin (DPH) administered to 4 subjects increased the MCR of MP from 424 +/- 71 to 977 +/- 132 (P less than 0.01), and decreased the half-life from 149 +/- 44 to 69 +/- 7 (P less than 0.001).","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),,69,149342,DB00252,Phenytoin
,6185649,plasma half-life,"The mean plasma half-life of valproate, using a one-compartment model, was 10.9 +/- 1.3 h (mean +/- SD).",Plasma concentrations of valproate during maintenance therapy in epileptic children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6185649/),h,10.9,149798,DB00252,Phenytoin
,23658067,time of maximum concentration,"However, the time of maximum concentration was higher in T/T2677T/T3435 subjects (10 h) than in G/G2677C/C3435 subjects (6 h).",Studies on pharmacokinetic mechanism of phenytoin resistance in refractory epilepsy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658067/),h,10,150077,DB00252,Phenytoin
,23658067,time of maximum concentration,"However, the time of maximum concentration was higher in T/T2677T/T3435 subjects (10 h) than in G/G2677C/C3435 subjects (6 h).",Studies on pharmacokinetic mechanism of phenytoin resistance in refractory epilepsy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658067/),h,6,150078,DB00252,Phenytoin
,7361796,Peak free drug levels,Peak free drug levels were 1.01--1.60 microgram/ml.,Phenytoin toxicity and blood levels after a large oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7361796/),[μg] / [ml],1.01,151831,DB00252,Phenytoin
,7361796,Time to reach total,"Time to reach total and free peak plasma levels was long and variable (6--14 hours and 2--10 hours, respectively).",Phenytoin toxicity and blood levels after a large oral dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7361796/),h,6--14,151832,DB00252,Phenytoin
,7361796,free peak plasma levels,"Time to reach total and free peak plasma levels was long and variable (6--14 hours and 2--10 hours, respectively).",Phenytoin toxicity and blood levels after a large oral dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7361796/),h,2--10,151833,DB00252,Phenytoin
,7361796,protein binding,Phenytoin protein binding (11.9--13.6%) was relatively stable among patients and at various plasma levels.,Phenytoin toxicity and blood levels after a large oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7361796/),%,11.9,151834,DB00252,Phenytoin
,8038465,trough concentrations,Phenobarbital dosage was subsequently reduced to 150 mg/d; this resulted in phenobarbital trough concentrations of 60 micrograms/mL.,Potential pharmacokinetic interaction between felbamate and phenobarbital. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8038465/),[μg] / [ml],60,152050,DB00252,Phenytoin
,24562047,concentration,"Analysis of variance showed a correlation of dose with LCM concentrations (r = 0.53, P < 0.001), and women had statistically higher mean LCM concentration than did men, 37.2 ± 23.6 versus 26.8 ± 12.9 μmol/L (P = 0.001).","Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24562047/),,26,153175,DB00252,Phenytoin
,10210027,Tmax,"Tmax was 2.4 h (62%, P=0.021) shorter in fosphenytoin vs phenytoin treated rats.",Phenytoin pharmacokinetics following oral administration of phenytoin suspension and fosphenytoin solution to rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10210027/),h,2.4,153546,DB00252,Phenytoin
,9884091,steady-state concentration,Male Wistar rats received a 40 mg kg(-1) intravenous dose of PHT over 5 min either alone or in combination with an infusion of VPA resulting in a steady-state concentration of 115.5+/-4.9 microg ml(-1).,Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884091/),[μg] / [ml],115.5,153620,DB00252,Phenytoin
,9884091,Vmax,"The pharmacokinetic parameters Vmax and Km were, respectively, 294+/-63 microg min(-1) and 7.8+/-2.4 microg ml(-1) in the absence of VPA and 562+/-40 microg min(-1) and 15.6+/-0.9 microg ml(-1) upon administration in combination with VPA.",Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884091/),[μg] / [min],294,153621,DB00252,Phenytoin
,9884091,Vmax,"The pharmacokinetic parameters Vmax and Km were, respectively, 294+/-63 microg min(-1) and 7.8+/-2.4 microg ml(-1) in the absence of VPA and 562+/-40 microg min(-1) and 15.6+/-0.9 microg ml(-1) upon administration in combination with VPA.",Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884091/),[μg] / [min],562,153622,DB00252,Phenytoin
,9884091,Km,"The pharmacokinetic parameters Vmax and Km were, respectively, 294+/-63 microg min(-1) and 7.8+/-2.4 microg ml(-1) in the absence of VPA and 562+/-40 microg min(-1) and 15.6+/-0.9 microg ml(-1) upon administration in combination with VPA.",Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884091/),[μg] / [ml],7.8,153623,DB00252,Phenytoin
,9884091,Km,"The pharmacokinetic parameters Vmax and Km were, respectively, 294+/-63 microg min(-1) and 7.8+/-2.4 microg ml(-1) in the absence of VPA and 562+/-40 microg min(-1) and 15.6+/-0.9 microg ml(-1) upon administration in combination with VPA.",Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884091/),[μg] / [ml],15.6,153624,DB00252,Phenytoin
,9884091,ke0,"The assessment of PHT concentrations at the effect site was based on the effect-compartment model, yielding mean ke0 values of 0.128 and 0.107 min(-1) in the presence and absence of VPA, respectively.",Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884091/),1/[min],0.128,153625,DB00252,Phenytoin
,9884091,ke0,"The assessment of PHT concentrations at the effect site was based on the effect-compartment model, yielding mean ke0 values of 0.128 and 0.107 min(-1) in the presence and absence of VPA, respectively.",Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884091/),1/[min],0.107,153626,DB00252,Phenytoin
,9884091,EC50%,A shift of EC50%TGS from 13.27+3.55 to 4.32+/-0.52 microg ml(-1) was observed upon combination with VPA (P<0.01).,Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884091/),[μg] / [ml],13.27,153627,DB00252,Phenytoin
,9884091,EC50%,A shift of EC50%TGS from 13.27+3.55 to 4.32+/-0.52 microg ml(-1) was observed upon combination with VPA (P<0.01).,Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884091/),[μg] / [ml],4.32,153628,DB00252,Phenytoin
,1418866,ED50s,"Specifically, after 14 days of aminophylline treatment, ED50s for carbamazepine and diphenylhydantoin were 26 and 19 mg/kg, respectively.",Anticonvulsant activity of carbamazepine and diphenylhydantoin against maximal electroshock in mice chronically treated with aminophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418866/),[mg] / [kg],26,153843,DB00252,Phenytoin
,1418866,ED50s,"Specifically, after 14 days of aminophylline treatment, ED50s for carbamazepine and diphenylhydantoin were 26 and 19 mg/kg, respectively.",Anticonvulsant activity of carbamazepine and diphenylhydantoin against maximal electroshock in mice chronically treated with aminophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418866/),[mg] / [kg],19,153844,DB00252,Phenytoin
,1418866,ED50s,"These ED50s were significantly elevated compared to values determined after acute aminophylline treatment (21.2 and 14.9 mg/kg, respectively).",Anticonvulsant activity of carbamazepine and diphenylhydantoin against maximal electroshock in mice chronically treated with aminophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418866/),[mg] / [kg],21.2,153845,DB00252,Phenytoin
,1418866,ED50s,"These ED50s were significantly elevated compared to values determined after acute aminophylline treatment (21.2 and 14.9 mg/kg, respectively).",Anticonvulsant activity of carbamazepine and diphenylhydantoin against maximal electroshock in mice chronically treated with aminophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418866/),[mg] / [kg],14.9,153846,DB00252,Phenytoin
,9784933,absolute bioavailability,"Although nisoldipine is almost completely absorbed, its absolute bioavailability from the CC tablet is only 5.5%, as a result of significant first-pass metabolism in the gut and liver.",Clinical pharmacokinetics of nisoldipine coat-core. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9784933/),%,5.5,154456,DB00252,Phenytoin
,9109895,Dose-normalized Cmax,"Dose-normalized Cmax was higher in children taking valproate (18.2 +/- 5.0 ng/mL/mg) than in the induced children (14.8 +/- 6.9 ng/mL/mg), but the difference was not statistically significant.",A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),[ng] / [mg·ml],18.2,155190,DB00252,Phenytoin
,9109895,Dose-normalized Cmax,"Dose-normalized Cmax was higher in children taking valproate (18.2 +/- 5.0 ng/mL/mg) than in the induced children (14.8 +/- 6.9 ng/mL/mg), but the difference was not statistically significant.",A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),[ng] / [mg·ml],14.8,155191,DB00252,Phenytoin
,9109895,Dose-normalized area under the plasma concentration-time curve from time zero to infinite time,Dose-normalized area under the plasma concentration-time curve from time zero to infinite time was significantly higher (p = 0.002) in children taking valproate (176.5 +/- 54.7 ng.hr/mL/mg) than in induced children (92.4 +/- 56.7 ng.hr/mL/mg).,A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),[h·ng] / [mg·ml],176.5,155192,DB00252,Phenytoin
,9109895,Dose-normalized area under the plasma concentration-time curve from time zero to infinite time,Dose-normalized area under the plasma concentration-time curve from time zero to infinite time was significantly higher (p = 0.002) in children taking valproate (176.5 +/- 54.7 ng.hr/mL/mg) than in induced children (92.4 +/- 56.7 ng.hr/mL/mg).,A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),[h·ng] / [mg·ml],92.4,155193,DB00252,Phenytoin
,9109895,oral clearance,"Similarly, oral clearance in the children taking valproate (96 +/- 39 mL/min) was half that of the induced children (207 +/- 91 mL/min).",A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),[ml] / [min],96,155194,DB00252,Phenytoin
,9109895,oral clearance,"Similarly, oral clearance in the children taking valproate (96 +/- 39 mL/min) was half that of the induced children (207 +/- 91 mL/min).",A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),[ml] / [min],207,155195,DB00252,Phenytoin
,9109895,Half-life,"Half-life in children taking valproate (5.7 hr) was almost twice that for the induced children (3.2 hr), and the elimination rate constant was significantly lower (p < 0.02) for the children taking valproate than for the induced children.",A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),h,5.7,155196,DB00252,Phenytoin
,9109895,Half-life,"Half-life in children taking valproate (5.7 hr) was almost twice that for the induced children (3.2 hr), and the elimination rate constant was significantly lower (p < 0.02) for the children taking valproate than for the induced children.",A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),h,3.2,155197,DB00252,Phenytoin
,9109895,Volume of distribution,Volume of distribution was similar in the children taking valproate (52 +/- 9 L) and the induced children (59 +/- 29 L).,A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),l,52,155198,DB00252,Phenytoin
,9109895,Volume of distribution,Volume of distribution was similar in the children taking valproate (52 +/- 9 L) and the induced children (59 +/- 29 L).,A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),l,59,155199,DB00252,Phenytoin
,8404751,plasma FNR concentration,"After an 8-week baseline period, a single-dose pharmacokinetic study was performed for each patient to calculate a loading dose and maintenance dosage necessary to achieve a target plasma FNR concentration of 30 ng/ml.",Increasing plasma concentration tolerability study of flunarizine in comedicated epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8404751/),[ng] / [ml],30,155293,DB00252,Phenytoin
,12102670,area under the curve (AUC) ratio,"In nine of the 12 patients, PHT plasma concentrations remained stable, with a mean (+/-SD) area under the curve (AUC) ratio (combination therapy/monotherapy) of 1.13 +/- 0.17 (range, 0.89-1.23).",Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102670/),,1.13,155947,DB00252,Phenytoin
,12102670,AUC ratios,"Three patients had AUC ratios of 1.25, 1.39, and 1.55, respectively, and with the addition of TPM (800, 400, and 400 mg daily, respectively), their peak PHT plasma concentrations increased from 15 to 21 mg/L, 28 to 36 mg/L, and 27 to 41 mg/L, respectively.",Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102670/),,1.25,155948,DB00252,Phenytoin
,12102670,AUC ratios,"Three patients had AUC ratios of 1.25, 1.39, and 1.55, respectively, and with the addition of TPM (800, 400, and 400 mg daily, respectively), their peak PHT plasma concentrations increased from 15 to 21 mg/L, 28 to 36 mg/L, and 27 to 41 mg/L, respectively.",Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102670/),,1.39,155949,DB00252,Phenytoin
,12102670,AUC ratios,"Three patients had AUC ratios of 1.25, 1.39, and 1.55, respectively, and with the addition of TPM (800, 400, and 400 mg daily, respectively), their peak PHT plasma concentrations increased from 15 to 21 mg/L, 28 to 36 mg/L, and 27 to 41 mg/L, respectively.",Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102670/),,1.55,155950,DB00252,Phenytoin
,12102670,peak PHT plasma concentrations,"Three patients had AUC ratios of 1.25, 1.39, and 1.55, respectively, and with the addition of TPM (800, 400, and 400 mg daily, respectively), their peak PHT plasma concentrations increased from 15 to 21 mg/L, 28 to 36 mg/L, and 27 to 41 mg/L, respectively.",Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102670/),[mg] / [l],15 to 21,155951,DB00252,Phenytoin
,12102670,peak PHT plasma concentrations,"Three patients had AUC ratios of 1.25, 1.39, and 1.55, respectively, and with the addition of TPM (800, 400, and 400 mg daily, respectively), their peak PHT plasma concentrations increased from 15 to 21 mg/L, 28 to 36 mg/L, and 27 to 41 mg/L, respectively.",Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102670/),[mg] / [l],28 to 36,155952,DB00252,Phenytoin
,12102670,peak PHT plasma concentrations,"Three patients had AUC ratios of 1.25, 1.39, and 1.55, respectively, and with the addition of TPM (800, 400, and 400 mg daily, respectively), their peak PHT plasma concentrations increased from 15 to 21 mg/L, 28 to 36 mg/L, and 27 to 41 mg/L, respectively.",Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102670/),[mg] / [l],27 to 41,155953,DB00252,Phenytoin
,18591503,elimination half-life,The mean elimination half-life was 40 hours.,Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18591503/),h,40,156846,DB00252,Phenytoin
,18591503,time to reach steady-state,The prolonged elimination half-life suggests that most patients can take PHT once daily and the time to reach steady-state may extend to 2-3 weeks.,Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18591503/),weeks,2-3,156847,DB00252,Phenytoin
,11198504,volume of distribution,"The volume of distribution and the serum clearance of valproate were approximately 0.245 L/kg and 25 mL/h/kg, respectively.",Intravenous valproate dosing in neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11198504/),[l] / [kg],0.245,157020,DB00252,Phenytoin
,11198504,serum clearance,"The volume of distribution and the serum clearance of valproate were approximately 0.245 L/kg and 25 mL/h/kg, respectively.",Intravenous valproate dosing in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11198504/),[ml] / [h·kg],25,157021,DB00252,Phenytoin
,6782238,total clearance,"Valproate is shown to significantly increase the total clearance, i.e., 23.8 to 30.4 ml . min-1 .","Interaction between phenytoin, 5-(p-hydroxyphenyl)-5-phenylhydantoin and valproate in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6782238/),[ml] / [min],23.8 to 30.4,157403,DB00252,Phenytoin
,6782238,volume of distribution,"kg-1 and volume of distribution, i.e., 0.92 to 1.25 liter .","Interaction between phenytoin, 5-(p-hydroxyphenyl)-5-phenylhydantoin and valproate in the rat. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6782238/),l,0.92 to 1.25,157404,DB00252,Phenytoin
,8287032,mean residence time (MRT),"VPDPH and VADPH were more rapidly eliminated from plasma and brain than DPH, giving smaller mean residence time (MRT) values (0.92 and 0.85 h) and much smaller cortex/plasma concentration ratio than those of DPH.",Pharmacokinetic analysis of phenytoin and its derivatives in plasma and brain in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287032/),h,0.92,157958,DB00252,Phenytoin
,8287032,mean residence time (MRT),"VPDPH and VADPH were more rapidly eliminated from plasma and brain than DPH, giving smaller mean residence time (MRT) values (0.92 and 0.85 h) and much smaller cortex/plasma concentration ratio than those of DPH.",Pharmacokinetic analysis of phenytoin and its derivatives in plasma and brain in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287032/),h,0.85,157959,DB00252,Phenytoin
,9099448,AUC,"The mean predicted AUC of flunarizine was 1230 +/- 717 ng h mL-1, whereas the observed AUC was 1203 +/- 900 ng h mL-1.",A limited sampling method for the estimation of flunarizine area under the curve (AUC) and maximum plasma concentration (Cmax). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099448/),[h·ng] / [ml],1230,159481,DB00252,Phenytoin
,9099448,AUC,"The mean predicted AUC of flunarizine was 1230 +/- 717 ng h mL-1, whereas the observed AUC was 1203 +/- 900 ng h mL-1.",A limited sampling method for the estimation of flunarizine area under the curve (AUC) and maximum plasma concentration (Cmax). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099448/),[h·ng] / [ml],1203,159482,DB00252,Phenytoin
,9099448,Cmax,The mean predicted Cmax of flunarizine was 86 +/- 32 ng mL-1 as compared to an observed mean Cmax of 90 +/- 42 ng mL-1.,A limited sampling method for the estimation of flunarizine area under the curve (AUC) and maximum plasma concentration (Cmax). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099448/),[ng] / [ml],86,159483,DB00252,Phenytoin
,9099448,Cmax,The mean predicted Cmax of flunarizine was 86 +/- 32 ng mL-1 as compared to an observed mean Cmax of 90 +/- 42 ng mL-1.,A limited sampling method for the estimation of flunarizine area under the curve (AUC) and maximum plasma concentration (Cmax). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099448/),[ng] / [ml],90,159484,DB00252,Phenytoin
,1649676,half-lives,"The average CBZ half-lives in single- and multiple-dose phases were 50.1 +/- 12.1 (mean +/- SD) hours and 26.1 +/- 4.2 hours and the clearances were 16.4 +/- 3.3 ml/kg/h and 45.3 +/- 23.4 ml/kg/h respectively, both with significant differences (p less than 0.005).",Metabolism of carbamazepine: evidence of autoinduction in Chinese. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1649676/),h,50.1,160641,DB00252,Phenytoin
,1649676,half-lives,"The average CBZ half-lives in single- and multiple-dose phases were 50.1 +/- 12.1 (mean +/- SD) hours and 26.1 +/- 4.2 hours and the clearances were 16.4 +/- 3.3 ml/kg/h and 45.3 +/- 23.4 ml/kg/h respectively, both with significant differences (p less than 0.005).",Metabolism of carbamazepine: evidence of autoinduction in Chinese. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1649676/),h,26.1,160642,DB00252,Phenytoin
,1649676,clearances,"The average CBZ half-lives in single- and multiple-dose phases were 50.1 +/- 12.1 (mean +/- SD) hours and 26.1 +/- 4.2 hours and the clearances were 16.4 +/- 3.3 ml/kg/h and 45.3 +/- 23.4 ml/kg/h respectively, both with significant differences (p less than 0.005).",Metabolism of carbamazepine: evidence of autoinduction in Chinese. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1649676/),[ml] / [h·kg],16.4,160643,DB00252,Phenytoin
,1649676,clearances,"The average CBZ half-lives in single- and multiple-dose phases were 50.1 +/- 12.1 (mean +/- SD) hours and 26.1 +/- 4.2 hours and the clearances were 16.4 +/- 3.3 ml/kg/h and 45.3 +/- 23.4 ml/kg/h respectively, both with significant differences (p less than 0.005).",Metabolism of carbamazepine: evidence of autoinduction in Chinese. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1649676/),[ml] / [h·kg],45.3,160644,DB00252,Phenytoin
,6374250,half-life,"Pharmacokinetic analysis showed that the half-life of prednisolone was shorter in the anticonvulsant group compared to the controls, based on both total (2.3 +/- 0.4 vs. 3.4 +/- 0.2 hr (SD), P less than 0.01) and unbound (1.7 +/- 0.3 vs. 2.4 +/- 0.2 hr, P less than 0.01) concentrations.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),h,2.3,160807,DB00252,Phenytoin
,6374250,half-life,"Pharmacokinetic analysis showed that the half-life of prednisolone was shorter in the anticonvulsant group compared to the controls, based on both total (2.3 +/- 0.4 vs. 3.4 +/- 0.2 hr (SD), P less than 0.01) and unbound (1.7 +/- 0.3 vs. 2.4 +/- 0.2 hr, P less than 0.01) concentrations.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),h,3.4,160808,DB00252,Phenytoin
,6374250,unbound,"Pharmacokinetic analysis showed that the half-life of prednisolone was shorter in the anticonvulsant group compared to the controls, based on both total (2.3 +/- 0.4 vs. 3.4 +/- 0.2 hr (SD), P less than 0.01) and unbound (1.7 +/- 0.3 vs. 2.4 +/- 0.2 hr, P less than 0.01) concentrations.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),h,1.7,160809,DB00252,Phenytoin
,6374250,unbound,"Pharmacokinetic analysis showed that the half-life of prednisolone was shorter in the anticonvulsant group compared to the controls, based on both total (2.3 +/- 0.4 vs. 3.4 +/- 0.2 hr (SD), P less than 0.01) and unbound (1.7 +/- 0.3 vs. 2.4 +/- 0.2 hr, P less than 0.01) concentrations.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),h,2.4,160810,DB00252,Phenytoin
,6374250,Total drug clearance,Total drug clearance was 10.4 +/- 2.8 liters/hr (0.171 +/- 0.087 liters/hr X kg) in the anticonvulsant group versus 7.2 +/- 1.2 liters/hr (0.100 +/- 0.014 liters/hr X kg) in the controls (P less than 0.05).,Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h],10.4,160811,DB00252,Phenytoin
,6374250,Total drug clearance,Total drug clearance was 10.4 +/- 2.8 liters/hr (0.171 +/- 0.087 liters/hr X kg) in the anticonvulsant group versus 7.2 +/- 1.2 liters/hr (0.100 +/- 0.014 liters/hr X kg) in the controls (P less than 0.05).,Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h·kg],0.171,160812,DB00252,Phenytoin
,6374250,Total drug clearance,Total drug clearance was 10.4 +/- 2.8 liters/hr (0.171 +/- 0.087 liters/hr X kg) in the anticonvulsant group versus 7.2 +/- 1.2 liters/hr (0.100 +/- 0.014 liters/hr X kg) in the controls (P less than 0.05).,Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h],7.2,160813,DB00252,Phenytoin
,6374250,Total drug clearance,Total drug clearance was 10.4 +/- 2.8 liters/hr (0.171 +/- 0.087 liters/hr X kg) in the anticonvulsant group versus 7.2 +/- 1.2 liters/hr (0.100 +/- 0.014 liters/hr X kg) in the controls (P less than 0.05).,Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h·kg],0.100,160814,DB00252,Phenytoin
,6374250,Unbound prednisolone clearance,"Unbound prednisolone clearance was 57.2 +/- 12.1 versus 46.4 +/- 8.7 liters/hr (P greater than 0.05) and for weight-corrected estimates 0.886 +/- 0.224 liters/hr X kg versus 0.644 +/- 0.115 liters/hr X kg (P less than 0.05) in the two groups, respectively.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h],57.2,160815,DB00252,Phenytoin
,6374250,Unbound prednisolone clearance,"Unbound prednisolone clearance was 57.2 +/- 12.1 versus 46.4 +/- 8.7 liters/hr (P greater than 0.05) and for weight-corrected estimates 0.886 +/- 0.224 liters/hr X kg versus 0.644 +/- 0.115 liters/hr X kg (P less than 0.05) in the two groups, respectively.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h],46.4,160816,DB00252,Phenytoin
,6374250,Unbound prednisolone clearance,"Unbound prednisolone clearance was 57.2 +/- 12.1 versus 46.4 +/- 8.7 liters/hr (P greater than 0.05) and for weight-corrected estimates 0.886 +/- 0.224 liters/hr X kg versus 0.644 +/- 0.115 liters/hr X kg (P less than 0.05) in the two groups, respectively.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h·kg],0.886,160817,DB00252,Phenytoin
,6374250,Unbound prednisolone clearance,"Unbound prednisolone clearance was 57.2 +/- 12.1 versus 46.4 +/- 8.7 liters/hr (P greater than 0.05) and for weight-corrected estimates 0.886 +/- 0.224 liters/hr X kg versus 0.644 +/- 0.115 liters/hr X kg (P less than 0.05) in the two groups, respectively.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h·kg],0.644,160818,DB00252,Phenytoin
,2690330,volume of distribution,The volume of distribution is 0.3 litres/kg corresponding to the volume of extracellular water.,Omeprazole: pharmacokinetics and metabolism in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2690330/),[l] / [kg],0.3,161885,DB00252,Phenytoin
less,2690330,half-life,"The half-life is less than 1 hour, and omeprazole is almost entirely cleared from plasma within 3-4 hours.",Omeprazole: pharmacokinetics and metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2690330/),h,1,161886,DB00252,Phenytoin
,2690330,Bioavailability,Bioavailability after a single dose is 35% and increases during repeated once-daily dosing to 60%.,Omeprazole: pharmacokinetics and metabolism in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2690330/),%,35,161887,DB00252,Phenytoin
,2690330,Bioavailability,Bioavailability after a single dose is 35% and increases during repeated once-daily dosing to 60%.,Omeprazole: pharmacokinetics and metabolism in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2690330/),%,60,161888,DB00252,Phenytoin
,760753,oral bioavailability,"3 The oral bioavailability (mean +/- s.e. mean) was significantly lower in the epileptic patients than in the normal subjects (0.77 +/- 0.03 and 0.89 +/- 0.02 respectively, P less than 0.01), whereas the urinary excretion total (free+conjugated) paracetamol was almost identical in the two groups.",Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/760753/),,0.77,162430,DB00252,Phenytoin
,760753,oral bioavailability,"3 The oral bioavailability (mean +/- s.e. mean) was significantly lower in the epileptic patients than in the normal subjects (0.77 +/- 0.03 and 0.89 +/- 0.02 respectively, P less than 0.01), whereas the urinary excretion total (free+conjugated) paracetamol was almost identical in the two groups.",Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/760753/),,0.89,162431,DB00252,Phenytoin
,3994563,elimination half-life,Obese subjects compared with controls had prolonged phenytoin elimination half-life (19.9 v 12.0 hours).,Phenytoin disposition in obesity. Determination of loading dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994563/),h,19.9,162854,DB00252,Phenytoin
,3994563,elimination half-life,Obese subjects compared with controls had prolonged phenytoin elimination half-life (19.9 v 12.0 hours).,Phenytoin disposition in obesity. Determination of loading dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994563/),h,12.0,162855,DB00252,Phenytoin
,3994563,Total metabolic clearance,"Total metabolic clearance of phenytoin was greater in obese than in control groups, although the difference was not significant (59 v 39 mL/min).",Phenytoin disposition in obesity. Determination of loading dose. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994563/),[ml] / [min],59,162856,DB00252,Phenytoin
,3994563,Total metabolic clearance,"Total metabolic clearance of phenytoin was greater in obese than in control groups, although the difference was not significant (59 v 39 mL/min).",Phenytoin disposition in obesity. Determination of loading dose. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994563/),[ml] / [min],39,162857,DB00252,Phenytoin
,3994563,Vd,"Phenytoin half-life, inversely proportional to clearance and directly proportional to volume of distribution (Vd), was prolonged in obesity mainly as a result of the increase in Vd in obese subjects (84 v 40 L).",Phenytoin disposition in obesity. Determination of loading dose. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994563/),l,84,162858,DB00252,Phenytoin
,3994563,Vd,"Phenytoin half-life, inversely proportional to clearance and directly proportional to volume of distribution (Vd), was prolonged in obesity mainly as a result of the increase in Vd in obese subjects (84 v 40 L).",Phenytoin disposition in obesity. Determination of loading dose. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994563/),l,40,162859,DB00252,Phenytoin
,10368078,half-life,"The half-life of FOS was 4.5, 9.2, and 9.5 min for the three groups, respectively.",Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368078/),min,4.5,163477,DB00252,Phenytoin
,10368078,half-life,"The half-life of FOS was 4.5, 9.2, and 9.5 min for the three groups, respectively.",Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368078/),min,9.2,163478,DB00252,Phenytoin
,10368078,half-life,"The half-life of FOS was 4.5, 9.2, and 9.5 min for the three groups, respectively.",Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368078/),min,9.5,163479,DB00252,Phenytoin
,9094065,peak concentrations,The peak concentrations at 7.26 +/- 4.77 h was 11.95 +/- 2.8 micrograms/ml.,Single oral loading dose of phenytoin: a pharmacokinetics study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9094065/),[μg] / [ml],11.95,163784,DB00252,Phenytoin
,9094065,peak concentration,"For males, the peak concentration at 9.71 +/- 5.94 h was 23.89 +/- 5.46 micrograms/ml and that for females was 21.46 +/- 5.08 micrograms/ml at 7.71 +/- 3.73 h, respectively.",Single oral loading dose of phenytoin: a pharmacokinetics study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9094065/),[μg] / [ml],23.89,163785,DB00252,Phenytoin
,9094065,peak concentration,"For males, the peak concentration at 9.71 +/- 5.94 h was 23.89 +/- 5.46 micrograms/ml and that for females was 21.46 +/- 5.08 micrograms/ml at 7.71 +/- 3.73 h, respectively.",Single oral loading dose of phenytoin: a pharmacokinetics study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9094065/),[μg] / [ml],21.46,163786,DB00252,Phenytoin
,6677874,Plasma half-life,Plasma half-life determined in 12 infants aged 6 weeks to 12 months ranged between 7.9 to 24.9 hours (mean 12.8 +/- 3.6 hours).,"Oral phenytoin in infancy: dose requirement, absorption, and elimination. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6677874/),h,7.9 to 24.9,164408,DB00252,Phenytoin
,6677874,Plasma half-life,Plasma half-life determined in 12 infants aged 6 weeks to 12 months ranged between 7.9 to 24.9 hours (mean 12.8 +/- 3.6 hours).,"Oral phenytoin in infancy: dose requirement, absorption, and elimination. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6677874/),h,12.8,164409,DB00252,Phenytoin
,3391153,epoxide to parent ratio,"The CBZ epoxide to parent ratio increased to 0.46 and 0.39, respectively during FBM treatment.",Felbamate increases phenytoin but decreases carbamazepine concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391153/),,0.46,164545,DB00252,Phenytoin
,3391153,epoxide to parent ratio,"The CBZ epoxide to parent ratio increased to 0.46 and 0.39, respectively during FBM treatment.",Felbamate increases phenytoin but decreases carbamazepine concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391153/),,0.39,164546,DB00252,Phenytoin
,9029404,CS50,"CR 2039 [[4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl]phenylbenza m ide], in doses of 10, 50, and 100 mg/kg i.p., significantly elevated the threshold for electroconvulsions, increasing the CS50 (current strength 50% in mA) values from 6.3 to 7.2, 7.5, and 7.6 mA, respectively.","Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029404/),ma,6.3,165985,DB00252,Phenytoin
,9029404,CS50,"CR 2039 [[4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl]phenylbenza m ide], in doses of 10, 50, and 100 mg/kg i.p., significantly elevated the threshold for electroconvulsions, increasing the CS50 (current strength 50% in mA) values from 6.3 to 7.2, 7.5, and 7.6 mA, respectively.","Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029404/),ma,7.2,165986,DB00252,Phenytoin
,9029404,CS50,"CR 2039 [[4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl]phenylbenza m ide], in doses of 10, 50, and 100 mg/kg i.p., significantly elevated the threshold for electroconvulsions, increasing the CS50 (current strength 50% in mA) values from 6.3 to 7.2, 7.5, and 7.6 mA, respectively.","Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029404/),ma,7.5,165987,DB00252,Phenytoin
,9029404,CS50,"CR 2039 [[4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl]phenylbenza m ide], in doses of 10, 50, and 100 mg/kg i.p., significantly elevated the threshold for electroconvulsions, increasing the CS50 (current strength 50% in mA) values from 6.3 to 7.2, 7.5, and 7.6 mA, respectively.","Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029404/),ma,7.6,165988,DB00252,Phenytoin
,8529326,area under the concentration-time curve (AUC),"Phenytoin decreased the area under the concentration-time curve (AUC) of itraconazole by more than 90%, from 3203 to 224 ng.hr/ml, accompanied by a decrease in half-life from 22.3 to 3.8 hours.",Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),[h·ng] / [ml],3203,166050,DB00252,Phenytoin
,8529326,area under the concentration-time curve (AUC),"Phenytoin decreased the area under the concentration-time curve (AUC) of itraconazole by more than 90%, from 3203 to 224 ng.hr/ml, accompanied by a decrease in half-life from 22.3 to 3.8 hours.",Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),[h·ng] / [ml],224,166051,DB00252,Phenytoin
,8529326,half-life,"Phenytoin decreased the area under the concentration-time curve (AUC) of itraconazole by more than 90%, from 3203 to 224 ng.hr/ml, accompanied by a decrease in half-life from 22.3 to 3.8 hours.",Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),h,22.3,166052,DB00252,Phenytoin
,8529326,half-life,"Phenytoin decreased the area under the concentration-time curve (AUC) of itraconazole by more than 90%, from 3203 to 224 ng.hr/ml, accompanied by a decrease in half-life from 22.3 to 3.8 hours.",Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),h,3.8,166053,DB00252,Phenytoin
,8529326,AUC,Similar changes were observed for hydroxyitraconazole AUC (decreased from 6224 to 315 ng.hr/ml) and half-life (11.3 versus 2.9 hours).,Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),[h·ng] / [ml],6224,166054,DB00252,Phenytoin
,8529326,AUC,Similar changes were observed for hydroxyitraconazole AUC (decreased from 6224 to 315 ng.hr/ml) and half-life (11.3 versus 2.9 hours).,Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),[h·ng] / [ml],315,166055,DB00252,Phenytoin
,8529326,half-life,Similar changes were observed for hydroxyitraconazole AUC (decreased from 6224 to 315 ng.hr/ml) and half-life (11.3 versus 2.9 hours).,Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),h,11.3,166056,DB00252,Phenytoin
,8529326,half-life,Similar changes were observed for hydroxyitraconazole AUC (decreased from 6224 to 315 ng.hr/ml) and half-life (11.3 versus 2.9 hours).,Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),h,2.9,166057,DB00252,Phenytoin
,2401249,conversion half-life (t 1/2),The conversion half-life (t 1/2) of ACC-9653 to PHT was 9.3 +/- 2.7 min.,Absolute bioavailability of phenytoin after 3-phosphoryloxymethyl phenytoin disodium (ACC-9653) administration to humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2401249/),min,9.3,166728,DB00252,Phenytoin
,2401249,bioavailability,The PHT area under the curve (AUC) was not statistically different between treatments; the bioavailability of PHT after ACC-9653 was 99 +/- 11%.,Absolute bioavailability of phenytoin after 3-phosphoryloxymethyl phenytoin disodium (ACC-9653) administration to humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2401249/),%,99,166729,DB00252,Phenytoin
,25952988,unbound concentrations,"Initial estimates suggested that a loading dose of 25 mg/kg would attain unbound concentrations of 1-2 μg/ml; however, this dose produced concentrations above 3-6 μg/ml, which resulted in clinically significant toxicity.",Use of IV fosphenytoin pharmacokinetics to determine the loading dose for a clinical trial of canine status epilepticus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25952988/),[μg] / [ml],1-2,166797,DB00252,Phenytoin
,25952988,alpha-phase half-life,A two-compartment model best fit the PHT concentration data with alpha-phase half-life of 2-5 min and elimination half-life of ~5 h.,Use of IV fosphenytoin pharmacokinetics to determine the loading dose for a clinical trial of canine status epilepticus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25952988/),min,2-5,166798,DB00252,Phenytoin
,25952988,elimination half-life,A two-compartment model best fit the PHT concentration data with alpha-phase half-life of 2-5 min and elimination half-life of ~5 h.,Use of IV fosphenytoin pharmacokinetics to determine the loading dose for a clinical trial of canine status epilepticus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25952988/),h,5,166799,DB00252,Phenytoin
,33447943,apparent clearance,The median value of apparent clearance for children (0.074 L/h/kg [range 0.038-0.079]) was higher than that for adults (0.054 L/h/kg [range 0.039-0.061]).,Population Pharmacokinetics of Levetiracetam: A Systematic Review. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33447943/),[l] / [h·kg],0.074,169024,DB00252,Phenytoin
,33447943,apparent clearance,The median value of apparent clearance for children (0.074 L/h/kg [range 0.038-0.079]) was higher than that for adults (0.054 L/h/kg [range 0.039-0.061]).,Population Pharmacokinetics of Levetiracetam: A Systematic Review. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33447943/),[l] / [h·kg],0.054,169025,DB00252,Phenytoin
,7229908,Km,"The resulting population parameter estimates differ considerably (population mean Km, for example, is estimated as 1.57, 5.36, and 4.44 micrograms/ml by the naive pooled data, two-stage, and NONMEN approaches, respectively).",Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229908/),[μg] / [ml],1.57,169931,DB00252,Phenytoin
,7229908,Km,"The resulting population parameter estimates differ considerably (population mean Km, for example, is estimated as 1.57, 5.36, and 4.44 micrograms/ml by the naive pooled data, two-stage, and NONMEN approaches, respectively).",Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229908/),[μg] / [ml],5.36,169932,DB00252,Phenytoin
,7229908,Km,"The resulting population parameter estimates differ considerably (population mean Km, for example, is estimated as 1.57, 5.36, and 4.44 micrograms/ml by the naive pooled data, two-stage, and NONMEN approaches, respectively).",Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229908/),[μg] / [ml],4.44,169933,DB00252,Phenytoin
,20206792,formation clearance,Treatment with folic acid was associated with a significantly increased mean (SD) formation clearance of (S)-7-hydroxywarfarin (1.096 [0.816] vs 1.608 [1.302] mL/min; P = 0.048).,"Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206792/),[ml] / [min],1.096,170560,DB00252,Phenytoin
,20206792,formation clearance,Treatment with folic acid was associated with a significantly increased mean (SD) formation clearance of (S)-7-hydroxywarfarin (1.096 [0.816] vs 1.608 [1.302] mL/min; P = 0.048).,"Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206792/),[ml] / [min],1.608,170561,DB00252,Phenytoin
,4032274,terminal elimination half-life,The terminal elimination half-life is approximately 4 h.,Pharmacokinetics of propylene glycol in humans during multiple dosing regimens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032274/),h,4,171143,DB00252,Phenytoin
,4032274,apparent total body clearance,The average apparent total body clearance is approximately 0.1 L/kg X h and may be concentration dependent.,Pharmacokinetics of propylene glycol in humans during multiple dosing regimens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032274/),[l] / [h·kg],0.1,171144,DB00252,Phenytoin
,4032274,apparent volume of distribution,"The apparent volume of distribution is approximately 0.5 L/kg, approximating total body water.",Pharmacokinetics of propylene glycol in humans during multiple dosing regimens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032274/),[l] / [kg],0.5,171145,DB00252,Phenytoin
,9454785,Vmax,"Vmax and Km values were, respectively, 386 +/- 31 microg . min-1 and 15.4 +/- 2.2 microg .",Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9454785/),[μg] / [min],386,171531,DB00252,Phenytoin
,9454785,Km,"Vmax and Km values were, respectively, 386 +/- 31 microg . min-1 and 15.4 +/- 2.2 microg .",Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9454785/),μg,15.4,171532,DB00252,Phenytoin
,9454785,ke0,"The relationship between phenytoin plasma concentrations and effect site was estimated by an equilibration kinetics routine, yielding mean ke0 values of 0.108 and 0.077 min-1 for the anticonvulsant and EEG effects, respectively.",Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9454785/),1/[min],0.108,171533,DB00252,Phenytoin
,9454785,ke0,"The relationship between phenytoin plasma concentrations and effect site was estimated by an equilibration kinetics routine, yielding mean ke0 values of 0.108 and 0.077 min-1 for the anticonvulsant and EEG effects, respectively.",Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9454785/),1/[min],0.077,171534,DB00252,Phenytoin
,9454785,coefficient (B),This approach yielded a coefficient (B) of 2.0 +/- 0.4 microA . ml . microg-1 and an exponent (n) of 2.7 +/- 0.9.,Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9454785/),[ml·μa] / [μg],2.0,171535,DB00252,Phenytoin
,9454785,exponent (n),This approach yielded a coefficient (B) of 2.0 +/- 0.4 microA . ml . microg-1 and an exponent (n) of 2.7 +/- 0.9.,Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9454785/),,2.7,171536,DB00252,Phenytoin
,9454785,EC50,"The derived EC50 value of 12.5 +/- 1. 3 microg . ml-1 for the EEG effect coincides with the ""therapeutic range"" in humans.",Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9454785/),[μg] / [ml],12.5,171537,DB00252,Phenytoin
,2694113,Vd (L),"The final models for felbamate clearance and volume of distribution (Vd) were as follows: Cl(L/hr) = 2.43 + 0.429*CDCR/240, Vd (L) = 51.","Pharmacokinetics of felbamate, a novel antiepileptic drug: application of mixed-effect modeling to clinical trials. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2694113/),,51,171864,DB00252,Phenytoin
,29171002,apparent clearance (CL/F),"In the absence of antiepileptic drugs (AEDs) affecting perampanel PK, estimated perampanel apparent clearance (CL/F) was 0.668 L/h (all subjects) and 0.682 L/h (adolescent subjects).",Pharmacokinetic/pharmacodynamic analysis of adjunctive perampanel in subjects with partial-onset seizures. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29171002/),[l] / [h],0.668,172319,DB00252,Phenytoin
,29171002,apparent clearance (CL/F),"In the absence of antiepileptic drugs (AEDs) affecting perampanel PK, estimated perampanel apparent clearance (CL/F) was 0.668 L/h (all subjects) and 0.682 L/h (adolescent subjects).",Pharmacokinetic/pharmacodynamic analysis of adjunctive perampanel in subjects with partial-onset seizures. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29171002/),[l] / [h],0.682,172320,DB00252,Phenytoin
,3720707,total alpha level,The total alpha level was 0.10.,Single dose comparison of the relative bioavailability of phenytoin suspension and extended capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3720707/),,0.10,172846,DB00252,Phenytoin
,22765768,peak plasma concentrations (C(max)),"In the two treatment periods, the mean ± SD peak plasma concentrations (C(max)) were 18.6 ± 8.0 ng/mL (ivabradine alone) and 6.5 ± 3.1 ng/mL (ivabradine after pre-treatment with phenytoin).",Pharmacokinetic interaction between ivabradine and phenytoin in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22765768/),[ng] / [ml],18.6,172979,DB00252,Phenytoin
,22765768,peak plasma concentrations (C(max)),"In the two treatment periods, the mean ± SD peak plasma concentrations (C(max)) were 18.6 ± 8.0 ng/mL (ivabradine alone) and 6.5 ± 3.1 ng/mL (ivabradine after pre-treatment with phenytoin).",Pharmacokinetic interaction between ivabradine and phenytoin in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22765768/),[ng] / [ml],6.5,172980,DB00252,Phenytoin
,22765768,times,"The mean ± SD times taken to reach C(max) (t(max)) were 1.2 ± 0.7 h and 0.8 ± 0.6 h, respectively, and the total areas under the plasma concentration-time curve from time zero to infinity (AUC(∞)) were 62.3 ± 18.7 ng · h/mL and 19.2 ± 17.0 ng · h/mL, respectively.",Pharmacokinetic interaction between ivabradine and phenytoin in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22765768/),h,1.2,172981,DB00252,Phenytoin
,22765768,times,"The mean ± SD times taken to reach C(max) (t(max)) were 1.2 ± 0.7 h and 0.8 ± 0.6 h, respectively, and the total areas under the plasma concentration-time curve from time zero to infinity (AUC(∞)) were 62.3 ± 18.7 ng · h/mL and 19.2 ± 17.0 ng · h/mL, respectively.",Pharmacokinetic interaction between ivabradine and phenytoin in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22765768/),h,0.8,172982,DB00252,Phenytoin
,22765768,total areas under the plasma concentration-time curve from time zero to infinity (AUC(∞)),"The mean ± SD times taken to reach C(max) (t(max)) were 1.2 ± 0.7 h and 0.8 ± 0.6 h, respectively, and the total areas under the plasma concentration-time curve from time zero to infinity (AUC(∞)) were 62.3 ± 18.7 ng · h/mL and 19.2 ± 17.0 ng · h/mL, respectively.",Pharmacokinetic interaction between ivabradine and phenytoin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22765768/),[h·ng] / [ml],62.3,172983,DB00252,Phenytoin
,22765768,total areas under the plasma concentration-time curve from time zero to infinity (AUC(∞)),"The mean ± SD times taken to reach C(max) (t(max)) were 1.2 ± 0.7 h and 0.8 ± 0.6 h, respectively, and the total areas under the plasma concentration-time curve from time zero to infinity (AUC(∞)) were 62.3 ± 18.7 ng · h/mL and 19.2 ± 17.0 ng · h/mL, respectively.",Pharmacokinetic interaction between ivabradine and phenytoin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22765768/),[h·ng] / [ml],19.2,172984,DB00252,Phenytoin
,22765768,bioavailability,"This study showed that phenytoin has an important effect on the pharmacokinetics of ivabradine in healthy subjects, reducing its bioavailability by approximately 70%.",Pharmacokinetic interaction between ivabradine and phenytoin in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22765768/),%,70,172985,DB00252,Phenytoin
,10800057,clearance,"The administration of CP less than 24 h after the last dose of Bu resulted in: (1) a significantly (P = 0.003) lower clearance for cyclophosphamide was observed in group A (0.036 l/h/kg) compared to 0.055 and 0.055 l/h/kg, in the B and TBI groups, respectively; (2) significantly (P = 0.002) longer elimination half-life in group A (10.93 h) than in groups B and TBI (6.87 and 7.52 h, respectively); (3) significantly (P < 0.001) lower exposure to the cytotoxic metabolite (4-OHCP), expressed as the ratio AUC4-OHCP/AUCCP, in group A (0.0053) than that obtained in group B (0.013) and group TBI (0.012); (4) the patients in group A had a significantly (P < 0.05) higher incidence of VOD (seven of 12) than the other groups, B and TBI (2/14 and 1/10, respectively); and (5) mucositis was significantly higher in group A patients (8/12), being seen in only one patient in group B and none in the TBI group.",The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10800057/),[l] / [h·kg],0.036,173748,DB00252,Phenytoin
,10800057,clearance,"The administration of CP less than 24 h after the last dose of Bu resulted in: (1) a significantly (P = 0.003) lower clearance for cyclophosphamide was observed in group A (0.036 l/h/kg) compared to 0.055 and 0.055 l/h/kg, in the B and TBI groups, respectively; (2) significantly (P = 0.002) longer elimination half-life in group A (10.93 h) than in groups B and TBI (6.87 and 7.52 h, respectively); (3) significantly (P < 0.001) lower exposure to the cytotoxic metabolite (4-OHCP), expressed as the ratio AUC4-OHCP/AUCCP, in group A (0.0053) than that obtained in group B (0.013) and group TBI (0.012); (4) the patients in group A had a significantly (P < 0.05) higher incidence of VOD (seven of 12) than the other groups, B and TBI (2/14 and 1/10, respectively); and (5) mucositis was significantly higher in group A patients (8/12), being seen in only one patient in group B and none in the TBI group.",The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10800057/),[l] / [h·kg],0.055,173749,DB00252,Phenytoin
,10800057,elimination half-life,"The administration of CP less than 24 h after the last dose of Bu resulted in: (1) a significantly (P = 0.003) lower clearance for cyclophosphamide was observed in group A (0.036 l/h/kg) compared to 0.055 and 0.055 l/h/kg, in the B and TBI groups, respectively; (2) significantly (P = 0.002) longer elimination half-life in group A (10.93 h) than in groups B and TBI (6.87 and 7.52 h, respectively); (3) significantly (P < 0.001) lower exposure to the cytotoxic metabolite (4-OHCP), expressed as the ratio AUC4-OHCP/AUCCP, in group A (0.0053) than that obtained in group B (0.013) and group TBI (0.012); (4) the patients in group A had a significantly (P < 0.05) higher incidence of VOD (seven of 12) than the other groups, B and TBI (2/14 and 1/10, respectively); and (5) mucositis was significantly higher in group A patients (8/12), being seen in only one patient in group B and none in the TBI group.",The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10800057/),h,10.93,173750,DB00252,Phenytoin
,10800057,elimination half-life,"The administration of CP less than 24 h after the last dose of Bu resulted in: (1) a significantly (P = 0.003) lower clearance for cyclophosphamide was observed in group A (0.036 l/h/kg) compared to 0.055 and 0.055 l/h/kg, in the B and TBI groups, respectively; (2) significantly (P = 0.002) longer elimination half-life in group A (10.93 h) than in groups B and TBI (6.87 and 7.52 h, respectively); (3) significantly (P < 0.001) lower exposure to the cytotoxic metabolite (4-OHCP), expressed as the ratio AUC4-OHCP/AUCCP, in group A (0.0053) than that obtained in group B (0.013) and group TBI (0.012); (4) the patients in group A had a significantly (P < 0.05) higher incidence of VOD (seven of 12) than the other groups, B and TBI (2/14 and 1/10, respectively); and (5) mucositis was significantly higher in group A patients (8/12), being seen in only one patient in group B and none in the TBI group.",The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10800057/),h,6.87,173751,DB00252,Phenytoin
,10800057,elimination half-life,"The administration of CP less than 24 h after the last dose of Bu resulted in: (1) a significantly (P = 0.003) lower clearance for cyclophosphamide was observed in group A (0.036 l/h/kg) compared to 0.055 and 0.055 l/h/kg, in the B and TBI groups, respectively; (2) significantly (P = 0.002) longer elimination half-life in group A (10.93 h) than in groups B and TBI (6.87 and 7.52 h, respectively); (3) significantly (P < 0.001) lower exposure to the cytotoxic metabolite (4-OHCP), expressed as the ratio AUC4-OHCP/AUCCP, in group A (0.0053) than that obtained in group B (0.013) and group TBI (0.012); (4) the patients in group A had a significantly (P < 0.05) higher incidence of VOD (seven of 12) than the other groups, B and TBI (2/14 and 1/10, respectively); and (5) mucositis was significantly higher in group A patients (8/12), being seen in only one patient in group B and none in the TBI group.",The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10800057/),h,7.52,173752,DB00252,Phenytoin
,1732431,systemic clearance,"The mean systemic clearance (range) for the six anticonvulsant-treated patients studied during 22 courses of therapy was 32 mL/min/m2 (range, 21 to 54 mL/min/m2), significantly higher (P less than .001) than the mean value of 13 mL/min/m2 (range, 7 to 17 mL/min/m2) for the control patients studied during 26 courses of therapy.",Increased teniposide clearance with concomitant anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732431/),[ml] / [m2·min],32,175387,DB00252,Phenytoin
,1732431,systemic clearance,"The mean systemic clearance (range) for the six anticonvulsant-treated patients studied during 22 courses of therapy was 32 mL/min/m2 (range, 21 to 54 mL/min/m2), significantly higher (P less than .001) than the mean value of 13 mL/min/m2 (range, 7 to 17 mL/min/m2) for the control patients studied during 26 courses of therapy.",Increased teniposide clearance with concomitant anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732431/),[ml] / [m2·min],13,175388,DB00252,Phenytoin
,1233994,Maximum serum concentrations,Maximum serum concentrations ranged from 1.56 mug/ml.,Pharmacokinetics of a single dose of phenytoin in man measured by radioimmunoassay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233994/),[μg] / [ml],1.56,175892,DB00252,Phenytoin
,1233994,plasma half-life,The mean plasma half-life of the drug under these conditions was 9.81 +/- 0.66 (s.e. mean) hours.,Pharmacokinetics of a single dose of phenytoin in man measured by radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233994/),h,9.81,175893,DB00252,Phenytoin
,1868813,plasma levels,"""Active"" plasma levels ranged from approximately 300 ng/ml in the MES threshold test to approximately 1,300 ng/ml in the MES test.","Ralitoline: a reevaluation of anticonvulsant profile and determination of ""active"" plasma concentrations in comparison with prototype antiepileptic drugs in mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868813/),[ng] / [ml],300,177484,DB00252,Phenytoin
,1868813,plasma levels,"""Active"" plasma levels ranged from approximately 300 ng/ml in the MES threshold test to approximately 1,300 ng/ml in the MES test.","Ralitoline: a reevaluation of anticonvulsant profile and determination of ""active"" plasma concentrations in comparison with prototype antiepileptic drugs in mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868813/),[ng] / [ml],"1,300",177485,DB00252,Phenytoin
,25199779,relative bioavailability,Posaconazole relative bioavailability was 55% lower in patients who received posaconazole than in healthy volunteers.,Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25199779/),%,55,177817,DB00252,Phenytoin
,1261151,plasma elimination t1/2,"The mean plasma elimination t1/2 was the same following intravenous (16.8 +/- 1.3 hr) and oral (17.1 +/- 1.5 hr) doses of phenytoin; however, following chronic oral administration, the t1/2 increased to 18.9 +/- 1.5 hr (p less than 0.05).",Phenytoin: pharmacokinetics and bioavailability. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261151/),h,16.8,178872,DB00252,Phenytoin
,1261151,plasma elimination t1/2,"The mean plasma elimination t1/2 was the same following intravenous (16.8 +/- 1.3 hr) and oral (17.1 +/- 1.5 hr) doses of phenytoin; however, following chronic oral administration, the t1/2 increased to 18.9 +/- 1.5 hr (p less than 0.05).",Phenytoin: pharmacokinetics and bioavailability. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261151/),h,17.1,178873,DB00252,Phenytoin
,1261151,t1/2,"The mean plasma elimination t1/2 was the same following intravenous (16.8 +/- 1.3 hr) and oral (17.1 +/- 1.5 hr) doses of phenytoin; however, following chronic oral administration, the t1/2 increased to 18.9 +/- 1.5 hr (p less than 0.05).",Phenytoin: pharmacokinetics and bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261151/),h,18.9,178874,DB00252,Phenytoin
,1261151,absolute bioavailability,The absolute bioavailability of an oral dosage form (Dilantin Kapseals) varied from 57.7 to 85.6% when based on the relationship between the corresponding single dose areas under the curve (AUCs).,Phenytoin: pharmacokinetics and bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261151/),%,57.7 to 85.6,178875,DB00252,Phenytoin
,1261151,bioavailability,"When based on the comparison of the AUC for multiple oral dosing with the single iv dose area, average bioavailability was 85.9% (71.8 to 106.3).",Phenytoin: pharmacokinetics and bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261151/),%,85.9,178876,DB00252,Phenytoin
,7863246,bioavailability,"Antacid ingestion decreased the bioavailability of famotidine, ranitidine and cimetidine by 20-25%, and the bioavailability of nizatidine by 12%.",Drug interactions of H2-receptor antagonists. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7863246/),,12,179873,DB00252,Phenytoin
less,7277391,urinary excretion,"The compound was excreted unchanged in rat feces (94% in 18 days), urinary excretion less than 0.5%.",A nonmetabolized analogue of phenytoin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7277391/),%,0.5,181211,DB00252,Phenytoin
,7277391,half-life of elimination,The half-life of elimination of [14C]1 from plasma was 67-72 h (ip and iv) in rats and 115 h (ip) in mice.,A nonmetabolized analogue of phenytoin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7277391/),h,67-72,181212,DB00252,Phenytoin
,7277391,half-life of elimination,The half-life of elimination of [14C]1 from plasma was 67-72 h (ip and iv) in rats and 115 h (ip) in mice.,A nonmetabolized analogue of phenytoin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7277391/),h,115,181213,DB00252,Phenytoin
,26011141,FREL,The mean FREL of FPHT was 1.21 (95% confidence interval [CI] 1.07-1.35).,Relative bioavailability of orally administered fosphenytoin sodium injection compared with phenytoin sodium injection in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011141/),,1.21,181957,DB00252,Phenytoin
,26011141,maximum serum concentration (Cmax ),The median (range) maximum serum concentration (Cmax ) values were significantly higher after FPHT administration compared with PHT: 10.7 (9.0-19.4) mg/L versus 5.0 (3.2-8.9) mg/L (p=0.002).,Relative bioavailability of orally administered fosphenytoin sodium injection compared with phenytoin sodium injection in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011141/),[mg] / [l],10.7,181958,DB00252,Phenytoin
,26011141,maximum serum concentration (Cmax ),The median (range) maximum serum concentration (Cmax ) values were significantly higher after FPHT administration compared with PHT: 10.7 (9.0-19.4) mg/L versus 5.0 (3.2-8.9) mg/L (p=0.002).,Relative bioavailability of orally administered fosphenytoin sodium injection compared with phenytoin sodium injection in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011141/),[mg] / [l],5.0,181959,DB00252,Phenytoin
,26011141,time to reach Cmax,"The PHT concentration after oral administration of FPHT displayed faster absorption compared with PHT, with a median (range) time to reach Cmax of 1.0 (0.5-2.0) hours versus 6.0 (2.0-24.0) hours (p=0.008).",Relative bioavailability of orally administered fosphenytoin sodium injection compared with phenytoin sodium injection in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011141/),h,1.0,181960,DB00252,Phenytoin
,26011141,time to reach Cmax,"The PHT concentration after oral administration of FPHT displayed faster absorption compared with PHT, with a median (range) time to reach Cmax of 1.0 (0.5-2.0) hours versus 6.0 (2.0-24.0) hours (p=0.008).",Relative bioavailability of orally administered fosphenytoin sodium injection compared with phenytoin sodium injection in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011141/),h,6.0,181961,DB00252,Phenytoin
,7157458,Vmax,"The Vmax values (mg/kg/day) were 16.1 without allopurinol, and 12.4 and 10.9 with allopurinol (150 and 200 mg/day), respectively, whereas those for Km remained relatively constant (3.9 to 4.9 microgram/ml).",Phenytoin--allopurinol interaction: Michaelis--Menten kinetic parameters of phenytoin with and without allopurinol in a child with Lesch--Nyhan syndrome. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7157458/),,16.1,182138,DB00252,Phenytoin
,7157458,Vmax,"The Vmax values (mg/kg/day) were 16.1 without allopurinol, and 12.4 and 10.9 with allopurinol (150 and 200 mg/day), respectively, whereas those for Km remained relatively constant (3.9 to 4.9 microgram/ml).",Phenytoin--allopurinol interaction: Michaelis--Menten kinetic parameters of phenytoin with and without allopurinol in a child with Lesch--Nyhan syndrome. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7157458/),,12.4,182139,DB00252,Phenytoin
,7157458,Vmax,"The Vmax values (mg/kg/day) were 16.1 without allopurinol, and 12.4 and 10.9 with allopurinol (150 and 200 mg/day), respectively, whereas those for Km remained relatively constant (3.9 to 4.9 microgram/ml).",Phenytoin--allopurinol interaction: Michaelis--Menten kinetic parameters of phenytoin with and without allopurinol in a child with Lesch--Nyhan syndrome. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7157458/),,10.9,182140,DB00252,Phenytoin
,7157458,Km,"The Vmax values (mg/kg/day) were 16.1 without allopurinol, and 12.4 and 10.9 with allopurinol (150 and 200 mg/day), respectively, whereas those for Km remained relatively constant (3.9 to 4.9 microgram/ml).",Phenytoin--allopurinol interaction: Michaelis--Menten kinetic parameters of phenytoin with and without allopurinol in a child with Lesch--Nyhan syndrome. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7157458/),[μg] / [ml],3.9 to 4.9,182141,DB00252,Phenytoin
,3359738,maximum rate,"Based on these results, a dose of 15 mg/kg divided into 3 intravenous injections administered 2 hours apart at a maximum rate of 50 mg/min is recommended.",Intravenous phenytoin loading in patients after neurosurgery and in status epilepticus. A population pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3359738/),[mg] / [min],50,184458,DB00252,Phenytoin
,3266736,elimination half-life,The elimination half-life of the untreated control group (n = 27) was 4.62 h.,Effects of drugs on aminophylline elimination in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,4.62,184893,DB00252,Phenytoin
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.09,184894,DB00252,Phenytoin
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.47,184895,DB00252,Phenytoin
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.19,184896,DB00252,Phenytoin
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2,184897,DB00252,Phenytoin
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.85,184898,DB00252,Phenytoin
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.74,184899,DB00252,Phenytoin
,7272175,Plasma concentrations,Plasma concentrations of DPH varied from 5.1 to 20.4 microgram ml-1 (mean +/- s.e.mean 12.2 +/- 0.9).,Acetanilide and paracetamol pharmacokinetics before and during phenytoin administration: genetic control of induction? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7272175/),[μg] / [ml],12.2,185007,DB00252,Phenytoin
,7272175,SSPC,"2 The SSPC of AA before exposure to DPH varied from 0.06 to 0.67 microgram ml-1 (mean +/- s.e.mean 0.24 +/- 0.02), and following exposure from 0.03 to 0.47 microgram ml-1 (mean +/- s.e.mean 0.15 +/- 0.02).",Acetanilide and paracetamol pharmacokinetics before and during phenytoin administration: genetic control of induction? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7272175/),[μg] / [ml],0.06 to 0.67,185008,DB00252,Phenytoin
,7272175,SSPC,"2 The SSPC of AA before exposure to DPH varied from 0.06 to 0.67 microgram ml-1 (mean +/- s.e.mean 0.24 +/- 0.02), and following exposure from 0.03 to 0.47 microgram ml-1 (mean +/- s.e.mean 0.15 +/- 0.02).",Acetanilide and paracetamol pharmacokinetics before and during phenytoin administration: genetic control of induction? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7272175/),[μg] / [ml],0.24,185009,DB00252,Phenytoin
,7272175,SSPC,"2 The SSPC of AA before exposure to DPH varied from 0.06 to 0.67 microgram ml-1 (mean +/- s.e.mean 0.24 +/- 0.02), and following exposure from 0.03 to 0.47 microgram ml-1 (mean +/- s.e.mean 0.15 +/- 0.02).",Acetanilide and paracetamol pharmacokinetics before and during phenytoin administration: genetic control of induction? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7272175/),,0.15,185010,DB00252,Phenytoin
,7272175,SSPC,"3 The SSPC of PL before exposure to DPH varied from 1.2 to 4.4 microgram ml-1 (mean +/- s.e.mean 2.7 +/- 0.13), and following exposure from 1.1 to 3.8 microgram ml-1 (mean +/- s.e.mean 2.2 +/- 0.13).",Acetanilide and paracetamol pharmacokinetics before and during phenytoin administration: genetic control of induction? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7272175/),[μg] / [ml],1.2 to 4.4,185011,DB00252,Phenytoin
,7272175,SSPC,"3 The SSPC of PL before exposure to DPH varied from 1.2 to 4.4 microgram ml-1 (mean +/- s.e.mean 2.7 +/- 0.13), and following exposure from 1.1 to 3.8 microgram ml-1 (mean +/- s.e.mean 2.2 +/- 0.13).",Acetanilide and paracetamol pharmacokinetics before and during phenytoin administration: genetic control of induction? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7272175/),[μg] / [ml],2.7,185012,DB00252,Phenytoin
,7272175,SSPC,"3 The SSPC of PL before exposure to DPH varied from 1.2 to 4.4 microgram ml-1 (mean +/- s.e.mean 2.7 +/- 0.13), and following exposure from 1.1 to 3.8 microgram ml-1 (mean +/- s.e.mean 2.2 +/- 0.13).",Acetanilide and paracetamol pharmacokinetics before and during phenytoin administration: genetic control of induction? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7272175/),,2.2,185013,DB00252,Phenytoin
,9029743,clearance,"The clearance and volume of distribution of felbamate were 41.1 ml/h/kg and 908 ml/kg, respectively.",Population pharmacokinetics of felbamate in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029743/),[ml] / [h·kg],41.1,185907,DB00252,Phenytoin
,9029743,volume of distribution,"The clearance and volume of distribution of felbamate were 41.1 ml/h/kg and 908 ml/kg, respectively.",Population pharmacokinetics of felbamate in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029743/),[ml] / [kg],908,185908,DB00252,Phenytoin
,7634814,Initial free p,Initial free phenytoin fractions ranged between 0.08 and 0.15.,Pharmacokinetics of phenytoin in children with acute neurotrauma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7634814/),,0.08 and 0.15,186288,DB00252,Phenytoin
,7634814,fractions,Initial free phenytoin fractions ranged between 0.08 and 0.15.,Pharmacokinetics of phenytoin in children with acute neurotrauma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7634814/),,0.08 and 0.15,186289,DB00252,Phenytoin
,12504914,electroconvulsive threshold,"(2S,2R)-4-Methylglutamic acid (SYM 2081), a potent selective agonist of GluR5 and GluR6 kainate receptor subtypes, applied at the dose of 15.5 mg/kg, equal to its CD(16) value (i.e., a dose required to induce convulsions in 16% of mice), significantly decreased the electroconvulsive threshold from 7.0 to 5.8 mA.",Low-affinity kainate receptor-mediated events reduce the protective activity of phenobarbital and diphenylhydantoin against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504914/),m,7.0,186820,DB00252,Phenytoin
,12504914,electroconvulsive threshold,"(2S,2R)-4-Methylglutamic acid (SYM 2081), a potent selective agonist of GluR5 and GluR6 kainate receptor subtypes, applied at the dose of 15.5 mg/kg, equal to its CD(16) value (i.e., a dose required to induce convulsions in 16% of mice), significantly decreased the electroconvulsive threshold from 7.0 to 5.8 mA.",Low-affinity kainate receptor-mediated events reduce the protective activity of phenobarbital and diphenylhydantoin against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504914/),m,5,186821,DB00252,Phenytoin
,12504914,ED(50),"The respective ED(50) values were increased from 18.5 to 23.8 mg/kg for phenobarbital, and from 11.7 to 14.7 mg/kg for diphenylhydantoin.",Low-affinity kainate receptor-mediated events reduce the protective activity of phenobarbital and diphenylhydantoin against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504914/),[mg] / [kg],18.5 to 23.8,186822,DB00252,Phenytoin
,12504914,ED(50),"The respective ED(50) values were increased from 18.5 to 23.8 mg/kg for phenobarbital, and from 11.7 to 14.7 mg/kg for diphenylhydantoin.",Low-affinity kainate receptor-mediated events reduce the protective activity of phenobarbital and diphenylhydantoin against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504914/),[mg] / [kg],11.7 to 14.7,186823,DB00252,Phenytoin
,9646011,elimination half-life,Peak concentration in serum is reached after 1 to 2 hours and the elimination half-life is between 1 and 3 hours.,Pharmacokinetic optimisation of the treatment of neurocysticercosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646011/),h,1 and 3,187764,DB00252,Phenytoin
,9646011,half-life,Concentrations of ALBSO are highly variable between individuals and it has a half-life of between 6 and 15 hours.,Pharmacokinetic optimisation of the treatment of neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646011/),h,6 and 15,187765,DB00252,Phenytoin
,2704892,serum half life,The serum half life after intravenous injection ranged from 3.1 to 3.6 hours before and 1.3 to 1.6 hours after a two-week period of oral treatment.,Pharmacokinetics of three formulations of diphenylhydantoin in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2704892/),h,3.1 to 3.6,188268,DB00252,Phenytoin
,2704892,serum half life,The serum half life after intravenous injection ranged from 3.1 to 3.6 hours before and 1.3 to 1.6 hours after a two-week period of oral treatment.,Pharmacokinetics of three formulations of diphenylhydantoin in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2704892/),h,1.3 to 1.6,188269,DB00252,Phenytoin
,2704892,bioavailability,The bioavailability of the formulations varied from 43 to 54 per cent.,Pharmacokinetics of three formulations of diphenylhydantoin in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2704892/),%,43 to 54,188270,DB00252,Phenytoin
,17220566,C/D ratio,"The dose of metoprolol and patient age were significantly higher in the MET group when compared with the MET+AMD group (1.00+/-0.480 versus 0.767+/-0.418 mg/kg/day, p<0.050; 68.6+/-10.6 versus 57.6+/-14.1 years, p<0.001, respectively), but the C/D ratio was significantly lower in the MET group than in the MET+AMD group (90.8+/-64.0 versus 136+/-97.8, p<0.01).",Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220566/),,90.8,189038,DB00252,Phenytoin
,17220566,C/D ratio,"The dose of metoprolol and patient age were significantly higher in the MET group when compared with the MET+AMD group (1.00+/-0.480 versus 0.767+/-0.418 mg/kg/day, p<0.050; 68.6+/-10.6 versus 57.6+/-14.1 years, p<0.001, respectively), but the C/D ratio was significantly lower in the MET group than in the MET+AMD group (90.8+/-64.0 versus 136+/-97.8, p<0.01).",Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220566/),,136,189039,DB00252,Phenytoin
,2126946,AUC,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·pg] / [ml],806,189197,DB00252,Phenytoin
,2126946,AUC,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·pg] / [ml],411,189198,DB00252,Phenytoin
,2126946,AUC,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],33.6,189199,DB00252,Phenytoin
,2126946,AUC,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],19.5,189200,DB00252,Phenytoin
,2126946,Ng,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],33.6,189201,DB00252,Phenytoin
,2126946,Ng,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],19.5,189202,DB00252,Phenytoin
,2126946,AUC,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·pg] / [ml],1163,189203,DB00252,Phenytoin
,2126946,AUC,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·pg] / [ml],672,189204,DB00252,Phenytoin
,2126946,AUC,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],22.9,189205,DB00252,Phenytoin
,2126946,AUC,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],13.8,189206,DB00252,Phenytoin
,2126946,Ng,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],22.9,189207,DB00252,Phenytoin
,2126946,Ng,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],13.8,189208,DB00252,Phenytoin
,1395360,apparent volume of distribution,"The apparent volume of distribution of [R,S]-vigabatrin was approximately 0.8 L/kg.",Vigabatrin. Clinical pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1395360/),[l] / [kg],0.8,189507,DB00252,Phenytoin
,1395360,half-life,"The half-life of [R,S]-vigabatrin was between 5.3 and 7.4h, the half-life of the enantiomers were 7.5 and 8.1h for the S(+) and the R(-) forms, respectively.",Vigabatrin. Clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1395360/),h,5.3 and 7.4,189508,DB00252,Phenytoin
,1395360,half-life,"The half-life of [R,S]-vigabatrin was between 5.3 and 7.4h, the half-life of the enantiomers were 7.5 and 8.1h for the S(+) and the R(-) forms, respectively.",Vigabatrin. Clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1395360/),h,7.5,189509,DB00252,Phenytoin
,1395360,half-life,"The half-life of [R,S]-vigabatrin was between 5.3 and 7.4h, the half-life of the enantiomers were 7.5 and 8.1h for the S(+) and the R(-) forms, respectively.",Vigabatrin. Clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1395360/),h,8.1,189510,DB00252,Phenytoin
,1395360,urinary recovery,"The major route of elimination was renal excretion; urinary recovery of the [R,S]-vigabatrin was close to 70%.",Vigabatrin. Clinical pharmacokinetics. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1395360/),%,70,189511,DB00252,Phenytoin
,1395360,half-life,"In adults with epilepsy, the half-life of the [R,S]-vigabatrin ranged from 4.2 and 5.6h, similar to that measured in healthy adults.",Vigabatrin. Clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1395360/),h,4.2,189512,DB00252,Phenytoin
,1395360,half-life,"In adults with epilepsy, the half-life of the [R,S]-vigabatrin ranged from 4.2 and 5.6h, similar to that measured in healthy adults.",Vigabatrin. Clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1395360/),h,5.6,189513,DB00252,Phenytoin
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,2.6,189846,DB00252,Phenytoin
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,15.8,189847,DB00252,Phenytoin
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,22.3,189848,DB00252,Phenytoin
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,16.3,189849,DB00252,Phenytoin
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,3.2,189850,DB00252,Phenytoin
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,0.8,189851,DB00252,Phenytoin
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,7.5,189852,DB00252,Phenytoin
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,7.7,189853,DB00252,Phenytoin
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,16.0,189854,DB00252,Phenytoin
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,1.5,189855,DB00252,Phenytoin
,10369622,Apparent volume of distribution (Vd),Apparent volume of distribution (Vd) following a 20 mg/kg loading dose was 0.29 L/kg.,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[l] / [kg],0.29,190062,DB00252,Phenytoin
,10369622,steady-state total concentrations,Maintenance infusions of 4-6 mg/kg/h produced steady-state total concentrations of 66 mg/L and 92.4 mg/L (unbound concentration 44.6 mg/L).,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[mg] / [l],66,190063,DB00252,Phenytoin
,10369622,steady-state total concentrations,Maintenance infusions of 4-6 mg/kg/h produced steady-state total concentrations of 66 mg/L and 92.4 mg/L (unbound concentration 44.6 mg/L).,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[mg] / [l],92.4,190064,DB00252,Phenytoin
,10369622,unbound concentration,Maintenance infusions of 4-6 mg/kg/h produced steady-state total concentrations of 66 mg/L and 92.4 mg/L (unbound concentration 44.6 mg/L).,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[mg] / [l],44.6,190065,DB00252,Phenytoin
,10369622,Clearance,Clearance ranged from 63-66 mL/h/kg.,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[ml] / [h·kg],63-66,190066,DB00252,Phenytoin
,10369622,Total,"Total and unbound steady-state VPA concentrations were 32.9 mg/L and 21.2 mg/L, respectively.",Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[mg] / [l],32.9,190067,DB00252,Phenytoin
,10369622,unbound steady-state VPA concentrations,"Total and unbound steady-state VPA concentrations were 32.9 mg/L and 21.2 mg/L, respectively.",Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[mg] / [l],21.2,190068,DB00252,Phenytoin
,10369622,Unbound fractions,Unbound fractions (48.3% and 66%) were significantly higher than normal.,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),%,48.3,190069,DB00252,Phenytoin
,10369622,Unbound fractions,Unbound fractions (48.3% and 66%) were significantly higher than normal.,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),%,66,190070,DB00252,Phenytoin
,6710554,Vmax,"Their calculated average Vmax (the maximal rate of elimination) was significantly higher than the average for their age (12.21 and 9.28 mg/kg/day, respectively) (p less than 0.05).",Influence of bioavailability on the calculated Michaelis-Menten parameters of phenytoin in children. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6710554/),[mg] / [d·kg],12.21,190612,DB00252,Phenytoin
,6710554,Vmax,"Their calculated average Vmax (the maximal rate of elimination) was significantly higher than the average for their age (12.21 and 9.28 mg/kg/day, respectively) (p less than 0.05).",Influence of bioavailability on the calculated Michaelis-Menten parameters of phenytoin in children. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6710554/),[mg] / [d·kg],9.28,190613,DB00252,Phenytoin
,6710554,maximal rate of elimination,"Their calculated average Vmax (the maximal rate of elimination) was significantly higher than the average for their age (12.21 and 9.28 mg/kg/day, respectively) (p less than 0.05).",Influence of bioavailability on the calculated Michaelis-Menten parameters of phenytoin in children. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6710554/),[mg] / [d·kg],12.21,190614,DB00252,Phenytoin
,6710554,maximal rate of elimination,"Their calculated average Vmax (the maximal rate of elimination) was significantly higher than the average for their age (12.21 and 9.28 mg/kg/day, respectively) (p less than 0.05).",Influence of bioavailability on the calculated Michaelis-Menten parameters of phenytoin in children. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6710554/),[mg] / [d·kg],9.28,190615,DB00252,Phenytoin
,3755676,AUC48,The phenytoin AUC48 was reduced from 173.6 +/- 22.6 mg .,Effect of sucralfate on phenytoin bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3755676/),mg,173.6,191442,DB00252,Phenytoin
,3755676,AUC120,"h/L to 157.1 +/- 19.6 mg . h/L (p less than 0.02), and the phenytoin AUC120 was reduced from 200.5 +/- 31.9 mg .",Effect of sucralfate on phenytoin bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3755676/),mg,200.5,191443,DB00252,Phenytoin
,6985719,half-life,The drug was absorbed and excreted rapidly; the mean half-life was 9.6 hours.,Sodium valproate: pharmacokinetics and effectivensss in treating intractable seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6985719/),h,9.6,191690,DB00252,Phenytoin
,328018,half-life,After withdrawal of DPA the half-life was about 14 h in adult patients.,Preliminary observations on valproic acid kinetics in patients with epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/328018/),h,14,192230,DB00252,Phenytoin
<,26517379,concentration at 2h post infusion (C2h),"Loading with doses of 18 mg/kg, blood levels were sub-therapeutic in 22/100 (concentration at 2h post infusion (C2h) <10 μg/mL), therapeutic in 62/100 (C2h 10-20 μg/mL), and supra-therapeutic in 16/100 (C2h>20 μg/mL).",Comparing paediatric intravenous phenytoin doses using physiologically based pharmacokinetic (PBPK) modelling software. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26517379/),[μg] / [ml],10,192236,DB00252,Phenytoin
,26517379,C2h,"Loading with doses of 18 mg/kg, blood levels were sub-therapeutic in 22/100 (concentration at 2h post infusion (C2h) <10 μg/mL), therapeutic in 62/100 (C2h 10-20 μg/mL), and supra-therapeutic in 16/100 (C2h>20 μg/mL).",Comparing paediatric intravenous phenytoin doses using physiologically based pharmacokinetic (PBPK) modelling software. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26517379/),[μg] / [ml],10-20,192237,DB00252,Phenytoin
>,26517379,C2h,"Loading with doses of 18 mg/kg, blood levels were sub-therapeutic in 22/100 (concentration at 2h post infusion (C2h) <10 μg/mL), therapeutic in 62/100 (C2h 10-20 μg/mL), and supra-therapeutic in 16/100 (C2h>20 μg/mL).",Comparing paediatric intravenous phenytoin doses using physiologically based pharmacokinetic (PBPK) modelling software. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26517379/),[μg] / [ml],20,192238,DB00252,Phenytoin
,26517379,C2h,"Increasing from 18 to 20 mg/kg increased the mean C2h from 16.0 to 17.9 μg/mL, and the mean AUC from 145 to 162 μg/mL/h.",Comparing paediatric intravenous phenytoin doses using physiologically based pharmacokinetic (PBPK) modelling software. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26517379/),[μg] / [ml],16.0 to 17.9,192239,DB00252,Phenytoin
,26517379,AUC,"Increasing from 18 to 20 mg/kg increased the mean C2h from 16.0 to 17.9 μg/mL, and the mean AUC from 145 to 162 μg/mL/h.",Comparing paediatric intravenous phenytoin doses using physiologically based pharmacokinetic (PBPK) modelling software. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26517379/),[μg] / [h·ml],145,192240,DB00252,Phenytoin
,26517379,AUC,"Increasing from 18 to 20 mg/kg increased the mean C2h from 16.0 to 17.9 μg/mL, and the mean AUC from 145 to 162 μg/mL/h.",Comparing paediatric intravenous phenytoin doses using physiologically based pharmacokinetic (PBPK) modelling software. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26517379/),[μg] / [h·ml],162,192241,DB00252,Phenytoin
>,26517379,C2h,"A C2h>30 μg/mL was predicted in 4% and 8% of children in the 18 and 20 mg/kg doses, with 3% predicted to have a C2h>40 μg/mL following either dose.",Comparing paediatric intravenous phenytoin doses using physiologically based pharmacokinetic (PBPK) modelling software. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26517379/),[μg] / [ml],30,192242,DB00252,Phenytoin
>,26517379,C2h,"A C2h>30 μg/mL was predicted in 4% and 8% of children in the 18 and 20 mg/kg doses, with 3% predicted to have a C2h>40 μg/mL following either dose.",Comparing paediatric intravenous phenytoin doses using physiologically based pharmacokinetic (PBPK) modelling software. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26517379/),[μg] / [ml],40,192243,DB00252,Phenytoin
,17535024,overall survival,The overall survival of the whole group was 14 months.,Fractionated stereotactic radiotherapy boost and weekly paclitaxel in malignant gliomas clinical and pharmacokinetics results. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535024/),month,14,194361,DB00252,Phenytoin
,17535024,survival,"The median survival for RPA prognostic classes III, IV, V, and VI were 20, 14, 12, and 11 months.",Fractionated stereotactic radiotherapy boost and weekly paclitaxel in malignant gliomas clinical and pharmacokinetics results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535024/),month,20,194362,DB00252,Phenytoin
,17535024,survival,"The median survival for RPA prognostic classes III, IV, V, and VI were 20, 14, 12, and 11 months.",Fractionated stereotactic radiotherapy boost and weekly paclitaxel in malignant gliomas clinical and pharmacokinetics results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535024/),month,14,194363,DB00252,Phenytoin
,17535024,survival,"The median survival for RPA prognostic classes III, IV, V, and VI were 20, 14, 12, and 11 months.",Fractionated stereotactic radiotherapy boost and weekly paclitaxel in malignant gliomas clinical and pharmacokinetics results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535024/),month,12,194364,DB00252,Phenytoin
,17535024,survival,"The median survival for RPA prognostic classes III, IV, V, and VI were 20, 14, 12, and 11 months.",Fractionated stereotactic radiotherapy boost and weekly paclitaxel in malignant gliomas clinical and pharmacokinetics results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535024/),month,11,194365,DB00252,Phenytoin
,19043374,peak plasma concentration,A women with a prehistory of cerebral seizures was presented following a severe iatrogenic phenytoin overdose with a peak plasma concentration of 117 mg/L.,Treatment of severe intravenous phenytoin overdose with hemodialysis and hemoperfusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19043374/),[mg] / [l],117,194966,DB00252,Phenytoin
,19043374,half-life,"Thus, three sessions of a four-hour long combination of activated charcoal hemoperfusion and high-flux hemodialysis were performed resulting in considerably reduced half-life during these measures of about 7-13 hours compared to the native half-life wavering between 40-100 hours.",Treatment of severe intravenous phenytoin overdose with hemodialysis and hemoperfusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19043374/),h,7-13,194967,DB00252,Phenytoin
,19043374,half-life,"Thus, three sessions of a four-hour long combination of activated charcoal hemoperfusion and high-flux hemodialysis were performed resulting in considerably reduced half-life during these measures of about 7-13 hours compared to the native half-life wavering between 40-100 hours.",Treatment of severe intravenous phenytoin overdose with hemodialysis and hemoperfusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19043374/),h,40-100,194968,DB00252,Phenytoin
,7332730,apparent Km,3 The apparent Km was similar in children (7.5 +/- 1.2 mg/l) and adults (9.4 +/- 2.3 mg/l).,Pharmacokinetics of phenytoin in children. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332730/),[mg] / [l],7.5,196249,DB00252,Phenytoin
,7332730,apparent Km,3 The apparent Km was similar in children (7.5 +/- 1.2 mg/l) and adults (9.4 +/- 2.3 mg/l).,Pharmacokinetics of phenytoin in children. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332730/),[mg] / [l],9.4,196250,DB00252,Phenytoin
,7332730,Vmax,4 Vmax differed significantly (P less than 0.001) between children (20.4 +/- 2.1 mg kg-1 day-1) and adults (8.7 +/- 0.7 mg kg-1 day-1).,Pharmacokinetics of phenytoin in children. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332730/),[mg] / [d·kg],20.4,196251,DB00252,Phenytoin
,7332730,Vmax,4 Vmax differed significantly (P less than 0.001) between children (20.4 +/- 2.1 mg kg-1 day-1) and adults (8.7 +/- 0.7 mg kg-1 day-1).,Pharmacokinetics of phenytoin in children. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332730/),[mg] / [d·kg],8.7,196252,DB00252,Phenytoin
,10996503,plasma concentrations,LTG dose of 369+/-236 mg per day (8.1+/-5.9 mg/kg per day) achieved LTG plasma concentrations of 6.8+/-3.3 microg/ml.,Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10996503/),[μg] / [ml],6.8,196945,DB00252,Phenytoin
,10996503,oral clearance (Cl/F),"The observed LTG monotherapy, LTG+IND, and LTG+VPA oral clearance (Cl/F) were 0. 69+/-0.2, 1.60+/-0.65 and 0.2+/-0.05 ml/kg per min, respectively.",Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10996503/),[ml] / [kg·min],0. 69,196946,DB00252,Phenytoin
,10996503,oral clearance (Cl/F),"The observed LTG monotherapy, LTG+IND, and LTG+VPA oral clearance (Cl/F) were 0. 69+/-0.2, 1.60+/-0.65 and 0.2+/-0.05 ml/kg per min, respectively.",Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10996503/),[ml] / [kg·min],1.60,196947,DB00252,Phenytoin
,10996503,oral clearance (Cl/F),"The observed LTG monotherapy, LTG+IND, and LTG+VPA oral clearance (Cl/F) were 0. 69+/-0.2, 1.60+/-0.65 and 0.2+/-0.05 ml/kg per min, respectively.",Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10996503/),[ml] / [kg·min],0.2,196948,DB00252,Phenytoin
,17516704,apparent elimination half-life (t((1/2))),In plasma after a single oral administration of oxcarbazepine the mean apparent elimination half-life (t((1/2))) of MHD in adults was 8-9h.,Overview of the clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516704/),h,8-9,197924,DB00252,Phenytoin
,17516704,ki [inhibition constant],"In vitro, MHD inhibits the cytochrome P450 (CYP) 2C19 (ki [inhibition constant] = 88 micromol/L).",Overview of the clinical pharmacokinetics of oxcarbazepine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516704/),[μM] / [l],88,197925,DB00252,Phenytoin
,1233257,serum half-life,The mean serum half-life was 19.28 h +/- 5.87 (SD).,Comparative drug elimination in man-diphenylhydantoin and amobarbital. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233257/),h,19.28,198873,DB00252,Phenytoin
,1233257,apparent elimination half-life,"In the case of one subject, the urinary excretion of p-HPPH plateaued five days after DPH administration and the apparent elimination half-life determined from the p-HPPH urinary excretion data was 19.16 h as compared to the value of 19.53 h calculated from the DPH serum levels.",Comparative drug elimination in man-diphenylhydantoin and amobarbital. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233257/),h,19.16,198874,DB00252,Phenytoin
,1233257,apparent elimination half-life,"In the case of one subject, the urinary excretion of p-HPPH plateaued five days after DPH administration and the apparent elimination half-life determined from the p-HPPH urinary excretion data was 19.16 h as compared to the value of 19.53 h calculated from the DPH serum levels.",Comparative drug elimination in man-diphenylhydantoin and amobarbital. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233257/),h,19.53,198875,DB00252,Phenytoin
,3121288,AUCs,"AUCs (mg x h/L) were not different (p greater than 0.05) for A (222.1 +/- 86.9), B (233.9 +/- 92.9), and C (226.0 +/- 95.7).",Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3121288/),[h·mg] / [l],222.1,199468,DB00252,Phenytoin
,3121288,AUCs,"AUCs (mg x h/L) were not different (p greater than 0.05) for A (222.1 +/- 86.9), B (233.9 +/- 92.9), and C (226.0 +/- 95.7).",Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3121288/),[h·mg] / [l],233.9,199469,DB00252,Phenytoin
,3121288,AUCs,"AUCs (mg x h/L) were not different (p greater than 0.05) for A (222.1 +/- 86.9), B (233.9 +/- 92.9), and C (226.0 +/- 95.7).",Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3121288/),[h·mg] / [l],226.0,199470,DB00252,Phenytoin
,3121288,Tmax,"Tmax (h) was significantly shorter (p less than 0.05) when PHT was administered with Ensure (B = 8.5 +/- 3.0, C = 5.3 +/- 2.0) than without Ensure (A = 18.5 +/- 10.5).",Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3121288/),h,8.5,199471,DB00252,Phenytoin
,3121288,Tmax,"Tmax (h) was significantly shorter (p less than 0.05) when PHT was administered with Ensure (B = 8.5 +/- 3.0, C = 5.3 +/- 2.0) than without Ensure (A = 18.5 +/- 10.5).",Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3121288/),h,5.3,199472,DB00252,Phenytoin
,3121288,Tmax,"Tmax (h) was significantly shorter (p less than 0.05) when PHT was administered with Ensure (B = 8.5 +/- 3.0, C = 5.3 +/- 2.0) than without Ensure (A = 18.5 +/- 10.5).",Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3121288/),h,18.5,199473,DB00252,Phenytoin
,3121288,excretion,"The HPPH excretion (mg/80 h) was not different (p greater than 0.05) for A (225.6 +/- 48.5), B (238.6 +/- 26.6), and C (229.9 +/- 45.6).",Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3121288/),[mg] / [80·h],225.6,199474,DB00252,Phenytoin
,3121288,excretion,"The HPPH excretion (mg/80 h) was not different (p greater than 0.05) for A (225.6 +/- 48.5), B (238.6 +/- 26.6), and C (229.9 +/- 45.6).",Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3121288/),[mg] / [80·h],238.6,199475,DB00252,Phenytoin
,3121288,excretion,"The HPPH excretion (mg/80 h) was not different (p greater than 0.05) for A (225.6 +/- 48.5), B (238.6 +/- 26.6), and C (229.9 +/- 45.6).",Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3121288/),[mg] / [80·h],229.9,199476,DB00252,Phenytoin
,3121288,Relative bioavailability,"Relative bioavailability was B/A = 1.07 +/- 0.21, C/A = 1.01 +/- 0.14.",Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3121288/),,1.07,199477,DB00252,Phenytoin
,3121288,B/A,"Relative bioavailability was B/A = 1.07 +/- 0.21, C/A = 1.01 +/- 0.14.",Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3121288/),,1.07,199478,DB00252,Phenytoin
,3121288,C/A,"Relative bioavailability was B/A = 1.07 +/- 0.21, C/A = 1.01 +/- 0.14.",Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3121288/),,1.01,199479,DB00252,Phenytoin
,12160664,time to fourth seizure,Remacemide hydrochloride showed a significantly ( P= 0.045) longer median time to fourth seizure compared with placebo (6.8 vs. 3.8 days).,"A double-blind, placebo-controlled study of remacemide hydrochloride in patients with refractory epilepsy following pre-surgical assessment. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12160664/),d,6.8,199964,DB00252,Phenytoin
,12160664,time to fourth seizure,Remacemide hydrochloride showed a significantly ( P= 0.045) longer median time to fourth seizure compared with placebo (6.8 vs. 3.8 days).,"A double-blind, placebo-controlled study of remacemide hydrochloride in patients with refractory epilepsy following pre-surgical assessment. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12160664/),d,3.8,199965,DB00252,Phenytoin
,2775612,t 1/2,"Despite this, (i) the mean +/- s.d. t 1/2 for phenytoin was statistically significantly shorter in pregnancy than post-natally (31 +/- 14 vs 39 +/- 28 h), (ii) the mean +/- s.d. whole plasma clearance was also statistically significant greater (0.025 +/- 0.012 vs 0.021 +/- 0.013 kg-1 h-1) and (iii) the mean +/- s.d.",The effect of pregnancy in humans on the pharmacokinetics of stable isotope labelled phenytoin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775612/),h,31,200417,DB00252,Phenytoin
,2775612,t 1/2,"Despite this, (i) the mean +/- s.d. t 1/2 for phenytoin was statistically significantly shorter in pregnancy than post-natally (31 +/- 14 vs 39 +/- 28 h), (ii) the mean +/- s.d. whole plasma clearance was also statistically significant greater (0.025 +/- 0.012 vs 0.021 +/- 0.013 kg-1 h-1) and (iii) the mean +/- s.d.",The effect of pregnancy in humans on the pharmacokinetics of stable isotope labelled phenytoin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775612/),h,39,200418,DB00252,Phenytoin
,2775612,whole plasma clearance,"Despite this, (i) the mean +/- s.d. t 1/2 for phenytoin was statistically significantly shorter in pregnancy than post-natally (31 +/- 14 vs 39 +/- 28 h), (ii) the mean +/- s.d. whole plasma clearance was also statistically significant greater (0.025 +/- 0.012 vs 0.021 +/- 0.013 kg-1 h-1) and (iii) the mean +/- s.d.",The effect of pregnancy in humans on the pharmacokinetics of stable isotope labelled phenytoin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775612/),1/[h·kg],0.025,200419,DB00252,Phenytoin
,2775612,whole plasma clearance,"Despite this, (i) the mean +/- s.d. t 1/2 for phenytoin was statistically significantly shorter in pregnancy than post-natally (31 +/- 14 vs 39 +/- 28 h), (ii) the mean +/- s.d. whole plasma clearance was also statistically significant greater (0.025 +/- 0.012 vs 0.021 +/- 0.013 kg-1 h-1) and (iii) the mean +/- s.d.",The effect of pregnancy in humans on the pharmacokinetics of stable isotope labelled phenytoin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775612/),1/[h·kg],0.021,200420,DB00252,Phenytoin
,2775612,Vmax,Vmax for phenytoin elimination was statistically significantly greater in pregnancy (1170 +/- 600 mg day-1) than post-natally (780 +/- 470 mg day-1).,The effect of pregnancy in humans on the pharmacokinetics of stable isotope labelled phenytoin. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775612/),[mg] / [d],1170,200421,DB00252,Phenytoin
,2775612,Vmax,Vmax for phenytoin elimination was statistically significantly greater in pregnancy (1170 +/- 600 mg day-1) than post-natally (780 +/- 470 mg day-1).,The effect of pregnancy in humans on the pharmacokinetics of stable isotope labelled phenytoin. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775612/),[mg] / [d],780,200422,DB00252,Phenytoin
,2775612,apparent Km,"Although the mean +/- s.d. apparent Km was higher in pregnancy (18.2 +/- 8.4 mg l-1, expressed in terms of whole plasma drug concentrations, compared with 10.2 +/- 7.4 mg l-1 post-natally), the difference was not statistically significant.",The effect of pregnancy in humans on the pharmacokinetics of stable isotope labelled phenytoin. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775612/),[mg] / [l],18.2,200423,DB00252,Phenytoin
,2775612,apparent Km,"Although the mean +/- s.d. apparent Km was higher in pregnancy (18.2 +/- 8.4 mg l-1, expressed in terms of whole plasma drug concentrations, compared with 10.2 +/- 7.4 mg l-1 post-natally), the difference was not statistically significant.",The effect of pregnancy in humans on the pharmacokinetics of stable isotope labelled phenytoin. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775612/),[mg] / [l],10.2,200424,DB00252,Phenytoin
,2775612,apparent Km,"However, if the apparent Km value was expressed in terms of plasma water phenytoin concentrations the difference (pregnant 2.50 +/- 0.85 mg l-1: post-natally 1.16 +/- 0.65 mg l-1) was statistically significant.",The effect of pregnancy in humans on the pharmacokinetics of stable isotope labelled phenytoin. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775612/),[mg] / [l],2.50,200425,DB00252,Phenytoin
,2775612,apparent Km,"However, if the apparent Km value was expressed in terms of plasma water phenytoin concentrations the difference (pregnant 2.50 +/- 0.85 mg l-1: post-natally 1.16 +/- 0.65 mg l-1) was statistically significant.",The effect of pregnancy in humans on the pharmacokinetics of stable isotope labelled phenytoin. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775612/),[mg] / [l],1.16,200426,DB00252,Phenytoin
,9533548,urinary recovery,"Topotecan undergoes both renal and hepatic elimination, with topotecan urinary recovery ranging from 60 to 70%.",Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533548/),%,60 to 70,202905,DB00252,Phenytoin
,9533548,clearance,"Phenytoin coadministration increased lactone and total topotecan clearance from 43.4 +/- 1.9 L/h/m2 to 62.9 +/- 6.4 L/h/m2, and 20.8 +/- 2.8 L/h/m2 to 30.6 +/- 4.1 L/h/m2, respectively (P < 0.05).",Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533548/),[l] / [h·m2],62.9,202906,DB00252,Phenytoin
,9533548,clearance,"Phenytoin coadministration increased lactone and total topotecan clearance from 43.4 +/- 1.9 L/h/m2 to 62.9 +/- 6.4 L/h/m2, and 20.8 +/- 2.8 L/h/m2 to 30.6 +/- 4.1 L/h/m2, respectively (P < 0.05).",Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533548/),[l] / [h·m2],20.8,202907,DB00252,Phenytoin
,9533548,clearance,"Phenytoin coadministration increased lactone and total topotecan clearance from 43.4 +/- 1.9 L/h/m2 to 62.9 +/- 6.4 L/h/m2, and 20.8 +/- 2.8 L/h/m2 to 30.6 +/- 4.1 L/h/m2, respectively (P < 0.05).",Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533548/),[l] / [h·m2],30.6,202908,DB00252,Phenytoin
,9533548,plasma AUC,"Concomitant phenytoin increased the plasma AUC of total N-desmethyl topotecan from 7.5 +/- 0.68 ng/ml x h to 16.3 +/- 0.53 ng/ml x h (P < 0.05) at plasma AUC of total topotecan of 226.0 +/- 5.5 ng/ml x h and 240.9 +/- 39.8 ng/ml x h, respectively.",Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533548/),[ng] / [h·ml],7.5,202909,DB00252,Phenytoin
,9533548,plasma AUC,"Concomitant phenytoin increased the plasma AUC of total N-desmethyl topotecan from 7.5 +/- 0.68 ng/ml x h to 16.3 +/- 0.53 ng/ml x h (P < 0.05) at plasma AUC of total topotecan of 226.0 +/- 5.5 ng/ml x h and 240.9 +/- 39.8 ng/ml x h, respectively.",Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533548/),[ng] / [h·ml],16.3,202910,DB00252,Phenytoin
,9533548,plasma AUC,"Concomitant phenytoin increased the plasma AUC of total N-desmethyl topotecan from 7.5 +/- 0.68 ng/ml x h to 16.3 +/- 0.53 ng/ml x h (P < 0.05) at plasma AUC of total topotecan of 226.0 +/- 5.5 ng/ml x h and 240.9 +/- 39.8 ng/ml x h, respectively.",Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533548/),[ng] / [h·ml],226.0,202911,DB00252,Phenytoin
,9533548,plasma AUC,"Concomitant phenytoin increased the plasma AUC of total N-desmethyl topotecan from 7.5 +/- 0.68 ng/ml x h to 16.3 +/- 0.53 ng/ml x h (P < 0.05) at plasma AUC of total topotecan of 226.0 +/- 5.5 ng/ml x h and 240.9 +/- 39.8 ng/ml x h, respectively.",Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533548/),[ng] / [h·ml],240.9,202912,DB00252,Phenytoin
,11673755,elimination half-life,"The elimination half-life was 103 hours, namely, about 5 times longer than the mean value generally quoted (22 hours).",Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673755/),h,103,204184,DB00252,Phenytoin
,11673755,elimination half-life,"The elimination half-life was 103 hours, namely, about 5 times longer than the mean value generally quoted (22 hours).",Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673755/),h,22,204185,DB00252,Phenytoin
,18521585,total plasma clearance,The CPT therapy was found to increase the total plasma clearance from 0.26 to 0.75 L min(-1).,Pharmacokinetic-pharmacodynamic modeling of the influence of chronic phenytoin therapy on the rocuronium bromide response in patients undergoing brain surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18521585/),[l] / [min],0.26,205526,DB00252,Phenytoin
,18521585,total plasma clearance,The CPT therapy was found to increase the total plasma clearance from 0.26 to 0.75 L min(-1).,Pharmacokinetic-pharmacodynamic modeling of the influence of chronic phenytoin therapy on the rocuronium bromide response in patients undergoing brain surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18521585/),[l] / [min],0.75,205527,DB00252,Phenytoin
,18521585,k(e0),"The PD model parameter estimates were k(e0)= 0.073 min(-1), IC(50) (the steady-state plasma concentration eliciting half of the maximum response) = 836 ng mL(-1) and gamma = 3.13.",Pharmacokinetic-pharmacodynamic modeling of the influence of chronic phenytoin therapy on the rocuronium bromide response in patients undergoing brain surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18521585/),1/[min],0.073,205528,DB00252,Phenytoin
,18521585,IC(50) (the,"The PD model parameter estimates were k(e0)= 0.073 min(-1), IC(50) (the steady-state plasma concentration eliciting half of the maximum response) = 836 ng mL(-1) and gamma = 3.13.",Pharmacokinetic-pharmacodynamic modeling of the influence of chronic phenytoin therapy on the rocuronium bromide response in patients undergoing brain surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18521585/),[ng] / [ml],836,205529,DB00252,Phenytoin
,18521585,steady-state plasma concentration eliciting half of the maximum response),"The PD model parameter estimates were k(e0)= 0.073 min(-1), IC(50) (the steady-state plasma concentration eliciting half of the maximum response) = 836 ng mL(-1) and gamma = 3.13.",Pharmacokinetic-pharmacodynamic modeling of the influence of chronic phenytoin therapy on the rocuronium bromide response in patients undergoing brain surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18521585/),[ng] / [ml],836,205530,DB00252,Phenytoin
,18521585,gamma,"The PD model parameter estimates were k(e0)= 0.073 min(-1), IC(50) (the steady-state plasma concentration eliciting half of the maximum response) = 836 ng mL(-1) and gamma = 3.13.",Pharmacokinetic-pharmacodynamic modeling of the influence of chronic phenytoin therapy on the rocuronium bromide response in patients undergoing brain surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18521585/),,3.13,205531,DB00252,Phenytoin
,18521585,clearance,"Chronic phenytoin therapy increases the clearance of rocuronium from 0.26 to 0.75 L min(-1) but has no effect on the k(e0), IC(50) or gamma parameters.",Pharmacokinetic-pharmacodynamic modeling of the influence of chronic phenytoin therapy on the rocuronium bromide response in patients undergoing brain surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18521585/),[l] / [min],0.26,205532,DB00252,Phenytoin
,2621577,central volume of distribution (Vdc),"Mean pharmacokinetic parameter estimates for iv 1 in these patients were central volume of distribution (Vdc) of 0.040 +/- 0.0084 L/kg and plasma disappearance half-life (t1/2 alpha) of 8.0 +/- 2.9 min (""conversion"" t1/2).",Phenytoin prodrug 3-phosphoryloxymethyl phenytoin (ACC-9653): pharmacokinetics in patients following intravenous and intramuscular administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2621577/),[l] / [kg],0.040,206136,DB00252,Phenytoin
,2621577,plasma disappearance half-life (t1/2 alpha),"Mean pharmacokinetic parameter estimates for iv 1 in these patients were central volume of distribution (Vdc) of 0.040 +/- 0.0084 L/kg and plasma disappearance half-life (t1/2 alpha) of 8.0 +/- 2.9 min (""conversion"" t1/2).",Phenytoin prodrug 3-phosphoryloxymethyl phenytoin (ACC-9653): pharmacokinetics in patients following intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2621577/),min,8.0,206137,DB00252,Phenytoin
,2621577,clearance (CL),Overall mean clearance (CL) was 0.24 +/- 0.080 L/kg/h in the 10 patients.,Phenytoin prodrug 3-phosphoryloxymethyl phenytoin (ACC-9653): pharmacokinetics in patients following intravenous and intramuscular administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2621577/),[l] / [h·kg],0.24,206138,DB00252,Phenytoin
,2621577,rate constant (ka),Mean pharmacokinetic parameter estimates for im 1 were a rate constant (ka) of 2.47 +/- 1.41 h-1 and an absolute bioavailability (F) of 100.5 +/- 20.3%.,Phenytoin prodrug 3-phosphoryloxymethyl phenytoin (ACC-9653): pharmacokinetics in patients following intravenous and intramuscular administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2621577/),1/[h],2.47,206139,DB00252,Phenytoin
,2621577,absolute bioavailability (F),Mean pharmacokinetic parameter estimates for im 1 were a rate constant (ka) of 2.47 +/- 1.41 h-1 and an absolute bioavailability (F) of 100.5 +/- 20.3%.,Phenytoin prodrug 3-phosphoryloxymethyl phenytoin (ACC-9653): pharmacokinetics in patients following intravenous and intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2621577/),%,100.5,206140,DB00252,Phenytoin
,2621577,tmax,"Mean observed tmax values for phenytoin were 0.57 +/- 0.26 and 1.46 +/- 0.76 h following iv and im 1, respectively.",Phenytoin prodrug 3-phosphoryloxymethyl phenytoin (ACC-9653): pharmacokinetics in patients following intravenous and intramuscular administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2621577/),h,0.57,206141,DB00252,Phenytoin
,2621577,tmax,"Mean observed tmax values for phenytoin were 0.57 +/- 0.26 and 1.46 +/- 0.76 h following iv and im 1, respectively.",Phenytoin prodrug 3-phosphoryloxymethyl phenytoin (ACC-9653): pharmacokinetics in patients following intravenous and intramuscular administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2621577/),h,1.46,206142,DB00252,Phenytoin
,8598183,area under the plasma concentration-time curve (AUC),"In patients with epilepsy, the area under the plasma concentration-time curve (AUC) of midazolam (mean +/- SEM) was only 5.7% (0.60 +/- 0.16 vs. 10.5 +/- 0.6 microgram x min/ml), and the peak midazolam concentration was 7.4% (5.2 +/- 1.2 vs. 70.4 +/- 9.0 ng/ml) of its value in control subjects (p < 0.001).",Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8598183/),[min·μg] / [ml],0.60,206565,DB00252,Phenytoin
,8598183,area under the plasma concentration-time curve (AUC),"In patients with epilepsy, the area under the plasma concentration-time curve (AUC) of midazolam (mean +/- SEM) was only 5.7% (0.60 +/- 0.16 vs. 10.5 +/- 0.6 microgram x min/ml), and the peak midazolam concentration was 7.4% (5.2 +/- 1.2 vs. 70.4 +/- 9.0 ng/ml) of its value in control subjects (p < 0.001).",Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8598183/),[min·μg] / [ml],10.5,206566,DB00252,Phenytoin
,8598183,peak midazolam concentration,"In patients with epilepsy, the area under the plasma concentration-time curve (AUC) of midazolam (mean +/- SEM) was only 5.7% (0.60 +/- 0.16 vs. 10.5 +/- 0.6 microgram x min/ml), and the peak midazolam concentration was 7.4% (5.2 +/- 1.2 vs. 70.4 +/- 9.0 ng/ml) of its value in control subjects (p < 0.001).",Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8598183/),[ng] / [ml],5.2,206567,DB00252,Phenytoin
,8598183,peak midazolam concentration,"In patients with epilepsy, the area under the plasma concentration-time curve (AUC) of midazolam (mean +/- SEM) was only 5.7% (0.60 +/- 0.16 vs. 10.5 +/- 0.6 microgram x min/ml), and the peak midazolam concentration was 7.4% (5.2 +/- 1.2 vs. 70.4 +/- 9.0 ng/ml) of its value in control subjects (p < 0.001).",Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8598183/),[ng] / [ml],70.4,206568,DB00252,Phenytoin
,8598183,elimination half-life (t l/2),The elimination half-life (t l/2) of midazolam was 1.3 +/- 0.2 h in patients and 3.1 +/- 0.1 h in controls (p < 0.001).,Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8598183/),h,1.3,206569,DB00252,Phenytoin
,8598183,elimination half-life (t l/2),The elimination half-life (t l/2) of midazolam was 1.3 +/- 0.2 h in patients and 3.1 +/- 0.1 h in controls (p < 0.001).,Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8598183/),h,3.1,206570,DB00252,Phenytoin
,3504395,peak brain levels,"A significant increase in the amount of PHT entering the brain during the convulsive status was found, with peak brain levels at 45 min (12 +/- 3.2 micrograms/g vs. 6.0 +/- 0.8 in normal cats, P less than 0.05).",Distribution of diphenylhydantoin in the brain during experimental status epilepticus of the cat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3504395/),[μg] / [g],12,206626,DB00252,Phenytoin
,3504395,peak brain levels,"A significant increase in the amount of PHT entering the brain during the convulsive status was found, with peak brain levels at 45 min (12 +/- 3.2 micrograms/g vs. 6.0 +/- 0.8 in normal cats, P less than 0.05).",Distribution of diphenylhydantoin in the brain during experimental status epilepticus of the cat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3504395/),,6.0,206627,DB00252,Phenytoin
,20308820,recovery rate,The recovery rate of the in vitro assay was 36% at a pump rate of 1 microL/min.,Feasibility of microdialysis to determine interstitial rocuronium concentration in the muscle tissue of anesthetized neurosurgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20308820/),%,36,206740,DB00252,Phenytoin
,20308820,pump rate,The recovery rate of the in vitro assay was 36% at a pump rate of 1 microL/min.,Feasibility of microdialysis to determine interstitial rocuronium concentration in the muscle tissue of anesthetized neurosurgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20308820/),[μl] / [min],1,206741,DB00252,Phenytoin
,27390048,50% inhibitory,"The 50% inhibitory 5-FU concentration for CYP2C9 synthesis and the degradation rate constant of CYP2C9 were estimated to be 0.00310 ng/mL and 0.0768 day-1, respectively.",Pharmacokinetic model analysis of interaction between phenytoin and capecitabine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390048/),[ng] / [ml],0.00310,208880,DB00252,Phenytoin
,27390048,degradation rate constant,"The 50% inhibitory 5-FU concentration for CYP2C9 synthesis and the degradation rate constant of CYP2C9 were estimated to be 0.00310 ng/mL and 0.0768 day-1, respectively.",Pharmacokinetic model analysis of interaction between phenytoin and capecitabine. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390048/),1/[d],0.0768,208881,DB00252,Phenytoin
,8530713,systemic bioavailability,Oral estrogens have minimal systemic bioavailability (2% to 10%) due to gut and liver (first-pass) metabolism.,Pharmacokinetic and pharmacologic variation between different estrogen products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8530713/),%,2,209255,DB00252,Phenytoin
,8530713,systemic bioavailability,Oral estrogens have minimal systemic bioavailability (2% to 10%) due to gut and liver (first-pass) metabolism.,Pharmacokinetic and pharmacologic variation between different estrogen products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8530713/),%,10,209256,DB00252,Phenytoin
,8530713,terminal half lives,The terminal half lives for the different estrogen compounds (after oral or intravenous administration) vary from 1-12 hours.,Pharmacokinetic and pharmacologic variation between different estrogen products. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8530713/),h,1-12,209257,DB00252,Phenytoin
,2921305,Vm,"The Vm and Km of a 60-kg adult out-patient were estimated to be 369 mg/day and 3.67 mg/l, respectively.",Population pharmacokinetics of phenytoin from routine clinical data in Japan. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2921305/),[mg] / [d],369,209612,DB00252,Phenytoin
,2921305,Km,"The Vm and Km of a 60-kg adult out-patient were estimated to be 369 mg/day and 3.67 mg/l, respectively.",Population pharmacokinetics of phenytoin from routine clinical data in Japan. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2921305/),[mg] / [l],3.67,209613,DB00252,Phenytoin
,2921305,F,"When the F of phenytoin is assumed to be 100% in the patients prescribed a tablet, the F value in the patients prescribed a powder was 89.5%.",Population pharmacokinetics of phenytoin from routine clinical data in Japan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2921305/),%,100,209614,DB00252,Phenytoin
,2921305,F,"When the F of phenytoin is assumed to be 100% in the patients prescribed a tablet, the F value in the patients prescribed a powder was 89.5%.",Population pharmacokinetics of phenytoin from routine clinical data in Japan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2921305/),%,89.5,209615,DB00252,Phenytoin
,1527539,relative bioavailability,Phenytoin BP tablets manufactured by Regent Laboratories (now withdrawn) had a relative bioavailability of only 76% compared with tablets manufactured by A H Cox and Company.,Bioavailability and dissolution of proprietary and generic formulations of phenytoin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1527539/),%,76,210014,DB00252,Phenytoin
,3677565,Unbound phenytoin fraction,Unbound phenytoin fraction ranged from 0.073 to 0.25.,Disposition of phenytoin in critically ill trauma patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677565/),,0.073 to 0.25,210500,DB00252,Phenytoin
,3677565,volume of distribution,"Variable estimates using the Michaelis-Menten model were as follows: volume of distribution, 0.76 +/- 0.15 L/kg (0.58-1.01 L/kg); Vmax, 568 +/- 197 mg/day (350-937 mg/day); and Km, 4.5 +/- 1.8 mg/L (1.8-6.2 mg/L).",Disposition of phenytoin in critically ill trauma patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677565/),[l] / [kg],0.76,210501,DB00252,Phenytoin
,3677565,Vmax,"Variable estimates using the Michaelis-Menten model were as follows: volume of distribution, 0.76 +/- 0.15 L/kg (0.58-1.01 L/kg); Vmax, 568 +/- 197 mg/day (350-937 mg/day); and Km, 4.5 +/- 1.8 mg/L (1.8-6.2 mg/L).",Disposition of phenytoin in critically ill trauma patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677565/),[mg] / [d],568,210502,DB00252,Phenytoin
,3677565,Km,"Variable estimates using the Michaelis-Menten model were as follows: volume of distribution, 0.76 +/- 0.15 L/kg (0.58-1.01 L/kg); Vmax, 568 +/- 197 mg/day (350-937 mg/day); and Km, 4.5 +/- 1.8 mg/L (1.8-6.2 mg/L).",Disposition of phenytoin in critically ill trauma patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677565/),[mg] / [l],4.5,210503,DB00252,Phenytoin
,19429015,"maximal concentration, C(max)","In vehicle pre-treated rats, hippocampal phenobarbital concentrations were lower in MP (maximal concentration, C(max): 6.0+/-0.6 microg ml(-1), p<0.05) than in C animals (C(max): 9.4+/-0.9 microg ml(-1)).",Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429015/),[μg] / [ml],6.0,210613,DB00252,Phenytoin
,19429015,C(max),"In vehicle pre-treated rats, hippocampal phenobarbital concentrations were lower in MP (maximal concentration, C(max): 6.0+/-0.6 microg ml(-1), p<0.05) than in C animals (C(max): 9.4+/-0.9 microg ml(-1)).",Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429015/),[μg] / [ml],9.4,210614,DB00252,Phenytoin
,19429015,C(max),Control rats pre-treated with nimodipine showed similar results (C(max): 10.7+/-0.6 microg ml(-1)) than those pre-treated with vehicle.,Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429015/),[μg] / [ml],10.7,210615,DB00252,Phenytoin
,19429015,C(max),"Nimodipine pre-treatment in MP rats enhanced hippocampal phenobarbital concentrations (C(max): 10.2+/-1.0 microg ml(-1), p<0.05) as compared with vehicle pre-treatment.",Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429015/),[μg] / [ml],10.2,210616,DB00252,Phenytoin
,29342085,Cmax,"This model was subsequently extended to predict human brain morphine concentrations, and predicted a ROB Cmax of 21.7 ± 6.41 ng/mL when compared to ""better"" (10.1 ng/mL) or ""worse"" (29.8 ng/mL) brain tissue regions with a FC Cmax of 62.12 ± 17.32 ng/mL and a HC Cmax of 182.2 ± 51.2 ng/mL.",Development of a Region-Specific Physiologically Based Pharmacokinetic Brain Model to Assess Hippocampus and Frontal Cortex Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29342085/),[ng] / [ml],21.7,211340,DB00252,Phenytoin
,29342085,Cmax,"This model was subsequently extended to predict human brain morphine concentrations, and predicted a ROB Cmax of 21.7 ± 6.41 ng/mL when compared to ""better"" (10.1 ng/mL) or ""worse"" (29.8 ng/mL) brain tissue regions with a FC Cmax of 62.12 ± 17.32 ng/mL and a HC Cmax of 182.2 ± 51.2 ng/mL.",Development of a Region-Specific Physiologically Based Pharmacokinetic Brain Model to Assess Hippocampus and Frontal Cortex Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29342085/),[ng] / [ml],10.1,211341,DB00252,Phenytoin
,29342085,Cmax,"This model was subsequently extended to predict human brain morphine concentrations, and predicted a ROB Cmax of 21.7 ± 6.41 ng/mL when compared to ""better"" (10.1 ng/mL) or ""worse"" (29.8 ng/mL) brain tissue regions with a FC Cmax of 62.12 ± 17.32 ng/mL and a HC Cmax of 182.2 ± 51.2 ng/mL.",Development of a Region-Specific Physiologically Based Pharmacokinetic Brain Model to Assess Hippocampus and Frontal Cortex Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29342085/),[ng] / [ml],29.8,211342,DB00252,Phenytoin
,29342085,Cmax,"This model was subsequently extended to predict human brain morphine concentrations, and predicted a ROB Cmax of 21.7 ± 6.41 ng/mL when compared to ""better"" (10.1 ng/mL) or ""worse"" (29.8 ng/mL) brain tissue regions with a FC Cmax of 62.12 ± 17.32 ng/mL and a HC Cmax of 182.2 ± 51.2 ng/mL.",Development of a Region-Specific Physiologically Based Pharmacokinetic Brain Model to Assess Hippocampus and Frontal Cortex Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29342085/),[ng] / [ml],62.12,211343,DB00252,Phenytoin
,29342085,Cmax,"This model was subsequently extended to predict human brain morphine concentrations, and predicted a ROB Cmax of 21.7 ± 6.41 ng/mL when compared to ""better"" (10.1 ng/mL) or ""worse"" (29.8 ng/mL) brain tissue regions with a FC Cmax of 62.12 ± 17.32 ng/mL and a HC Cmax of 182.2 ± 51.2 ng/mL.",Development of a Region-Specific Physiologically Based Pharmacokinetic Brain Model to Assess Hippocampus and Frontal Cortex Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29342085/),[ng] / [ml],182.2,211344,DB00252,Phenytoin
,9433391,total area under the plasma zolpidem concentration-time curve,The total area under the plasma zolpidem concentration-time curve after administration of rifampin was 27% of that after administration of placebo (336 +/- 67 versus 1202 +/- 157 ng.hr/ml [mean value +/- SEM; p < 0.01]).,Rifampin reduces plasma concentrations and effects of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[h·ng] / [ml],336,212367,DB00252,Phenytoin
,9433391,total area under the plasma zolpidem concentration-time curve,The total area under the plasma zolpidem concentration-time curve after administration of rifampin was 27% of that after administration of placebo (336 +/- 67 versus 1202 +/- 157 ng.hr/ml [mean value +/- SEM; p < 0.01]).,Rifampin reduces plasma concentrations and effects of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[h·ng] / [ml],1202,212368,DB00252,Phenytoin
,9433391,peak plasma concentration,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[ng] / [ml],293,212369,DB00252,Phenytoin
,9433391,peak plasma concentration,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[ng] / [ml],117,212370,DB00252,Phenytoin
,9433391,elimination half-life,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),h,2.5,212371,DB00252,Phenytoin
,9433391,elimination half-life,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),h,1.6,212372,DB00252,Phenytoin
,16918714,free fraction,"Mean total phenytoin concentration was 11.7 mg/l, free phenytoin 1.25 mg/l and phenytoin free fraction 0.107.","Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918714/),,0.107,212443,DB00252,Phenytoin
,3720209,SSSC,"The pharmacokinetic values, dosages, and SSSCs were used for predicting the dosage required to attain an SSSC of 14.9 mg/L.",Comparison of four single-point phenytoin dosage prediction techniques using computer-simulated pharmacokinetic values. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3720209/),[mg] / [l],14.9,212536,DB00252,Phenytoin
,22281062,effective doses (ED(50),"Moreover, HMIPPS (50mg/kg) significantly enhanced the anticonvulsant activity of phenobarbital and valproate in the mouse maximal electroshock-induced seizure model by reducing their median effective doses (ED(50) values) from 23.25mg/kg to 16.82 mg/kg (P<0.01; for phenobarbital) and from 259.3mg/kg to 189.7 mg/kg (P<0.001; for valproate), respectively.",Influence of N-hydroxymethyl-p-isopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22281062/),[mg] / [kg],23.25,213580,DB00252,Phenytoin
,22281062,effective doses (ED(50),"Moreover, HMIPPS (50mg/kg) significantly enhanced the anticonvulsant activity of phenobarbital and valproate in the mouse maximal electroshock-induced seizure model by reducing their median effective doses (ED(50) values) from 23.25mg/kg to 16.82 mg/kg (P<0.01; for phenobarbital) and from 259.3mg/kg to 189.7 mg/kg (P<0.001; for valproate), respectively.",Influence of N-hydroxymethyl-p-isopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22281062/),[mg] / [kg],16.82,213581,DB00252,Phenytoin
,22281062,effective doses (ED(50),"Moreover, HMIPPS (50mg/kg) significantly enhanced the anticonvulsant activity of phenobarbital and valproate in the mouse maximal electroshock-induced seizure model by reducing their median effective doses (ED(50) values) from 23.25mg/kg to 16.82 mg/kg (P<0.01; for phenobarbital) and from 259.3mg/kg to 189.7 mg/kg (P<0.001; for valproate), respectively.",Influence of N-hydroxymethyl-p-isopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22281062/),[mg] / [kg],259.3,213582,DB00252,Phenytoin
,22281062,effective doses (ED(50),"Moreover, HMIPPS (50mg/kg) significantly enhanced the anticonvulsant activity of phenobarbital and valproate in the mouse maximal electroshock-induced seizure model by reducing their median effective doses (ED(50) values) from 23.25mg/kg to 16.82 mg/kg (P<0.01; for phenobarbital) and from 259.3mg/kg to 189.7 mg/kg (P<0.001; for valproate), respectively.",Influence of N-hydroxymethyl-p-isopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22281062/),[mg] / [kg],189.7,213583,DB00252,Phenytoin
,22281062,ED(50),"HMIPPS (25mg/kg) significantly potentiated the anticonvulsant action of valproate by reducing its ED(50) value from 259.3mg/kg to 210.6 mg/kg (P>0.05), but not that of phenobarbital, phenytoin and carbamazepine in the mouse maximal electroshock-induced seizure model.",Influence of N-hydroxymethyl-p-isopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22281062/),[mg] / [kg],259.3,213584,DB00252,Phenytoin
,22281062,ED(50),"HMIPPS (25mg/kg) significantly potentiated the anticonvulsant action of valproate by reducing its ED(50) value from 259.3mg/kg to 210.6 mg/kg (P>0.05), but not that of phenobarbital, phenytoin and carbamazepine in the mouse maximal electroshock-induced seizure model.",Influence of N-hydroxymethyl-p-isopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22281062/),[mg] / [kg],210.6,213585,DB00252,Phenytoin
,28230619,apparent volume of distribution,"Based on a one-compartment model with first order absorption and elimination, the apparent volume of distribution was 105 L/70 kg, and the apparent clearance was allometrically related to the body weight as 2.25 L·h·70 kg without carbamazepine or phenytoin.",Population Pharmacokinetics of Topiramate in Japanese Pediatric and Adult Patients With Epilepsy Using Routinely Monitored Data. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28230619/),[l] / [70·kg],105,214960,DB00252,Phenytoin
,28230619,apparent clearance,Combination treatment with carbamazepine or phenytoin increased the apparent clearance to 3.51 L·h·70 kg.,Population Pharmacokinetics of Topiramate in Japanese Pediatric and Adult Patients With Epilepsy Using Routinely Monitored Data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28230619/),70·h·kg·l,3.51,214961,DB00252,Phenytoin
,3127188,percent relative bioavailability,The percent relative bioavailability of phenytoin with enteral feedings was 101.7 percent.,Influence of enteral feedings on phenytoin sodium absorption from capsules. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127188/),%,101.7,214986,DB00252,Phenytoin
,11493369,half-life,The plasma level of PHT declined with a half-life of 5.38 h after PHT alone and 4.03 h after PHT and PR given together.,"Effects of Paeoniae Radix, a traditional Chinese medicine, on the pharmacokinetics of phenytoin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11493369/),h,5.38,215128,DB00252,Phenytoin
,11493369,half-life,The plasma level of PHT declined with a half-life of 5.38 h after PHT alone and 4.03 h after PHT and PR given together.,"Effects of Paeoniae Radix, a traditional Chinese medicine, on the pharmacokinetics of phenytoin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11493369/),h,4.03,215129,DB00252,Phenytoin
up to,1743171,bioavailability,"Storage of carbamazepine (CBZ) and phenytoin (PHT) formulations in hot, humid conditions alters the dosage form and reduces bioavailability up to 50%.",Pharmacokinetic pitfalls of present antiepileptic medications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743171/),%,50,215613,DB00252,Phenytoin
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,4.9,216455,DB00252,Phenytoin
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,9.2,216456,DB00252,Phenytoin
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,1.0,216457,DB00252,Phenytoin
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,6.2,216458,DB00252,Phenytoin
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,2.4,216459,DB00252,Phenytoin
,21692812,clearance,"The clearance was of 2.37, 0.935, and 27.9 mL · min/kg, respectively, for phenytoin, theophylline, and diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[min·ml] / [kg],2.37,216460,DB00252,Phenytoin
,21692812,clearance,"The clearance was of 2.37, 0.935, and 27.9 mL · min/kg, respectively, for phenytoin, theophylline, and diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[min·ml] / [kg],0.935,216461,DB00252,Phenytoin
,21692812,clearance,"The clearance was of 2.37, 0.935, and 27.9 mL · min/kg, respectively, for phenytoin, theophylline, and diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[min·ml] / [kg],27.9,216462,DB00252,Phenytoin
,21692812,C(MAX),"The C(MAX) was 44.7 and 305.2 ng/mL for oxazepam and nordiazepam, respectively, after diazepam administration.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[ng] / [ml],44.7,216463,DB00252,Phenytoin
,21692812,C(MAX),"The C(MAX) was 44.7 and 305.2 ng/mL for oxazepam and nordiazepam, respectively, after diazepam administration.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[ng] / [ml],305.2,216464,DB00252,Phenytoin
,567761,Volumes of distribution,"Volumes of distribution were relatively constant (mean = 0.78 +/- 0.11 liters per kilogram), but half-lives varied considerably and were prolonged (mean = 51 +/- 32 hours) because of the large doses administered.",Intravenous phenytoin: clinical and pharmacokinetic aspects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/567761/),[l] / [kg],0.78,217668,DB00252,Phenytoin
,567761,half-lives,"Volumes of distribution were relatively constant (mean = 0.78 +/- 0.11 liters per kilogram), but half-lives varied considerably and were prolonged (mean = 51 +/- 32 hours) because of the large doses administered.",Intravenous phenytoin: clinical and pharmacokinetic aspects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/567761/),h,51,217669,DB00252,Phenytoin
,9470324,Elimination rate constant,"Elimination rate constant and half-life were 0.2 h-1 and 19 h, respectively.",Bioavailability of phenytoin sodium capsules available in Thailand. Part II: In vivo study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9470324/),1/[h],0.2,221742,DB00252,Phenytoin
,9470324,half-life,"Elimination rate constant and half-life were 0.2 h-1 and 19 h, respectively.",Bioavailability of phenytoin sodium capsules available in Thailand. Part II: In vivo study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9470324/),h,19,221743,DB00252,Phenytoin
,9470324,maximum concentration (Cmax),"The maximum concentration (Cmax) and time to peak (Tmax) were 1.98 micrograms/ml and 9.6 h, respectively.",Bioavailability of phenytoin sodium capsules available in Thailand. Part II: In vivo study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9470324/),[μg] / [ml],1.98,221744,DB00252,Phenytoin
,9470324,time to peak (Tmax),"The maximum concentration (Cmax) and time to peak (Tmax) were 1.98 micrograms/ml and 9.6 h, respectively.",Bioavailability of phenytoin sodium capsules available in Thailand. Part II: In vivo study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9470324/),h,9.6,221745,DB00252,Phenytoin
,26379109,flow rate,"Analyses were performed using a UHPLC-MS/MS system equipped with an electrospray ionization interface operating in the positive ionization mode using a C18 reversed-phase column with a mobile phase of water:acetonitrile (68:31, v/v) containing 0.1% acetic acid eluting in a gradient mode with a flow rate of 0.3 mL/min.",Development and validation of a UHPLC-MS/MS bioanalytical method to quantify in plasma the analgesic candidate PT-31 following a preliminary pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26379109/),[ml] / [min],0.3,222837,DB00252,Phenytoin
,26379109,retention times,"PT-31 and phenytoin (internal standard) retention times were roughly 1.0 and 1.5 min, respectively.",Development and validation of a UHPLC-MS/MS bioanalytical method to quantify in plasma the analgesic candidate PT-31 following a preliminary pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26379109/),min,1.0,222838,DB00252,Phenytoin
,26379109,retention times,"PT-31 and phenytoin (internal standard) retention times were roughly 1.0 and 1.5 min, respectively.",Development and validation of a UHPLC-MS/MS bioanalytical method to quantify in plasma the analgesic candidate PT-31 following a preliminary pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26379109/),min,1.5,222839,DB00252,Phenytoin
,10613611,serum Cmin,All patients had serum Cmin ticlopidine values of 0.06 to 0.25 microg/mL when receiving ticlopidine.,Ticlopidine inhibits phenytoin clearance. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613611/),[μg] / [ml],0.06 to 0.25,224020,DB00252,Phenytoin
,10613611,Km,Mean phenytoin Km significantly increased from 5.8 to 12.3 during ticlopidine coadministration compared with administration of phenytoin alone (P = .02).,Ticlopidine inhibits phenytoin clearance. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613611/),,5.8,224021,DB00252,Phenytoin
,10613611,Km,Mean phenytoin Km significantly increased from 5.8 to 12.3 during ticlopidine coadministration compared with administration of phenytoin alone (P = .02).,Ticlopidine inhibits phenytoin clearance. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613611/),,12.3,224022,DB00252,Phenytoin
,11327452,elimination half-life,"Mean (+/- SD) elimination half-life following a single IV or PO administration was 12.6+/-2.8 and 13.9+/-6.3 hours, respectively, and was 11.2+/-4.0 hours following twice-daily administration for 5 days.","Disposition, elimination, and bioavailability of phenytoin and its major metabolite in horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327452/),h,12.6,225500,DB00252,Phenytoin
,11327452,elimination half-life,"Mean (+/- SD) elimination half-life following a single IV or PO administration was 12.6+/-2.8 and 13.9+/-6.3 hours, respectively, and was 11.2+/-4.0 hours following twice-daily administration for 5 days.","Disposition, elimination, and bioavailability of phenytoin and its major metabolite in horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327452/),h,13.9,225501,DB00252,Phenytoin
,11327452,elimination half-life,"Mean (+/- SD) elimination half-life following a single IV or PO administration was 12.6+/-2.8 and 13.9+/-6.3 hours, respectively, and was 11.2+/-4.0 hours following twice-daily administration for 5 days.","Disposition, elimination, and bioavailability of phenytoin and its major metabolite in horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327452/),h,11.2,225502,DB00252,Phenytoin
,11327452,F,Values for F ranged from 14.5 to 84.7%.,"Disposition, elimination, and bioavailability of phenytoin and its major metabolite in horses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327452/),%,14,225503,DB00252,Phenytoin
,11327452,F,Values for F ranged from 14.5 to 84.7%.,"Disposition, elimination, and bioavailability of phenytoin and its major metabolite in horses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327452/),%,84,225504,DB00252,Phenytoin
,11327452,peak plasma concentration (Cmax),Mean peak plasma concentration (Cmax) following single oral administration was 1.8+/-0.68 microg/ml.,"Disposition, elimination, and bioavailability of phenytoin and its major metabolite in horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327452/),[μg] / [ml],1.8,225505,DB00252,Phenytoin
,11327452,Steady-state plasma concentrations,Steady-state plasma concentrations following twice-daily administration for 5 days was 4.0+/-1.8 microg/ml.,"Disposition, elimination, and bioavailability of phenytoin and its major metabolite in horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327452/),[μg] / [ml],4.0,225506,DB00252,Phenytoin
,34255318,total clearance,The population mean value of lamotrigine total clearance generated in the final model (with covariates) was 2.12 L/hr.,Population Pharmacokinetics Modeling of Lamotrigine in Jordanian Epileptic Patients Using Dried Blood Spot Sampling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34255318/),[l] / [h],2.12,226356,DB00252,Phenytoin
,21640186,area under the plasma concentration-time curve (AUC),"After per oral phenytoin dosing, the mean area under the plasma concentration-time curve (AUC) was found to be 35.03±1.83hμg/ml which was increased significantly, i.e. 62.33±2.49hμg/ml (P<0.001) when verapamil was co-administered.",Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with verapamil in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21640186/),[hμg] / [ml],35.03,227035,DB00252,Phenytoin
,21640186,area under the plasma concentration-time curve (AUC),"After per oral phenytoin dosing, the mean area under the plasma concentration-time curve (AUC) was found to be 35.03±1.83hμg/ml which was increased significantly, i.e. 62.33±2.49hμg/ml (P<0.001) when verapamil was co-administered.",Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with verapamil in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21640186/),[hμg] / [ml],62.33,227036,DB00252,Phenytoin
,21640186,maximum plasma concentration,Similarly the mean maximum plasma concentration of phenytoin increased from 3.2±0.148μg/ml without verapamil to 6.983±0.272μg/ml (P<0.001) with verapamil.,Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with verapamil in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21640186/),[μg] / [ml],3.2,227037,DB00252,Phenytoin
,21640186,maximum plasma concentration,Similarly the mean maximum plasma concentration of phenytoin increased from 3.2±0.148μg/ml without verapamil to 6.983±0.272μg/ml (P<0.001) with verapamil.,Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with verapamil in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21640186/),[μg] / [ml],6.983,227038,DB00252,Phenytoin
,8897274,pKa,CNG-DPH is poorly water soluble and has a pKa of 5.3.,"Bioavailability and anticonvulsant activity of 2-cyanoguanidinophenytoin, a structural analogue of phenytoin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897274/),,5.3,227931,DB00252,Phenytoin
,8897274,log P,"At pH 7.4, log P was 1.16, from which a pH-independent log P of 3 can be calculated.","Bioavailability and anticonvulsant activity of 2-cyanoguanidinophenytoin, a structural analogue of phenytoin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897274/),,1.16,227932,DB00252,Phenytoin
,8897274,log P,"At pH 7.4, log P was 1.16, from which a pH-independent log P of 3 can be calculated.","Bioavailability and anticonvulsant activity of 2-cyanoguanidinophenytoin, a structural analogue of phenytoin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897274/),,3,227933,DB00252,Phenytoin
,1970781,Systemic,"Systemic and intrinsic phenytoin clearance, which averaged 12 and 41.5 ml/min/kg, respectively, for the three phenytoin infusions, were both dose independent, and were unaltered by the three salicylate treatments.",Phenytoin disposition in the pregnant rat. Dose-dependent studies and salicylate effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970781/),[ml] / [kg·min],12,228413,DB00252,Phenytoin
,1970781,Systemic,"Systemic and intrinsic phenytoin clearance, which averaged 12 and 41.5 ml/min/kg, respectively, for the three phenytoin infusions, were both dose independent, and were unaltered by the three salicylate treatments.",Phenytoin disposition in the pregnant rat. Dose-dependent studies and salicylate effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970781/),[ml] / [kg·min],41.5,228414,DB00252,Phenytoin
,1970781,intrinsic p,"Systemic and intrinsic phenytoin clearance, which averaged 12 and 41.5 ml/min/kg, respectively, for the three phenytoin infusions, were both dose independent, and were unaltered by the three salicylate treatments.",Phenytoin disposition in the pregnant rat. Dose-dependent studies and salicylate effects. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970781/),[ml] / [kg·min],12,228415,DB00252,Phenytoin
,1970781,intrinsic p,"Systemic and intrinsic phenytoin clearance, which averaged 12 and 41.5 ml/min/kg, respectively, for the three phenytoin infusions, were both dose independent, and were unaltered by the three salicylate treatments.",Phenytoin disposition in the pregnant rat. Dose-dependent studies and salicylate effects. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970781/),[ml] / [kg·min],41.5,228416,DB00252,Phenytoin
,1970781,clearance,"Systemic and intrinsic phenytoin clearance, which averaged 12 and 41.5 ml/min/kg, respectively, for the three phenytoin infusions, were both dose independent, and were unaltered by the three salicylate treatments.",Phenytoin disposition in the pregnant rat. Dose-dependent studies and salicylate effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970781/),[ml] / [kg·min],41.5,228417,DB00252,Phenytoin
,21532277,maximal elimination rates (V(max)),"The mean maximal elimination rates (V(max)) in groups I, II, III and IV were 13.1, 11.2, 10.2 and 8.0 mg/day/kg, respectively, with statistically significant differences among groups (p=0.012, Kruskal-Wallis analysis).",[Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21532277/),[mg] / [d·kg],13.1,228557,DB00252,Phenytoin
,21532277,maximal elimination rates (V(max)),"The mean maximal elimination rates (V(max)) in groups I, II, III and IV were 13.1, 11.2, 10.2 and 8.0 mg/day/kg, respectively, with statistically significant differences among groups (p=0.012, Kruskal-Wallis analysis).",[Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21532277/),[mg] / [d·kg],11.2,228558,DB00252,Phenytoin
,21532277,maximal elimination rates (V(max)),"The mean maximal elimination rates (V(max)) in groups I, II, III and IV were 13.1, 11.2, 10.2 and 8.0 mg/day/kg, respectively, with statistically significant differences among groups (p=0.012, Kruskal-Wallis analysis).",[Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21532277/),[mg] / [d·kg],10.2,228559,DB00252,Phenytoin
,21532277,maximal elimination rates (V(max)),"The mean maximal elimination rates (V(max)) in groups I, II, III and IV were 13.1, 11.2, 10.2 and 8.0 mg/day/kg, respectively, with statistically significant differences among groups (p=0.012, Kruskal-Wallis analysis).",[Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21532277/),[mg] / [d·kg],8.0,228560,DB00252,Phenytoin
,21532277,intrinsic metabolic activity (V(max)/K(m)),"The intrinsic metabolic activity (V(max)/K(m)) of groups I, II, III and IV were 2.9, 2.2, 1.5 and 1.1 l/day/kg, respectively (p=0.009), again with significant differences among groups.",[Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy]. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21532277/),[l] / [d·kg],2.9,228561,DB00252,Phenytoin
,21532277,intrinsic metabolic activity (V(max)/K(m)),"The intrinsic metabolic activity (V(max)/K(m)) of groups I, II, III and IV were 2.9, 2.2, 1.5 and 1.1 l/day/kg, respectively (p=0.009), again with significant differences among groups.",[Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy]. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21532277/),[l] / [d·kg],2.2,228562,DB00252,Phenytoin
,21532277,intrinsic metabolic activity (V(max)/K(m)),"The intrinsic metabolic activity (V(max)/K(m)) of groups I, II, III and IV were 2.9, 2.2, 1.5 and 1.1 l/day/kg, respectively (p=0.009), again with significant differences among groups.",[Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy]. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21532277/),[l] / [d·kg],1.5,228563,DB00252,Phenytoin
,21532277,intrinsic metabolic activity (V(max)/K(m)),"The intrinsic metabolic activity (V(max)/K(m)) of groups I, II, III and IV were 2.9, 2.2, 1.5 and 1.1 l/day/kg, respectively (p=0.009), again with significant differences among groups.",[Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy]. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21532277/),[l] / [d·kg],1.1,228564,DB00252,Phenytoin
less,21532277,total processing time,"With a total processing time for this assay of less than 3 hours, prediction of the optimal phenytoin dosage based on the CYP2C9 and CYP2C19 genotypes will be possible before commencement of therapy, resulting in the prevention of phenytoin overdoses in pediatric patients with epilepsy.",[Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21532277/),h,3,228565,DB00252,Phenytoin
,7002338,t1/2,No cases of peripheral neuropathy were seen and the plasma misonidazole t1/2 of 8.6 +/- 0.62 (S.D.) hours were low.,The Cambridge glioma trial of misonidazole and radiation therapy with associated pharmacokinetic studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7002338/),h,8.6,229875,DB00252,Phenytoin
,2268899,Vm,"The Vm and Km of a 60 kg adult outpatient treated with PHT alone were estimated to be 325 mg/d and 2.41 micrograms/ml, respectively, while for a same size individual taking PHT with co-anticonvulsants respective estimates were 351 mg/d and 3.18 micrograms/ml.",Population pharmacokinetics of phenytoin from routine clinical data in Japan: an update. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2268899/),[mg] / [d],325,229919,DB00252,Phenytoin
,2268899,Vm,"The Vm and Km of a 60 kg adult outpatient treated with PHT alone were estimated to be 325 mg/d and 2.41 micrograms/ml, respectively, while for a same size individual taking PHT with co-anticonvulsants respective estimates were 351 mg/d and 3.18 micrograms/ml.",Population pharmacokinetics of phenytoin from routine clinical data in Japan: an update. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2268899/),[mg] / [d],351,229920,DB00252,Phenytoin
,2268899,Km,"The Vm and Km of a 60 kg adult outpatient treated with PHT alone were estimated to be 325 mg/d and 2.41 micrograms/ml, respectively, while for a same size individual taking PHT with co-anticonvulsants respective estimates were 351 mg/d and 3.18 micrograms/ml.",Population pharmacokinetics of phenytoin from routine clinical data in Japan: an update. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2268899/),[μg] / [ml],2.41,229921,DB00252,Phenytoin
,2268899,Km,"The Vm and Km of a 60 kg adult outpatient treated with PHT alone were estimated to be 325 mg/d and 2.41 micrograms/ml, respectively, while for a same size individual taking PHT with co-anticonvulsants respective estimates were 351 mg/d and 3.18 micrograms/ml.",Population pharmacokinetics of phenytoin from routine clinical data in Japan: an update. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2268899/),[mg] / [d],351,229922,DB00252,Phenytoin
,2268899,Km,"The Vm and Km of a 60 kg adult outpatient treated with PHT alone were estimated to be 325 mg/d and 2.41 micrograms/ml, respectively, while for a same size individual taking PHT with co-anticonvulsants respective estimates were 351 mg/d and 3.18 micrograms/ml.",Population pharmacokinetics of phenytoin from routine clinical data in Japan: an update. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2268899/),[μg] / [ml],3.18,229923,DB00252,Phenytoin
,15595577,infusion rate,Nine patients requiring intensive care therapy and artificial ventilation for several days received piritramide with a median infusion rate of 5 mg h(-1) (range 4.8-10 mg h(-1)) for a median period of 69.9 h (range 49-89 h) for analgesia and sedation.,The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),[mg] / [h],5,230807,DB00252,Phenytoin
,15595577,volumes of distribution V1,"The concentration-time course after the end of the infusion was adequately described with a three-compartment model in eight patients and a two-compartment model in one patient (standard two-stage geometric mean and 16-84% quantile: volumes of distribution V1 = 47.9 (26.8-85.8)L, V2 = 402 (241-672)L, V3 = 332 (124-885)L; clearances Cl1 = 66.5 (53.2-83.0)Lh(-1), Cl2 = 215 (125-369)Lh(-1), Cl3 = 18.4 (9.2-36.8) Lh(-1)).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),l,47.9,230808,DB00252,Phenytoin
,15595577,V2,"The concentration-time course after the end of the infusion was adequately described with a three-compartment model in eight patients and a two-compartment model in one patient (standard two-stage geometric mean and 16-84% quantile: volumes of distribution V1 = 47.9 (26.8-85.8)L, V2 = 402 (241-672)L, V3 = 332 (124-885)L; clearances Cl1 = 66.5 (53.2-83.0)Lh(-1), Cl2 = 215 (125-369)Lh(-1), Cl3 = 18.4 (9.2-36.8) Lh(-1)).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),l,402,230809,DB00252,Phenytoin
,15595577,V3,"The concentration-time course after the end of the infusion was adequately described with a three-compartment model in eight patients and a two-compartment model in one patient (standard two-stage geometric mean and 16-84% quantile: volumes of distribution V1 = 47.9 (26.8-85.8)L, V2 = 402 (241-672)L, V3 = 332 (124-885)L; clearances Cl1 = 66.5 (53.2-83.0)Lh(-1), Cl2 = 215 (125-369)Lh(-1), Cl3 = 18.4 (9.2-36.8) Lh(-1)).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),l,332,230810,DB00252,Phenytoin
,15595577,clearances Cl1,"The concentration-time course after the end of the infusion was adequately described with a three-compartment model in eight patients and a two-compartment model in one patient (standard two-stage geometric mean and 16-84% quantile: volumes of distribution V1 = 47.9 (26.8-85.8)L, V2 = 402 (241-672)L, V3 = 332 (124-885)L; clearances Cl1 = 66.5 (53.2-83.0)Lh(-1), Cl2 = 215 (125-369)Lh(-1), Cl3 = 18.4 (9.2-36.8) Lh(-1)).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),1/[lh],66.5,230811,DB00252,Phenytoin
,15595577,Cl2,"The concentration-time course after the end of the infusion was adequately described with a three-compartment model in eight patients and a two-compartment model in one patient (standard two-stage geometric mean and 16-84% quantile: volumes of distribution V1 = 47.9 (26.8-85.8)L, V2 = 402 (241-672)L, V3 = 332 (124-885)L; clearances Cl1 = 66.5 (53.2-83.0)Lh(-1), Cl2 = 215 (125-369)Lh(-1), Cl3 = 18.4 (9.2-36.8) Lh(-1)).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),1/[lh],215,230812,DB00252,Phenytoin
,15595577,Cl3,"The concentration-time course after the end of the infusion was adequately described with a three-compartment model in eight patients and a two-compartment model in one patient (standard two-stage geometric mean and 16-84% quantile: volumes of distribution V1 = 47.9 (26.8-85.8)L, V2 = 402 (241-672)L, V3 = 332 (124-885)L; clearances Cl1 = 66.5 (53.2-83.0)Lh(-1), Cl2 = 215 (125-369)Lh(-1), Cl3 = 18.4 (9.2-36.8) Lh(-1)).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),1/[lh],18.4,230813,DB00252,Phenytoin
,15595577,steady-state volume of distribution,"Both the steady-state volume of distribution (782 L) and the terminal elimination half-life (17.4 h) were larger than predicted from single bolus pharmacokinetic studies (412.5 L and 10.4 h, respectively), the context-sensitive half-time after more than 72 h of administration was 32% shorter than predicted (285 vs. 420 min).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),l,782,230814,DB00252,Phenytoin
,15595577,steady-state volume of distribution,"Both the steady-state volume of distribution (782 L) and the terminal elimination half-life (17.4 h) were larger than predicted from single bolus pharmacokinetic studies (412.5 L and 10.4 h, respectively), the context-sensitive half-time after more than 72 h of administration was 32% shorter than predicted (285 vs. 420 min).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),l,412.5,230815,DB00252,Phenytoin
,15595577,terminal elimination half-life,"Both the steady-state volume of distribution (782 L) and the terminal elimination half-life (17.4 h) were larger than predicted from single bolus pharmacokinetic studies (412.5 L and 10.4 h, respectively), the context-sensitive half-time after more than 72 h of administration was 32% shorter than predicted (285 vs. 420 min).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),h,17.4,230816,DB00252,Phenytoin
,15595577,terminal elimination half-life,"Both the steady-state volume of distribution (782 L) and the terminal elimination half-life (17.4 h) were larger than predicted from single bolus pharmacokinetic studies (412.5 L and 10.4 h, respectively), the context-sensitive half-time after more than 72 h of administration was 32% shorter than predicted (285 vs. 420 min).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),l,412.5,230817,DB00252,Phenytoin
,15595577,terminal elimination half-life,"Both the steady-state volume of distribution (782 L) and the terminal elimination half-life (17.4 h) were larger than predicted from single bolus pharmacokinetic studies (412.5 L and 10.4 h, respectively), the context-sensitive half-time after more than 72 h of administration was 32% shorter than predicted (285 vs. 420 min).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),h,10.4,230818,DB00252,Phenytoin
,15595577,half-time,"Both the steady-state volume of distribution (782 L) and the terminal elimination half-life (17.4 h) were larger than predicted from single bolus pharmacokinetic studies (412.5 L and 10.4 h, respectively), the context-sensitive half-time after more than 72 h of administration was 32% shorter than predicted (285 vs. 420 min).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),min,285,230819,DB00252,Phenytoin
,15595577,half-time,"Both the steady-state volume of distribution (782 L) and the terminal elimination half-life (17.4 h) were larger than predicted from single bolus pharmacokinetic studies (412.5 L and 10.4 h, respectively), the context-sensitive half-time after more than 72 h of administration was 32% shorter than predicted (285 vs. 420 min).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),min,420,230820,DB00252,Phenytoin
,29683874,trough concentration,"Individual pharmacokinetic parameters were predicted by Bayesian estimation using NONMEM software, and the maintenance dose of fosphenytoin required to maintain the therapeutic trough concentration (10-20 mcg/mL) was calculated from the parameters.",Time-Dependent Decline in Serum Phenytoin Concentration With Heightened Convulsive Seizure Risk by Prolonged Administration of Fosphenytoin in Japanese: A Retrospective Study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29683874/),[mcg] / [ml],10-20,230987,DB00252,Phenytoin
,2864420,absolute bioavailability,The absolute bioavailability of phenytoin varied between 68 and 74%.,A comparative study of the bioavailability of five different phenytoin preparations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864420/),%,68 and 74,231180,DB00252,Phenytoin
,9131952,Steady-state plasma concentrations,"Steady-state plasma concentrations (mean microM +/- s.d.) were determined for tamoxifen (2.94 +/- 3.44), N-desmethyltamoxifen (4.37 +/- 2.13), N-desdimethyltamoxifen (1.49 +/- 0.54), 4-hydroxytamoxifen (0.13 +/- 0.05) and tamoxifen primary alcohol (1.07 +/- 0.46).",Tamoxifen metabolic patterns within a glioma patient population treated with high-dose tamoxifen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131952/),μM,2.94,231507,DB00252,Phenytoin
,9131952,Steady-state plasma concentrations,"Steady-state plasma concentrations (mean microM +/- s.d.) were determined for tamoxifen (2.94 +/- 3.44), N-desmethyltamoxifen (4.37 +/- 2.13), N-desdimethyltamoxifen (1.49 +/- 0.54), 4-hydroxytamoxifen (0.13 +/- 0.05) and tamoxifen primary alcohol (1.07 +/- 0.46).",Tamoxifen metabolic patterns within a glioma patient population treated with high-dose tamoxifen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131952/),μM,1.49,231508,DB00252,Phenytoin
,9131952,Steady-state plasma concentrations,"Steady-state plasma concentrations (mean microM +/- s.d.) were determined for tamoxifen (2.94 +/- 3.44), N-desmethyltamoxifen (4.37 +/- 2.13), N-desdimethyltamoxifen (1.49 +/- 0.54), 4-hydroxytamoxifen (0.13 +/- 0.05) and tamoxifen primary alcohol (1.07 +/- 0.46).",Tamoxifen metabolic patterns within a glioma patient population treated with high-dose tamoxifen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131952/),μM,0.13,231509,DB00252,Phenytoin
,9131952,Steady-state plasma concentrations,"Steady-state plasma concentrations (mean microM +/- s.d.) were determined for tamoxifen (2.94 +/- 3.44), N-desmethyltamoxifen (4.37 +/- 2.13), N-desdimethyltamoxifen (1.49 +/- 0.54), 4-hydroxytamoxifen (0.13 +/- 0.05) and tamoxifen primary alcohol (1.07 +/- 0.46).",Tamoxifen metabolic patterns within a glioma patient population treated with high-dose tamoxifen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131952/),μM,1.07,231510,DB00252,Phenytoin
,10613614,systemic clearance,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),[ml] / [min],925,231628,DB00252,Phenytoin
,10613614,systemic clearance,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),[ml] / [min],569,231629,DB00252,Phenytoin
,10613614,elimination half-life,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),h,12.7,231630,DB00252,Phenytoin
,10613614,elimination half-life,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),h,19.4,231631,DB00252,Phenytoin
,10613614,total area under the plasma concentration-time curve,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),[h·ng] / [ml],37.3,231632,DB00252,Phenytoin
,10613614,total area under the plasma concentration-time curve,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),[h·ng] / [ml],65.1,231633,DB00252,Phenytoin
,12915078,plasma free fraction (free/total concentration ratio),"The PHT plasma free fraction (free/total concentration ratio) was 0.25-0.31 and 0.26-0.31 for PHT and FosPHT, respectively.",A comparison of central brain (cerebrospinal and extracellular fluids) and peripheral blood kinetics of phenytoin after intravenous phenytoin and fosphenytoin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915078/),,0.25-0.31,231890,DB00252,Phenytoin
,12915078,plasma free fraction (free/total concentration ratio),"The PHT plasma free fraction (free/total concentration ratio) was 0.25-0.31 and 0.26-0.31 for PHT and FosPHT, respectively.",A comparison of central brain (cerebrospinal and extracellular fluids) and peripheral blood kinetics of phenytoin after intravenous phenytoin and fosphenytoin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915078/),,0.26-0.31,231891,DB00252,Phenytoin
,12915078,Tmax,Mean PHT Tmax values for CSF were 9-13 minutes.,A comparison of central brain (cerebrospinal and extracellular fluids) and peripheral blood kinetics of phenytoin after intravenous phenytoin and fosphenytoin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915078/),min,9-13,231892,DB00252,Phenytoin
up to,7936231,half-life,"Because of FNR's long half-life (up to 7 weeks), a parallel rather than crossover design was used.",Flunarizine for treatment of partial seizures: results of a concentration-controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7936231/),weeks,7,232227,DB00252,Phenytoin
,17957935,T(max),"Rate of phenytoin absorption from the prompt-release preparation was more prolonged after the 300mg dose (T(max) 4.5 h) than those of the 100- and 200-mg doses (T(max) 3.5 and 3 h, respectively).",Effect of doses on the bioavailability of phenytoin from a prompt-release and an extended-release preparation: single dose study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17957935/),h,4.5,232686,DB00252,Phenytoin
,17957935,T(max),"Rate of phenytoin absorption from the prompt-release preparation was more prolonged after the 300mg dose (T(max) 4.5 h) than those of the 100- and 200-mg doses (T(max) 3.5 and 3 h, respectively).",Effect of doses on the bioavailability of phenytoin from a prompt-release and an extended-release preparation: single dose study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17957935/),h,3.5,232687,DB00252,Phenytoin
,17957935,T(max),"Rate of phenytoin absorption from the prompt-release preparation was more prolonged after the 300mg dose (T(max) 4.5 h) than those of the 100- and 200-mg doses (T(max) 3.5 and 3 h, respectively).",Effect of doses on the bioavailability of phenytoin from a prompt-release and an extended-release preparation: single dose study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17957935/),h,3,232688,DB00252,Phenytoin
,17957935,T(max),"Similarly, the T(max) of the 200- and the 300-mg extended-release preparation (5.5 and 4 h) were more prolonged than the 100-mg dose (3 h).",Effect of doses on the bioavailability of phenytoin from a prompt-release and an extended-release preparation: single dose study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17957935/),h,5.5,232689,DB00252,Phenytoin
,17957935,T(max),"Similarly, the T(max) of the 200- and the 300-mg extended-release preparation (5.5 and 4 h) were more prolonged than the 100-mg dose (3 h).",Effect of doses on the bioavailability of phenytoin from a prompt-release and an extended-release preparation: single dose study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17957935/),h,4,232690,DB00252,Phenytoin
,17957935,T(max),"Similarly, the T(max) of the 200- and the 300-mg extended-release preparation (5.5 and 4 h) were more prolonged than the 100-mg dose (3 h).",Effect of doses on the bioavailability of phenytoin from a prompt-release and an extended-release preparation: single dose study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17957935/),h,3,232691,DB00252,Phenytoin
,17957935,AUC ratio,"The extent of absorption (AUC(0-infinity)) of 100-mg phenytoin was bioequivalent between the two preparations [mean AUC ratio (90% CI) of 1.15 (1.11-1.18)], however, for higher doses, the prompt-release products produced higher bioavailability than the extended-release products [mean AUC ratio (90% CI) of 1.19 (1.07-1.33) and 1.17 (0.98-1.38), respectively for the 200- and 300-mg doses].",Effect of doses on the bioavailability of phenytoin from a prompt-release and an extended-release preparation: single dose study. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17957935/),,1.19,232692,DB00252,Phenytoin
,17957935,AUC ratio,"The extent of absorption (AUC(0-infinity)) of 100-mg phenytoin was bioequivalent between the two preparations [mean AUC ratio (90% CI) of 1.15 (1.11-1.18)], however, for higher doses, the prompt-release products produced higher bioavailability than the extended-release products [mean AUC ratio (90% CI) of 1.19 (1.07-1.33) and 1.17 (0.98-1.38), respectively for the 200- and 300-mg doses].",Effect of doses on the bioavailability of phenytoin from a prompt-release and an extended-release preparation: single dose study. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17957935/),,1.17,232693,DB00252,Phenytoin
,17957935,half-lives,The difference in the bioavailability did not affect the elimination of phenytoin and their half-lives were comparable (11-13 h).,Effect of doses on the bioavailability of phenytoin from a prompt-release and an extended-release preparation: single dose study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17957935/),h,11-13,232694,DB00252,Phenytoin
,32737897,relative bioavailability,"Lower carbamazepine concentrations under KD were modelled as decreased relative bioavailability (44%), potentially related to decreased fraction absorbed (unexpected for this lipophilic drug), increased intestinal/hepatic metabolism and/or decreased protein-binding with KD.","Drug-drug and drug-food interactions in an infant with early-onset SCN2A epilepsy treated with carbamazepine, phenytoin and a ketogenic diet. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32737897/),%,44,232721,DB00252,Phenytoin
,3423424,clearance,The mean clearance at 40 hours (5.1 +/- 1.1 ml/min per kg; mean +/- SE) was significantly greater than that at 16 hours (3.1 +/- 0.5 ml/min per kg; p less than 0.05).,Phenytoin pharmacokinetics in the rabbit: evidence of rapid autoinduction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3423424/),[ml] / [kg·min],5.1,233846,DB00252,Phenytoin
,3423424,clearance,The mean clearance at 40 hours (5.1 +/- 1.1 ml/min per kg; mean +/- SE) was significantly greater than that at 16 hours (3.1 +/- 0.5 ml/min per kg; p less than 0.05).,Phenytoin pharmacokinetics in the rabbit: evidence of rapid autoinduction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3423424/),[ml] / [kg·min],3.1,233847,DB00252,Phenytoin
,9551846,maximal plasma concentration,After both injections the maximal plasma concentration of phenytoin was about 30 microg/ml.,Anticonvulsant effect of fosphenytoin in amygdala-kindled rats: comparison with phenytoin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551846/),[μg] / [ml],30,233979,DB00252,Phenytoin
,9551846,relative bioavailability,The relative bioavailability of fosphenytoin was 83%.,Anticonvulsant effect of fosphenytoin in amygdala-kindled rats: comparison with phenytoin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551846/),%,83,233980,DB00252,Phenytoin
,6887340,bioavailability,Phenytoin achieved a peak concentration in serum within 1-4 h after p.o. administration and was poorly absorbed with a bioavailability of 34.5 +/- 8.6%.,Pharmacokinetics of phenytoin (diphenylhydantoin) in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887340/),%,34.5,234160,DB00252,Phenytoin
,6887340,serum steady-state concentrations,Oral dosage regimens were calculated on the basis of a dosing interval of 8 h to provide average serum steady-state concentrations of 5 and 10 micrograms/ml for phenytoin.,Pharmacokinetics of phenytoin (diphenylhydantoin) in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887340/),[μg] / [ml],5,234161,DB00252,Phenytoin
,6887340,serum steady-state concentrations,Oral dosage regimens were calculated on the basis of a dosing interval of 8 h to provide average serum steady-state concentrations of 5 and 10 micrograms/ml for phenytoin.,Pharmacokinetics of phenytoin (diphenylhydantoin) in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887340/),[μg] / [ml],10,234162,DB00252,Phenytoin
,16600575,50% effective dose,"For example, in the proportion of 1:1 the theoretically calculated 50% effective dose for additivity (ED(50add)) was 138 mg/kg, while the experimentally derived ED(50) for the mixture (ED(50mix)) was 85.2 mg/kg.",Isobolographic analysis of interactions between losigamone and conventional antiepileptic drugs in the mouse maximal electroshock model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16600575/),,138,234359,DB00252,Phenytoin
,16600575,ED(50),"For example, in the proportion of 1:1 the theoretically calculated 50% effective dose for additivity (ED(50add)) was 138 mg/kg, while the experimentally derived ED(50) for the mixture (ED(50mix)) was 85.2 mg/kg.",Isobolographic analysis of interactions between losigamone and conventional antiepileptic drugs in the mouse maximal electroshock model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16600575/),[mg] / [kg],85.2,234360,DB00252,Phenytoin
,22246398,serum concentration,The mean ± SD serum concentration of OHC was 14.47 ± 8.28 μg/mL at a mean daily dose of 16.22 ± 7.99 mg/kg.,Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22246398/),[μg] / [ml],14.47,235025,DB00252,Phenytoin
,17222753,maximum concentration,"Mean (percent coefficient of variation) maximum concentration, volume of distribution, half-life, and clearance were 3.6 microg/mL (13.8%), 22.6 L/m2 (20.2%), 2.73 hours (27.5%), and 109 mL/min/m2 (26%), respectively.",Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17222753/),[μg] / [ml],3.6,235378,DB00252,Phenytoin
,17222753,clearance,"Mean (percent coefficient of variation) maximum concentration, volume of distribution, half-life, and clearance were 3.6 microg/mL (13.8%), 22.6 L/m2 (20.2%), 2.73 hours (27.5%), and 109 mL/min/m2 (26%), respectively.",Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17222753/),[ml] / [m2·min],109,235379,DB00252,Phenytoin
,17222753,areas under the curve,The mean (percent coefficient of variation) and median daily areas under the curve were 4873 (21.8%) and 4871 microM x minute.,Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17222753/),min·μM,4871,235380,DB00252,Phenytoin
,3459864,Brain/plasma concentration ratio,"Brain/plasma concentration ratio of I was about 1.3, whereas that of II was about 0.05.","Biopharmaceutical studies on hydantoin derivatives. V. Pharmacokinetics and pharmacodynamics of 5,5-diphenylhydantoin and 1-benzenesulfonyl-5,5-diphenylhydantoin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459864/),,1.3,236528,DB00252,Phenytoin
,3459864,Brain/plasma concentration ratio,"Brain/plasma concentration ratio of I was about 1.3, whereas that of II was about 0.05.","Biopharmaceutical studies on hydantoin derivatives. V. Pharmacokinetics and pharmacodynamics of 5,5-diphenylhydantoin and 1-benzenesulfonyl-5,5-diphenylhydantoin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459864/),,0.05,236529,DB00252,Phenytoin
,3459864,Plasma protein binding,"Plasma protein binding of I having pKa value of 8.30 was about 88%, whereas that of II having pKa value of 4.89 was about 99%.","Biopharmaceutical studies on hydantoin derivatives. V. Pharmacokinetics and pharmacodynamics of 5,5-diphenylhydantoin and 1-benzenesulfonyl-5,5-diphenylhydantoin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459864/),%,88,236530,DB00252,Phenytoin
,3459864,Plasma protein binding,"Plasma protein binding of I having pKa value of 8.30 was about 88%, whereas that of II having pKa value of 4.89 was about 99%.","Biopharmaceutical studies on hydantoin derivatives. V. Pharmacokinetics and pharmacodynamics of 5,5-diphenylhydantoin and 1-benzenesulfonyl-5,5-diphenylhydantoin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459864/),%,99,236531,DB00252,Phenytoin
,11524464,bioavailability,"Based on AUC(0-infinity), bioavailability of the Mylan product administered with food was 13% lower than that observed with Dilantin Kapseals.",Effect of food on absorption of Dilantin Kapseals and Mylan extended phenytoin sodium capsules. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11524464/),%,13,236859,DB00252,Phenytoin
,3621584,relative oral/intramuscular bioavailability,"The relative oral/intramuscular bioavailability of amitriptyline was only 13%, and the steady-state concentrations of this drug on four consecutive days were acutely subtherapeutic (i.e., 3.6, 3.7, 3.9, and 3.7 micrograms/L).",Decreased drug absorption in a patient with Behçet's syndrome. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621584/),%,13,237079,DB00252,Phenytoin
,3621584,steady-state concentrations,"The relative oral/intramuscular bioavailability of amitriptyline was only 13%, and the steady-state concentrations of this drug on four consecutive days were acutely subtherapeutic (i.e., 3.6, 3.7, 3.9, and 3.7 micrograms/L).",Decreased drug absorption in a patient with Behçet's syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621584/),μ,3.6,237080,DB00252,Phenytoin
,3621584,steady-state concentrations,"The relative oral/intramuscular bioavailability of amitriptyline was only 13%, and the steady-state concentrations of this drug on four consecutive days were acutely subtherapeutic (i.e., 3.6, 3.7, 3.9, and 3.7 micrograms/L).",Decreased drug absorption in a patient with Behçet's syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621584/),μ,3.7,237081,DB00252,Phenytoin
,3621584,steady-state concentrations,"The relative oral/intramuscular bioavailability of amitriptyline was only 13%, and the steady-state concentrations of this drug on four consecutive days were acutely subtherapeutic (i.e., 3.6, 3.7, 3.9, and 3.7 micrograms/L).",Decreased drug absorption in a patient with Behçet's syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621584/),μ,3.9,237082,DB00252,Phenytoin
,19649625,CLint.liver,"Simulations of PHT clearance were most accurate when based on ‘albumin-adjusted’ in vitro kinetic data, and they identified inter-individual variability outside the reported range of pharmacokinetic studies in healthy volunteers (CLint.liver = 4.6–22.5 L h−1 vs. CLint.liver.0–96 hr = 2.4–40.1 L h−1).",Assessment of inter-individual variability in predicted phenytoin clearance. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19649625/),[l] / [h],4.6–22.5,237630,DB00252,Phenytoin
,19649625,CLint.liver.0,"Simulations of PHT clearance were most accurate when based on ‘albumin-adjusted’ in vitro kinetic data, and they identified inter-individual variability outside the reported range of pharmacokinetic studies in healthy volunteers (CLint.liver = 4.6–22.5 L h−1 vs. CLint.liver.0–96 hr = 2.4–40.1 L h−1).",Assessment of inter-individual variability in predicted phenytoin clearance. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19649625/),[l] / [h],2.4–40.1,237631,DB00252,Phenytoin
>,14570767,IC50,"In the absence of preincubation, the racemate was found to be a weak inhibitor (IC50 > 100 microM) of phenacetin O-deethylation (POD) (CYP1A2), paclitaxel 6alpha-hydroxylation (CYP2C8), diclofenac 4'-hydroxylation (CYP2C9), (S)-mephenytoin 4'-hydroxylation (CYP2C19), bufuralol 1'-hydroxylation (CYP2D6), testosterone 6beta-hydroxylation (CYP3A4), chlorzoxazone 6-hydroxylation (CYP2E1), and bupropion hydroxylation (CYP2B6).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,100,238065,DB00252,Phenytoin
,14570767,kinact,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238066,DB00252,Phenytoin
,14570767,apparent KI,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238067,DB00252,Phenytoin
,14570767,kinact/KIratio,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0003,238068,DB00252,Phenytoin
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.037,238069,DB00252,Phenytoin
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,98.2,238070,DB00252,Phenytoin
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0004,238071,DB00252,Phenytoin
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.012,238072,DB00252,Phenytoin
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,66.6,238073,DB00252,Phenytoin
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0002,238074,DB00252,Phenytoin
,7725375,half-life,"After concentration decrease with time was taken into account (average half-life estimate of 4.6 h), age was identified as a major factor responsible for between-patient variability.",Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability for moclobemide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7725375/),h,4.6,239962,DB00252,Phenytoin
,2743707,Serum AUC,"Serum AUC increased from 245 +/- 37.6 to 342 +/- 87.3 mg.hr/L (p = 0.007); area under the first moment curve increased from 5666 +/- 1003 to 11,632 +/- 4198 mg.hr2/L (p = 0.008); the time-averaged total body clearance decreased from 1.57 +/- 0.3 to 1.17 +/- 0.33 L/hr (p = 0.0004); and the apparent elimination half-life increased from 16.1 +/- 1.32 to 22.6 +/- 3.8 hours (p = 0.001) for phenytoin during phase II.",Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743707/),[h·mg] / [l],245,241153,DB00252,Phenytoin
,2743707,Serum AUC,"Serum AUC increased from 245 +/- 37.6 to 342 +/- 87.3 mg.hr/L (p = 0.007); area under the first moment curve increased from 5666 +/- 1003 to 11,632 +/- 4198 mg.hr2/L (p = 0.008); the time-averaged total body clearance decreased from 1.57 +/- 0.3 to 1.17 +/- 0.33 L/hr (p = 0.0004); and the apparent elimination half-life increased from 16.1 +/- 1.32 to 22.6 +/- 3.8 hours (p = 0.001) for phenytoin during phase II.",Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743707/),[h·mg] / [l],342,241154,DB00252,Phenytoin
,2743707,area under the first moment curve,"Serum AUC increased from 245 +/- 37.6 to 342 +/- 87.3 mg.hr/L (p = 0.007); area under the first moment curve increased from 5666 +/- 1003 to 11,632 +/- 4198 mg.hr2/L (p = 0.008); the time-averaged total body clearance decreased from 1.57 +/- 0.3 to 1.17 +/- 0.33 L/hr (p = 0.0004); and the apparent elimination half-life increased from 16.1 +/- 1.32 to 22.6 +/- 3.8 hours (p = 0.001) for phenytoin during phase II.",Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743707/),[hr2·mg] / [l],5666,241155,DB00252,Phenytoin
,2743707,area under the first moment curve,"Serum AUC increased from 245 +/- 37.6 to 342 +/- 87.3 mg.hr/L (p = 0.007); area under the first moment curve increased from 5666 +/- 1003 to 11,632 +/- 4198 mg.hr2/L (p = 0.008); the time-averaged total body clearance decreased from 1.57 +/- 0.3 to 1.17 +/- 0.33 L/hr (p = 0.0004); and the apparent elimination half-life increased from 16.1 +/- 1.32 to 22.6 +/- 3.8 hours (p = 0.001) for phenytoin during phase II.",Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743707/),[hr2·mg] / [l],"11,632",241156,DB00252,Phenytoin
,2743707,total body clearance,"Serum AUC increased from 245 +/- 37.6 to 342 +/- 87.3 mg.hr/L (p = 0.007); area under the first moment curve increased from 5666 +/- 1003 to 11,632 +/- 4198 mg.hr2/L (p = 0.008); the time-averaged total body clearance decreased from 1.57 +/- 0.3 to 1.17 +/- 0.33 L/hr (p = 0.0004); and the apparent elimination half-life increased from 16.1 +/- 1.32 to 22.6 +/- 3.8 hours (p = 0.001) for phenytoin during phase II.",Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743707/),[l] / [h],1.57,241157,DB00252,Phenytoin
,2743707,total body clearance,"Serum AUC increased from 245 +/- 37.6 to 342 +/- 87.3 mg.hr/L (p = 0.007); area under the first moment curve increased from 5666 +/- 1003 to 11,632 +/- 4198 mg.hr2/L (p = 0.008); the time-averaged total body clearance decreased from 1.57 +/- 0.3 to 1.17 +/- 0.33 L/hr (p = 0.0004); and the apparent elimination half-life increased from 16.1 +/- 1.32 to 22.6 +/- 3.8 hours (p = 0.001) for phenytoin during phase II.",Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743707/),[l] / [h],1.17,241158,DB00252,Phenytoin
,2743707,apparent elimination half-life,"Serum AUC increased from 245 +/- 37.6 to 342 +/- 87.3 mg.hr/L (p = 0.007); area under the first moment curve increased from 5666 +/- 1003 to 11,632 +/- 4198 mg.hr2/L (p = 0.008); the time-averaged total body clearance decreased from 1.57 +/- 0.3 to 1.17 +/- 0.33 L/hr (p = 0.0004); and the apparent elimination half-life increased from 16.1 +/- 1.32 to 22.6 +/- 3.8 hours (p = 0.001) for phenytoin during phase II.",Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743707/),h,16.1,241159,DB00252,Phenytoin
,2743707,apparent elimination half-life,"Serum AUC increased from 245 +/- 37.6 to 342 +/- 87.3 mg.hr/L (p = 0.007); area under the first moment curve increased from 5666 +/- 1003 to 11,632 +/- 4198 mg.hr2/L (p = 0.008); the time-averaged total body clearance decreased from 1.57 +/- 0.3 to 1.17 +/- 0.33 L/hr (p = 0.0004); and the apparent elimination half-life increased from 16.1 +/- 1.32 to 22.6 +/- 3.8 hours (p = 0.001) for phenytoin during phase II.",Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743707/),h,22.6,241160,DB00252,Phenytoin
,10197296,apparent oral clearance,The population mean apparent oral clearance of lamotrigine in adult patients receiving one concomitant enzyme-inducing antiepileptic drug and not valproic acid was estimated to be 1 mL/min/kg.,Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10197296/),[ml] / [kg·min],1,241375,DB00252,Phenytoin
,22268821,t(1/2),"Pharmacokinetic parameters for phenytoin in toxicity group of poor metabolizers showed a longer elimination half-life of a drug (t(1/2) = 35.3 h) and less clearance rate (CL = 468 mL/h) compared to intermediate metabolizers (t(1/2) = 33.2 h, CL = 674 mL/h) and extensive metabolizer (t(1/2) = 20.7 h, CL = 977 mL/h) in NAT2*5A polymorphism.",Genetic polymorphism of NAT2 metabolizing enzymes on phenytoin pharmacokinetics in Indian epileptic patients developing toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22268821/),h,35.3,241792,DB00252,Phenytoin
,22268821,clearance rate (CL,"Pharmacokinetic parameters for phenytoin in toxicity group of poor metabolizers showed a longer elimination half-life of a drug (t(1/2) = 35.3 h) and less clearance rate (CL = 468 mL/h) compared to intermediate metabolizers (t(1/2) = 33.2 h, CL = 674 mL/h) and extensive metabolizer (t(1/2) = 20.7 h, CL = 977 mL/h) in NAT2*5A polymorphism.",Genetic polymorphism of NAT2 metabolizing enzymes on phenytoin pharmacokinetics in Indian epileptic patients developing toxicity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22268821/),[ml] / [h],468,241793,DB00252,Phenytoin
,22268821,t(1/2),"Pharmacokinetic parameters for phenytoin in toxicity group of poor metabolizers showed a longer elimination half-life of a drug (t(1/2) = 35.3 h) and less clearance rate (CL = 468 mL/h) compared to intermediate metabolizers (t(1/2) = 33.2 h, CL = 674 mL/h) and extensive metabolizer (t(1/2) = 20.7 h, CL = 977 mL/h) in NAT2*5A polymorphism.",Genetic polymorphism of NAT2 metabolizing enzymes on phenytoin pharmacokinetics in Indian epileptic patients developing toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22268821/),h,33.2,241794,DB00252,Phenytoin
,22268821,CL,"Pharmacokinetic parameters for phenytoin in toxicity group of poor metabolizers showed a longer elimination half-life of a drug (t(1/2) = 35.3 h) and less clearance rate (CL = 468 mL/h) compared to intermediate metabolizers (t(1/2) = 33.2 h, CL = 674 mL/h) and extensive metabolizer (t(1/2) = 20.7 h, CL = 977 mL/h) in NAT2*5A polymorphism.",Genetic polymorphism of NAT2 metabolizing enzymes on phenytoin pharmacokinetics in Indian epileptic patients developing toxicity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22268821/),[ml] / [h],674,241795,DB00252,Phenytoin
,22268821,t(1/2),"Pharmacokinetic parameters for phenytoin in toxicity group of poor metabolizers showed a longer elimination half-life of a drug (t(1/2) = 35.3 h) and less clearance rate (CL = 468 mL/h) compared to intermediate metabolizers (t(1/2) = 33.2 h, CL = 674 mL/h) and extensive metabolizer (t(1/2) = 20.7 h, CL = 977 mL/h) in NAT2*5A polymorphism.",Genetic polymorphism of NAT2 metabolizing enzymes on phenytoin pharmacokinetics in Indian epileptic patients developing toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22268821/),h,20.7,241796,DB00252,Phenytoin
,22268821,CL,"Pharmacokinetic parameters for phenytoin in toxicity group of poor metabolizers showed a longer elimination half-life of a drug (t(1/2) = 35.3 h) and less clearance rate (CL = 468 mL/h) compared to intermediate metabolizers (t(1/2) = 33.2 h, CL = 674 mL/h) and extensive metabolizer (t(1/2) = 20.7 h, CL = 977 mL/h) in NAT2*5A polymorphism.",Genetic polymorphism of NAT2 metabolizing enzymes on phenytoin pharmacokinetics in Indian epileptic patients developing toxicity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22268821/),[ml] / [h],977,241797,DB00252,Phenytoin
,11185666,Vmaxbaseline,Rapid inhibition of metabolism (Vmaxbaseline = 2.82 +/- 2.35 mg/kg/day) was observed initially following injury.,"Altered phenytoin pharmacokinetics in children with severe, acute traumatic brain injury. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185666/),[mg] / [d·kg],2.82,242665,DB00252,Phenytoin
,11185666,Vmaxinduced,"This was followed by induction of metabolism as reflected by a Vmaxinduced of 20.79 +/- 13.71 mg/kg/day, which was approximately twofold higher than reported values for nonstressed children.","Altered phenytoin pharmacokinetics in children with severe, acute traumatic brain injury. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185666/),[mg] / [d·kg],20.79,242666,DB00252,Phenytoin
,16403497,effective dose (ED50),"Moreover, 2-PMPA administered i.p. at a constant dose of 150 mg/kg (the dose increasing the threshold for electroconvulsions) enhanced significantly the anticonvulsant action of valproate, by reducing its median effective dose (ED50) from 281.4 to 230.1 mg/kg (P<0.05).",2-phosphonomethyl-pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16403497/),[mg] / [kg],281.4,243510,DB00252,Phenytoin
,16403497,effective dose (ED50),"Moreover, 2-PMPA administered i.p. at a constant dose of 150 mg/kg (the dose increasing the threshold for electroconvulsions) enhanced significantly the anticonvulsant action of valproate, by reducing its median effective dose (ED50) from 281.4 to 230.1 mg/kg (P<0.05).",2-phosphonomethyl-pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16403497/),[mg] / [kg],230.1,243511,DB00252,Phenytoin
,22615660,CL,"For a patient weighting 60 kg, the typical CL and Vd were estimated to be 13.4 l/hr and 42.6 L, respectively.",Population pharmacokinetics of oral high-dose busulfan in adult patients undergoing hematopoietic stem cell transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22615660/),[l] / [h],13.4,245160,DB00252,Phenytoin
,22615660,Vd,"For a patient weighting 60 kg, the typical CL and Vd were estimated to be 13.4 l/hr and 42.6 L, respectively.",Population pharmacokinetics of oral high-dose busulfan in adult patients undergoing hematopoietic stem cell transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22615660/),l,42.6,245161,DB00252,Phenytoin
,17433925,elimination half-life,The elimination half-life for the entire patient population was approximately twofold longer than the value reported in the product labeling (40-50 h vs 22 h).,Factors affecting antiepileptic drug pharmacokinetics in community-dwelling elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17433925/),h,40-50,246570,DB00252,Phenytoin
,17433925,elimination half-life,The elimination half-life for the entire patient population was approximately twofold longer than the value reported in the product labeling (40-50 h vs 22 h).,Factors affecting antiepileptic drug pharmacokinetics in community-dwelling elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17433925/),h,22,246571,DB00252,Phenytoin
,17433925,elimination half-life,"Preliminary results from 67 patients on CBZ therapy (14 elderly, mean age 70 years; 53 younger adults, mean age 41 years) showed no apparent difference between elderly and adult patients in any parameter; however, the mean CBZ elimination half-life for the combined groups (21 h) was longer than previous estimates.",Factors affecting antiepileptic drug pharmacokinetics in community-dwelling elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17433925/),h,21,246572,DB00252,Phenytoin
,17199019,half-life,Human pharmacology studies have shown that brivaracetam has a half-life of 8 h and nearly complete bioavailability.,Brivaracetam (UCB 34714). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17199019/),h,8,248873,DB00252,Phenytoin
,9578000,Css,Twenty-five patients taking phenytoin (PHT) and/ or phenobarbital (PB) and/or primidone (PRM) underwent a rapid switchover to CBZ following a 10 mg/kg single-dose kinetic study (day 1) which allowed calculation of a maintenance dose necessary to yield a mean Css of 10.2 (+/-2.2) mg/l.,Rapid switchover to carbamazepine using pharmacokinetic parameters. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578000/),[mg] / [l],10.2,249787,DB00252,Phenytoin
,9578000,Css,"All patients completed the switchover to CBZ within a mean time period of 6 days (+/-2), reaching a mean maintenance dose of 1,639 mg/day (+/-370) which yielded a mean Css of 11.3 (+/-3.2) mg/l.",Rapid switchover to carbamazepine using pharmacokinetic parameters. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578000/),[mg] / [l],11.3,249788,DB00252,Phenytoin
,22612290,"half-life (t(1/2,eff) )","After ESL oral administration, the effective half-life (t(1/2,eff) ) of eslicarbazepine was 20-24 h, which is approximately two times longer than its terminal half-life (t(1/2)).",Pharmacokinetics and drug interactions of eslicarbazepine acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612290/),h,20-24,249977,DB00252,Phenytoin
,7363932,half-life of,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),min,323,250135,DB00252,Phenytoin
,7363932,half-life of,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),min,357,250136,DB00252,Phenytoin
,7363932,half-life of,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),min,344,250137,DB00252,Phenytoin
,7363932,clearances,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),[ml] / [kg·min],3.41,250138,DB00252,Phenytoin
,7363932,clearances,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),[ml] / [kg·min],4.08,250139,DB00252,Phenytoin
,7363932,clearances,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),[ml] / [kg·min],3.81,250140,DB00252,Phenytoin
,6230241,total body clearance,"Before and during phenytoin dosage in ten volunteers, the mean (+/-SD) total body clearance (ml min-1 kg-1) of both total and unbound prednisolone increased from 2.74 +/- 0.47 to 3.94 +/- 0.66 (P less than 0.001) and from 10.76 +/- 2.68 to 16.00 +/- 3.17 (P less than 0.001), respectively.",Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6230241/),[ml] / [kg·min],2.74,251561,DB00252,Phenytoin
,6230241,total body clearance,"Before and during phenytoin dosage in ten volunteers, the mean (+/-SD) total body clearance (ml min-1 kg-1) of both total and unbound prednisolone increased from 2.74 +/- 0.47 to 3.94 +/- 0.66 (P less than 0.001) and from 10.76 +/- 2.68 to 16.00 +/- 3.17 (P less than 0.001), respectively.",Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6230241/),[ml] / [kg·min],3.94,251562,DB00252,Phenytoin
,6230241,total body clearance,"Before and during phenytoin dosage in ten volunteers, the mean (+/-SD) total body clearance (ml min-1 kg-1) of both total and unbound prednisolone increased from 2.74 +/- 0.47 to 3.94 +/- 0.66 (P less than 0.001) and from 10.76 +/- 2.68 to 16.00 +/- 3.17 (P less than 0.001), respectively.",Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6230241/),[ml] / [kg·min],10.76,251563,DB00252,Phenytoin
,6230241,total body clearance,"Before and during phenytoin dosage in ten volunteers, the mean (+/-SD) total body clearance (ml min-1 kg-1) of both total and unbound prednisolone increased from 2.74 +/- 0.47 to 3.94 +/- 0.66 (P less than 0.001) and from 10.76 +/- 2.68 to 16.00 +/- 3.17 (P less than 0.001), respectively.",Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6230241/),[ml] / [kg·min],16.00,251564,DB00252,Phenytoin
,3603312,Vm,"The Vm and Km of 6.5 mg/kg/d and 13.6 mumol/l respectively, determined by using total serum concentration, could be to estimate phenytoin dosage requirements in a hospital population.",Population pharmacokinetics of phenytoin in South African black patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3603312/),[mg] / [d·kg],6.5,252047,DB00252,Phenytoin
,3603312,Km,"The Vm and Km of 6.5 mg/kg/d and 13.6 mumol/l respectively, determined by using total serum concentration, could be to estimate phenytoin dosage requirements in a hospital population.",Population pharmacokinetics of phenytoin in South African black patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3603312/),[μM] / [l],13.6,252048,DB00252,Phenytoin
,10809343,Cmax,"For the other four subjects, median rectal Cmax was significantly lower than oral Cmax (0.4 vs 1.9 microg/ml, p=0.028), median rectal Tmax did not differ from oral Tmax (11.9 vs 8.0 hrs, p=0.465), and median rectal AUClast, although highly variable, was significantly lower than oral AUClast (5.4 vs 36.2 microg x hr/ml, p=0.046).",Absorption of phenytoin from rectal suppositories formulated with a polyethylene glycol base. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10809343/),[μg] / [ml],0.4,252566,DB00252,Phenytoin
,10809343,Cmax,"For the other four subjects, median rectal Cmax was significantly lower than oral Cmax (0.4 vs 1.9 microg/ml, p=0.028), median rectal Tmax did not differ from oral Tmax (11.9 vs 8.0 hrs, p=0.465), and median rectal AUClast, although highly variable, was significantly lower than oral AUClast (5.4 vs 36.2 microg x hr/ml, p=0.046).",Absorption of phenytoin from rectal suppositories formulated with a polyethylene glycol base. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10809343/),[μg] / [ml],1.9,252567,DB00252,Phenytoin
,10809343,Tmax,"For the other four subjects, median rectal Cmax was significantly lower than oral Cmax (0.4 vs 1.9 microg/ml, p=0.028), median rectal Tmax did not differ from oral Tmax (11.9 vs 8.0 hrs, p=0.465), and median rectal AUClast, although highly variable, was significantly lower than oral AUClast (5.4 vs 36.2 microg x hr/ml, p=0.046).",Absorption of phenytoin from rectal suppositories formulated with a polyethylene glycol base. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10809343/),h,11.9,252568,DB00252,Phenytoin
,10809343,Tmax,"For the other four subjects, median rectal Cmax was significantly lower than oral Cmax (0.4 vs 1.9 microg/ml, p=0.028), median rectal Tmax did not differ from oral Tmax (11.9 vs 8.0 hrs, p=0.465), and median rectal AUClast, although highly variable, was significantly lower than oral AUClast (5.4 vs 36.2 microg x hr/ml, p=0.046).",Absorption of phenytoin from rectal suppositories formulated with a polyethylene glycol base. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10809343/),h,8.0,252569,DB00252,Phenytoin
,10809343,AUClast,"For the other four subjects, median rectal Cmax was significantly lower than oral Cmax (0.4 vs 1.9 microg/ml, p=0.028), median rectal Tmax did not differ from oral Tmax (11.9 vs 8.0 hrs, p=0.465), and median rectal AUClast, although highly variable, was significantly lower than oral AUClast (5.4 vs 36.2 microg x hr/ml, p=0.046).",Absorption of phenytoin from rectal suppositories formulated with a polyethylene glycol base. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10809343/),[h·μg] / [ml],5.4,252570,DB00252,Phenytoin
,10809343,AUClast,"For the other four subjects, median rectal Cmax was significantly lower than oral Cmax (0.4 vs 1.9 microg/ml, p=0.028), median rectal Tmax did not differ from oral Tmax (11.9 vs 8.0 hrs, p=0.465), and median rectal AUClast, although highly variable, was significantly lower than oral AUClast (5.4 vs 36.2 microg x hr/ml, p=0.046).",Absorption of phenytoin from rectal suppositories formulated with a polyethylene glycol base. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10809343/),[h·μg] / [ml],36.2,252571,DB00252,Phenytoin
,10809343,Tlag,"No Tlag was seen after oral administration, but with rectal administration the median Tlag was 2 hours.",Absorption of phenytoin from rectal suppositories formulated with a polyethylene glycol base. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10809343/),h,2,252572,DB00252,Phenytoin
,10809343,relative bioavailability,"The estimated relative bioavailability of rectal phenytoin suppositories based on AUC0-24 was 4.7%, with individual values ranging from 0-58.3%.",Absorption of phenytoin from rectal suppositories formulated with a polyethylene glycol base. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10809343/),%,4.7,252573,DB00252,Phenytoin
,10809343,relative bioavailability,"The estimated relative bioavailability of rectal phenytoin suppositories based on AUC0-24 was 4.7%, with individual values ranging from 0-58.3%.",Absorption of phenytoin from rectal suppositories formulated with a polyethylene glycol base. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10809343/),%,0-58.3,252574,DB00252,Phenytoin
,2605620,AUC (0-72 hr),The AUC (0-72 hr) for CAPS Phenytoin was 50.61 microgram/ml/hr compared to 45.09 au/ml/hr for Epanutin.,A comparative bioavailability of 2 oral solid phenytoin dosage forms. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2605620/),[μg] / [h·ml],50.61,254316,DB00252,Phenytoin
,2605620,AUC (0-72 hr),The AUC (0-72 hr) for CAPS Phenytoin was 50.61 microgram/ml/hr compared to 45.09 au/ml/hr for Epanutin.,A comparative bioavailability of 2 oral solid phenytoin dosage forms. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2605620/),[au] / [h·ml],45.09,254317,DB00252,Phenytoin
,2605620,"time to peak concentrations, Tmax","The time to peak concentrations, Tmax, was significantly longer in CAPS Phenytoin when compared to Epanutin being 3.75 hr and 3.25 hr respectively (P less than 0.05) and the peak concentrations Cmax, achieved after single dose administration showed that CAPS Phenytoin exhibited higher levels than Spanutin (1.76 au/ml and 1.58 au/ml respectively) although these differences were not statistically significant.",A comparative bioavailability of 2 oral solid phenytoin dosage forms. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2605620/),h,3.75,254318,DB00252,Phenytoin
,2605620,"time to peak concentrations, Tmax","The time to peak concentrations, Tmax, was significantly longer in CAPS Phenytoin when compared to Epanutin being 3.75 hr and 3.25 hr respectively (P less than 0.05) and the peak concentrations Cmax, achieved after single dose administration showed that CAPS Phenytoin exhibited higher levels than Spanutin (1.76 au/ml and 1.58 au/ml respectively) although these differences were not statistically significant.",A comparative bioavailability of 2 oral solid phenytoin dosage forms. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2605620/),h,3.25,254319,DB00252,Phenytoin
,2605620,peak concentrations Cmax,"The time to peak concentrations, Tmax, was significantly longer in CAPS Phenytoin when compared to Epanutin being 3.75 hr and 3.25 hr respectively (P less than 0.05) and the peak concentrations Cmax, achieved after single dose administration showed that CAPS Phenytoin exhibited higher levels than Spanutin (1.76 au/ml and 1.58 au/ml respectively) although these differences were not statistically significant.",A comparative bioavailability of 2 oral solid phenytoin dosage forms. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2605620/),[au] / [ml],1.76,254320,DB00252,Phenytoin
,2605620,peak concentrations Cmax,"The time to peak concentrations, Tmax, was significantly longer in CAPS Phenytoin when compared to Epanutin being 3.75 hr and 3.25 hr respectively (P less than 0.05) and the peak concentrations Cmax, achieved after single dose administration showed that CAPS Phenytoin exhibited higher levels than Spanutin (1.76 au/ml and 1.58 au/ml respectively) although these differences were not statistically significant.",A comparative bioavailability of 2 oral solid phenytoin dosage forms. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2605620/),[au] / [ml],1.58,254321,DB00252,Phenytoin
,7333060,half-life,"The half-life of antipyrine was significantly longer in the elderly than in the younger group, 756 +/- 318 and 465 +/- 110 minutes, respectively, and the MCR was correspondingly lower in the elderly even when calculated per litre of live volume, 22.8 +/- 7.8 and 36.3 +/- 8.9ml/minute/L liver volume, respectively.",Disposition of antipyrine and phenytoin correlated with age and liver volume in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333060/),min,756,255992,DB00252,Phenytoin
,7333060,half-life,"The half-life of antipyrine was significantly longer in the elderly than in the younger group, 756 +/- 318 and 465 +/- 110 minutes, respectively, and the MCR was correspondingly lower in the elderly even when calculated per litre of live volume, 22.8 +/- 7.8 and 36.3 +/- 8.9ml/minute/L liver volume, respectively.",Disposition of antipyrine and phenytoin correlated with age and liver volume in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333060/),min,465,255993,DB00252,Phenytoin
,7333060,MCR,"The half-life of antipyrine was significantly longer in the elderly than in the younger group, 756 +/- 318 and 465 +/- 110 minutes, respectively, and the MCR was correspondingly lower in the elderly even when calculated per litre of live volume, 22.8 +/- 7.8 and 36.3 +/- 8.9ml/minute/L liver volume, respectively.",Disposition of antipyrine and phenytoin correlated with age and liver volume in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333060/),[ml] / [l·min],22.8,255994,DB00252,Phenytoin
,7333060,MCR,"The half-life of antipyrine was significantly longer in the elderly than in the younger group, 756 +/- 318 and 465 +/- 110 minutes, respectively, and the MCR was correspondingly lower in the elderly even when calculated per litre of live volume, 22.8 +/- 7.8 and 36.3 +/- 8.9ml/minute/L liver volume, respectively.",Disposition of antipyrine and phenytoin correlated with age and liver volume in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333060/),[ml] / [l·min],36.3,255995,DB00252,Phenytoin
,7333060,clearance,"No significant differences in the 2 age groups were found in half-life and total clearance of phenytoin, but a reduced free phenytoin clearance was demonstrated in the elderly (240 +/- 92ml/minute/L liver volume) compared with the younger (325 +/- 81ml/minute/L liver volume) group.",Disposition of antipyrine and phenytoin correlated with age and liver volume in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333060/),[ml] / [l·liver·min·volume],240,255996,DB00252,Phenytoin
,7333060,clearance,"No significant differences in the 2 age groups were found in half-life and total clearance of phenytoin, but a reduced free phenytoin clearance was demonstrated in the elderly (240 +/- 92ml/minute/L liver volume) compared with the younger (325 +/- 81ml/minute/L liver volume) group.",Disposition of antipyrine and phenytoin correlated with age and liver volume in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333060/),[ml] / [l·min],325,255997,DB00252,Phenytoin
,6815599,clearance,"The antipyrine clearance at term (0.53 +/- 0.11 ml/min/kg, mean +/- SD) was lower than it was early during puerperium (0.70 +/- 0.14 ml/min/kg, P less than .05) and approximately 3 months after delivery (1.14 +/- 0.26 ml/min/kg, P less than .01).",Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6815599/),[ml] / [kg·min],0.53,256724,DB00252,Phenytoin
,6815599,clearance,"The antipyrine clearance at term (0.53 +/- 0.11 ml/min/kg, mean +/- SD) was lower than it was early during puerperium (0.70 +/- 0.14 ml/min/kg, P less than .05) and approximately 3 months after delivery (1.14 +/- 0.26 ml/min/kg, P less than .01).",Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6815599/),[ml] / [kg·min],0.70,256725,DB00252,Phenytoin
,6815599,clearance,"The antipyrine clearance at term (0.53 +/- 0.11 ml/min/kg, mean +/- SD) was lower than it was early during puerperium (0.70 +/- 0.14 ml/min/kg, P less than .05) and approximately 3 months after delivery (1.14 +/- 0.26 ml/min/kg, P less than .01).",Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6815599/),[ml] / [kg·min],1.14,256726,DB00252,Phenytoin
,6815599,clearance,"The antipyrine clearance in nonpregnant epileptics (1.17 +/- 0.44 ml/min/kg) was comparable to that found 3 months after delivery, whereas it was significantly (P less than .01) higher than that found in healthy women (0.47 +/- 0.02 ml/min/kg).",Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6815599/),[ml] / [kg·min],1.17,256727,DB00252,Phenytoin
,6815599,clearance,"The antipyrine clearance in nonpregnant epileptics (1.17 +/- 0.44 ml/min/kg) was comparable to that found 3 months after delivery, whereas it was significantly (P less than .01) higher than that found in healthy women (0.47 +/- 0.02 ml/min/kg).",Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6815599/),[ml] / [kg·min],0.47,256728,DB00252,Phenytoin
,2900742,terminal half-life,It has a terminal half-life of 9 hr.,Pharmacokinetics of cannabidiol in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900742/),h,9,257531,DB00252,Phenytoin
,2900742,total body clearance,The total body clearance of CBD was 17 liters/hr (after the 45-mg dose) and 16 liters/hr (after the 90-mg dose).,Pharmacokinetics of cannabidiol in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900742/),[l] / [h],17,257532,DB00252,Phenytoin
,2900742,total body clearance,The total body clearance of CBD was 17 liters/hr (after the 45-mg dose) and 16 liters/hr (after the 90-mg dose).,Pharmacokinetics of cannabidiol in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900742/),[l] / [h],16,257533,DB00252,Phenytoin
,2900742,extraction ratio,"This clearance value, after its normalization to blood clearance using mathematical equations, approaches the value of the hepatic blood flow; the extraction ratio in the liver is 0.74.",Pharmacokinetics of cannabidiol in dogs. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900742/),,0.74,257534,DB00252,Phenytoin
,2900742,volume of distribution,"CBD was observed to have a large volume of distribution, approximately 100 liters.",Pharmacokinetics of cannabidiol in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900742/),l,100,257535,DB00252,Phenytoin
,2900742,oral bioavailability,"In the other three, the oral bioavailability ranged from 13 to 19%.",Pharmacokinetics of cannabidiol in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900742/),%,13 to 19,257536,DB00252,Phenytoin
,7874071,pKa,"Judging from their pKa values (5.68 and 5.91 for VADPH and VPDPH, respectively) and pH-solubilities, VADPH and VPDPH were acidic compounds, while MNDPH was basic.",Physicochemical and hydrolytic characteristics of phenytoin derivatives. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7874071/),,5.68,258918,DB00252,Phenytoin
,7874071,pKa,"Judging from their pKa values (5.68 and 5.91 for VADPH and VPDPH, respectively) and pH-solubilities, VADPH and VPDPH were acidic compounds, while MNDPH was basic.",Physicochemical and hydrolytic characteristics of phenytoin derivatives. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7874071/),,5.91,258919,DB00252,Phenytoin
,42344,time to peak concentration (Tmax),"The time to peak concentration (Tmax) for mephenytoin was 1 hour, with a half-life (T 1/2) of 7 hours; the T 1/2 of its metabolite, 5-ethyl-5-phenylhydantion, was 96 hours.",Clinical pharmacology of mephenytoin and ethotoin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/42344/),h,1,259166,DB00252,Phenytoin
,42344,half-life (T 1/2),"The time to peak concentration (Tmax) for mephenytoin was 1 hour, with a half-life (T 1/2) of 7 hours; the T 1/2 of its metabolite, 5-ethyl-5-phenylhydantion, was 96 hours.",Clinical pharmacology of mephenytoin and ethotoin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/42344/),h,7,259167,DB00252,Phenytoin
,42344,T 1/2,"The time to peak concentration (Tmax) for mephenytoin was 1 hour, with a half-life (T 1/2) of 7 hours; the T 1/2 of its metabolite, 5-ethyl-5-phenylhydantion, was 96 hours.",Clinical pharmacology of mephenytoin and ethotoin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/42344/),h,96,259168,DB00252,Phenytoin
,42344,Tmax,"Ethotoin Tmax was 2 hours, with a T 1/2 of 5 hours.",Clinical pharmacology of mephenytoin and ethotoin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/42344/),h,2,259169,DB00252,Phenytoin
,42344,T 1/2,"Ethotoin Tmax was 2 hours, with a T 1/2 of 5 hours.",Clinical pharmacology of mephenytoin and ethotoin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/42344/),h,5,259170,DB00252,Phenytoin
,346287,elimination half-life,"After single oral doses of carbamazepine, the absorption is fairly complete and the elimination half-life is about 35 hours (range 18 to 65 hours).",Clinical pharmacokinetics of carbamazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/346287/),h,35,260413,DB00252,Phenytoin
,346287,half-life,"During multiple dosing, the half-life is decreased to 10-20 hours, probably due to autoinduction of the oxidative metabolism of the drug.",Clinical pharmacokinetics of carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/346287/),h,10-20,260414,DB00252,Phenytoin
,346287,plasma protein binding,The plasma protein binding of the metabolite is about 50% compared with about 75% for the parent drug.,Clinical pharmacokinetics of carbamazepine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/346287/),%,50,260415,DB00252,Phenytoin
,346287,plasma protein binding,The plasma protein binding of the metabolite is about 50% compared with about 75% for the parent drug.,Clinical pharmacokinetics of carbamazepine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/346287/),%,75,260416,DB00252,Phenytoin
,346287,plasma half-lives,"In newborns exposed to the drug during fetal life, the plasma half-lives were relatively short (8.2 to 28.1 hours) indicating an induction of carbamazepine metabolism during gestation.",Clinical pharmacokinetics of carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/346287/),h,8.2 to 28.1,260417,DB00252,Phenytoin
,11604257,activities,"In rats with PCM and PCMC, the phenytoin hydroxylation (to form pHPPH) activities were significantly smaller (164, 103 and 95.3 pmol/min per mg protein for the control rats, and rats with PCM and PCMC, respectively) than that in control rats.",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),[pM] / [mg·min],164,261522,DB00252,Phenytoin
,11604257,activities,"In rats with PCM and PCMC, the phenytoin hydroxylation (to form pHPPH) activities were significantly smaller (164, 103 and 95.3 pmol/min per mg protein for the control rats, and rats with PCM and PCMC, respectively) than that in control rats.",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),[pM] / [mg·min],103,261523,DB00252,Phenytoin
,11604257,activities,"In rats with PCM and PCMC, the phenytoin hydroxylation (to form pHPPH) activities were significantly smaller (164, 103 and 95.3 pmol/min per mg protein for the control rats, and rats with PCM and PCMC, respectively) than that in control rats.",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),[pM] / [mg·min],95.3,261524,DB00252,Phenytoin
,11604257,intrinsic clearance,"In rats with PCMC, the intrinsic clearance of phenytoin, CL(int) was significantly slower than those in control rats and rats with PCM (0.175, 0.131 and 0.044 ml/min).",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),[ml] / [min],0.175,261525,DB00252,Phenytoin
,11604257,intrinsic clearance,"In rats with PCMC, the intrinsic clearance of phenytoin, CL(int) was significantly slower than those in control rats and rats with PCM (0.175, 0.131 and 0.044 ml/min).",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),[ml] / [min],0.131,261526,DB00252,Phenytoin
,11604257,intrinsic clearance,"In rats with PCMC, the intrinsic clearance of phenytoin, CL(int) was significantly slower than those in control rats and rats with PCM (0.175, 0.131 and 0.044 ml/min).",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),[ml] / [min],0.044,261527,DB00252,Phenytoin
,11604257,CL(int),"In rats with PCMC, the intrinsic clearance of phenytoin, CL(int) was significantly slower than those in control rats and rats with PCM (0.175, 0.131 and 0.044 ml/min).",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),[ml] / [min],0.175,261528,DB00252,Phenytoin
,11604257,CL(int),"In rats with PCMC, the intrinsic clearance of phenytoin, CL(int) was significantly slower than those in control rats and rats with PCM (0.175, 0.131 and 0.044 ml/min).",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),[ml] / [min],0.131,261529,DB00252,Phenytoin
,11604257,CL(int),"In rats with PCMC, the intrinsic clearance of phenytoin, CL(int) was significantly slower than those in control rats and rats with PCM (0.175, 0.131 and 0.044 ml/min).",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),[ml] / [min],0.044,261530,DB00252,Phenytoin
,11604257,maximum velocity,"In rats with PCM, the maximum velocity (0.344, 0.203 and 0.196 microg/min), apparent volume of distribution in central compartment (44.4, 65.4 and 72.2 ml/kg) of phenytoin, and total area under the plasma concentration-time curve from time zero to time infinity (609, 714 and 1210 microg min/ml), renal clearance (20.5, 13.4 and 4.67 ml/min per kg) and 24-h urinary excretion (54.7, 35.6 and 32.5% of intravenous dose of phenytoin) of pHPPH were not returned to control levels by cysteine supplementation (rats with PCMC).",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),[μg] / [min],0.344,261531,DB00252,Phenytoin
,11604257,maximum velocity,"In rats with PCM, the maximum velocity (0.344, 0.203 and 0.196 microg/min), apparent volume of distribution in central compartment (44.4, 65.4 and 72.2 ml/kg) of phenytoin, and total area under the plasma concentration-time curve from time zero to time infinity (609, 714 and 1210 microg min/ml), renal clearance (20.5, 13.4 and 4.67 ml/min per kg) and 24-h urinary excretion (54.7, 35.6 and 32.5% of intravenous dose of phenytoin) of pHPPH were not returned to control levels by cysteine supplementation (rats with PCMC).",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),[μg] / [min],0.203,261532,DB00252,Phenytoin
,11604257,maximum velocity,"In rats with PCM, the maximum velocity (0.344, 0.203 and 0.196 microg/min), apparent volume of distribution in central compartment (44.4, 65.4 and 72.2 ml/kg) of phenytoin, and total area under the plasma concentration-time curve from time zero to time infinity (609, 714 and 1210 microg min/ml), renal clearance (20.5, 13.4 and 4.67 ml/min per kg) and 24-h urinary excretion (54.7, 35.6 and 32.5% of intravenous dose of phenytoin) of pHPPH were not returned to control levels by cysteine supplementation (rats with PCMC).",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),[μg] / [min],0.196,261533,DB00252,Phenytoin
,11604257,apparent volume of distribution in central compartment,"In rats with PCM, the maximum velocity (0.344, 0.203 and 0.196 microg/min), apparent volume of distribution in central compartment (44.4, 65.4 and 72.2 ml/kg) of phenytoin, and total area under the plasma concentration-time curve from time zero to time infinity (609, 714 and 1210 microg min/ml), renal clearance (20.5, 13.4 and 4.67 ml/min per kg) and 24-h urinary excretion (54.7, 35.6 and 32.5% of intravenous dose of phenytoin) of pHPPH were not returned to control levels by cysteine supplementation (rats with PCMC).",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),[ml] / [kg],44.4,261534,DB00252,Phenytoin
,11604257,apparent volume of distribution in central compartment,"In rats with PCM, the maximum velocity (0.344, 0.203 and 0.196 microg/min), apparent volume of distribution in central compartment (44.4, 65.4 and 72.2 ml/kg) of phenytoin, and total area under the plasma concentration-time curve from time zero to time infinity (609, 714 and 1210 microg min/ml), renal clearance (20.5, 13.4 and 4.67 ml/min per kg) and 24-h urinary excretion (54.7, 35.6 and 32.5% of intravenous dose of phenytoin) of pHPPH were not returned to control levels by cysteine supplementation (rats with PCMC).",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),[ml] / [kg],65.4,261535,DB00252,Phenytoin
,11604257,apparent volume of distribution in central compartment,"In rats with PCM, the maximum velocity (0.344, 0.203 and 0.196 microg/min), apparent volume of distribution in central compartment (44.4, 65.4 and 72.2 ml/kg) of phenytoin, and total area under the plasma concentration-time curve from time zero to time infinity (609, 714 and 1210 microg min/ml), renal clearance (20.5, 13.4 and 4.67 ml/min per kg) and 24-h urinary excretion (54.7, 35.6 and 32.5% of intravenous dose of phenytoin) of pHPPH were not returned to control levels by cysteine supplementation (rats with PCMC).",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),[ml] / [kg],72.2,261536,DB00252,Phenytoin
,11604257,total area under the plasma concentration-time curve from time zero to time infinity,"In rats with PCM, the maximum velocity (0.344, 0.203 and 0.196 microg/min), apparent volume of distribution in central compartment (44.4, 65.4 and 72.2 ml/kg) of phenytoin, and total area under the plasma concentration-time curve from time zero to time infinity (609, 714 and 1210 microg min/ml), renal clearance (20.5, 13.4 and 4.67 ml/min per kg) and 24-h urinary excretion (54.7, 35.6 and 32.5% of intravenous dose of phenytoin) of pHPPH were not returned to control levels by cysteine supplementation (rats with PCMC).",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),[min·μg] / [ml],609,261537,DB00252,Phenytoin
,11604257,total area under the plasma concentration-time curve from time zero to time infinity,"In rats with PCM, the maximum velocity (0.344, 0.203 and 0.196 microg/min), apparent volume of distribution in central compartment (44.4, 65.4 and 72.2 ml/kg) of phenytoin, and total area under the plasma concentration-time curve from time zero to time infinity (609, 714 and 1210 microg min/ml), renal clearance (20.5, 13.4 and 4.67 ml/min per kg) and 24-h urinary excretion (54.7, 35.6 and 32.5% of intravenous dose of phenytoin) of pHPPH were not returned to control levels by cysteine supplementation (rats with PCMC).",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),[min·μg] / [ml],714,261538,DB00252,Phenytoin
,11604257,total area under the plasma concentration-time curve from time zero to time infinity,"In rats with PCM, the maximum velocity (0.344, 0.203 and 0.196 microg/min), apparent volume of distribution in central compartment (44.4, 65.4 and 72.2 ml/kg) of phenytoin, and total area under the plasma concentration-time curve from time zero to time infinity (609, 714 and 1210 microg min/ml), renal clearance (20.5, 13.4 and 4.67 ml/min per kg) and 24-h urinary excretion (54.7, 35.6 and 32.5% of intravenous dose of phenytoin) of pHPPH were not returned to control levels by cysteine supplementation (rats with PCMC).",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),[min·μg] / [ml],1210,261539,DB00252,Phenytoin
,11604257,renal clearance,"In rats with PCM, the maximum velocity (0.344, 0.203 and 0.196 microg/min), apparent volume of distribution in central compartment (44.4, 65.4 and 72.2 ml/kg) of phenytoin, and total area under the plasma concentration-time curve from time zero to time infinity (609, 714 and 1210 microg min/ml), renal clearance (20.5, 13.4 and 4.67 ml/min per kg) and 24-h urinary excretion (54.7, 35.6 and 32.5% of intravenous dose of phenytoin) of pHPPH were not returned to control levels by cysteine supplementation (rats with PCMC).",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),[ml] / [kg·min],20.5,261540,DB00252,Phenytoin
,11604257,renal clearance,"In rats with PCM, the maximum velocity (0.344, 0.203 and 0.196 microg/min), apparent volume of distribution in central compartment (44.4, 65.4 and 72.2 ml/kg) of phenytoin, and total area under the plasma concentration-time curve from time zero to time infinity (609, 714 and 1210 microg min/ml), renal clearance (20.5, 13.4 and 4.67 ml/min per kg) and 24-h urinary excretion (54.7, 35.6 and 32.5% of intravenous dose of phenytoin) of pHPPH were not returned to control levels by cysteine supplementation (rats with PCMC).",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),[ml] / [kg·min],13.4,261541,DB00252,Phenytoin
,11604257,renal clearance,"In rats with PCM, the maximum velocity (0.344, 0.203 and 0.196 microg/min), apparent volume of distribution in central compartment (44.4, 65.4 and 72.2 ml/kg) of phenytoin, and total area under the plasma concentration-time curve from time zero to time infinity (609, 714 and 1210 microg min/ml), renal clearance (20.5, 13.4 and 4.67 ml/min per kg) and 24-h urinary excretion (54.7, 35.6 and 32.5% of intravenous dose of phenytoin) of pHPPH were not returned to control levels by cysteine supplementation (rats with PCMC).",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),[ml] / [kg·min],4.67,261542,DB00252,Phenytoin
,11604257,urinary excretion,"In rats with PCM, the maximum velocity (0.344, 0.203 and 0.196 microg/min), apparent volume of distribution in central compartment (44.4, 65.4 and 72.2 ml/kg) of phenytoin, and total area under the plasma concentration-time curve from time zero to time infinity (609, 714 and 1210 microg min/ml), renal clearance (20.5, 13.4 and 4.67 ml/min per kg) and 24-h urinary excretion (54.7, 35.6 and 32.5% of intravenous dose of phenytoin) of pHPPH were not returned to control levels by cysteine supplementation (rats with PCMC).",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),%,54.7,261543,DB00252,Phenytoin
,11604257,urinary excretion,"In rats with PCM, the maximum velocity (0.344, 0.203 and 0.196 microg/min), apparent volume of distribution in central compartment (44.4, 65.4 and 72.2 ml/kg) of phenytoin, and total area under the plasma concentration-time curve from time zero to time infinity (609, 714 and 1210 microg min/ml), renal clearance (20.5, 13.4 and 4.67 ml/min per kg) and 24-h urinary excretion (54.7, 35.6 and 32.5% of intravenous dose of phenytoin) of pHPPH were not returned to control levels by cysteine supplementation (rats with PCMC).",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),%,35.6,261544,DB00252,Phenytoin
,11604257,urinary excretion,"In rats with PCM, the maximum velocity (0.344, 0.203 and 0.196 microg/min), apparent volume of distribution in central compartment (44.4, 65.4 and 72.2 ml/kg) of phenytoin, and total area under the plasma concentration-time curve from time zero to time infinity (609, 714 and 1210 microg min/ml), renal clearance (20.5, 13.4 and 4.67 ml/min per kg) and 24-h urinary excretion (54.7, 35.6 and 32.5% of intravenous dose of phenytoin) of pHPPH were not returned to control levels by cysteine supplementation (rats with PCMC).",Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604257/),%,32.5,261545,DB00252,Phenytoin
,26681081,Volume of distribution,"Volume of distribution, clearance, and half-life median values (95 % CI) for phenobarbital in the whole study population (n=37) were 0.48 (0.41-0.56) l/kg, 0.0034 (0.0028-0.0040) l/h/kg, and 93.7 (88.1-99.2) h, respectively.",Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681081/),[l] / [kg],0.48,261685,DB00252,Phenytoin
,26681081,clearance,"Volume of distribution, clearance, and half-life median values (95 % CI) for phenobarbital in the whole study population (n=37) were 0.48 (0.41-0.56) l/kg, 0.0034 (0.0028-0.0040) l/h/kg, and 93.7 (88.1-99.2) h, respectively.",Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681081/),[l] / [h·kg],0.0034,261686,DB00252,Phenytoin
,26681081,half-life,"Volume of distribution, clearance, and half-life median values (95 % CI) for phenobarbital in the whole study population (n=37) were 0.48 (0.41-0.56) l/kg, 0.0034 (0.0028-0.0040) l/h/kg, and 93.7 (88.1-99.2) h, respectively.",Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681081/),h,93.7,261687,DB00252,Phenytoin
,6694030,rate constant,"The mean +/- SEM values for the observed parameters were as follows: rate constant for the disposition of paraldehyde 0.0680 +/- 0.0071 hr,-1 half-life 10.2 +/- 1.0 hr; volume of distribution 1.73 +/- 0.20 L/kg; clearance 0.121 +/- 0.023 L/hr/kg.",Pharmacokinetics of paraldehyde disposition in the neonate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6694030/),h,0.0680,262549,DB00252,Phenytoin
,6694030,-1 half-life,"The mean +/- SEM values for the observed parameters were as follows: rate constant for the disposition of paraldehyde 0.0680 +/- 0.0071 hr,-1 half-life 10.2 +/- 1.0 hr; volume of distribution 1.73 +/- 0.20 L/kg; clearance 0.121 +/- 0.023 L/hr/kg.",Pharmacokinetics of paraldehyde disposition in the neonate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6694030/),h,10.2,262550,DB00252,Phenytoin
,6694030,volume of distribution,"The mean +/- SEM values for the observed parameters were as follows: rate constant for the disposition of paraldehyde 0.0680 +/- 0.0071 hr,-1 half-life 10.2 +/- 1.0 hr; volume of distribution 1.73 +/- 0.20 L/kg; clearance 0.121 +/- 0.023 L/hr/kg.",Pharmacokinetics of paraldehyde disposition in the neonate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6694030/),[l] / [kg],1.73,262551,DB00252,Phenytoin
,6694030,clearance,"The mean +/- SEM values for the observed parameters were as follows: rate constant for the disposition of paraldehyde 0.0680 +/- 0.0071 hr,-1 half-life 10.2 +/- 1.0 hr; volume of distribution 1.73 +/- 0.20 L/kg; clearance 0.121 +/- 0.023 L/hr/kg.",Pharmacokinetics of paraldehyde disposition in the neonate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6694030/),[l] / [h·kg],0.121,262552,DB00252,Phenytoin
,517820,half-life,The mean half-life of the drug in adult dogs injected IV was 4.5 hours.,Relationship between serum and brain concentrations of phenytoin in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/517820/),h,4.5,262555,DB00252,Phenytoin
,508562,acute LD50,The acute LD50 for MIS was increased from 1.54 to 1.90 g/kg after phenobarbitone pretreatment and 1.78 g/kg after phenytoin pretreatment.,Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/508562/),[g] / [kg],1.54,264004,DB00252,Phenytoin
,508562,acute LD50,The acute LD50 for MIS was increased from 1.54 to 1.90 g/kg after phenobarbitone pretreatment and 1.78 g/kg after phenytoin pretreatment.,Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/508562/),[g] / [kg],1.90,264005,DB00252,Phenytoin
,508562,acute LD50,The acute LD50 for MIS was increased from 1.54 to 1.90 g/kg after phenobarbitone pretreatment and 1.78 g/kg after phenytoin pretreatment.,Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/508562/),[g] / [kg],1.78,264006,DB00252,Phenytoin
,9055139,unbound fraction,The mean (+/- SEM) unbound fraction of phenytoin increased from 0.17 +/- 0.02 on day 1 to 0.24 +/- 0.04 on day 10 (P < 0.05).,Effect of acute phase response on phenytoin metabolism in neurotrauma patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9055139/),,0.17,264545,DB00252,Phenytoin
,9055139,unbound fraction,The mean (+/- SEM) unbound fraction of phenytoin increased from 0.17 +/- 0.02 on day 1 to 0.24 +/- 0.04 on day 10 (P < 0.05).,Effect of acute phase response on phenytoin metabolism in neurotrauma patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9055139/),,0.24,264546,DB00252,Phenytoin
,9055139,Vmax delta,"Mean (+/- SEM) pharmacokinetic parameter estimates for unbound phenytoin were: Vmax delta = 605 +/- 92 mg/day, VmaxB = 149 +/- 26.3 mg/day, K(ind) = 0.013 +/- 0.004 hr-1.",Effect of acute phase response on phenytoin metabolism in neurotrauma patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9055139/),[mg] / [d],605,264547,DB00252,Phenytoin
,9055139,VmaxB,"Mean (+/- SEM) pharmacokinetic parameter estimates for unbound phenytoin were: Vmax delta = 605 +/- 92 mg/day, VmaxB = 149 +/- 26.3 mg/day, K(ind) = 0.013 +/- 0.004 hr-1.",Effect of acute phase response on phenytoin metabolism in neurotrauma patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9055139/),[mg] / [d],149,264548,DB00252,Phenytoin
,9055139,K(ind),"Mean (+/- SEM) pharmacokinetic parameter estimates for unbound phenytoin were: Vmax delta = 605 +/- 92 mg/day, VmaxB = 149 +/- 26.3 mg/day, K(ind) = 0.013 +/- 0.004 hr-1.",Effect of acute phase response on phenytoin metabolism in neurotrauma patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9055139/),1/[h],0.013,264549,DB00252,Phenytoin
up to,8838248,free plasma concentrations,Treatment with 50 mg/kg resulted in free plasma concentrations of up to 5.0 mumol/l during the 24 hr period following the final dose.,Phenytoin causes phalangeal hypoplasia in the rabbit fetus at clinically relevant free plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838248/),[μM] / [l],5.0,265214,DB00252,Phenytoin
up to,8838248,free plasma concentrations,Significantly higher free plasma concentrations were observed at the two higher dose levels; up to 9.7 mumol/l at 100 mg/kg and 12.7 mumol/l at 150 mg/kg.,Phenytoin causes phalangeal hypoplasia in the rabbit fetus at clinically relevant free plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838248/),[μM] / [l],9.7,265215,DB00252,Phenytoin
,8838248,free plasma concentrations,Significantly higher free plasma concentrations were observed at the two higher dose levels; up to 9.7 mumol/l at 100 mg/kg and 12.7 mumol/l at 150 mg/kg.,Phenytoin causes phalangeal hypoplasia in the rabbit fetus at clinically relevant free plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838248/),[μM] / [l],12.7,265216,DB00252,Phenytoin
,3580513,area under the isoxicam plasma concentration-time curve (AUC infinity),The area under the isoxicam plasma concentration-time curve (AUC infinity) increased from 389 +/- 66 to 464 +/- 62 micrograms h ml-1 (+/- SEM) (p less than 0.05) after treatment with phenytoin.,The effect of administration of phenytoin on the pharmacokinetics of isoxicam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580513/),[h·μg] / [ml],389,265379,DB00252,Phenytoin
,3580513,area under the isoxicam plasma concentration-time curve (AUC infinity),The area under the isoxicam plasma concentration-time curve (AUC infinity) increased from 389 +/- 66 to 464 +/- 62 micrograms h ml-1 (+/- SEM) (p less than 0.05) after treatment with phenytoin.,The effect of administration of phenytoin on the pharmacokinetics of isoxicam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580513/),[h·μg] / [ml],464,265380,DB00252,Phenytoin
,3580513,absorption rate constant,This increase was due to an increase in isoxicam bioavailability; the absorption rate constant for isoxicam increased correspondingly from 0.34 +/- 0.06 to 1.16 +/- 0.38 h-1 (p less than 0.05).,The effect of administration of phenytoin on the pharmacokinetics of isoxicam. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580513/),1/[h],0.34,265381,DB00252,Phenytoin
,3580513,absorption rate constant,This increase was due to an increase in isoxicam bioavailability; the absorption rate constant for isoxicam increased correspondingly from 0.34 +/- 0.06 to 1.16 +/- 0.38 h-1 (p less than 0.05).,The effect of administration of phenytoin on the pharmacokinetics of isoxicam. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580513/),1/[h],1.16,265382,DB00252,Phenytoin
,20216111,trough concentrations,"Pharmacokinetic parameters of phenytoin were not significantly different between the 2 groups; trough concentrations, 1.9 +/- 1.7 (0.5-4.9) versus 2.2 +/- 1.8 (1.0-6.5) microg/mL; Cmax, 6.6 +/- 3.4 (2.5-9.1) versus 7.3 +/- 6.7 (2.7-8.4) microg/mL; tmax, 5.1 +/- 3.1 (3.1-8.2) versus 4.6 +/- 2.7 (2.3-8.4) hours; area under the curve, 52.2 +/- 40.1 (41.1-61.2) versus 62.3 +/- 84.7 (30.2-77.2) microg/h/mL, in the NGT fed versus the oral fed, respectively.",Phenytoin blood concentrations in hospitalized geriatric patients: oral versus nasogastric feeding tube administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20216111/),[μg] / [ml],1.9,266018,DB00252,Phenytoin
,20216111,trough concentrations,"Pharmacokinetic parameters of phenytoin were not significantly different between the 2 groups; trough concentrations, 1.9 +/- 1.7 (0.5-4.9) versus 2.2 +/- 1.8 (1.0-6.5) microg/mL; Cmax, 6.6 +/- 3.4 (2.5-9.1) versus 7.3 +/- 6.7 (2.7-8.4) microg/mL; tmax, 5.1 +/- 3.1 (3.1-8.2) versus 4.6 +/- 2.7 (2.3-8.4) hours; area under the curve, 52.2 +/- 40.1 (41.1-61.2) versus 62.3 +/- 84.7 (30.2-77.2) microg/h/mL, in the NGT fed versus the oral fed, respectively.",Phenytoin blood concentrations in hospitalized geriatric patients: oral versus nasogastric feeding tube administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20216111/),[μg] / [ml],2.2,266019,DB00252,Phenytoin
,20216111,Cmax,"Pharmacokinetic parameters of phenytoin were not significantly different between the 2 groups; trough concentrations, 1.9 +/- 1.7 (0.5-4.9) versus 2.2 +/- 1.8 (1.0-6.5) microg/mL; Cmax, 6.6 +/- 3.4 (2.5-9.1) versus 7.3 +/- 6.7 (2.7-8.4) microg/mL; tmax, 5.1 +/- 3.1 (3.1-8.2) versus 4.6 +/- 2.7 (2.3-8.4) hours; area under the curve, 52.2 +/- 40.1 (41.1-61.2) versus 62.3 +/- 84.7 (30.2-77.2) microg/h/mL, in the NGT fed versus the oral fed, respectively.",Phenytoin blood concentrations in hospitalized geriatric patients: oral versus nasogastric feeding tube administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20216111/),[μg] / [ml],6.6,266020,DB00252,Phenytoin
,20216111,Cmax,"Pharmacokinetic parameters of phenytoin were not significantly different between the 2 groups; trough concentrations, 1.9 +/- 1.7 (0.5-4.9) versus 2.2 +/- 1.8 (1.0-6.5) microg/mL; Cmax, 6.6 +/- 3.4 (2.5-9.1) versus 7.3 +/- 6.7 (2.7-8.4) microg/mL; tmax, 5.1 +/- 3.1 (3.1-8.2) versus 4.6 +/- 2.7 (2.3-8.4) hours; area under the curve, 52.2 +/- 40.1 (41.1-61.2) versus 62.3 +/- 84.7 (30.2-77.2) microg/h/mL, in the NGT fed versus the oral fed, respectively.",Phenytoin blood concentrations in hospitalized geriatric patients: oral versus nasogastric feeding tube administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20216111/),[μg] / [ml],7.3,266021,DB00252,Phenytoin
,20216111,tmax,"Pharmacokinetic parameters of phenytoin were not significantly different between the 2 groups; trough concentrations, 1.9 +/- 1.7 (0.5-4.9) versus 2.2 +/- 1.8 (1.0-6.5) microg/mL; Cmax, 6.6 +/- 3.4 (2.5-9.1) versus 7.3 +/- 6.7 (2.7-8.4) microg/mL; tmax, 5.1 +/- 3.1 (3.1-8.2) versus 4.6 +/- 2.7 (2.3-8.4) hours; area under the curve, 52.2 +/- 40.1 (41.1-61.2) versus 62.3 +/- 84.7 (30.2-77.2) microg/h/mL, in the NGT fed versus the oral fed, respectively.",Phenytoin blood concentrations in hospitalized geriatric patients: oral versus nasogastric feeding tube administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20216111/),h,5.1,266022,DB00252,Phenytoin
,20216111,tmax,"Pharmacokinetic parameters of phenytoin were not significantly different between the 2 groups; trough concentrations, 1.9 +/- 1.7 (0.5-4.9) versus 2.2 +/- 1.8 (1.0-6.5) microg/mL; Cmax, 6.6 +/- 3.4 (2.5-9.1) versus 7.3 +/- 6.7 (2.7-8.4) microg/mL; tmax, 5.1 +/- 3.1 (3.1-8.2) versus 4.6 +/- 2.7 (2.3-8.4) hours; area under the curve, 52.2 +/- 40.1 (41.1-61.2) versus 62.3 +/- 84.7 (30.2-77.2) microg/h/mL, in the NGT fed versus the oral fed, respectively.",Phenytoin blood concentrations in hospitalized geriatric patients: oral versus nasogastric feeding tube administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20216111/),h,4.6,266023,DB00252,Phenytoin
,20216111,area under the curve,"Pharmacokinetic parameters of phenytoin were not significantly different between the 2 groups; trough concentrations, 1.9 +/- 1.7 (0.5-4.9) versus 2.2 +/- 1.8 (1.0-6.5) microg/mL; Cmax, 6.6 +/- 3.4 (2.5-9.1) versus 7.3 +/- 6.7 (2.7-8.4) microg/mL; tmax, 5.1 +/- 3.1 (3.1-8.2) versus 4.6 +/- 2.7 (2.3-8.4) hours; area under the curve, 52.2 +/- 40.1 (41.1-61.2) versus 62.3 +/- 84.7 (30.2-77.2) microg/h/mL, in the NGT fed versus the oral fed, respectively.",Phenytoin blood concentrations in hospitalized geriatric patients: oral versus nasogastric feeding tube administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20216111/),[μg] / [h·ml],52.2,266024,DB00252,Phenytoin
,20216111,area under the curve,"Pharmacokinetic parameters of phenytoin were not significantly different between the 2 groups; trough concentrations, 1.9 +/- 1.7 (0.5-4.9) versus 2.2 +/- 1.8 (1.0-6.5) microg/mL; Cmax, 6.6 +/- 3.4 (2.5-9.1) versus 7.3 +/- 6.7 (2.7-8.4) microg/mL; tmax, 5.1 +/- 3.1 (3.1-8.2) versus 4.6 +/- 2.7 (2.3-8.4) hours; area under the curve, 52.2 +/- 40.1 (41.1-61.2) versus 62.3 +/- 84.7 (30.2-77.2) microg/h/mL, in the NGT fed versus the oral fed, respectively.",Phenytoin blood concentrations in hospitalized geriatric patients: oral versus nasogastric feeding tube administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20216111/),[μg] / [h·ml],62.3,266025,DB00252,Phenytoin
,3360972,half-life,"Compared with control, metronidazole significantly prolonged phenytoin half-life (23 versus 16 hours, P less than .02) and reduced its clearance (.28 versus .33 mL/min/kg, P less than .005), known to depend on aromatic hydroxylation.",Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360972/),h,23,267062,DB00252,Phenytoin
,3360972,half-life,"Compared with control, metronidazole significantly prolonged phenytoin half-life (23 versus 16 hours, P less than .02) and reduced its clearance (.28 versus .33 mL/min/kg, P less than .005), known to depend on aromatic hydroxylation.",Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360972/),h,16,267063,DB00252,Phenytoin
,3360972,clearance,"Compared with control, metronidazole significantly prolonged phenytoin half-life (23 versus 16 hours, P less than .02) and reduced its clearance (.28 versus .33 mL/min/kg, P less than .005), known to depend on aromatic hydroxylation.",Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360972/),[ml] / [kg·min],.28,267064,DB00252,Phenytoin
,3360972,clearance,"Compared with control, metronidazole significantly prolonged phenytoin half-life (23 versus 16 hours, P less than .02) and reduced its clearance (.28 versus .33 mL/min/kg, P less than .005), known to depend on aromatic hydroxylation.",Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360972/),[ml] / [kg·min],.33,267065,DB00252,Phenytoin
,6601779,Brain-blood concentration ratios,"Brain-blood concentration ratios at 50 minutes were 1.37 and 1.06 in gray and white matter, respectively, similar but less variable than steady-state DPH ratios reported in human brain surgical samples.",Brain regional pharmacokinetics of 11C-labeled diphenylhydantoin: positron emission tomography in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6601779/),,1.37,267283,DB00252,Phenytoin
,6601779,Brain-blood concentration ratios,"Brain-blood concentration ratios at 50 minutes were 1.37 and 1.06 in gray and white matter, respectively, similar but less variable than steady-state DPH ratios reported in human brain surgical samples.",Brain regional pharmacokinetics of 11C-labeled diphenylhydantoin: positron emission tomography in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6601779/),,1.06,267284,DB00252,Phenytoin
,8617708,trough plasma phenytoin concentrations,Concurrent treatment with sertraline (16 subjects) or placebo (13 subjects) was initiated on Day 8 and continued throughout the study in those subjects whose trough plasma phenytoin concentrations were between 5 and 20 micrograms/mL.,Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8617708/),[μg] / [ml],5 and 20,267713,DB00252,Phenytoin
,3575876,extraction ratios,"The drugs, antipyrine, phenytoin, indocyanine green, and d-propranolol, have extraction ratios from 0.01 to 0.99 in the rat.",Effect of Fluosol-DA hemodilution on the kinetics of hepatically eliminated drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3575876/),,0,268182,DB00252,Phenytoin
,6784613,elimination half-life,"After IV injection of 10 mg/kg, the average elimination half-life was 4.4 hours, which is in good agreement with previous studies.",Clinical pharmacokinetics of phenytoin in the dog: a reevaluation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6784613/),h,4.4,268226,DB00252,Phenytoin
,6784613,Bioavailability,Bioavailability from tablet formulation was rather poor (av 36% compared with that obtained with IV) and showed great variation between dogs.,Clinical pharmacokinetics of phenytoin in the dog: a reevaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6784613/),%,36,268227,DB00252,Phenytoin
,21233690,recovery,"Urinary metabolite recovery was surprisingly low, 35.4% ± 15.7% in younger patients (age 21-49 years old) and 32.9% ± 15.0% in patients aged 65 to 93 years.",Excretion of the principal urinary metabolites of phenytoin and absolute oral bioavailability determined by use of a stable isotope in patients with epilepsy. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233690/),%,35.4,268329,DB00252,Phenytoin
,21233690,recovery,"Urinary metabolite recovery was surprisingly low, 35.4% ± 15.7% in younger patients (age 21-49 years old) and 32.9% ± 15.0% in patients aged 65 to 93 years.",Excretion of the principal urinary metabolites of phenytoin and absolute oral bioavailability determined by use of a stable isotope in patients with epilepsy. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233690/),%,32.9,268330,DB00252,Phenytoin
,21233690,Absolute bioavailability,"Absolute bioavailability was 86.4% ± 19.4% and 92.5% ± 25.2%, respectively.",Excretion of the principal urinary metabolites of phenytoin and absolute oral bioavailability determined by use of a stable isotope in patients with epilepsy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233690/),%,86.4,268331,DB00252,Phenytoin
,21233690,Absolute bioavailability,"Absolute bioavailability was 86.4% ± 19.4% and 92.5% ± 25.2%, respectively.",Excretion of the principal urinary metabolites of phenytoin and absolute oral bioavailability determined by use of a stable isotope in patients with epilepsy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233690/),%,92.5,268332,DB00252,Phenytoin
,7955800,area under the plasma concentration-time curve [AUC(0-6)],"After dose 21, area under the plasma concentration-time curve [AUC(0-6)] for tirilazad mesylate was significantly lower (p = 0.0061) after phenytoin treatment (3029 +/- 982 ng.hr/ml) than after tirilazad mesylate alone (4647 +/- 1562 ng.hr/ml).",The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955800/),[h·ng] / [ml],3029,268833,DB00252,Phenytoin
,7955800,area under the plasma concentration-time curve [AUC(0-6)],"After dose 21, area under the plasma concentration-time curve [AUC(0-6)] for tirilazad mesylate was significantly lower (p = 0.0061) after phenytoin treatment (3029 +/- 982 ng.hr/ml) than after tirilazad mesylate alone (4647 +/- 1562 ng.hr/ml).",The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955800/),[h·ng] / [ml],4647,268834,DB00252,Phenytoin
,7955800,AUC(0-6),"AUC(0-6) for U-89,678 after dose 21 was reduced from 1485 +/- 1173 ng.hr/ml after tirilazad mesylate alone to 195 +/- 223 ng.hr/ml after phenytoin coadministration.",The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955800/),[h·ng] / [ml],1485,268835,DB00252,Phenytoin
,7955800,AUC(0-6),"AUC(0-6) for U-89,678 after dose 21 was reduced from 1485 +/- 1173 ng.hr/ml after tirilazad mesylate alone to 195 +/- 223 ng.hr/ml after phenytoin coadministration.",The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955800/),[h·ng] / [ml],195,268836,DB00252,Phenytoin
,3082590,AUC,Prior to sodium valproate therapy the mean AUC for EE2 was 880 +/- 109 pg/ml X h (+/- S.E.) and for levonorgestrel it was 29.1 +/- 2.9 ng/ml X h (n = 4).,The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082590/),[pg] / [h·ml],880,269574,DB00252,Phenytoin
,3082590,AUC,Prior to sodium valproate therapy the mean AUC for EE2 was 880 +/- 109 pg/ml X h (+/- S.E.) and for levonorgestrel it was 29.1 +/- 2.9 ng/ml X h (n = 4).,The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082590/),[ng] / [h·ml],29.1,269575,DB00252,Phenytoin
,3082590,AUC,"Between two and four months after sodium valproate therapy the mean AUC figures had not changed significantly, the figure for EE2 being 977 +/- 130 pg/ml X h and for levonorgestrel 29.2 +/- 1.9 ng/ml X h (p greater than or equal to 0.1 in each case).",The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082590/),[pg] / [h·ml],977,269576,DB00252,Phenytoin
,3082590,AUC,"Between two and four months after sodium valproate therapy the mean AUC figures had not changed significantly, the figure for EE2 being 977 +/- 130 pg/ml X h and for levonorgestrel 29.2 +/- 1.9 ng/ml X h (p greater than or equal to 0.1 in each case).",The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082590/),[ng] / [h·ml],29.2,269577,DB00252,Phenytoin
,1587059,Peak serum concentrations,Peak serum concentrations of 19.8 and 17.8 mg/L were measured.,Phenobarbital pharmacokinetics in obesity. A case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587059/),[mg] / [l],19.8,269640,DB00252,Phenytoin
,1587059,Peak serum concentrations,Peak serum concentrations of 19.8 and 17.8 mg/L were measured.,Phenobarbital pharmacokinetics in obesity. A case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587059/),[mg] / [l],17.8,269641,DB00252,Phenytoin
,1587059,apparent volume of distribution (Vd),"An apparent volume of distribution (Vd) of 154.9L (0.82 L/kg TBW), total body clearance (CL) of 29 ml/min (1.74 L/h) and elimination half-life of 61h were determined.",Phenobarbital pharmacokinetics in obesity. A case report. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587059/),l,154.9,269642,DB00252,Phenytoin
,1587059,total body clearance (CL),"An apparent volume of distribution (Vd) of 154.9L (0.82 L/kg TBW), total body clearance (CL) of 29 ml/min (1.74 L/h) and elimination half-life of 61h were determined.",Phenobarbital pharmacokinetics in obesity. A case report. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587059/),[ml] / [min],29,269643,DB00252,Phenytoin
,1587059,elimination half-life,"An apparent volume of distribution (Vd) of 154.9L (0.82 L/kg TBW), total body clearance (CL) of 29 ml/min (1.74 L/h) and elimination half-life of 61h were determined.",Phenobarbital pharmacokinetics in obesity. A case report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587059/),h,61,269644,DB00252,Phenytoin
,3750373,t1/2,"The approximate values for t1/2 were 36.4 h in plasma and 54.2 h in RBC for patients treated with CBZ, and 27.1 h in plasma and 35.8 h in RBC for patients treated with PHT.",Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750373/),h,36.4,269758,DB00252,Phenytoin
,3750373,t1/2,"The approximate values for t1/2 were 36.4 h in plasma and 54.2 h in RBC for patients treated with CBZ, and 27.1 h in plasma and 35.8 h in RBC for patients treated with PHT.",Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750373/),h,54.2,269759,DB00252,Phenytoin
,3750373,t1/2,"The approximate values for t1/2 were 36.4 h in plasma and 54.2 h in RBC for patients treated with CBZ, and 27.1 h in plasma and 35.8 h in RBC for patients treated with PHT.",Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750373/),h,27.1,269760,DB00252,Phenytoin
,3750373,t1/2,"The approximate values for t1/2 were 36.4 h in plasma and 54.2 h in RBC for patients treated with CBZ, and 27.1 h in plasma and 35.8 h in RBC for patients treated with PHT.",Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750373/),h,35.8,269761,DB00252,Phenytoin
,6317740,Systemic bioavailability,Systemic bioavailability is approximately 70% with cimetidine and 50% with ranitidine.,Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),%,70,269860,DB00252,Phenytoin
,6317740,Systemic bioavailability,Systemic bioavailability is approximately 70% with cimetidine and 50% with ranitidine.,Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),%,50,269861,DB00252,Phenytoin
,6317740,elimination half-lives,"The elimination half-lives of cimetidine and ranitidine are 1.7-2.1 hours and 2.1-3.1 hours, respectively, with apparent volumes of distribution approximating 50L and 75L, respectively.",Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),h,1.7-2.1,269862,DB00252,Phenytoin
,6317740,elimination half-lives,"The elimination half-lives of cimetidine and ranitidine are 1.7-2.1 hours and 2.1-3.1 hours, respectively, with apparent volumes of distribution approximating 50L and 75L, respectively.",Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),h,2.1-3.1,269863,DB00252,Phenytoin
,6317740,apparent volumes of distribution,"The elimination half-lives of cimetidine and ranitidine are 1.7-2.1 hours and 2.1-3.1 hours, respectively, with apparent volumes of distribution approximating 50L and 75L, respectively.",Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),l,50,269864,DB00252,Phenytoin
,6317740,apparent volumes of distribution,"The elimination half-lives of cimetidine and ranitidine are 1.7-2.1 hours and 2.1-3.1 hours, respectively, with apparent volumes of distribution approximating 50L and 75L, respectively.",Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),l,75,269865,DB00252,Phenytoin
,4041330,half-life,"In the anticonvulsant-treated group, the half-life of cortisol in plasma (73 +/- 5 min, mean +/- s.e. mean) and saliva (83 +/- 5 min, mean +/- s.e. mean) was reduced significantly (P less than 0.01 plasma, P less than 0.05 saliva) from that observed in healthy volunteers.",Anticonvulsant therapy and cortisol elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041330/),min,73,269970,DB00252,Phenytoin
,4041330,half-life,"In the anticonvulsant-treated group, the half-life of cortisol in plasma (73 +/- 5 min, mean +/- s.e. mean) and saliva (83 +/- 5 min, mean +/- s.e. mean) was reduced significantly (P less than 0.01 plasma, P less than 0.05 saliva) from that observed in healthy volunteers.",Anticonvulsant therapy and cortisol elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041330/),min,83,269971,DB00252,Phenytoin
,12915337,half-life,"Although its half-life is relatively short (6 to 8 hours), its duration of action is longer than anticipated from its pharmacokinetics in plasma, and a twice-daily dosing regimen is adequate to produce the desired response.",The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915337/),h,6 to 8,271378,DB00252,Phenytoin
,10217336,concentration/dose (C/D) ratio,"In 20 patients in monotherapy, the concentration/dose (C/D) ratio was 65 (range: 50-84) nmol/L/mg (mean and 95% confidence interval, antilog from lognormal distribution).",Lamotrigine drug interactions in a TDM material. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217336/),[nM] / [l·mg],65,272553,DB00252,Phenytoin
less,10217336,C/D ratio,"In 37 patients with concomitant carbamazepine treatment, the C/D ratio was less than half that of the patients in monotherapy; 31 (2146) nmol/L/mg, and in 14 patients with phenytoin, it was even lower; 17 (13-23) nmol/L/mg.",Lamotrigine drug interactions in a TDM material. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217336/),[nM] / [l·mg],31,272554,DB00252,Phenytoin
,10217336,C/D ratio,"In 37 patients with concomitant carbamazepine treatment, the C/D ratio was less than half that of the patients in monotherapy; 31 (2146) nmol/L/mg, and in 14 patients with phenytoin, it was even lower; 17 (13-23) nmol/L/mg.",Lamotrigine drug interactions in a TDM material. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217336/),[nM] / [l·mg],17,272555,DB00252,Phenytoin
,10217336,C/D,Valproic acid significantly increased the C/D to 251 (200-320) nmol/L/mg in 13 patients.,Lamotrigine drug interactions in a TDM material. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217336/),[nM] / [l·mg],251,272556,DB00252,Phenytoin
,6502166,oral bioavailability,"Apparent volume of distribution was similar in the two groups, but the group treated with phenytoin had an almost statistically significantly shorter dexamethasone mean terminal half-life, an approximately trebled mean plasma clearance, and a mean oral bioavailability of the steroid of only 33%, compared with a mean 84% oral bioavailability in those not receiving phenytoin.",Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502166/),%,33,273269,DB00252,Phenytoin
,6502166,oral bioavailability,"Apparent volume of distribution was similar in the two groups, but the group treated with phenytoin had an almost statistically significantly shorter dexamethasone mean terminal half-life, an approximately trebled mean plasma clearance, and a mean oral bioavailability of the steroid of only 33%, compared with a mean 84% oral bioavailability in those not receiving phenytoin.",Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502166/),%,84,273270,DB00252,Phenytoin
,10427465,half-life,Rapid elimination occurs in healthy individuals (half-life 0.5 to 4.0 h).,Clinical pharmacokinetics and pharmacodynamics of bromfenac. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10427465/),h,0.5 to 4.0,273887,DB00252,Phenytoin
more,12848783,plasma unbound phenytoin concentration,"After all routes of administration, a plasma unbound phenytoin concentration of more than 1 microg x ml(-1) was rapidly (within 5-20 min) attained.",Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848783/),[μg] / [ml],1,273952,DB00252,Phenytoin
,12848783,steady state free phenytoin concentrations,"Mean (95% confidence interval) steady state free phenytoin concentrations were 2.1 (1.7, 2.4; i.v. phenytoin, n = 6), 1.5 (0.96, 2.1; i.v. fosphenytoin, n = 11) and 1.4 (0.5, 2.4; i.m. fosphenytoin, n = 6), and were not statistically different for the three routes of administration.",Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848783/),,2.1,273953,DB00252,Phenytoin
,12848783,steady state free phenytoin concentrations,"Mean (95% confidence interval) steady state free phenytoin concentrations were 2.1 (1.7, 2.4; i.v. phenytoin, n = 6), 1.5 (0.96, 2.1; i.v. fosphenytoin, n = 11) and 1.4 (0.5, 2.4; i.m. fosphenytoin, n = 6), and were not statistically different for the three routes of administration.",Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848783/),,1.5,273954,DB00252,Phenytoin
,12848783,steady state free phenytoin concentrations,"Mean (95% confidence interval) steady state free phenytoin concentrations were 2.1 (1.7, 2.4; i.v. phenytoin, n = 6), 1.5 (0.96, 2.1; i.v. fosphenytoin, n = 11) and 1.4 (0.5, 2.4; i.m. fosphenytoin, n = 6), and were not statistically different for the three routes of administration.",Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848783/),,1.4,273955,DB00252,Phenytoin
,12848783,times,"Median times (range) to peak plasma phenytoin concentrations following the loading dose were 0.08 (0.08-0.17), 0.37 (0.33-0.67) and 0.38 (0.17-2.0) h for i.v. fosphenytoin, i.v. phenytoin and i.m. fosphenytoin, respectively.",Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848783/),h,0.08,273956,DB00252,Phenytoin
,12848783,times,"Median times (range) to peak plasma phenytoin concentrations following the loading dose were 0.08 (0.08-0.17), 0.37 (0.33-0.67) and 0.38 (0.17-2.0) h for i.v. fosphenytoin, i.v. phenytoin and i.m. fosphenytoin, respectively.",Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848783/),h,0.37,273957,DB00252,Phenytoin
,12848783,times,"Median times (range) to peak plasma phenytoin concentrations following the loading dose were 0.08 (0.08-0.17), 0.37 (0.33-0.67) and 0.38 (0.17-2.0) h for i.v. fosphenytoin, i.v. phenytoin and i.m. fosphenytoin, respectively.",Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848783/),h,0.38,273958,DB00252,Phenytoin
,12848783,concentration ratio,"CSF: plasma phenytoin concentration ratio ranged from 0.12 to 0.53 (median = 0.28, n = 16).",Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848783/),,0.28,273959,DB00252,Phenytoin
